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Chapter 1 
Targeting of antigen presenting cells with 
mannosylated conjugates 
Introduction 
The immune system consists of a large variety of cells that continuously control and protect the 
body against foreign and aberrant cells. It can be divided into an innate and an adaptive part, that 
recognize these malignant cells through non-specific general traits (the innate part) or through 
highly specific interactions, as developed in the adaptive part of the immune system. Innate 
immune cells can instantly battle pathogens and aberrant cells after sensing danger or pathogen-
associated molecular patterns (DAMPs and PAMPs). When the innate system does not suffice in 
eradication, adaptive immune cells are recruited to generate a selective response. The adaptive 
immune system serves two goals. It generates a strong tailored immune response with high 
specificity, and secondly, it generates lasting immunity by the formation of memory cells. Upon 
recognition of their specific target, the adaptive immune cells start to proliferate to form large 
numbers of specific cells. A small portion of these cells transforms into memory cells, which can 
be readily reactivated and allows the immune system to generate a fast and specific response when 
re-challenged by the same pathogen or aberrant cell.  
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The adaptive immune system has been exploited for centuries in the treatment of diseases. At the 
end of the eighteenth century, Edward Jenner successfully immunized the first human by 
challenging his immune system with cowpox, thereby effectively protecting him from smallpox.1 
Since Jenner, many other therapies that exploit the power and specificity of immune cells have 
been developed. In the last decades, immunotherapies have revolutionized cancer treatment with 
the development of chimeric antigen receptor (CAR) T cells and checkpoint inhibitors.2,3 The 
inhibition of checkpoints can result in the restoration of immune responses and has successfully 
treated various tumors were traditional cytotoxic therapies failed.4,5 Immunotherapies often rely 
on T cells, a specific set of adaptive immune cells and the amount of tumor-infiltrating T cells has 
been shown to be a prognostic marker for success in immunotherapy.6,7 However, the presence of 
T cells does not guarantee a sufficient response if the T cells are not tumor-reactive. For example, 
by sequencing the T cell receptor (TCR) of intratumoral T cells, Scheper et al.8, demonstrated that 
the majority of the T cells were not tumor-reactive. Furthermore, other immune cells, besides T 
cells, are required to generate a long-lasting response against malignant cells.9 A possible method 
to improve T cell based therapies is by active immunization against cancer cells by challenging the 
immune system with specific tumor-associated antigens (TAAs) to mount a specific T cell response 
to target aberrant cells or help improve and elongate the immune-response.10,11 
Innate immune cells can distinguish foreign and damaged cells from normal cells using pathogen 
recognizing receptors (PRRs). These receptors recognize distinct molecular motives that have been 
preserved in pathogens such as viral and bacterial DNA, RNA, carbohydrates, and lipids. Upon 
recognition, the innate immune cells are activated and generate signals to recruit other immune 
cells to the site of infection. Among the innate cells are dendritic cells (DCs) that play a pivotal 
role in the activation of the adaptive immune system. DCs are antigen-presenting cells (APCs) that 
can present (peptide) antigens on their cell surface in a protein called the major histocompatibility 
complex (MHC). Two types of (classic) MHC proteins exist of which class I (MHC-I) presents 
antigens from endogenous proteins from the cytosol and class II (MHC-II) antigens from 
endocytosed (pathogenic) proteins. MHC-I is present on all cells and presents epitopes containing 
8-11 amino acids. It allows for the detection of aberrant cells through the interaction with cytotoxic 
T cells (CTL or CD8+), to induce programmed cell death. MHC-II is only expressed by 
professional APCs such as dendritic cells (DCs), B cells, and macrophages. MHC-II presents 
epitopes with a less stringent size restriction (generally in the 13-17 amino acids length range) to T 
helper cells (Th cells or CD4+), that in turn stimulate effector cells and help prolong the immune 
response.12 T cells recognize the combination of MHC occupied with an epitope via the T cell 
receptor (TCR). Although antigens presented in MHC-II are obtained via endocytosis of pathogens 
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and antigens presented in MHC-I are derived from the cytosol, professional APCs present a small 
amount of the endocytosed antigen in the MHC-I. This route is called antigen cross-presentation 
and allows for immunity against tumors and viruses.13 Importantly, the recognition of epitope-
MHC is not sufficient to activate T cells and additional stimuli from the APC, in the form of co-
stimulatory proteins such as CD40 and cytokines, are required. APCs upregulate the levels of these 
stimuli when their PRRs recognize PAMPs.  
Mammalian immune cells express a multitude of PRRs which are divided into subfamilies based 
on their structure and the ligands they bind. The four well-defined families are the C-type lectin 
receptors (CLRs), toll-like receptors (TLRs), nucleotide-binding oligomerization domain-like 
receptors (NOD-like or NLRs) and the retinoic acid-inducible gene-I-like receptors (RIG-like, or 
RLRs).14 Occasionally, new PRRs are identified that could potentially increase the number of PRR 
families.15 The focus of this thesis is on the CLR and TLR families. TLRs recognize different type 
of PAMPs such as bacterial lipopeptides and bacterial and viral RNA and DNA and have been 
extensively explored to acquire adjuvants for vaccine development.16,17 CLRs recognize viral, 
bacterial, and fungal derived glycans. Both soluble and transmembrane CLRs exist that bind 
carbohydrates in a calcium depending manner. The transmembrane CLRs are classified into two 
classes based on whether the position of their N-terminus is extra- (type I) or intra-cellular (type 
II). The CLR family recognizes various carbohydrates, for example, dectin-1 recognizes β-glucans, 
and the macrophage galactose-type lectin (MGL) recognizes N-acetyl galactosamine containing 
structures. Several CLRs can recognize mannose structures, which is the main subject of the 
research described in this Thesis. These include the mannose-binding lectin (MBL), the mannose 
receptor (MR, or CD206), dendritic cell-specific intercellular adhesion molecule-3-grabbing non-
integrin (DC-SIGN or CD209), and Langerin (CD207) and are discussed in the following sections. 
MBL 
The mannose-binding lectin (MBL) is a soluble CLR, which contains an N-terminal cysteine-rich 
region and a C-type lectin domain that can bind mannose, fucose, and GlcNAc type of 
carbohydrates. The cysteine-rich domain forms disulfide bonds with other MBL peptides, creating 
a trimeric structure with 45 Å spacing between the CRDs.18 These subunits can multimerize further 
into a tetrameric complex, forming a bouquet-like structure with 12 CRDs per complex (See Figure 
1).19 The affinity of a single MBL protein is low, but when multimerized it can bind with high 
avidity to the neutral carbohydrates mentioned above.20 Pathogen recognition by MBL can initiate 
activation of the innate complement system via the lectin pathway.21 Additionally, binding of MBL 
enhances phagocytosis,22 thereby trafficking pathogens towards phagosomes, where it can lead to 
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the engagement of TLR2/TLR6, and MBL can thus act as a TLR co-receptor.23 Due to the 
complexity of the complement system, antigen targeting using MBL is hardly explored. However, 
it can help to target antigens toward germinal centers which could start an appropriate adaptive 
immune response.24 
MR 
The mannose receptor (MR, or CD206) is a C-type lectin receptor that is found on the surface of 
endothelial cells, macrophages, Langerhans cells (LCs) and (immature) DCs. The MR occurs both 
as a monomer and dimer, and both complexes can bind mannosides,25,26 but dimerization is 
required for the binding of larger particles such as HIV-1.27 The receptor consists of a short C-
terminal intracellular domain (type I CLR), a transmembrane domain linked to eight C-type 
carbohydrate recognition domains (CRDs), which can bind mannose, fucose, and N-acetyl 
glucosamine containing carbohydrates in a Ca2+ dependent manner.26,28 These are followed by a 
fibronectin type-II domain and a cysteine-rich domain on the N-terminus (see Figure 1). The 
cysteine-rich domain can bind sulfated carbohydrates in a Ca2+ independent manner,29,30 and the 
fibronectin domain can bind and endocytose collagen.31 Human MR has eight CRDs with only a 
small amount of homology between them and varying affinities towards mannose structures.32 
CRD-8 is the closest to the C-terminus and the transmembrane domain. Of all eight CRDs, only 
isolated CRD-4 is able to bind mannosides with a significant affinity, and it binds monosaccharides 
with similar specificity as the MBL.33 However, CRDs 4-8 are required to achieve the binding 
affinities of the natural MR, indicating that these also have a role to play in the binding of 
mannosides.25,28 Targeting antigens towards the MR can serve two functions: enhancing cell 
maturation and antigen presentation. Although the MR lacks an intracellular signaling motive, 
engagement of the receptor can induce cytokine production, although the pathway through which 
this occurs remains unknown29,34 and it has been speculated that other mannose-binding receptors 
are responsible for these signals.35 Colocalization of the MR and antigen suggest that they can be 
transported together toward early endosomes, which enables the cross-presentation of the 
antigen.36,37 Together, these findings make the MR an attractive target for cell-specific vaccine 
development, as described in previous reviews.38,39 However, it has proven to be challenging to 
study the binding affinity of this receptor in vivo because of the low expression levels of the MR 
on the cell surface. In addition,  the poor stability of the receptor, when overexpressed, complicates 
the determination of ligand affinity in vitro. The stability of the MR can be improved through small 
alterations in the receptor's amino acid sequence, but this often modifies the properties of the 
receptor.40  
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DC-SIGN 
Dendritic cell-specific intercellular adhesion molecule-3-grabbing non-integrin (DC-SIGN or 
CD209) is a C-type lectin present on dendritic cells and specific macrophage subsets.41 DC-SIGN 
is a type II CLR and bears multiple internalization motives and a signaling motive on its 
intracellular domain. The extracellular part of DC-SIGN contains a flexible neck region and a CRD 
that can both bind mannose, fucose, and GlcNAc-like structures. DC-SIGN multimerizes into 
tetrameric structures on the cell surface, improving the binding avidity to pathogens (see Figure 
1).42 In these tetrameric structures, the minimal distance between CRDs is 40 Å.43 Upon binding 
of these CRDs, the receptor can induce signaling and it has been shown that mannosylated 
antigens can activate Ras-1 signaling resulting in an inflammatory response.44 Binding the same 
CRD with fucosylated antigen, however, induces a different inflammatory response resulting in 
different T cell subsets. Thus, DC-SIGN can effectively skew the T cell response to stimulate TH1 
or TH17 cell (through mannoside activation) or induce a TH2 response (by binding of fucoses).44–
46 DC-SIGN is also a scavenging receptor that can rapidly internalize antigens upon binding.47–49 
These combined functions make DC-SIGN an attractive target for vaccine development.50,51 DC-
SIGN mediated endocytosis can traffic antigens towards different types of endosomes.52 For 
example, large structures such as HIV-1 are trafficked towards late endosomes/lysosomes 
resulting in MHC-II presentation,53 while smaller fragments can be trafficked towards early 
endosomes, thereby improving cross-presentation.54 
Langerin 
The skin is an attractive site for vaccinations since it contains large quantities of Langerhans cells 
(LCs), professional APCs which are a subset of DCs.55 LCs express the CLR Langerin (CD207),56 
which is a type II transmembrane protein with a CRD that has a preference for mannose, fucose, 
and GlcNAc, similar to DC-SIGN. Affinity studies with an array of carbohydrates suggest that 
langerin can also bind sulfated oligosaccharides.57,58 The receptor is expressed as a trimeric complex 
on the cell surface, binding multivalent carbohydrates (see Figure 1). Unlike DC-SIGN, scavenging 
by Langerin traffics antigens to Birbeck granules instead of endosomes. These Birbeck granules 
can degrade particles such as viruses, which allows LCs to act as a natural barrier against viral 
infections, for example, by HIV-1.59,60 These findings have sparked a large interest in the 
development of ligands that are either specific for Langerin or DC-SIGN.58,61 More information 
on vaccine strategies via Langerin is reviewed by Dam et al.51 and Stoitzner et al.62 
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Figure 1: Mannose-binding C-type Lectin Receptors.  
 
Schematic representation of mannose-binding C-type lectin receptors and the ligands that bind the different binding 
domains of the receptors.   
 
Targeting of mannose-binding CLRs 
Endocytosis by APCs via CLRs has gained much attention in the last decades, focusing on two 
distinct approaches. Ligands have been developed to block CLR-mediated endocytosis to prevent 
pathogens from hijacking the CLR internalization pathway for transfection. Alternatively, CLR-
binders have been developed to target specific cargo into APCs via the CLRs. Although both 
strategies serve opposite functions, the design principles underlying the development of ligands 
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designed for either purpose is of relevance for the other application as well. The design of 
endocytosis blocking ligands has resulted in a large number of glycomimics that can bind with high 
affinity and selectivity for one CLR over another.63–69 Besides improved affinity and selectivity, 
replacing native ligands with glycomimics can improve their stability against enzymatic 
degradation.70 For example, Bordoni et al.71 synthesized 2 and 3, carba-analogues of the α1,2-
dimannoside 1, which lack the endocyclic oxygen, as enzymatic stable ligands for DC-SIGN 
(Figure 2). Tamburrini et al.72 improved the stability of the α1,2-glycosidic bond in carba pseudo 
mannoside 4 by the introduction of a thioglycosidic bond, forming pseudo disaccharide 5 (Figure 
2). The affinity for CLRs can be further enhanced by the multivalent presentation of mannoside(-
mimic)s by clustering the ligands on different types of carriers. Viral infection can be stopped 
effectively using ligands with nM affinities based on carriers systems such as dendrimers,73,74 
molecular rods,75 gold nanoparticles (AuNPs),76,77 and polymers.43  
Figure 2: Stabilized pseudo mannosides. 
 
 
Exploiting CLRs to target antigens towards antigen-presenting cells 
The second approach to utilize CLR mediated endocytosis aims at the delivery of cargo towards 
APCs. One potential method to achieve this comprises the use of antibodies. Sehgal et al.78 have 
recently reviewed different strategies for DC vaccination, including anti-CLR antibody conjugates. 
Cruz et al.79 combined antigen-coated nanoparticles with anti-DC-SIGN antibodies and Breman 
et al.80 combined anti-MR antibodies with a peptide antigen to deliver the antigens to APCs. 
Although both approaches improved the uptake efficacy, the level of T cell reactivity was similar 
to unconjugated antigens, suggesting that antigen presentation was not improved.  
Carriers to deliver antigens. 
Targeting CLRs with mannosylated constructs is a popular method to deliver cargo to APCs. This 
targeting is often achieved with multivalent carriers that contain mannosides and a cargo of 
interest, such as an antigen, and this approach has been reviewed extensively.78,81,82 Carriers 
exploited for selective targeting are often similar to those used for blocking of viral entry. For 
example, Zhu et al.83 reported a mannosylated cationic lipid-hybrid polymersome, that combined 
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an ovalbumin antigen with two TLR agonists (Imiquimod and monophosphoryl lipid A) and 
induced strong activation and a synergistic antitumor immune response. Schulze and Wamhoff et 
al.61,84 selectively targeted antigens to LCs, using liposomes coated with Langerin specific 
glycomimic 6 or mannoses 7 (Figure 3). Liposomes with 6 could selectively deliver their content 
(e.g., fluorophore84 or Doxorubicin61) to Langerin+ cells when compared with the mannosylated 
liposomes which were also endocytosed by other CLRs. As a proof of concept, Frison et al.85 used 
an oligopeptide carrier with lysine repeats that were functionalized with carbohydrates to provide 
constructs such as 8 (See Figure 3). Incorporation of a fluorescein label allowed to track the uptake 
and routing of the conjugates via either the MR or DC-SIGN. Their results have shown that 
binding avidity increased with a higher number of mannosides (n=2 < n=3) and also that 
fucosylated constructs (Lewis A, Lewis B, or Lewis X) could be internalized by DC-SIGN, but not 
by the MR, demonstrating that these receptors can be discriminated using the appropriate glycans. 
Dong et al.86 grafted mannosides on carbon nanotubes (9) which could adsorb a model OVA 
antigen. These nanotubes were efficiently engulfed by DCs indicating that such nanotubes could 
be potent nanovectors for antigen delivery, which could lead to selective drug delivery applications. 
Shinchi et al.87 conjugated both mannosides and a TLR7 agonist to gold nanoparticles (10, Figure 
3), which improved the activity of the TLR7 ligand. Co-administration of these nanoparticles with 
OVA as a model epitope resulted in a more efficient presentation due to improved activation of 
the APC. Wilson et al.88 developed methacrylic acid co-polymers equipped with mannosides and a 
resiquimod analog as side groups, that were reversibly conjugated to an antigen (11, Figure 3). 
When both the mannoside and resiquimod were combined in a single polymer, the humoral 
response and the cellular immunity were improved. These results demonstrate that the 
introduction of ligands for both TLR7 and mannose-binding CLRs in one construct can improve 
the effectiveness of the immune response. Another mannosylated polymer carrier was synthesized 
by Jarvis et al.,54 who utilized a ring-opening polymerization approach to generate multiple 
functionalized polymers (12, Figure 3). Both soluble polymers and polymer aggregates were 
obtained, and the fate of antigen routing proved to be dependent on the physical properties of the 
carrier.89 These results showed that soluble antigen is routed toward early endosomes, ideal for 
antigen cross-presentation,52 while aggregates are directed to compartments that are more suitable 
for CD4+ presentation.90 This size-dependent routing is not only affected by the size of the carrier, 
but also by the type of CLR targeted. When Fehres et al.91 compared Lewis Y functionalized 
synthetic long peptides (SLPs) with liposomes, the routing fate and antigen presentation capacity 
proved to depend on the CLR responsible for the trafficking. The best antigen presentation via 
langerin was achieved with SLPs, and presentation via DC-SIGN using antigen-loaded liposomes. 
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Figure 3: Multivalent CLR targeting carriers. 
 
 
Although multivalent systems, such as those described above, have been successfully applied for 
improvement of antigen (cross-)presentation, the heterogeneous character of the carriers can result 
in incoherent effects. Therefore, much effort has been directed at the development of well-defined 
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single molecules such as synthetic long peptides and defined dendrimers. For example, based on 
the results obtained with 8, Srinivas et al.92 synthesized constructs such as 13 (Figure 4) in which 
four repeating lysines were functionalized with glycosyl residues and conjugated to a Melan-
A/Mart-1 melanoma epitope (Melan-A16-40). The antigen cross-presentation was enhanced by 
binding to MR or DC-SIGN. Similar  immunological results were obtained by Rauen et al.93 who 
generated mannosylated SLPs (14, Figure 4) comprising a lysine residue with two α-mannosides 
connected to either the MHC-I restricted OVA257-264, the MHC-II restricted OVA323-339, or the 
MHC-I restricted HPV E743-63 epitope. It was demonstrated that mannosylation94,95 of the synthetic 
long peptide enhanced cross-presentation but not MHC-II antigen presentation, indicating that 
the mannosides in this construct routes the antigen towards the early endosomes. Grandjeun et 
al.96 developed a synthetic approach to generate mannosylated dendrimers (15, Figure 4) to 
specifically target mannose-binding CLRs on DCs. Their dendrimers are based on branching 
lysines that were conjugated to an epitope via an N-terminal hydrazino-ligation. In an alternative 
approach, McIntosh et al.97 conjugated one or two complex Man9 structures to a synthetic peptide 
using an enzymatic glycosylation strategy to form native N glycan 16. The mannosylation improved 
binding to APCs, and the antigen was effectively presented as long as the epitope was not 
glycosylated. Glaffig et al.98 combined a MUC-1 epitope with both a mannose targeting moiety and 
a tetanus toxoid (TTox) as an helper T cell epitope via squarate conjugation (17, Figure 4). Mouse 
immunized with this construct exhibited stronger IgG antibody titers in comparison with a control 
construct that lacked the mannosides. 
The incorporation of additional adjuvants can further improve the effectiveness of mannosylated 
antigens.99 For example, Moyle et al.100 synthesized mannosylated conjugates 18 bearing an HPV 
E744-62 epitope and a lipid-core-peptide (LCP) adjuvant.101 The trifunctional conjugates were able 
to protect against TC-1 tumor cells. Sedaghat et al.102 synthesized similar constructs in which an 
OVA323-339 MHC-II epitope was combined with self-adjuvating lipids, a reporter group, and 
targeting mannosides (19, Figure 5). Both the lipids and mannosides in the constructs played a 
significant role in the receptor-mediated uptake.  
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Figure 4: Mannosylated antigen. 
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Figure 5: Mannosylated trifunctional conjugates. 
 
  
CHAPTER 1 
13 
Outline of this Thesis 
This Thesis presents studies on the targeting of mannosylated conjugates to C-type lectin receptors 
(CLRs) present on antigen presenting cells. Chapter 2 describes a systematic approach to 
determine the effect of both the number and type of mannosides on the affinity for the three 
mannoside binding transmembrane CLRs: the MR, DC-SIGN, and Langerin. The affinities of the 
clusters was determined using different in vitro techniques, including a new method that utilizes 
super-resolution microscopy. The established affinities directed the selection of the mannoside 
clusters to be used in follow-up studies in this Thesis. Chapter 3 describes improvements in the 
synthesis of a known Toll-like receptor (TLR) agonist which allows the use in solid-phase peptide 
synthesis. This agonist is combined with clusters selected from Chapter 2 to more effectively target 
the ligand to APCs. Combining the results of Chapters 2 and 3, Chapter 4 describes the synthesis 
of peptide conjugates in which the TLR agonist, the CLR targeting mannoside clusters, and a 
peptide antigen are incorporated. These peptides are evaluated for their ability to mature APCs 
and cross-present the antigen. Analogs of these conjugates in which amino acids, functionalized 
with an acid-stable C-mannoside is incorporated are the subject of Chapter 5. Both the synthesis 
of a C-mannosyl lysine building block and its use in the inline SPPS synthesis of peptides are 
described. The antigen-presenting capacities of these conjugates are assessed and compared to the 
O-mannose analogs. As an alternative to peptidic mannoside carriers, Chapter 6 describes the 
synthesis of glycosylated benzene tri-amides (BTAs) that can self-assemble into supramolecular 
fibers. Such systems could be considered in future work for a dynamic carrier for antigen and 
adjuvants. Finally, Chapter 7 summarizes all the findings in this Thesis and discusses future 
directions that could be taken to follow up on data generated in this Thesis.  
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Mannose-binding C-type lectin receptors (CLRs) have been studied extensively because of the role 
they play on immune cells in signaling and internalization of antigens.4–7 The mannose receptor 
(MR or CD206), DC-specific ICAM-3 grabbing non-integrin (DC-SIGN or CD209), and Langerin 
(CD207) have been successfully exploited for the (prevention of) uptake of antigens, via multiple 
strategies including the use of antibodies and ligands that can bind the receptor’s carbohydrate-
recognition domains (CRDs, see Chapter 1). Although all three receptors contain mannose-
binding CRDs, the structures of the receptors are quite distinct (see Chapter 1). Where DC-SIGN 
and Langerin both have only one CRD, the human MR has eight CRDs that can bind mannosides 
with differing affinities.8 The receptors are able to multimerize: DC-SIGN can form a tetramer,9 
while Langerin forms a trimeric structure.10 The MR occurs as either a monomer11 or as a dimer12 
in the presence of Ca2+. As a result of the multimerization of the receptor and the multiple CRDs, 
 
aPart of this work is published in Hogervorst & Li et al. 20191 
bPart of this work has been submitted by Hogervorst & Li et al. 20202  
cPart of this work is part of Riera Brillas et al. 20203, manuscript in preparation 
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the affinity for mannosides increases when mannosides are presented in a clustered manner with 
multiple mannosides in close proximity of each other. This so-called multivalent effect, in which 
the affinity increases more than the sum of affinities of the presented mannosides, is often 
exploited when targeting ligands to these CLRs. By incorporating readily available mono-
mannosides in dendrimers, nanoparticles, liposomes or viral particles, these mannosides are 
presented in a multivalent manner resulting in high-avidity binding.13–17 The binding affinity of a 
mono-mannoside however, is generally smaller than the affinity of more complex oligo-
mannosides.18 Targeting the CLRs with more complex larger oligomannosides with distinct stereo- 
and regio-isomers and intrinsic multivalency results in increased affinity.19,20 An often-utilized 
mannoside is the Man9 scaffold (Figure 1) that is known to bind DC-SIGN with high affinity. Both 
strategies have previously been used to deliver cargo to DCs to enhance uptake of constructs.21–25 
Utilizing more complex mannosides allows for a smaller scaffold and fewer number of mannoside 
copies. However, the synthesys of high mannose structures is time and labor-intensive and 
obtaining these structures in large quantities is challenging.26–29 
Due to the differences in the receptors, different preferences for mannosides in terms of their 
configuration and multivalent presentation is expected.30,31 However, studies that simultaneously 
study the effect of mannoside configuration and varying multivalent presentation in a defined 
manner are scarce,32 and often only determine binding affinity for one of the receptors. The goal 
of the present chapter is to study the effect of different mannoside configurations and the number 
of presented oligomannosides on binding affinity, in a defined and systematic approach. By 
dissecting the Man9-structure in smaller oligomannosides, five fragments were selected that each 
represents a part of the main structure. The selected fragments are the mono-, α1,2-di-, α1,3-di-, 
α1,6-di- and α1,3-α1,6-tri-mannoside, coded as A-E (See Figure 1). By the use of a scaffold that 
allowed the incorporation of 1, 2, 3, or 6 copies of these mannoside fragments, an array of 
constructs was obtained that can be used to systematically study the effect of multivalency and 
configuration on the affinity for each of the three CLRs. 
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Figure 1. Man9 “high mannose” N-glycan structure. 
 
Mono-, di- and tri-mannosides used in this chapter are based on the substructures in the “high mannose” N-glycan above. 
 
Results and Discussion 
The assembly of the mannoside array hinges on the Cu(I) catalyzed azide-alkyne cycloaddition 
(CuAAC) of propargyl mannosides with azide functionalized peptide scaffolds. The synthesis of 
the scaffolds was achieved via solid-phase peptide synthesis (SPPS) and resulted in five different 
backbones with 1, 2, 3, or 6 azides, forming scaffolds 20-24 (Scheme 1). 
Scheme 1: Synthesis of backbone.  
 
Reagents and conditions: HCTU, DIPEA, DMF (20: 81%; 21: 50%; 22: 44%; 23: 44%; 24: 30%). 
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The design of the scaffolds 20-24 is based on the following considerations. To match the length 
of the largest, hexavalent scaffold 23 with the trivalent backbone 22, glycine residues were 
incorporated in the latter scaffold to separate the azidolysines. Similarly, the azidolysines in the 
divalent scaffold 21 were also separated by glycine residues. In divalent scaffold 24, the same 
spacing in terms of the number of atoms between the outermost azides, as in hexavalent scaffold 
23, was introduced. This spacing was achieved with a glycine and a tri-ethylene glycol moiety, to 
ensure water solubility while maintaining similar spacing. All scaffolds contained a lysine at the C-
terminus for further functionalization. SPPS of the scaffolds started with the coupling of Fmoc-
Lys(Boc)-OH as the first amino acid on Tentagel® S-RAM amide resin followed by elongation 
using standard Fmoc protocol with HCTU as condensating agent. After completion of the 
oligopeptides, the scaffolds were deprotected and cleaved from resin under acidic conditions 
followed by purification via RP-HPLC resulting in peptides: 20 (in 81% yield, 93% per step); 21: 
(in 50% yield, 87% per step); 22: (in 44% yield, 89% per step); 23: (in 44% yield, 90% per step) 
and 24: (in 30% yield, 82% per step).a 
With the azidopeptide scaffolds 20-24 in hand, propargyl mannosides 25-29, galactose 30 and sulfo 
GalNAc 31 were prepared using reported procedures (Scheme 2).1,3,33–35 These propargyl glycosides 
were selected based on their ability to bind the CLRs of interest. They can either bind all three 
CLRs (mannosides 25-29), none of the three receptors (galactose 30, to be used as a negative 
control) or only the MR via its cysteine-rich domain (sulfo GalNAc 31). Series A-E are derived 
from the N-glycan high mannose structure Man9 (see Figure 1). The A series combines the azido 
peptides with propargyl α-ᴅ-mannose (25);33 the B series uses propargyl α1,2-di-α-ᴅ-mannosides 
(26);1 representing the mono- and di-saccharides found at the end of the Man9-antennas; the C 
series uses propargyl α1,3-di-α-ᴅ-mannosides (27);1 the D series uses propargyl α1,6-di-α-ᴅ-
mannosides (28);1 the E series employs propargyl α1,3-α1,6-tri-α-ᴅ-mannosides (29),34 representing 
the di- and tri-saccharides found in the core motive. The G series uses propargyl β-ᴅ-galactoside 
(30);35 and the S series uses a propargyl 4-sulfo-β-ᴅ-N-acetyl-galactosamine (31).3 
The assembly of the array was achieved by conjugation of the propargyl glycosides 25-29 and azido 
peptides 20-24 by CuAAC (Scheme 2). Many aqueous CuAAC conjugations have been described 
in literature,36 but many of these require the use of significant amounts of copper.37–39 Although 
the use of a large amount of copper catalyst did provide fast and high yielding conjugation 
reactions, the purification and especially the removal of copper, proved to be troublesome. An 
 
a Whether the low conversion for 24 is caused by the lower temperature during the coupling or whether the product 
is lost during workup and/or purification was not determined. 
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earlier described method to remove copper with Cuprisorb™,40 gave variable results. Attempts to 
circumvent these issues by reducing the amount of copper resulted in varying yields. Major 
improvements in the conjugation were achieved by i) lowering the amount of copper in 
combination with the addition of tris(3-hydroxypropyltriazolylmethyl)amine (THPTA) to stabilize 
the Cu(I) species;36 ii) reducing the concentration of dissolved oxygen in the reaction mixture by 
purging solvents with argon; iii) increasing the temperature of the reaction; iv) addition of N,N-
diisopropylethylamine (DIPEA); and v) reduction of Cu(II) with a smaller amount of sodium 
ascorbate to prevent over-reduction of Cu cations to metallic copper. The remaining copper was 
scavenged using Quadrasil® AP resin, and the 27 prepared clusters 32-58 were purified by either 
HPLC or gel filtration. 
 
All the conjugation reactions leading to the clusters 32-58 required separation of unreacted 
glycosides from the desired products, for which size exclusion gel filtration and RP-HPLC were 
explored. Due to the hydrophilic character of both the products and unreacted propargyl 
glycosides only minimal differences in retention times were observed using either C18 or C30 RP-
HPLC columns. To prevent co-elution, only small injection volumes were tolerated, making 
purification by RP-HPLC very solvent and time-demanding. In addition, the constructs showed 
little UV absorption and tended to fragment during electron spray ionization (ESI), leading to 
relatively high loss of product during HPLC purification when relying on these monitoring 
techniques. On the other hand, the use of an HW40S size exclusion column provided a large 
difference in retention time between the clusters and the monomers, allowing for single run 
purifications. Unlike the HPLC, the gel filtration setup allowed for fraction monitoring by 
refractive index (RI) and the synthesized clusters displayed a strong RI signal. This high sensitivity 
allowed for high recovery during fraction collection. Altogether, the larger difference in elution 
time, the single run purifications, and the smaller losses because of the more sensitive monitoring, 
made gel filtration the method of choice for purification of these clusters. In total 27 clusters (32-
58) were obtained that varied in the type of glycosides and varied in number of presented 
glycosides (Scheme 2). All 27 clusters contain an unfunctionalized C-terminal lysine for further 
conjugation purposes.  
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Scheme 2: Synthesis of library. 
 
Reagents and conditions: a) starting from ᴅ-mannose 33; b) starting from 25 1; c) starting from 25 34; d) starting from ᴅ-galactose 35; e) 
starting from ᴅ-galactose 3; f) CuI, THPTA, DIPEA, DMSO, H2O (32: 39%; 33: 68%; 34: 99%; 35: 85%; 36: 99%; 37: 57%; 
38: 61%; 39: 41%; 40: 14%; 41: 28%; 42: 43%; 43: 53%; 44: 30%; 45: 69%; 46: 80%; 47: 82%; 48: 85%; 49: 80%; 50: 
82%; 51: 98%; 52: 99%; 53: 57%; 54: 85%; 55: 88%; 56: 83%; 57: 99%; 58: 17%); g) BiotinO-NHS, DIPEA, DMSO (59: 
99%; 60: 16%; 61: 17%; 62: 50%; 63: 14%; 64: 19%; 65: 49%; 66: 99%; 67: 76%; 68: 49%; 69: 63%; 70: 33%; 71: 96%; 
72: 90%; 73: 51%; 74: 59%; 75: 62%; 76: 62%; 77: 56%; 78: 85%); g) ATTO655-NHS, DIPEA, DMSO (79: 88%; 80: 
84%; 81: 45%; 82: 95%; 83: 100%; 84: 6%; 85: 62%; 86: 34%; 87: 81%; 88: 89%; 89: 43%; 90: 26%; 91: 11%); h) 
AlexaFluor488-NHS, DIPEA, DMSO (92: 46%; 93: 34%; 94: 6%); i) ATTO565-NHS, DIPEA, DMSO (95: 43%; 96: 
43%; 97: 17%). 
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Table 1: SPR results. 
 DC-SIGN Langerin 
Cluster Kd app (µM) IC50 (µM) Kd app (µM) IC50 (µM) 
1A = 32  N.D.  N.D 
2A = 38  2605±95  2424±30 
3A = 45  736.7±3.4 43  
6A = 50 7.8±0.4  3.4±1.4  
1B = 33  2343±109  4138±773 
2B = 39  189.3±3.4  181±4 
3B = 46 19.5±0.5  48  
6B = 51 0.95±0.04  3.2±1.7  
1C = 34  N.D  N.D. 
2C = 40  567.5±1.2  1415±13 
3C = 47  172.0±1.5  281±14 
6C = 52 1.17±0.25  3.9±1.5  
1D = 35  6961.5±3038.5  N.D. 
2D = 41  410.9±0.3 16  
3D = 48 48.7±2.6  9.8  
6D = 53 6.6±1.2  12.3±0.7  
1E = 36  1518.5±250.5  N.D. 
2E = 42  305.6±4.8 278  
3E = 49 2.44±0.04  4.2  
6E = 54 2.78±0.02  6.5±2.7  
1G = 37  N.D.  N.D. 
2G = 43  N.D.  N.D. 
 
Surface plasmon resonance (SPR) analysis of clusters for ECD DC-SIGN and ECD Langerin. Direct interaction experiments resulted 
in an apparent Kd, and competition experiments resulted in an IC50. N.D. = Not Determined because binding affinity was too low to 
assess a reliable IC50. 
 
The majority of the constructs were tested for their affinity for DC-SIGN and Langerin via Surface 
plasmon resonance (SPR) assays (Table 1).41 The apparent Kd was calculated in direct interaction 
mode using a surface functionalized with the DC-SIGN extracellular domains (ECDs) in an 
oriented manner. In this assay, the tetrameric DC-SIGN ECD was attached to the surface of the 
sensor chip via the N-terminus of its neck oligomerization domain, thus presenting its four 
carbohydrate recognition domains towards the solvent, realistically mimicking the presentation of 
the receptor on the cell surface.42 For some of the low-affinity ligands, binding in the mM range, 
it was not possible to determine their affinity with this assay, and therefore a competition 
experiment was performed providing IC50 values.43 When the galactose clusters 37 and 43 were 
tested, their affinity was too low to be determined, thereby excluding a-specific binding interactions 
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of the scaffold. When comparing equivalent clusters, the α1,2-di-mannoside (B series) bound with 
the highest affinity. The hexavalent presentation (n=6) of the oligomannosides led to micromolar 
affinity of these clusters for DC-SIGN. 51 showed the highest affinity in the library with an 
apparent Kd of 0.95 µM, followed by the α1,3-dimannoside cluster 52 (1.17 µM), the trimannoside 
clusters 49 (2.44 µM) and 54 (2.78 µM). Interestingly, the affinity of the trisaccharide series (E 
series) did not improve from the tri- to the hexavalent representation (49 versus 54). A potential 
explanation for this effect could be that the spacing of clusters is more important for the larger tri-
mannosides. For the monovalent mannosides 32 and 34, a reliable IC50 could not be determined 
in this setup, indicating that their binding affinity for DC-SIGN is too weak to establish a reliable 
measurement. For Langerin the results were very similar to DC-SIGN with avidity improving with 
an increasing amount of mannoside copies, although the effect of the mannoside configuration 
appeared to be less prominent (Table 1). 
To enable visualization of the clusters in cellular experiments, a biotin handle was introduced that 
could be identified using fluorescent streptavidin antibodies. Treatment of mannoside clusters 32-
54 with biotin-N-hydroxysuccinimide (NHS) ester gave biotinylated mannoside clusters 59-78 (R 
= R2, Scheme 2). Because of the large differences in polarity between the products and starting 
compounds, and the small scale of the biotinylation, RP-HPLC proved to be the most efficient 
purification method for the biotinylated clusters. The twenty biotinylated mannoside clusters (59-
78) were next tested for their affinity for and uptake by CLRs on monocyte derived DCs (moDCs). 
When the biotinylated clusters were assessed for their binding to cellular DC-SIGN, similar trends 
as revealed by the SPR experiments were observed. In the used assay, clusters 59-78 were allowed 
to bind to moDCs for 30 minutes at 4°C. After washing of the cells at 4°C, the number of attached 
clusters were quantified by staining with a fluorescent streptavidin and quantification by flow 
cytometry (Figure 2, top). The α1,2-mannosides (B series) showed enhanced binding in 
comparison to the mono-mannoside and the α1,6- or α1,3-dimannosides, in line with the SPR data 
and earlier results.44 When increasing the number of mannosides from 3 to 6 for the tri-mannoside 
(73 to 78) and the α1,6-dimannoside (72 to 77), the affinity did not increase, again illustrating the 
potential influence of the spacing in the used scaffold. Similar experiments were performed with a 
transfected B-cell line expressing Langerin (EBV Langerin+). Again, the results were in line with 
the affinities obtained via SPR, showing a strong effect of the number of mannoside copies. The 
type of mannoside appeared to have relatively little influence on binding in this assay, although the 
highest affinities were observed for the α1,6-di and tri-mannoside clusters. (Figure 2, bottom) 
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Figure 2: Affinity towards DC-SIGN (top) or Langerin (bottom) via FACS. 
 
Binding of the biotinylated mannoside library to DC-SIGN on moDCs (top) or to Langerin on EBV cells (bottom) was measured by 
flow cytometry. Normalized to the negative control. MoDCs were incubated with biotinylated constructs (30 min, 4 °C, 10 µM). (-) = 
negative control (PBS); (+) = positive control (1 µg/mL of Lewis Y conjugated polyacrylamide); Serie A in gray; B in blue; C in red; D 
in green; and E in orange. 
Figure 3: Internalization of cluster by moDCs (DC-SIGN) via FACS. 
 
The internalization of the mannoside clusters by moDCs was measured by flow cytometry. One donor is depicted here as representation of 
four. Cells were incubated with clusters (20 µM on ice for one hour and after incubated at 37 °C for different time spans). Quantification 
with an external fluorophore allowed quantification of the remaining clusters on the cell surface as an indirect measure of uptake. clusters 
75, 76 & 77 are rapidly internalized, while 78 remains longer at the surface. 
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Active internalization can take place when the cells are allowed to warm up, leading to the 
diminished presence of the ligand on the surface of the cells. Quantifying the amount of 
biotinylated clusters on the cell surface as a function of time can then provide an indication for 
the rate of uptake over time (Figure 3). Using this assay, the rate of uptake for clusters 75-78 was 
determined to show a difference with respect to the affinity for DC-SIGN. The di-mannosides 75-
77 were internalized relatively fast, while the tri-mannoside 78 remained longer on the cell surface. 
Although the DC-SIGN mediated uptake mechanism is known,45 the initiation trigger for 
endocytosis upon DC-SIGN-ligand binding remains unclear. Recognition of the di-mannoside 
clusters could lead to different signaling and a difference in the rate of uptake. Experiments to 
determine the affinity on cellular langerin are still ongoing.  
Although affinity for, and uptake via the MR of mannose ligands has been the subject of many 
studies, stable expression of functional MR remains challenging. The receptor can be stabilized 
through small alterations in its amino acid sequence, but this often modifies the properties of the 
receptor.46 In an attempt to study the kinetics of the MR in a more natural setting, the kinetics of 
the natural cellular receptor was studied with stochastic optical reconstruction microscopy 
(STORM). A selection of conjugates was functionalized with a laser dye using their activated N-
hydroxysuccinimide (NHS) esters to generate the clusters within minutes with high conversion 
(Scheme 2). Besides the default ATTO655 dye (R = R3), AlexaFluor488 (R = R4) and ATTO565 
(R = R5) were appended on the clusters, to allow for co-localization and Förster resonance energy 
transfer (FRET) experiments. For optimal results, the clusters containing the sulfate-carrying 
glycans 44, 55, 58 were converted from the ammonium salts, obtained after their purification using 
aqueous NH4HCO3, into the corresponding sodium salts using a Na+-exchange resin. The clusters 
decorated with the ATTO655 or ATTO565 laser dyes allow for tracking of single molecules 
binding to the mannose receptor (also see Chapter 5).  
In this STORM experiment, only clusters that remain at the same location for a certain time will 
be observed. Since unbound clusters move to fast due to diffusion, only clusters that are fixed will 
be observed. This can be either in cellular compartments or bound to receptors. When Chinese 
hamster ovary (CHO) cells transfected with the MR were subjected to cluster 81, the clusters 
localized on the cell surface (see Figure 4, right panel). When the same experiments were 
performed with CHO cells that lack the MR, the clusters did not localize, indicating that this 
localization is MR dependent (Figure 4, left panel). When these MR+ CHO cells were subjected to 
a selection of ATTO655 clusters, cellular localization of fluorophores showed a trend with more 
signal for the hexavalent clusters, indicating that larger clusters are trafficked more readily into the 
CHO cells (see Figure 5). Additionally, by following individual fluorescent events, an average 
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binding time can be determined, which correlates with the affinity of the cluster for the receptor 
(Figure 6). This binding time was determined for a selection of clusters and demonstrated that 
affinity increases from mono- to di- to tri-mannoside. When comparing clusters bearing the 
monomannoside (79, 81, 89, and 85), affinity is similar for the clusters bearing one or two 
mannoside copies, and only increases for the hexavalent clusters 85. One potential explanation for 
the increase in affinity could be that the distance between the two outermost mannosides in the 
hexavalent cluster is long enough to bind two CRDs simultaneously. However, since bi-valent 
cluster 89 was designed to match the spacer length with that of hexavalent cluster 85, and these 
do not match in affinity, this hypothesis seems unlikely. For the trisaccharide series (80, 83, 90, 
and 87) similar trends were observed. The α12-dimannoside cluster 82 shows an affinity between 
the mono- and tri-mannoside analogs. Finally, clusters bearing the sulfo GalNAc were tested (84, 
91, and 88). These clusters are designed to bind the cysteine-rich domain, of which unlike CRDs, 
only one is present per receptor. Strikingly, no change in affinity was observed when the number 
of sulfo GalNAc copies were increased. This observation, in combination with the fact that 
increasing the spacing between two mannoside copies did not increase the affinity, could indicate 
that the multivalent effect observed for the mannoside clusters is due to the presence of multiple 
CRDs in one receptor and not due to binding multiple receptors simultaneously.  
Figure 4: comparison between CHO and MR transfected CHO cells using 81. 
 
CHO-K1 (left) and CHO-MR (right) cells were incubated with 81 (5 nM, at 4 °C), in this experiment the focus area is photo-bleach, 
followed by a short restoration time in which new ATTO-655 clusters can bind the receptors present on the cell surface. Area imaged with 
a 640 nm laser (40 mW). 
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Figure 5: Density map using STORM microscopy.  
 
CHO-MR cells were incubated with ATTO655 functionalized mannoside clusters (5 nM) and imaged with a 640 nm laser (40 mW) 
Clusters with high affinity are endocytosed faster compared with lower affinity clusters, resulting in higher density of clusters within the cells. 
Figure 6: binding time (τ) from combined trajectories (± SE) determined by STORM. 
 
Incubation of CHO-MR cells with ATTO655 functionalized mannoside clusters at 37°C allowed for singe particle tracking. Trajectory 
lengths from at least 5 images per probes were combined, plotted in a histogram and fitted with a single exponential decay function wherefrom 
τ was determined. Serie A in gray; B in blue; E in orange; and S in purple. 
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Conclusion 
This chapter has described the synthesis of a systematic library of clusters, consisting of defined 
mannosides (mono-, di- and tri-mannosides) that are presented in an increasing number (n=1, 2, 
3, or 6) on a well-defined oligopeptide scaffold, which allowed the simultaneous studying of the 
effect of mannoside configuration and multivalency on the binding affinity for DC-SIGN, 
langerin, and the MR. The reaction conditions to conjugate the azidopeptides with the propargyl 
mannosides and the purification procedures were optimized to allow for the effective assembly of 
the sizable library of clusters. Further decoration of the constructs via the C-terminal lysine with 
either a biotin affinity tag or fluorescent dyes was successful and enabled the use of the conjugates 
in FACS and STORM experiments. The highest affinity for DC-SIGN can be obtained by the 
highest number of copies and the α1,2-dimannoside (B series). The type of mannoside appeared 
to have relatively little influence on the affinity for Langerin, and the highest affinity is mainly 
obtained by the highest number of copies. The introduction of laser dyes allowed for the MR to 
be studied in a more natural setting. These results indicate that the binding affinity for either one 
or two mannoside copies does not differ significantly, however affinity increases when six copies 
are presented. This increase is most likely not caused by the simultaneous binding of the outermost 
mannosides since bivalent clusters with similar spacing do not display this increment in affinity. 
Clusters that target the cysteine-rich domain show no multivalent effect, which would indicate that 
the multivalent effect observed for the mannoside clusters is not due to the simultaneous binding 
of two receptors. 
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Experimental 
General procedures: 
Reactions: All reactions were carried out in oven-dried glassware (85 °C). Prior to reactions traces 
of water and solvents were removed by co-evaporation with toluene where appropriate. Reactions 
sensitive to oxygen or moisture were carried out under an atmosphere of nitrogen. Solvents for 
reactions were of reagent grade and when anhydrous conditions were required, were stored over 
4Å molecular sieves (3Å for CH2Cl2, MeOH & HFIP) Et3N was dried over KOH pellets; and 
pyridine and DMF were used without molecular sieves. Solvents used for workup and column 
chromatography were of technical grade and used as received. Unless stated otherwise, solvents 
were removed by rotary evaporation under reduced pressure at 40 °C. All other chemicals (Sigma-
Aldrich, TCI, Carbosynth, Iris-Biotech, Merck, Boom, Honeywell & Biosolve) were used as 
received. The solid-phase peptide synthesis was performed on a TRIBUTE® Peptide Synthesizer 
(Gyros Protein Technologies AB, Arizona, USA) applying Fmoc based protocol. 
Purification: Silica gel column chromatography was performed on Screening Devices silica gel 60 
(0.004 - 0.063 mm). Gel filtrations were performed with an ÄKTA™explorer (GE Healthcare, 
Illinois, USA) using either a 1.6 x 60 cm, or 2.6 x 60 cm column with Toyopearl HW-40S resin 
eluting with a solution of NH4HCO3 (150 mM) or NH4OAc (150 mM) in MilliQ with 0 – 20% 
ACN. Fraction monitoring was performed using refractive index and with UV absorption at 260 
nm unless stated otherwise. Preparative high-pressure liquid chromatography was conducted on 
either a Gilson GX281 with an automatic fraction collector, Waters auto purifier prep LCMS 
coupled to a Waters SQ detector, or an Agilent1200 semi-prep system coupled to an Agilent 6120 
quadruple detector. Columns used are either: Gemini-NX 5µm C18, 110 Å, 250 x 10.0 mm, 5 
mL/min or Develosil RPAQUEOUS 10.0 x 250 mm, 5 mL/min in combination with eluents A: 
0.1% TFA in MilliQ in B: ACN. 
Analysis: Reaction progress was monitored using LC-MS analysis or TLC-analysis. TLC-analysis 
was performed on Merck 25 DC plastikfolien 60 F254. Visualization was carried out by irradiation 
with UV light (λ: 254 nm, 360 nm), followed by spraying with either 20% H2SO4 in EtOH (w/v); 
(NH4)6Mo7O24·4H2O (25 g/L) and (NH4)4Ce(SO4)4·2H2O (10 g/L) in 10% H2SO4 (aq.); ninhydrin 
(3 g/L) in EtOH/AcOH (20/1, v/v); or by dipping in anisaldehyde/H2SO4/EtOH (1/1/18, 
v/v/v); followed by charring >150 °C. LC-MS analysis was performed on one of the following 
LC-MS systems: A Thermo Finnigan LCQ Advantage MAX ion-trap mass spectrometer with an 
electrospray ion source coupled to Surveyor HPLC system (Thermo Finnegan), A Thermo 
Finnigan LCQ Fleet MAX ion-trap mass spectrometer with an electrospray ion source coupled to 
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Vanquish UHPLC system (Thermo Finnegan) or an Agilent Technologies 1260 Infinity LC system 
(detection simultaneously at 214 and 254 nm) coupled to a Agilent Technologies 6120 Quadrupole 
MS. Using an analytical Gemini C18 column (Phenomex, 50 x 4.60 mm, 3 microns) in combination 
with eluents A: H2O; B: ACN and C: 1% TFA (aq.) as the solvent system, in which the gradient 
was modified by changing the ratio of A in B in combination with 10% C. 1H and 13C NMR spectra 
were recorded on a 300/75, 400/100, or a 500/125 MHz spectrometer. Chemical shifts (δ) are 
given in ppm relative to tetramethylsilane as an internal standard. Coupling constants are given in 
Hz. All individual signals were assigned using 2D-NMR spectroscopy, HH-COSY, and HSQC. 
Optical rotations were measured on an Anton Paar Modular Circular Polarimeter MCP 100/150. 
IR spectra are reported in cm-1, and recorded on a Shimadzu FTIR-8300 or a PerkinElmer 
universal attenuated total reflectance (UATR; Single Reflection Diamond) Spectrum Two 
instrument. High resolution mass spectra were recorded either by direct injection (2 µL of a 2 µM 
solution in water/acetonitrile 50/50 (v/v) and 0.1% formic acid) on a Thermo Finnigan LTQ 
Orbitrap equipped with an electrospray ion source in positive mode (source voltage 3.5 kV, sheath 
gas flow 10, capillary temperature 250°C) with resolution R = 60,000 at m/z 400 (mass range m/z 
= 150-2,000) and dioctylphthalate (m/z = 391.2843) as a “lock mass”. Or were measured by direct 
injection (2 µL of a 1 µM solution in water/acetonitrile 50/50 (v/v) and 0.1% formic acid) using 
an ultimate 3000 UHPLC on a Thermo Finnigan Q executive HF Orbitrap equipped with an 
electrospray ion source in positive mode (source voltage 3.5 kV, sheath gas flow 10, capillary 
temperature 250°C) with resolution R = 240,000 at m/z 400 (mass range m/z = 150-3,000) with 
external lock and calibration. The high-resolution mass spectrometers were calibrated prior to 
measurements when δ > 1 ppm with a calibration mixture (Thermo Finnigan). 
 
General procedure for automated solid-phase synthesis: 
The solid-phase peptide synthesis was performed on a TRIBUTE® Peptide Synthesiser (Gyros Protein 
Technologies AB, Arizona, USA) applying Fmoc based protocol starting with Tentagel® S-RAM resin 
(~0.22 mmol/g) on a 100 µmol scale using established synthetic protocols.47 The consecutive steps 
performed in each cycle were: 
1) DMF wash (1x) followed by nitrogen purge; 2) Deprotection of the Fmoc-group with 20% piperidine in 
DMF (4 mL)(3 x 5 min); 3) DMF wash (3x) followed by nitrogen purge; 4) Coupling of the appropriate 
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amino acida in five-fold excess (unless stated otherwise);b 5) DMF wash (3x) followed by nitrogen purge; 6) 
capping with an Ac2O/DMF/DIPEA solution (4mL, 20/88/2, v/v/v) for 2 min; 7) DMF wash (2x). 
After the complete sequence capping was achieved by utilization of steps 1,2, 3, and 6 followed by washing 
with DMF (3x), DCM (3x), Et2O (2x), and nitrogen purge. 
Ac-Lys(N3)-Gly-Lys-NH2 (20). 
Ac-Lys(N3)-Gly-Lys(Boc)-Tentagel® S-RAM was transferred to a flask and treated for 
90 minutes with a cleavage cocktail (10 mL, TFA/TIS/H2O, 190/5/5, v/v/v). the 
resin was filtered off and washed with neat TFA (3 x 1 mL). The filtrate was 
concentrated, co-evaporated with toluene (2x). Purification via RP-HPLC (linear-gradient 5-30% B, 10 min) 
yielded title compound 20 as an clear oil after lyophilization (32.2 mg, 80.9 µmol, 81%). LC-MS: Rt = 2.79 
min (0 - 90% ACN; 13 min); 1H NMR (500 MHz, DMSO) δ 8.27 (t, J = 5.8 Hz, 1H, NH (G)), 8.14 (d, J = 
7.2 Hz, 1H, NH (K)), 7.77 (d, J = 8.2 Hz, 1H, NH (K)), 7.68 (s, 2H, CH2NH2), 7.29 (s, 1H, (CO)NHH), 
7.08 (s, 1H, (CO)NHH), 4.18 - 4.10 (m, 2H, CH), 3.75 (dd, J = 16.6, 6.0 Hz, 1H, CHH (G)), 3.66 (dd, J = 
16.6, 5.6 Hz, 1H, CHH (G)), 3.31 (td, J = 6.8, 1.2 Hz, 2H, CH2-N3), 2.74 (p, J = 6.5 Hz, 2H, CH2-NH2), 
1.85 (s, 3H, Ac), 1.75 - 1.61 (m, 2H, CH2), 1.51 (td, J = 12.1, 10.9, 4.7 Hz, 6H, CH2), 1.42 - 1.21 (m, 4H, 
CH2); 13C NMR (126 MHz, DMSO) δ 173.5, 172.4, 169.8, 168.7 (C=O), 52.9, 52.1 (CH), 50.5 (CH2-N3), 
42.2 (CH2 (G)), 38.7 (CH2-NH2), 31.3, 31.0, 27.9, 26.6, 22.6 (CH2), 22.5 (Ac), 22.2 (CH2); HRMS 
[C16H30N8O4 + H]+: 399.2475 found , 399.2463 calculated. 
Ac-Lys(N3)-Gly-Lys(N3)-Gly-Lys-NH2 (21).  
Ac-Lys(N3)-Gly-Lys(N3)-Gly-Lys(Boc)-Tentagel® S-RAM was transferred to a flask 
and treated for 90 minutes with a cleavage cocktail (10 mL, TFA/TIS/H2O, 190/5/5, 
v/v/v). The mixture was concentrated to approximately one mL after which the resin 
was filtered off into a cold mixture of diethylether/pentane (45 mL, 5/4, v/v) and the resin was washed off 
with neat TFA (3 x 1 mL) into the ether solution. This solution was centrifuged (10 minutes, 5000 rpm) 
after which the supernatant was removed and the precipitate was dried under nitrogen flow. Purification 
via RP-HPLC (linear-gradient 10-40% B, 10 min) yielded title compound 21 as a white powder after 
lyophilization (30.47 mg, 49.9 µmol, 49.9%). LC-MS: Rt = 4.21 min (0 - 90% ACN; 13 min); 1H NMR (500 
MHz, DMSO) δ 8.25 (dt, J = 17.2, 5.5 Hz, 2H, NH (G)), 8.13 (d, J = 7.1 Hz, 1H, NH (K)), 7.90 (d, J = 7.6 
Hz, 1H, NH (K)), 7.82 - 7.69 (m, 3H, NH (K), CH2NH2), 7.32 (s, 1H, (CO)NHH), 7.05 (s, 1H, (CO)NHH), 
4.28 - 4.06 (m, 3H, CH), 3.79 - 3.64 (m, 4H, CH2 (G)), 3.29 (q, J = 6.8 Hz, 4H, CH2-N3), 2.75 (q, J = 6.3 
Hz, 2H, CH2NH2), 1.85 (s, 3H, Ac), 1.75 - 1.44 (m, 12H, CH2), 1.42 - 1.20 (m, 6H, CH2); 13C NMR (126 
 
a The Fmoc amino acids applied in this synthesis were: Fmoc-Lys(Boc)-OH, Fmoc-Gly-OH, Fmoc-AEEA-OH 
(Carbosynth) and Fmoc-Lys(N3)-OH (4eq per coupling, IRIS biotech). 
 
b Generally, the Fmoc amino acid was dissolved in a HCTU solution in DMF (2.50 mL ,0.20 M, 0.5 mmol, 5 eq) This 
solution was transferred to the reaction vessel followed by a DIPEA solution in DMF (2.00 mL, 0.50 M, 1.0 mmol, 
10 eq) to initiate the coupling. Next, the reaction vessel was shaken for 60 min at room temperature. 
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MHz, DMSO) δ 173.5, 172.3, 172.0, 169.8, 169.1, 168.6 (C=O), 52.9, 52.6, 52.1 (CH), 50.5 (CH2-N3), 42.2, 
42.1 (CH2 (G)), 38.7 (CH2-NH2), 31.3, 31.2, 31.2, 31.1, 27.9, 27.9, 26.6, 22.6, 22.5 (CH2), 22.5 (Ac), 22.3 
(CH2); HRMS [C24H43N13O6 + H]+: 610.3539 found , 610.3532 calculated. 
Ac-Lys(N3)-Gly-Lys(N3)-Gly-Lys(N3)-Gly-Lys-NH2 (22).  
Ac-Lys(N3)-Gly-Lys(N3)-Gly-Lys(N3)-Gly-Lys(Boc)-Tentagel® S-RAM was 
transferred to a flask and treated for 90 minutes with a cleavage cocktail (10 mL, 
TFA/TIS/H2O, 190/5/5, v/v/v). The resin was filtered off into a cold mixture of 
diethylether/pentane (45 mL, 5/4, v/v) and the resin was washed off with neat TFA (3 x 1 mL) into the 
ether solution. This solution was centrifuged (10 minutes, 5000 rpm) after which the supernatant was 
removed and the precipitate was dried under nitrogen flow. Purification via RP-HPLC (linear-gradient 16-
38% B, 10 min) yielded title compound 22 as a white powder after lyophilization (36.01 mg, 43.9 µmol, 
43.9% (89% per step)). LC-MS: Rt = 4.80 min (0 - 90% ACN; 13 min); 1H NMR (400 MHz, DMSO) δ 8.33 
- 8.20 (m, 3H, NH (G)), 8.14 (d, J = 7.3 Hz, 1H, NH (K)), 7.97 (d, J = 7.7 Hz, 1H, NH (K)), 7.90 (d, J = 
7.8 Hz, 1H, NH (K)), 7.85 (d, J = 8.2 Hz, 1H, NH (K)), 7.70 (s, 2H, CH2NH2), 7.36 (s, 1H, (CO)NHH), 
7.09 (s, 1H, (CO)NHH), 4.33 - 4.09 (m, 4H, CH), 3.87 - 3.63 (m, 6H, CH2 (G)), 3.31 (tt, J = 6.9, 2.8 Hz, 
6H, CH2N3), 2.76 (t, J = 7.2 Hz, 2H, CH2NH2), 1.86 (s, 3H, Ac), 1.76 - 1.20 (m, 24H, CH2); 13C NMR (101 
MHz, DMSO) δ 173.9, 172.7, 172.4, 172.3, 170.2, 169.4, 169.3, 169.0 (C=O), 53.2, 52.9, 52.5 (CH), 51.0 
(CH2N3), 42.5 (CH2 (G)), 39.2 (CH2NH2), 31.7, 28.4, 28.3, 27.1, 23.1 (CH2), 22.9 (Ac), 22.9, 22.7 (CH2); 
HRMS [C32H56N18O8 + H]+: 821.4608 found, 821.4601 calculated. 
Ac-Lys(N3)-Lys(N3)-Lys(N3)-Lys(N3)-Lys(N3)-Lys(N3)-Gly-Lys-NH2 (23). 
Ac-Lys(N3)-Lys(N3)-Lys(N3)-Lys(N3)-Lys(N3)-Lys(N3)-Gly-Lys(Boc)-Tentagel® S-
RAM was transferred to a flask and treated for 90 minutes with a cleavage cocktail (10 
mL, TFA/TIS/H2O, 190/5/5, v/v/v). The mixture was concentrated to 
approximately one mL after which the resin was filtered off into a cold mixture of diethylether/pentane 
(45 mL, 5/4, v/v) and the resin was washed off with neat TFA (3 x 1 mL) into the ether solution. This 
solution was centrifuged (10 minutes, 5000 rpm) after which the supernatant was removed and the 
precipitate was dried under nitrogen flow and dissolved (1mL, t-BuOH/ACN/H2O, 1/1/1, v/v/v). 
Purification via RP-HPLC (linear-gradient 30-60% B, 10 min) yielded title compound 23 as a white powder 
after lyophilization (51.57 mg, 44.1 µmol, 44.1% (90% per step)). LC-MS: Rt = 6.70 min (0 - 90% ACN; 13 
min); 1H NMR (400 MHz, DMSO) δ 8.14 (t, J = 5.6 Hz, 1H, NH (G)), 8.09 - 8.01 (m, 2H, NH (K)), 7.92 
(dt, J = 18.6, 6.4 Hz, 5H, NH (K)), 7.70 (s, 2H, CH2NH2), 7.36 (s, 1H, (CO)NHH), 7.09 (s, 1H, (CO)NHH), 
4.32 - 4.10 (m, 7H, CH), 3.78 - 3.72 (m, 2H, CH2 (G)), 3.34 - 3.26 (m, 12H, CH2N3), 2.76 (s, 2H, CH2NH2), 
1.86 (s, 3H, Ac), 1.77 - 1.18 (m, 42H, CH2); 13C NMR (101 MHz, DMSO) δ 173.4, 171.9, 171.8, 171.5, 
171.4, 169.5, 168.5 (C=O), 52.3, 52.0 (CH), 50.5 (CH2N3), 42.5 (CH2 (G)), 38.7 (CH2NH2), 31.4, 27.9, 26.7, 
22.6 (CH2), 22.5 (Ac), 22.4 (CH2); HRMS [C46H80N28O9 + H]+: 1169.6738 found, 1169.6736 calculated. 
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Ac-Lys(N3)-AEEA-Gly-Lys(N3)-Gly-Lys-NH2 (24). 
Ac-Lys(N3)-AEEA-Gly-Lys(N3)-Gly-Lys(Boc)-Tentagel® S-RAM 
was synthesized using the general protocol, with 1 hour couplings at 
rt after it was washed and transferred to a flask and treated for 90 
minutes with a cleavage cocktail (10 mL, TFA/TIS/H2O, 190/5/5, v/v/v). The mixture was concentrated 
to approximately one mL after which the resin was filtered off into a cold mixture of diethylether/pentane 
(45 mL, 5/4, v/v) and the resin was washed off with neat TFA (3 x 1 mL) into the ether solution. This 
solution was centrifuged (10 minutes, 5000 rpm) after which the supernatant was removed and the 
precipitate was dried under nitrogen flow and dissolved (1mL, t-BuOH/ACN/H2O, 1/1/1, v/v/v). 
Purification via RP-HPLC (linear-gradient 30-60% B, 10 min) yielded title compound 24  as a white powder 
after lyophilization (22.57 mg, 29.6 µmol, 29.6% (82% per step)). LC-MS: Rt = 5.08 min (0 - 90% ACN; 13 
min); 1H NMR (400 MHz, DMSO) δ 8.28 (t, J = 5.7 Hz, 1H, NH), 8.17 (d, J = 7.6 Hz, 1H, NH), 8.04 – 
7.96 (m, 2H, NH), 7.88 – 7.81 (m, 2H, NH), 7.72 (s, 2H, NH2), 7.34 (s, 1H, CONHH), 7.08 (s, 1H, 
CONHH), 4.29 – 4.09 (m, 3H, CH (K)), 3.92 (s, 2H, O-CH2-CO), 3.81 (t, J = 4.9 Hz, 2H, CH2 (PEG)), 
3.72 (t, J = 5.8 Hz, 2H, CH2 (PEG)), 3.63 – 3.52 (m, 4H, CH2 (G, 2x)), 3.41 (t, J = 5.9 Hz, 2H, CH2 (PEG)), 
3.30 (td, J = 6.8, 2.8 Hz, 4H, CH2-N3), 3.25 – 3.16 (m, 2H, CH2 (PEG)), 2.75 (q, J = 6.5 Hz, 2H, CH2-
NH2), 1.83 (s, 3H, Ac), 1.76 – 1.16 (m, 18H, CH2 (K)); 13C NMR (101 MHz, DMSO) δ 173.9, 172.4, 172.3, 
170.0, 169.7, 169.3, 169.0 (C=O), 70.7, 70.3, 69.8, 69.4 (CH2 (PEG, 2x), CH2 (G, 2x)), 53.0, 52.7, 52.5 (CH 
(K)), 51.0 (CH2-N3), 42.6, 41.9, 39.2 (CH2 (PEG, 3x)), 38.9 (CH2-NH2), 32.1, 31.8, 31.7, 28.4, 27.1, 23.0, 
23.0 (CH2 (K)), 22.9 (Ac), 22.7(CH2 (K)); HRMS [C30H54N14O9 + 2H]2+: 378.21718 found, 378.21719 
calculated. 
 
General procedure for propargyl azide conjugation: 
All solvents used in these reactions were degassed by sonicating while bubbling argon through the 
solutions. The “general click protocol” used was the following procedure: A solution of 
azidopeptides in DMSO (0.5 M, 1eq) was mixed with a solution of propargyl glycoside in water 
(0.5 M, 1.2eq per azide) followed by addition of an aliquot of a stock solution of CuI (0.1 eq), 
THPTA (0.3 eq) and DIPEA (0.2 eq) in water ([Cu+] = 0.5 M). The reaction was stirred at 40°C, 
and the process was followed via LC-MS. When reactions do not progress and turn blue, a sodium 
ascorbate solution (0.2 - 1 eq, 1 M, aq.) was added. Generally, reactions were stirred overnight at 
40°C. When not complete after 16 hours, an extra aliquot of the copper stock was added. After 
completion a small amount of Quadrasil® AP (washed with water) was added, stirred for 1 h, 
filtered and applied on gel filtration (Toyopearl HW40S, 150 mM NH4HCO3 (aq., in some cases a 
percentage of ACN was added to the elution buffer), 1.6x60 cm, 1 mL/min) followed by 
lyophilization. 
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Ac-Lys(Man1)-Gly-Lys-NH2 (32). 
Azide 20 (5.37 mg, 13.48 µmol) was conjugated to propargyl mannoside 25 using 
the general click protocol. Compound 32 was obtained after purification by gel 
filtration (eluting buffer contains 10% ACN, eluted at 49.5 - 57 mL) followed by 
RP-HPLC (linear-gradient 8 - 16% B, 12 min) as a white powder (3.30 mg, 5.34 
µmol, 39%). LC-MS: Rt = 4.01 min (0 - 50% ACN; 13 min); 1H NMR (400 MHz, 
D2O) δ 8.03 (s, 1H, trzl), 4.94 (d, J=1.6, 1H, H-1), 4.68 (d, J=12.5, 1H Hz, CHH), 4.42 (t, J=6.6 Hz, 2H), 
4.27 (dd, J=9.4, 4.9 Hz, 1H), 4.18 (dd, J=8.7 Hz, 5.9, 1H), 3.97 - 3.52 (m, 8H), 2.94 (t, J=7.6 Hz, 2H), 1.98 
(s, 3H, Ac), 1.96 - 1.56 (m, 8H), 1.51 - 1.18 (m, 4H); HRMS [C25H44N8O10 + H]+: 617.3254 found, 617.3253 
calculated. 
Ac-Lys(1,2-Man2)-Gly-Lys-NH2 (33). 
Azide 20 (11.03 mg, 27.67 µmol) was conjugated to propargyl mannosides 26 
using the general click protocol. Compound 33 was obtained after purification by 
gel filtration (eluted at 50-62 mL) followed by RP-HPLC (linear-gradient 8 - 16% 
B, 12 min) as a white powder (14.71 mg, 18.88 µmol, 68%). LC-MS: Rt = 3.87 min 
(0 - 50% ACN; 13 min); 1H NMR (500 MHz, D2O) δ 8.07 (s, 1H, trzl), 5.19 (d, J 
= 1.6 Hz, 1H, H-1), 5.01 (d, J = 1.8 Hz, 1H, H-1′), 4.84 (d, J = 12.6 Hz, 1H, O-
CHH-trzl), 4.73 (d, J = 12.6 Hz, 1H, O-CHH-trzl), 4.47 (t, J = 6.9 Hz, 2H, CH2-trzl), 4.32 (dd, J = 9.5, 5.0 
Hz, 1H, CH), 4.23 (dd, J = 8.8, 5.7 Hz, 1H, CH), 4.08 (dd, J = 3.3, 1.8 Hz, 1H, H-2), 3.99 - 3.58 (m, 14H, 
CH, H-2′, H-3, H-3′, H-4, H-4′, H-5, H-5′, H-6, H-6′, CH2 (G)), 3.01 (td, J = 8.0, 2.1 Hz, 2H, CH2-NH2), 
2.03 (s, 3H, Ac), 2.00 - 1.64 (m, 8H, CH2), 1.54 - 1.24 (m, 4H, CH2); HRMS [C31H54N8O15 + H]+: 779.3784 
found,779.3781 calculated. 
Ac-Lys(1,3-Man2)-Gly-Lys-NH2 (34). 
Azide 20 (5.28 mg, 13.24 µmol) was conjugated to propargyl mannosides 27 
using the general click protocol. Compound 34 was obtained after purification 
by gel filtration (eluted at 42-55 mL) followed by RP-HPLC (linear-gradient 8 
- 16% B, 12 min) as a white powder (10.16 mg, 13.05 µmol, 99%). LC-MS: Rt 
= 3.89 min (0 - 50% ACN; 13 min); 1H NMR (500 MHz, D2O) δ 8.07 (s, 1H, 
trzl), 5.12 (d, J = 1.6 Hz, 1H, H-1), 4.97 (d, J = 1.7 Hz, 1H, H-1′), 4.85 (d, J = 12.4 Hz, 1H, O-CHH-trzl), 
4.76 - 4.72 (m, 1H, O-CHH-trzl), 4.47 (t, J = 7.1 Hz, 2H, CH2-trzl), 4.32 (dd, J = 9.4, 5.0 Hz, 1H, CH), 4.23 
(dd, J = 8.8, 5.8 Hz, 1H, CH), 4.09 (ddd, J = 12.9, 3.3, 1.8 Hz, 2H), 4.00 - 3.62 (m, 12H, CH2 (G), H-2, H-
2′, H-3, H-3′, H-4, H-4′, H-5, H-5′, H-6, H-6′), 3.06 - 2.95 (m, 2H, CH2NH2), 2.03 (s, 3H, Ac), 2.00 - 1.63 
(m, 8H, CH2), 1.54 - 1.27 (m, 4H, CH2); HRMS [C31H54N8O15 + H]+: 779.3785 found, 779.3781 calculated. 
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Ac-Lys(1,6-Man2)-Gly-Lys-NH2 (35). 
Azide 20 (4.81 mg, 12.06 µmol) was conjugated to propargyl mannosides 28 using 
the general click protocol. Compound 35 was obtained after purification by gel 
filtration (eluted at 51 - 60 mL) followed by RP-HPLC (linear-gradient 8 - 16% B, 
12 min) as a white powder (7.99 mg, 10.26 µmol, 85%). LC-MS: Rt = 3.95 min (0 
- 50% ACN; 13 min); HRMS [C31H54N8O15 + H]+: 779.3785 found, 779.3781 
calculated. 
Ac-Lys(Man3)-Gly-Lys-NH2 (36). 
Azide 20 (5.52 mg, 13.84 µmol) was conjugated to propargyl mannosides 29 
using the general click protocol. Compound (36) was obtained after 
purification by gel filtration (eluted at 46 - 55 mL) followed by RP-HPLC 
(linear-gradient 8 - 16% B, 12 min) as a white powder (12.99 mg, 13.80 µmol, 
99%). LC-MS: Rt = 4.15 min (0 - 50% ACN; 13 min); 1H NMR (500 MHz, 
D2O) δ 8.06 (s, 1H, trzl), 5.09 (s, 1H), 4.94 (s, 1H), 4.90 (s, 1H, H-1, H-1′, H-
1′′), 4.82 (d, J = 12.4 Hz, 1H, O-CHH-trzl), 4.74 (d, J = 12.6 Hz, 1H, O-CHH-trzl), 4.46 (t, J = 6.8 Hz, 2H, 
CH2-trzl), 4.30 (dd, J = 9.4, 4.9 Hz, 1H, CH), 4.22 (dd, J = 8.6, 5.8 Hz, 1H, CH), 4.14 - 3.58 (m, 20H, 
CH2(G), H-2, H-2′, H-2′′, H-3, H-3′, H-3′′, H-4, H-4′, H-4′′, H-5, H-5′, H-5′′, H-6, H-6′, H-6′′), 3.00 (t, J = 
7.4 Hz, 2H, CH2NH2), 2.02 (s, 3H, Ac), 1.92 - 1.23 (m, 18H, CH2); HRMS [C37H64N8O20 + H]+: 941.4316 
found, 941.4310 calculated. 
Ac-Lys(Gal)-Gly-Lys-NH2 (37). 
Azide 20 (5.54 mg, 13.90 µmol) was conjugated to propargyl galactoside 30 using 
the general click protocol. Compound 37 was obtained after purification by gel 
filtration (eluted at 46.5 - 51 mL) as a white powder (4.93 mg, 7.99 µmol, 57%). 
LC-MS: Rt = 4.02 min (0 - 50% ACN; 13 min); 1H NMR (500 MHz, D2O) δ 7.97 
(s, 1H, trzl), 5.03 (s, 1H, H-1), 4.75 (d, J = 13.4 Hz, 1H, O-CHH-trzl), 4.73 - 4.67 (m, 1H, O-CHH-trzl), 
4.39 (t, J = 6.8 Hz, 2H, CH2-trzl), 4.23 (dd, J = 9.5, 5.0 Hz, 1H, CH), 4.14 (dd, J = 8.7, 5.7 Hz, 1H, CH), 
4.00 (dd, J = 3.6, 1.7 Hz, 2H, CH2), 3.92 - 3.71 (m, 4H, H-2, H-3, H-4, H-5), 3.64 - 3.50 (m, 2H, H-6), 2.93 
(td, J = 8.0, 2.1 Hz, 2H, CH2NH2), 1.94 (s, 3H, Ac), 1.92 - 1.14 (m, 12H, CH2); HRMS [C25H44N8O10 + 
H]+: 617.32531 found, 617.3253 calculated. 
 
Ac-Lys(Man1)-Gly-Lys(Man1)-Gly-Lys-NH2 (38). 
Azide 21 (17.00 mg, 27.89 µmol) was conjugated to propargyl mannoside 25 using 
the general click protocol. Compound 38 was obtained after purification by gel 
filtration (eluted at 42-52 mL) as a white powder (17.66 mg, 16.88 µmol, 61%). LC-
MS: Rt = 4.37 min (0 - 50% ACN; 13 min); 1H NMR (500 MHz, D2O) δ 8.07 (s, 
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2H, trzl), 4.98 (s, 2H, H-1), 4.84 (dd, J = 12.5, 2.1 Hz, 2H, O-CHH-trzl), 4.73 (d, J = 12.4 Hz, 2H, O-CHH-
trzl), 4.51 - 4.42 (m, 4H, CH2-trzl), 4.36 (d, J = 2.6 Hz, 1H), 4.34 - 4.19 (m, 3H, CH), 4.14 - 4.10 (m, 1H), 
4.05 (d, J = 2.6 Hz, 2H), 4.03 - 3.57 (m, 16H, H-2, H-3, H-4, H-5, H-6, CH2 (G)), 3.01 (t, J = 6.6 Hz, 2H, 
CH2-NH2), 2.01 (s, 3H, Ac), 1.98 - 1.23 (m, 18H, CH2); HRMS [C42H71N13O18 + H]+: 1046.5118 found, 
1046.5113 calculated. 
Ac-Lys(1,2-Man2)-Gly-Lys(1,2-Man2)-Gly-Lys-NH2 (39). 
Azide 21 (4.58 mg, 7.51 µmol) was conjugated to propargyl mannosides 26 using 
the general click protocol. Compound 39 was obtained after purification by gel 
filtration (instead of HW40S resin a superdex30, 1.6x60 cm, column was used with 
150 mM NH4HCO3 aq. 1 mL/min as elution buffer; eluted at 65 - 76 mL) as a 
white powder (4.27 mg, 3.12 µmol, 41%). LC-MS: Rt = 4.31 min (0 - 50% ACN; 
13 min); HRMS [C54H91N13O28 + H]+: 1370.6175 found 1370.6169 calculated. 
Ac-Lys(1,3-Man2)-Gly-Lys(1,3-Man2)-Gly-Lys-NH2 (40). 
Azide 21 (8.14 mg, 13.36 µmol) was conjugated to propargyl mannosides 27 
using the general click protocol. Compound 40 was obtained after purification 
by gel filtration (eluted at 38.5 - 46 mL) as a white powder (2.48 mg, 1.81 µmol, 
14%). LC-MS: Rt = 4.46 min (0 - 50% ACN; 13 min); HRMS [C54H91N13O28 
+ H]+: 1370.6176 found, 1370.6169 calculated. 
Ac-Lys(1,6-Man2)-Gly-Lys(1,6-Man2)-Gly-Lys-NH2 (41). 
Azide 21 (4.22 mg, 6.92 µmol) was conjugated to propargyl mannosides 28 using 
the general click protocol. Compound 41 was obtained after purification by gel 
filtration (eluted at 39.5 - 47 mL) as a white powder (2.69 mg, 1.96 µmol, 28%). 
LC-MS: Rt = 4.31 min (0 - 50% ACN; 13 min); HRMS [C54H91N13O28 + H]+: 
1370.6177 found, 1370.6169 calculated. 
 
Ac-Lys(Man3)-Gly-Lys(Man3)-Gly-Lys-NH2 (42). 
Azide 21 (7.91 mg, 12.98 µmol) was conjugated to propargyl mannosides 29 
using the general click protocol. Compound 42 was obtained after purification 
by gel filtration (eluted at 34 - 44.5 mL) as a white powder (9.44 mg, 5.57 µmol, 
43%). LC-MS: Rt = 4.18 min (0 - 50% ACN; 13 min); HRMS [C66H111N13O38 
+ H]+: 1694.7229 found, 1694.7226 calculated. 
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Ac-Lys(Gal)-Gly-Lys(Gal)-Gly-Lys-NH2 (43). 
Azide 21 (6.07 mg, 9.95 µmol) was conjugated to propargyl galactoside 30 using the 
general click protocol. Compound 43 was obtained after purification by gel 
filtration (eluted at 44 - 52 mL) as a white powder (5.54 mg, 5.29 µmol, 53%). LC-
MS: Rt = 4.38 min (0 - 50% ACN; 13 min); 1H NMR (500 MHz, D2O) δ 7.97 (s, 
2H, trzl), 5.06 - 4.91 (m, 2H, H-1), 4.72 - 4.68 (m, 4H, O-CH2-trzl), 4.38 (t, J = 6.7 Hz, 4H, CH2-trzl), 4.27 
- 4.17 (m, 2H, CH), 4.14 (dd, J = 8.8, 5.7 Hz, 1H, CH), 4.04 - 3.98 (m, 4H, CH2 (G)), 3.92 - 3.71 (m, 8H, 
H-2, H-3, H-4, H-5), 3.64 - 3.50 (m, 4H, H-6), 2.92 (td, J = 8.0, 2.2 Hz, 2H, CH2NH2), 1.93 (s, 3H, Ac), 
1.91 - 1.07 (m, 18H, CH2 (K)); HRMS [C42H71N13O18 + H]+: 1046.51147 found, 1046.5113 calculated. 
Ac-Lys(4-SO3-GalNAc)-Gly-Lys(4-SO3-GalNAc)-Gly-Lys-NH2 (44). 
Azide 21 (5.0 µL, 0.2 M, 1.0 µmol) was conjugated to propargyl mannosides 31 
using the general click protocol. Compound 44 was obtained after purification by 
gel filtration (eluted at 34 - 44.5 mL) as a white powder (0.395 mg, 299 nmol, 30%). 
LC-MS: Rt = 3.69 min (0 - 50% ACN; 13 min); 1H NMR (400 MHz, D2O) δ 7.98 
(s, 2H, trzl), 4.89 (d, J = 12.9 Hz, 2H, O-CHH-trzl), 4.76 (d, J = 1.8 Hz, 2H, O-CHH-trzl), 4.65 (d, J = 2.9 
Hz, 2H, H-1), 4.57 (d, J = 7.8 Hz, 2H, H-2), 4.41 (t, J = 6.8 Hz, 4H, CH2-trzl), 4.24 (ddd, J = 11.8, 9.1, 5.3 
Hz, 2H, CH (K)), 4.17 (dd, J = 8.7, 5.8 Hz, 1H, CH (K)), 3.94 – 3.74 (m, 14H, H-3, H-4, H-5, H-6, CH2 
(G, 2x)), 2.95 (t, J = 7.0 Hz, 2H, CH2-NH2), 1.96 (s, 3H, Ac), 1.92 – 1.59 (m, 18H, NHAc (2x), CH2 (K)), 
1.46 – 1.20 (m, 6H, CH2 (K)); HRMS [C46H77N15O24S2 + 2H]2+: 644.74259 found, 644.74264 calculated. 
 
Ac-Lys(Man1)-Gly-Lys(Man1)-Gly-Lys(Man1)-Gly-Lys-NH2 (45). 
Azide 22 (2.92 mg, 3.56 µmol) was conjugated to propargyl mannosides 25 using 
the general click protocol. Compound 45 was obtained after purification by gel 
filtration (eluted at 38-46 mL) followed by RP-HPLC as a white powder (3.61 mg, 
2.44 µmol, 69%). LC-MS: Rt = 4.60 min (0 - 50% ACN; 13 min); 1H NMR (400 
MHz, D2O) δ 7.96 - 7.89 (m, 3H, trzl), 4.84 (s, 3H, H-1), 4.71 - 4.67 (m, 3H, O-
CHH-trzl), 4.58 (d, J = 12.5 Hz, 3H, O-CHH-trzl), 4.32 (t, J = 6.8 Hz, 6H, CH2-trzl), 4.22 - 4.04 (m, 4H, 
CH), 3.90 - 3.43 (m, 24H, CH2 (G), H-2, H-3, H-4, H-5, H-6), 2.87 (t, J = 7.5 Hz, 2H, CH2NH2), 1.87 (s, 
3H, Ac), 1.84 - 1.07 (m, 24H, CH2); 13C NMR (101 MHz, D2O) δ 143.4, 99.4 (C-1), 72.9, 70.4, 69.9, 66.6 
(C-2, C-3, C-4, C-5), 60.8 (C-6), 28.7; HRMS [C59H98N18O26 + 2H]2+: 738.3528 found, 738.3523 calculated.  
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Ac-Lys(1,2-Man2)-Gly-Lys(1,2-Man2)-Gly-Lys(1,2-Man2)-Gly-Lys-NH2 (46). 
Azide 22 (4.20 mg, 5.12 µmol) was conjugated to propargyl mannosides 26 using 
the general click protocol. Compound 46 was obtained after purification by gel 
filtration (eluted at 34 - 44.5 mL) as a white powder (8.01mg, 4.08 µmol, 80%). 
LC-MS: Rt = 4.45 min (0 - 50% ACN; 13 min); 1H NMR (500 MHz, D2O) δ 8.07 
(d, J = 2.3 Hz, 3H, trzl), 5.18 (s, 3H, H-1), 5.01 (s, 3H, H-1′), 4.83 (d, J = 12.4 Hz, 
3H, O-CHH-trzl), 4.72 (d, J = 12.7 Hz, 3H, O-CHH-trzl), 4.45 (t, J = 6.9 Hz, 6H, 
CH2-trzl), 4.30 (tt, J = 9.4, 5.1 Hz, 3H, CH), 4.23 (dd, J = 8.5, 6.0 Hz, 1H, CH), 4.08 (dd, J = 3.3, 1.8 Hz, 
3H, H-2), 4.00 - 3.59 (m, 42H, CH2 (G), H-2′, H-3, H-3′, H-4, H-4′, H-5, H-5′, H-6, H-6′), 3.01 (t, J = 7.0 
Hz, 2H, CH2NH2), 2.01 (s, 3H, Ac), 1.98 - 1.60 (m, 16H, CH2), 1.55 - 1.28 (m, 8H, CH2); HRMS 
[C77H128N18O41 + H]+: 1961.8643 found, 1961.8557 calculated. 
Ac-Lys(1,3-Man2)-Gly-Lys(1,3-Man2)-Gly-Lys(1,3-Man2)-Gly-Lys-NH2 (47). 
Azide 22 (2.92 mg, 3.56 µmol) was conjugated to propargyl mannosides 27 
using the general click protocol. Compound 47 was obtained after purification 
by gel filtration (buffer contains 10% ACN, eluted at 33.5 - 42.5 mL) as a white 
powder (5.71 mg, 2.91 µmol, 82%). LC-MS: Rt = 4.37 min (0 - 50% ACN; 13 
min); 1H NMR (400 MHz, D2O) δ 7.99 - 7.84 (m, 3H, trzl), 4.98 (s, 3H, H-1), 
4.83 (d, J = 1.5 Hz, 3H, H-1′), 4.76 - 4.66 (m, 3H, O-CHH-trzl), 4.60 (d, J = 12.4 Hz, 3H, O-CHH-trzl), 
4.32 (t, J = 6.8 Hz, 6H, CH2-trzl), 4.22 - 4.12 (m, 3H, CH), 4.09 (dd, J = 8.7, 5.6 Hz, 1H, CH), 4.00 - 3.42 
(m, 42H, CH2 (G), H-2, H-2′, H-3, H-3′, H-4, H-4′, H-5, H-5′, H-6, H-6′), 2.85 (t, J = 7.5 Hz, 2H, CH2NH2), 
1.87 (s, 3H, Ac), 1.85 - 1.09 (m, 24H, CH2); HRMS [C77H128N18O41 + H]+: 1961.8589 found 1961.8557 
calculated. 
Ac-Lys(1,6-Man2)-Gly-Lys(1,6-Man2)-Gly-Lys(1,6-Man2)-Gly-Lys-NH2 (48). 
Azide 22 (3.92 mg, 3.56 µmol) was conjugated to propargyl mannosides 28 using 
the general click protocol. Compound 48 was obtained after purification by gel 
filtration (eluted at 34 - 41.5 mL) as a white powder (5.96 mg, 3.04 µmol, 85%). 
LC-MS: Rt = 4.37 min (0 - 50% ACN; 13 min); 1H NMR (500 MHz, D2O) δ 8.03 
- 7.91 (m, 3H, trzl), 4.88 (s, 3H, H-1), 4.83 (s, 3H, H-1′), 4.74 (d, J = 12.6 Hz, 3H, 
O-CHH-trzl), 4.64 (d, J = 12.5 Hz, 3H, O-CHH-trzl), 4.37 (t, J = 6.9 Hz, 6H, 
CH2-trzl), 4.21 (tt, J = 9.2, 5.3 Hz, 3H, CH), 4.14 (dd, J = 8.8, 5.7 Hz, 1H, CH), 3.95 - 3.56 (m, 42H, CH2 
(G), H-2, H-2′, H-3, H-3′, H-4, H-4′, H-5, H-5′, H-6, H-6′), 2.88 (t, J = 7.1 Hz, 2H, CH2NH2), 1.92 (s, 3H, 
Ac), 1.90 - 1.51 (m, 16H, CH2), 1.44 - 1.14 (m, 8H, CH2); HRMS [C77H128N18O41 + H]+: 1961.8616 found, 
1961.8557 calculated. 
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Ac-Lys(Man3)-Gly-Lys(Man3)-Gly-Lys(Man3)-Gly-Lys-NH2 (49). 
Azide 22 (2.92 mg, 3.56 µmol) was conjugated to propargyl mannosides 29 
using the general click protocol. Compound 49 was obtained after purification 
by gel filtration (eluted at 31- 39.5 mL) as a white powder (6.97 mg, 2.85 µmol, 
80%). LC-MS: Rt = 4.54 min (0 - 50% ACN; 13 min); 1H NMR (500 MHz, 
D2O) δ 8.06 (d, J = 1.8 Hz, 3H, trzl), 5.10 (s, 3H), 4.95 (d, J = 1.5 Hz, 3H), 
4.91 (d, J = 1.2 Hz, 3H, H-1, H-1′ & H-1′′), 4.83 (d, J = 12.7 Hz, 3H, O-CHH-
trzl), 4.74 (d, J = 12.6 Hz, 3H, O-CHH-trzl), 4.46 (t, J = 6.9 Hz, 6H, CH2-trzl), 4.35 - 4.27 (m, 3H, CH), 
4.23 (dd, J = 8.8, 5.7 Hz, 1H, CH), 4.13 - 3.60 (m, 60H, CH2(G), H-2, H-2′, H-2′′, H-3, H-3′, H-3′′, H-4, H-
4′, H-4′′, H-5, H-5′, H-5′′, H-6, H-6′, H-6′′), 2.95 (t, J = 7.3 Hz, 2H, CH2NH2), 2.01 (s, 3H, Ac), 1.99 - 1.23 
(m, 24H, CH2); HRMS [C95H158N18O56 + 2H]2+: 1225.0138 found, 1225.01225 calculated. 
 
Ac-Lys(Man1)-Lys(Man1)-Lys(Man1)-Lys(Man1)-Lys(Man1)-Lys(Man1)-Gly-Lys-NH2 (50). 
Azide 23 (2.51 mg, 2.15 µmol) was conjugated to propargyl mannosides 25 using the 
general click protocol. Compound 50 was obtained after purification by gel filtration 
(buffer contained 20% ACN, eluted at 39-47 mL) as a white powder (4.31 mg, 1.76 
µmol, 82%). LC-MS: Rt = 4.73 min (0 - 50% ACN; 13 min); 1H NMR (500 MHz, 
D2O) δ 8.03 (d, J = 5.1 Hz, 6H, trzl), 4.96 (d, J = 1.8 Hz, 6H, H-1), 4.89 - 4.71 (m, 
146H, HDO, O-CHH-trzl), 4.67 (dd, J = 12.5, 2.9 Hz, 6H, O-CHH-trzl), 4.40 (t, J = 6.4 Hz, 12H, CH2-
trzl), 4.34 - 4.09 (m, 7H, CH (K)), 3.99 - 3.57 (m, 38H, H-2, H-3, H-4, H-5, H-6, CH2 (G)), 3.05 - 2.98 (m, 
2H, CH2-NH2), 2.01 (s, 3H, Ac), 1.97 - 1.20 (m, 42H, CH2); 13C NMR (126 MHz, D2O) δ 160.3, 143.5, 
125.0 (CH-trzl), 99.5 (C-1), 73.0, 70.6, 70.0, 66.7 (C-2, C-3, C-4, C-5), 60.9 (C-6), 59.8 (O-CH2-trzl), 50.1 
(CH2-trzl), 39.3 (CH2-NH2), 28.9, 22.1 (CH2); HRMS [C100H164N28O45 + 2H]2+: 1240.0857 found, 
1240.0790 calculated. 
Ac-Lys(1,2-Man2)-Lys(1,2-Man2)-Lys(1,2-Man2)-Lys(1,2-Man2)-Lys(1,2-Man2)-Lys(1,2-Man2)-
Gly-Lys-NH2 (51). 
Azide 23 (3.84 mg, 3.28 µmol) was conjugated to propargyl mannosides 26 using 
the general click protocol. Compound 51 was obtained after purification by gel 
filtration (buffer contained 20% ACN, eluted at 28 - 38 mL) as a white powder 
(11.10 mg, 3.21 µmol, 98%). LC-MS: Rt = 4.51 min (0 - 50% ACN; 13 min); 1H 
NMR (500 MHz, D2O) δ 8.09 - 7.91 (m, 6H, trzl), 5.13 (s, 6H, H-1), 4.95 (s, 6H, 
H-1’), 4.74 (d, J=12.6, 6H, O-CHH-trzl), 4.63 (d, J=12.5, 6H, O-CHH-trzl), 4.36 
(s, 12H, CH2-trzl), 4.30 - 4.05 (m, 7H, CH), 4.02 (dd, J = 3.2, 1.7 Hz, 6H, H-2), 4.01 - 3.50 (m, 68H, CH2 
(G), H-2′, H-3, H-3′, H-4, H-4′, H-5, H-5′, H-6, H-6′), 2.98 - 2.92 (m, 2H, CH2NH2), 1.95 (s, 3H, Ac), 1.91 
- 1.12 (m, 42H, CH2); 13C NMR (126 MHz, D2O) δ 143.4, 125.0 (CH-trzl), 105.0 (CH2), 102.3, 97.7 (C-1, 
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C-1′), 78.6, 73.2, 72.9, 70.3, 70.1, 69.9, 69.5, 66.8, 66.7, 60.9, 60.8, 59.8, 50.0, 22.0; HRMS [C136H224N28O75 
+ 2H]2+: 1726.2408 found, 1726.2375 calculated.  
Ac-Lys(1,3-Man2)-Lys(1,3-Man2)-Lys(1,3-Man2)-Lys(1,3-Man2)-Lys(1,3-Man2)-Lys(1,3-Man2)-
Gly-Lys-NH2 (52). 
Azide 23 (3.78 mg, 3.23 µmol) was conjugated to propargyl mannosides 27 
using the general click protocol. Compound 52 was obtained after purification 
by gel filtration (eluted at 30.5 - 39 mL) as a white powder (11.04 mg, 3.19 
µmol, 99%). LC-MS: Rt = 4.63 min (0 - 50% ACN; 13 min); 1H NMR (500 
MHz, D2O) δ 7.92 (d, J = 4.1 Hz, 6H, trzl), 4.97 (s, 6H, H-1), 4.81 (s, 6H, H-
1′), 4.69 - 4.66 (m, 6H, O-CHH-trzl), 4.56 (d, J = 12.6 Hz, 6H, O-CHH-trzl), 
4.28 (s, 12H, CH2-trzl), 4.19 - 3.97 (m, 7H, CH), 3.97 - 3.48 (m, 74H, CH2 (G), H-2, H-2′, H-3, H-3′, H-4, 
H-4′, H-5, H-5′, H-6, H-6′), 2.79 - 2.72 (m, 2H, CH2NH2), 1.87 (s, 3H, Ac), 1.84 - 1.44 (m, 28H, CH2), 1.40 
- 1.05 (m, 14H, CH2); 13C NMR (126 MHz, D2O) δ 143.5, 125.0, 102.4, 99.5 (C-1, C-1′), 78.3, 73.4, 73.1, 
70.4, 70.1, 69.6, 66.8, 66.0, 61.0, 60.8, 59.9, 50.1, 28.9; HRMS [C136H224N28O75 + 2H]2+: 1726.2405 found, 
1726.2375 calculated. 
Ac-Lys(1,6-Man2)-Lys(1,6-Man2)-Lys(1,6-Man2)-Lys(1,6-Man2)-Lys(1,6-Man2)-Lys(1,6-Man2)-
Gly-Lys-NH2 (53). 
Azide 23 (2.63 mg, 2.25 µmol) was conjugated to propargyl mannosides 28 using 
the general click protocol. Compound 53 was obtained after purification by gel 
filtration (eluted at 36 - 50 mL) as a white powder (4.45 mg, 1.29 µmol, 57%). LC-
MS: Rt = 4.63 min (0 - 50% ACN; 13 min); HRMS [C136H224N28O75 + 2H]2+: 
1726.2408 found, 1726.2375 calculated. 
 
Ac-Lys(Man3)-Lys(Man3)-Lys(Man3)-Lys(Man3)-Lys(Man3)-Lys(Man3)-Gly-Lys-NH2 (54). 
Azide 23 (6.90 mg, 5.90 µmol) was conjugated to propargyl mannosides 29 
using the general click protocol. Compound 54 was obtained after purification 
by gel filtration (eluted at 28 - 39 mL) as a white powder (22.22 mg, 5.02 µmol, 
85%). LC-MS: Rt = 4.34 min (0 - 50% ACN; 13 min); 1H NMR (500 MHz, 
D2O) δ 8.01 (s, 6H, trzl), 5.04 (s, 6H), 4.89 (s, 6H), 4.86 (s, 6H, H-1, H-1′, H-
1′′), 4.77 - 4.73 (m, 6H, O-CHH-trzl), 4.69 - 4.62 (m, 6H, O-CHH-trzl), 4.37 
(s, 12H, CH2-trzl), 4.28 - 4.14 (m, 7H, CH), 4.13 - 3.50 (m, 110H, CH2(G), H-2, H-2′, H-2′′, H-3, H-3′, H-
3′′, H-4, H-4′, H-4′′, H-5, H-5′, H-5′′, H-6, H-6′, H-6′′), 2.93 (t, J = 6.7 Hz, 2H, CH2NH2), 1.96 (s, 3H, Ac), 
1.91 - 1.14 (m, 42H, CH2); 13C NMR (126 MHz, D2O) δ 143.4, 124.9, 102.4, 99.6, 99.4 (C-1,C-1’& C-1’’), 
78.6, 73.3, 72.6, 71.2, 70.6, 70.3, 70.0, 69.9, 69.5, 69.5, 66.7, 65.4, 64.9, 60.9, 60.0, 50.0, 39.2, 28.9, 22.0; 
HRMS [C172H284N28O105 + 2H]2+: 2212.9033 found, 2212.8975 calculated. 
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Ac-Lys(4-SO3-GalNAc)-Lys(4-SO3-GalNAc)-Lys(4-SO3-GalNAc)-Lys(4-SO3-GalNAc)-Lys(4-SO3-
GalNAc)-Lys(4-SO3-GalNAc)-Gly-Lys-NH2 (55). 
Azide 23 (5.0 µL, 0.2 M, 1.0 µmol) was conjugated to propargyl mannosides 31 
using the general click protocol. Compound 55 was obtained after purification by 
gel filtration (eluted at 28 - 39 mL) as a white powder (1.17 mg, 884 nmol, 88%). 
LC-MS: Rt = 3.75 min (0 - 50% ACN; 13 min); 1H NMR (400 MHz, D2O) δ 7.87 
(s, 6H, trzl), 4.81 – 4.74 (m, 6H, O-CHH-trzl), 4.68 – 4.64 (m, 6H, O-CHH-trzl), 4.57 (d, J = 2.2 Hz, 6H, 
H-1), 4.47 (d, J = 7.4 Hz, 6H, H-2), 4.27 (d, J = 6.3 Hz, 12H, CH2-trzl), 4.19 – 3.93 (m, 7H, CH (K)), 3.84 
– 3.64 (m, 32H, H-3, H-4, H-5, H-6, CH2 (G)), 2.87 (t, J = 7.6 Hz, 2H, CH2NH2), 1.87 (s, 3H, Ac), 1.81 – 
1.48 (m, 46H, NHAc (6x), CH2 (K)), 1.20 (d, J = 7.0 Hz, 14H, CH2 (K)); HRMS [C112H182N34O63S6 + 3H]3+: 
1069.02205 found, 1069.02176 calculated. 
 
Ac-Lys(Man1)-AEEA-Gly-Lys(Man1)-Gly-Lys-NH2 (56). 
Azide 24 (5.28 mg, 7.00 µmol) was conjugated to propargyl 
mannosides 25 using the general click protocol. Compound 56 
was obtained after purification by gel filtration (buffer contained 
20% ACN, eluted at 39.5 - 47.5 mL) as a white powder (6.95 mg, 
5.84 µmol, 83%). LC-MS: Rt = 4.11 min (0 - 50% ACN; 13 min); 
1H NMR (400 MHz, D2O) δ 8.01 (d, J = 1.4 Hz, 2H, trzl), 4.92 (d, J = 1.5 Hz, 2H, H-1), 4.79 – 4.75 (m, 
2H, O-CHH-trzl), 4.67 (d, J = 2.3 Hz, 2H, O-CHH-trzl), 4.47 – 4.35 (m, 4H, CH2-trzl), 4.25 (td, J = 9.2, 
5.4 Hz, 3H, CH (K)), 4.13 (dd, J = 8.5, 5.9 Hz, 1H), 4.09 (s, 2H, CH2), 4.04 – 3.49 (m, 23H, H-2, H-3, H-
4, H-5, H-6, CH2 (PEG, 3x), CH2 (G, 2x)), 3.41 – 3.26 (m, 2H, CH2 (PEG)), 2.95 (t, J = 7.5 Hz, 2H, CH2-
NH2), 1.95 (s, 3H, Ac), 1.93 – 1.56 (m, 12H, CH2 (K)), 1.48 – 1.14 (m, 6H, CH2 (K)); HRMS [C48H82N14O21 
+ H] +: 1191.58528 found, 1191.58517 calculated. 
Ac-Lys(Man3)-AEEA-Gly-Lys(Man3)-Gly-Lys-NH2 (57). 
Azide 24 (5.28 mg, 7.00 µmol) was conjugated to propargyl 
mannosides 29 using the general click protocol. Compound 
57 was obtained after purification by gel filtration (buffer 
contained 20% ACN, eluted at 38 - 46 mL) as a white powder 
(12.8 mg, 7.00 µmol, 99%). LC-MS: Rt = 3.89 min (0 - 50% 
ACN; 13 min); 1H NMR (400 MHz, D2O) δ 8.01 (d, J = 1.7 
Hz, 2H, trzl), 5.03 (d, J = 1.5 Hz, 2H), 4.89 (s, 2H), 4.85 (d, J = 1.4 Hz, 2H, H-1, H-1′, H-1′′), 4.77 – 4.75 
(m, 2H, O-CHH-trzl), 4.68 (dd, J = 12.6, 1.5 Hz, 2H, O-CHH-trzl), 4.40 (q, J = 4.7 Hz, 4H, CH2-trzl), 4.24 
(td, J = 8.6, 7.9, 5.5 Hz, 2H, CH (K)), 4.13 (dd, J = 8.6, 5.9 Hz, 1H, CH (K)), 4.09 (s, 2H, CH2 (PEG)), 4.07 
– 3.53 (m, 46H, H-2, H-2′, H-2′′, H-3, H-3′, H-3′′, H-4, H-4′, H-4′′, H-5, H-5′, H-5′′, H-6, H-6′, H-6′′, CH2 
(PEG, 3x), CH2 (G, 2x)), 3.34 (q, J = 5.3 Hz, 2H, CH2 (PEG)), 2.95 (t, J = 7.5 Hz, 2H, CH2-NH2), 1.95 (s, 
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3H, Ac), 1.93 – 1.56 (m, 12H, CH2 (K)), 1.46 – 1.15 (m, 6H, CH2 (K)); HRMS [C72H122N14O41 + 2H] 2+: 
920.40110 found, 920.40187 calculated. 
Ac-Lys(4-SO3-GalNAc)-AEEA-Gly-Lys(4-SO3-GalNAc)-Gly-Lys-NH2 (58). 
Azide 24 (5.0 µL, 0.2 M, 1.0 µmol) was conjugated to propargyl 
mannosides 31 using the general click protocol. Compound 58 
was obtained after purification by gel filtration (buffer contained 
20% ACN, eluted at 38 - 46 mL) as a white powder (0.25 mg, 167 
nmol, 17%). LC-MS: Rt = 3.91 min (0 - 50% ACN; 13 min); 1H NMR (400 MHz, D2O) δ 7.99 (d, J = 2.3 
Hz, 2H, trzl), 4.90 (d, J = 12.9 Hz, 2H, O-CHH-trzl), 4.81 – 4.72 (m, 2H, O-CHH-trzl), 4.66 (d, J = 2.8 
Hz, 2H, H-1), 4.58 (d, J = 7.8 Hz, 2H, H-2), 4.41 (q, J = 3.5 Hz, 4H, CH2-trzl), 4.29 – 4.21 (m, 2H, CH 
(K)), 4.18 – 4.11 (m, 1H, CH (K)), 4.10 (s, 2H, CH2 (PEG)), 4.04 – 3.63 (m, 18H, H-3, H-4, H-5, H-6, CH2 
(PEG, 2x), CH2 (G, 2x)), 3.57 (t, J = 5.5 Hz, 2H, CH2 (PEG)), 3.41 – 3.30 (m, 2H, CH2 (PEG)), 2.96 (t, J 
= 7.3 Hz, 2H, CH2NH2), 1.96 (s, 3H, Ac), 1.93 – 1.57 (m, 18H, NHAc (2x), CH2 (K)), 1.48 – 1.18 (m, 6H, 
CH2 (K)); HRMS [C52H88N16O27S2 + 2H]2+: 717.27926 found, 717.27959 calculated. 
 
General procedure for biotinylation: 
The “general procedure” to introduce the biotin handle: Glycoclusters described above with a free 
amine were dissolved in DMSO (0.02 M). To this, a stock solution of Biotin-NHS (0.15 M, 3-4 
eq) and DIPEA (0.015 M, 0.3-0.4 eq) in DMSO was added and shaken overnight after which 
compounds were purified via RP-HPLC (linear gradient 10 - 16 % B in A, 12 min, 5 mL/min, 
Develosil RPAQUEOUS 10.0 x 250 mm) followed by lyophilization.  
 
Ac-Lys(Man1)-Gly-Lys(biotin)-NH2(59). 
Compound 32 (1.01 mg, 1.64 µmol) was coupled with biotin-NHS using the general 
procedure. Compound 59 was obtained after purification by RP-HPLC as a white 
powder (1.37 mg, 1.62 µmol, 99%). LC-MS: Rt = 5.28 min (0 - 50% ACN; 13 min); 
HRMS [C35H58N10O12S + H]+: 843.4031 found, 843.4029 calculated. 
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Ac-Lys(1,2-Man2)-Gly-Lys(biotin)-NH2(60). 
Compound 33 (8.97 mg, 11.51 µmol) was coupled with biotin-NHS using the 
general procedure. Compound 60 was obtained after purification by RP-HPLC as 
a white powder (1.90 mg, 1.89 µmol, 16%). LC-MS: Rt = 5.18 min (0 - 50% ACN; 
13 min); HRMS [C41H68N10O17S + 2H]2+: 503.2315 found, 503.2315 calculated. 
 
Ac-Lys(1,3-Man2)-Gly-Lys(biotin)-NH2 (61). 
Compound 34 (6.46 mg, 8.30 µmol) was coupled with biotin-NHS using the 
general procedure. Compound 61 was obtained after purification by RP-HPLC 
as a white powder (1.44 mg, 1.44 µmol, 17%). LC-MS: Rt = 5.23 min (0 - 50% 
ACN; 13 min); HRMS [C41H68N10O17S +2H]2+: 503.2316 found, 503.2315 
calculated. 
 
Ac-Lys(1,6-Man2)-Gly-Lys(biotin)-NH2 (62). 
Compound 35 (1.50 mg, 1.93 µmol) was coupled with biotin-NHS using the 
general procedure. Compound 62 was obtained after purification by RP-HPLC 
as a white powder (0.97 mg, 0.97 µmol, 50 %). LC-MS: Rt = 5.23 min (0 - 50% 
ACN; 13 min); HRMS [C41H68N10O17S + 2H]2+: 503.2314 found, 503.2315 
calculated. 
 
Ac-Lys(Man3)-Gly-Lys(biotin)-NH2 (63). 
Compound 36 (8.25 mg, 8.77 µmol) was coupled with biotin-NHS using the 
general procedure. Compound 63 was obtained after purification by RP-
HPLC as a white powder (1.48 mg, 1.26 µmol, 14%). LC-MS: Rt = 5.15 min 
(0 - 50% ACN; 13 min); HRMS [C47H78N10O22S + 2H]2+: 584.2582 found, 
584.2579 calculated. 
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Ac-Lys(Man1)-Gly-Lys(Man1)-Gly-Lys(biotin)-NH2(64). 
Compound 38 (11.06 mg, 10.57 µmol) was coupled with biotin-NHS using the 
general procedure. Compound 64 was obtained after purification by RP-HPLC as 
a white powder (2.62 mg, 2.06 µmol, 19%). LC-MS: Rt = 5.30 min (0 - 50% ACN; 
13 min); HRMS [C52H85N15O20S + 2H]2+: 636.7984 found, 636.7981 calculated. 
 
 
Ac-Lys(1,2-Man2)-Gly-Lys(1,2-Man2)-Gly-Lys(biotin)-NH2 (65). 
Compound 39 (2.67 mg, 1.95 µmol) was coupled with biotin-NHS using the 
general procedure. Compound 65 was obtained after purification by RP-HPLC as 
a white powder (1.52 mg, 0.95 µmol, 49%). LC-MS: Rt = 5.14 min (0 - 50% ACN; 
13 min); HRMS [C64H105N15O30S+2H]2+: 798.8514 found, 798.8509 calculated. 
 
 
Ac-Lys(1,3-Man2)-Gly-Lys(1,3-Man2)-Gly-Lys(biotin)-NH2 (66). 
Compound 40 (1.50 mg, 1.10 µmol) was coupled with biotin-NHS using the 
general procedure. Compound 66 was obtained after purification by RP-
HPLC as a white powder (1.74 mg, 1.09 µmol, 99%). LC-MS: Rt = 5.18 min 
(0 - 50% ACN; 13 min); HRMS [C64H105N15O30S+2H]2+: 798.8516 found, 
798.8509 calculated. 
 
Ac-Lys(1,6-Man2)-Gly-Lys(1,6-Man2)-Gly-Lys(biotin)-NH2 (67). 
Compound 41 (1.68 mg, 1.22 µmol) was coupled with biotin-NHS using the 
general procedure. Compound 67 was obtained after purification by RP-HPLC 
as a white powder (1.48 mg, 0.93 µmol, 76%). LC-MS: Rt = 5.11 min (0 - 50% 
ACN; 13 min); HRMS [C64H105N15O30S + 2H]2+: 798.8512 found, 798.8509 
calculated. 
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Ac-Lys(Man3)-Gly-Lys(Man3)-Gly-Lys(biotin)-NH2 (68). 
Compound 42 (6.02 mg, 3.55 µmol) was coupled with biotin-NHS using the 
general procedure. Compound 68 was obtained after purification by RP-
HPLC as a white powder (3.34 mg, 1.74 µmol, 49%). LC-MS: Rt = 5.02 min 
(0 - 50% ACN; 13 min); HRMS [C76H125N15O40S+ 2H]2+: 960.9051 found, 
960.9037 calculated. 
 
 
Ac-Lys(Man1)-Gly-Lys(Man1)-Gly-Lys(Man1)-Gly-Lys(biotin)-NH2(69). 
Compound 45 (2.63 mg, 1.78 µmol) was coupled with biotin-NHS using the general 
procedure. Compound 69 was obtained after purification by RP-HPLC as a white 
powder (1.92 mg, 1.13 µmol, 63%). LC-MS: Rt = 5.26 min (0 - 50% ACN; 13 min); 
HRMS [C69H112N20O28S +2H]2+: 851.3912 found, 851.3911 calculated. 
 
Ac-Lys(1,2-Man2)-Gly-Lys(1,2-Man2)-Gly-Lys(1,2-Man2)-Gly-Lys(biotin)-NH2 (70). 
Compound 46 (4.91 mg, 2.50 µmol) was coupled with biotin-NHS using the 
general procedure. Compound 70 was obtained after purification by RP-HPLC as 
a white powder (1.82 mg, 0.83 µmol, 33%). LC-MS: Rt = 5.07 min (0 - 50% ACN; 
13 min); HRMS [C87H142N20O43S + 2H]2+: 1094.9727 found, 1094.9718 
calculated. 
 
Ac-Lys(1,3-Man2)-Gly-Lys(1,3-Man2)-Gly-Lys(1,3-Man2)-Gly-Lys(biotin)-NH2 (71). 
Compound 47 (3.53 mg, 1.80 µmol) was coupled with biotin-NHS using the 
general procedure. Compound 71 was obtained after purification by RP-HPLC 
as a white powder (3.78 mg, 1.72 µmol, 96%). LC-MS: Rt = 5.13 min (0 - 50% 
ACN; 13 min); HRMS [C87H142N20O43S + 2H]2+: 1094.9719 found, 1094.9718 
calculated. 
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Ac-Lys(1,6-Man2)-Gly-Lys(1,6-Man2)-Gly-Lys(1,6-Man2)-Gly-Lys(biotin)-NH2 (72). 
Compound 48 (3.53 mg, 1.80 µmol) was coupled with biotin-NHS using the 
general procedure. Compound 72 was obtained after purification by RP-HPLC 
as a white powder (3.55 mg, 1.62 µmol, 90%). LC-MS: Rt = 5.09 min (0 - 50% 
ACN; 13 min); HRMS [C87H142N20O43S + 2H]2+: 1094.9721 found, 1094.9718 
calculated. 
 
Ac-Lys(Man3)-Gly-Lys(Man3)-Gly-Lys(Man3)-Gly-Lys(biotin)-NH2 (73). 
Compound 49 (4.41 mg, 1.80 µmol) was coupled with biotin-NHS using the 
general procedure. Compound 73 was obtained after purification by RP-
HPLC as a white powder (2.44 mg, 0.91 µmol, 51%). LC-MS: Rt = 4.94 min 
(0 - 50% ACN; 13 min); HRMS [C105H172N20O58S + 2H]2+: 1338.0503 found, 
1338.0510 calculated. 
 
 
Ac-Lys(Man1)-Lys(Man1)-Lys(Man1)-Lys(Man1)-Lys(Man1)-Lys(Man1)-Gly-Lys(biotin)-NH2(74). 
Compound 50 (1.75 mg, 0.72 µmol) was coupled with biotin-NHS using the general 
procedure. Compound 74 was obtained after purification by RP-HPLC as a white 
powder (1.14 mg, 0.42 µmol, 59%). LC-MS: Rt = 5.26 min (0 - 50% ACN; 13 min); 
HRMS [C110H178N30O47S + 2H]2+: 1353.1169 found, 1353.1178 calculated. 
 
Ac-Lys(1,2-Man2)-Lys(1,2-Man2)-Lys(1,2-Man2)-Lys(1,2-Man2)-Lys(1,2-Man2)-Lys(1,2-Man2)-
Gly-Lys(biotin)-NH2 (75). 
Compound 51 (5.24 mg, 1.60 µmol) was coupled with biotin-NHS using the 
general procedure. Compound 75 was obtained after purification by RP-HPLC as 
a white powder (3.65 mg, 0.99 µmol, 62%). LC-MS: Rt = 4.94 min (0 - 50% ACN; 
13 min); HRMS [C146H238N30O77S + 3H]3+: 1226.5201 found, 1226.5200 
calculated. 
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Ac-Lys(1,3-Man2)-Lys(1,3-Man2)-Lys(1,3-Man2)-Lys(1,3-Man2)-Lys(1,3-Man2)-Lys(1,3-Man2)-
Gly-Lys(biotin)-NH2 (76). 
Compound 52 (5.24 mg, 1.60 µmol) was coupled with biotin-NHS using the 
general procedure. Compound 76 was obtained after purification by RP-
HPLC as a white powder (3.65 mg, 0.99µmol, 62%). LC-MS: Rt = 5.00 min (0 
- 50% ACN; 13 min); HRMS [C146H238N30O77S + 3H]3+: 1226.5195 found, 
1226.5200 calculated. 
 
Ac-Lys(1,6-Man2)-Lys(1,6-Man2)-Lys(1,6-Man2)-Lys(1,6-Man2)-Lys(1,6-Man2)-Lys(1,6-Man2)-
Gly-Lys(biotin)-NH2 (77). 
Compound 53 (1.82 mg, 0.53 µmol) was coupled with biotin-NHS using the 
general procedure. Compound 77 was obtained after purification by RP-HPLC 
as a white powder (1.08 mg, 0.29 µmol, 56%). LC-MS: Rt = 4.94 min (0 - 50% 
ACN; 13 min); HRMS [C146H238N30O77S + 3H]3+: 1226.5203 found, 1226.5200 
calculated. 
 
Ac-Lys(Man3)-Lys(Man3)-Lys(Man3)-Lys(Man3)-Lys(Man3)-Lys(Man3)-Gly-Lys(biotin)-NH2 (78). 
Compound 54 (8.40 mg, 1.90 µmol) was coupled with biotin-NHS using the 
general procedure. Compound 78 was obtained after purification by RP-
HPLC as a white powder (7.50 mg, 1.61 µmol, 85%). LC-MS: Rt = 4.68 min 
(0 - 50% ACN; 13 min); HRMS [C182H298N30O107S + 3H]3+: 1550.9603 found, 
1550.9599 calculated. 
 
 
General procedure to introduce ATTO655: 
Glycoclusters with a free amine were dissolved in DMSO (2.0 mM). To this, a stock solution of 
ATTO655-NHS (5.0 mM, 2 eq) and DIPEA (0.01 M, 2 eq) in DMSO was added and shaken 
protected from light for one hour. After which the product was isolated either via RP-HPLC (linear 
gradient B in A, Gemini-NX 5µm C18, 110 Å, 250 x 10.0 mm, 5 mL/min, collection on λ: 610 
nm), or gel filtration (Toyopearl HW-40S, 150 mM NH4HCO3 aq. with 20% ACN, 1.6x60 cm, UV 
monitoring λ: 610 nm) followed by lyophilization. 
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Ac-Lys(Man1)-Gly-Lys(ATTO655)-NH2 (79). 
Compound 32 (267 nmol) was coupled with ATTO655-NHS using the general 
procedure. Compound 79 was obtained after purification by gel filtration (eluted 
at 130 - 165 mL) as a blue powder after lyophilization (0.265 mg, 235 nmol, 88%). 
LC-MS: Rt = 6.01 min (0 - 50% ACN; 13 min); HRMS [C52H75N11O15S+ 2H]2+: 
563.76566 found, 563.76552 calculated. 
 
Ac-Lys(Man3)-Gly-Lys(ATTO655)-NH2 (80). 
Compound 36 (200 nmol) was coupled with ATTO655-NHS using the 
general procedure. Compound 80 was obtained after purification by gel 
filtration (eluted at 95 - 110 mL) as a blue powder after lyophilization (0.245 
mg, 169 nmol, 84%). LC-MS: Rt = 6.83 min (0 - 50% ACN; 13 min); HRMS 
[C64H95N11O25S + 2H]2+: 725.81835 found, 725.81834 calculated. 
 
 
Ac-Lys(Man1)-Gly-Lys(Man1)-Gly-Lys(ATTO655)-NH2 (81). 
Compound 38 (200 nmol) was coupled with ATTO655-NHS using the general 
procedure. Compound 81 was obtained after purification by RP-HPLC (5 - 50 
% B in A, 10 min) as a blue powder after lyophilization (0.140 mg, 89 nmol, 
45%). LC-MS: Rt = 6.05 min (0 - 50% ACN; 13 min); HRMS [C69H102N16O23S 
+ 2H]2+: 778.35840 found, 778.35850 calculated. 
 
Ac-Lys(1,2-Man2)-Gly-Lys(1,2-Man2)-Gly-Lys(ATTO655)-NH2 (82). 
Compound 39 (100 nmol) was coupled with ATTO655-NHS using the general 
procedure. Compound 82 was obtained after purification by RP-HPLC (5 - 50 
% B in A, 10 min) as a blue powder after lyophilization (0.18 mg, 95 nmol, 
95%). LC-MS: Rt = 5.95 min (0 - 50% ACN; 13 min); HRMS [C81H122N16O33S 
+ 2H]2+: 940.41153 found, 940.41132 calculated. 
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Ac-Lys(Man3)-Gly-Lys(Man3)-Gly-Lys(ATTO655)-NH2 (83). 
Compound 42 (200 nmol) was coupled with ATTO655-NHS using the 
general procedure. Compound 83 was obtained after purification by RP-
HPLC (5 - 50 % B in A, 10 min) as a blue powder after lyophilization (0.45 
mg, 204 nmol, qnt). LC-MS: Rt = 5.86 min (0 - 50% ACN; 13 min); HRMS 
[C93H142N16O43S+ 2H]2+: 1102.96588 found, 1102.96567 calculated. 
 
Ac-Lys(4-SO3-GalNAc)-Gly-Lys(4-SO3-GalNAc)-Gly-Lys(ATTO655)-NH2 (84). 
Compound 44 (100 nmol) was coupled with ATTO655-NHS using the general 
procedure. Compound 84 was obtained after purification by RP-HPLC (linear-
gradient 7 - 46 % B in A, 10 min) as a blue powder after lyophilization (5.82 
nmol, 6%, ABS = 0.364 (2 mL, λ = 663 nm)). LC-MS: Rt = 5.29 min (0 - 50% 
ACN; 13 min); HRMS [C73H108N18O29S3 + 2H]2+: 899.34175 found, 899.34186 
calculated. 
 
Ac-Lys(Man1)-Lys(Man1)-Lys(Man1)-Lys(Man1)-Lys(Man1)-Lys(Man1)-Gly-Lys(ATTO655)-NH2 
(85). 
Compound 50 (293 nmol) was coupled with ATTO655-NHS using the general 
procedure. Compound 85 was obtained after purification by gel filtration (eluted 
at 46 - 58 mL) as a blue powder after lyophilization (0.54 mg, 180 nmol, 62%). 
LC-MS: Rt = 5.46 min (0 - 50% ACN; 13 min); HRMS [C127H195N31O50S + 3H]3+: 
996.78798 found, 996.78791 calculated. 
 
Ac-Lys(1,2-Man2)-Lys(1,2-Man2)-Lys(1,2-Man2)-Lys(1,2-Man2)-Lys(1,2-Man2)-Lys(1,2-Man2)-
Gly-Lys(ATTO655)-NH2 (86). 
Compound 51 (100 nmol) was coupled with ATTO655-NHS using the 
general procedure. Compound 86 was obtained after purification by gel 
filtration (eluted at 36 – 48 mL) as a blue powder after lyophilization (34 
nmol, 34%, ABS = 1.063 (4 mL, λ = 663 nm)). LC-MS: Rt = 5.32 min (0 - 
50% ACN; 13 min); HRMS [C163H255N31O80S + 3H]3+: 1320.89485 found, 
1320.89359 calculated. 
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Ac-Lys(Man3)-Lys(Man3)-Lys(Man3)-Lys(Man3)-Lys(Man3)-Lys(Man3)-Gly-Lys(ATTO655)-NH2 
(87). 
Compound 54 (234 nmol) was coupled with ATTO655-NHS using the general 
procedure. Compound 87 was obtained after purification by gel filtration (eluted 
at 33 - 45 mL) as a blue powder after lyophilization (0.935 mg, 190 nmol, 81%). 
LC-MS: Rt = 5.78 min (0 - 50% ACN; 13 min); HRMS [C199H315N31O110S + 
3H]3+: 1645.33311 found, 1645.33352 calculated. 
 
Ac-Lys(4-SO3-GalNAc)-Lys(4-SO3-GalNAc)-Lys(4-SO3-GalNAc)-Lys(4-SO3-GalNAc)-Lys(4-SO3-
GalNAc)-Lys(4-SO3-GalNAc)-Gly-Lys(ATTO655)-NH2 (88). 
Compound 55 (100 nmol) was coupled with ATTO655-NHS using the general 
procedure. Compound 90 was obtained after purification by RP-HPLC (linear-
gradient 7 - 47 % B in A, 10 min) as a blue powder after lyophilization (89 nmol, 
89%, ABS = 1.597 (7 mL, λ = 663 nm)). LC-MS: Rt = 4.57 min (0 - 50% ACN; 
13 min); HRMS [C139H213N37O68S7 + 2H + Na]3+: 1246.41578 found, 
1246.41561 calculated. 
 
Ac-Lys(Man1)-AEEA-Gly-Lys(Man1)-Gly-Lys(ATTO655)-NH2 (89). 
Compound 56 (100 nmol) was coupled with ATTO655-NHS 
using the general procedure. Compound 89 was obtained after 
purification by RP-HPLC (linear-gradient 7 - 46 % B in A, 10 
min) as a blue powder after lyophilization (43 nmol, 43%, ABS 
= 1.344 (4 mL, λ = 663 nm)). LC-MS: Rt = 5.44 min (0 - 50% 
ACN; 13 min); HRMS [C75H113N17O26S + 2H]2+: 850.89550 
found, 850.89544 calculated. 
Ac-Lys(Man3)-AEEA-Gly-Lys(Man3)-Gly-Lys(ATTO655)-NH2 (90). 
Compound 57 (100 nmol) was coupled with ATTO655-
NHS using the general procedure. Compound 90 was 
obtained after purification by RP-HPLC (linear-gradient 7 
- 47 % B in A, 10 min) as a blue powder after 
lyophilization (26.1 nmol, 26%, ABS = 0.818 (4 mL, λ = 
663 nm)). LC-MS: Rt = 5.23 min (0 - 50% ACN; 13 min); 
HRMS [C99H153N17O46S + 2H]2+: 1175.50270 found, 1175.50253 calculated. 
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Ac-Lys(4-SO3-GalNAc)-AEEA-Gly-Lys(4-SO3-GalNAc)-Gly-Lys(ATTO655)-NH2 (91). 
Compound 58 (100 nmol) was coupled with ATTO655-NHS 
using the general procedure. Compound 91 was obtained after 
purification by RP-HPLC (linear-gradient 7 - 47 % B in A, 10 
min) as a blue powder after lyophilization (10.6 nmol, 11%, 
ABS = 0.666 (2 mL, λ = 663 nm)). LC-MS: Rt = 5.30 min (0 - 
50% ACN; 13 min); HRMS [C79H119N19O32S3 + 2H]2+: 
971.87872 found, 971.87881 calculated. 
 
General procedure for the introduction of AlexaFluor488: 
Glycoclusters with a free amine were dissolved in DMSO (2.0 mM). To this, a stock solution of 
AF488-NHS (5.0 mM, 2 eq) and DIPEA (0.01 M, 2 eq) in DMSO was added and shaken protected 
from light for one hour. After which the product was isolated via gel filtration (Toyopearl HW-
40S, 1.6x60 cm, 150 mM NH4HCO3, 20% ACN, UV monitoring λ: 494 nm) followed by 
lyophilization. 
 
Ac-Lys(Man1)-Lys(Man1)-Lys(Man1)-Lys(Man1)-Lys(Man1)-Lys(Man1)-Gly-Lys(AF488)-NH2 (92). 
Compound 50 (200 nmol) was coupled with AF488-NHS using the general 
procedure. Compound 92 was obtained after purification by gel filtration 
(eluted at 28 – 35.5 mL) as a green solution or orange powder after 
lyophilization (94 nmol, 47%, ABS = 0.869 (8 mL, λ = 494 nm)). LC-MS: 
Rt = 5.59 min (0 - 50% ACN; 13 min); HRMS [C121H176N30O55S2 + 3H]3+: 
999.05260 found, 999.05286 calculated. 
Ac-Lys(Man3)-Lys(Man3)-Lys(Man3)-Lys(Man3)-Lys(Man3)-Lys(Man3)-Gly-Lys(AF488)-NH2 (93). 
Compound 54 (200 nmol) was coupled with AF488-NHS using the 
general procedure. Compound 87 was obtained after purification by gel 
filtration (eluted at 26.5 – 34 mL) as a green solution or orange powder 
after lyophilization (68 nmol, 34%, ABS = 1.243 (4 mL, λ = 494 nm)). 
LC-MS: Rt = 4.88 min (0 - 50% ACN; 13 min); HRMS 
[C193H296N30O115S2+ 3H]3+: 1647.59818 found, 1647.59842 calculated. 
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Ac-Lys(4-SO3-GalNAc)-Lys(4-SO3-GalNAc)-Lys(4-SO3-GalNAc)-Lys(4-SO3-GalNAc)-Lys(4-SO3-
GalNAc)-Lys(4-SO3-GalNAc)-Gly-Lys(AF488)-NH2 (94). 
Compound 55 (100 nmol) was coupled with AF488-NHS using the general 
procedure. Compound 90 was obtained after purification by gel filtration 
(eluted at 28 – 37 mL) as a green solution or orange powder after 
lyophilization (5.9 nmol, 6%, ABS = 0.216 (2 mL, λ = 494 nm)). LC-MS: 
Rt = 5.60 min (0 - 50% ACN; 13 min); HRMS [C133H194N36O73S8 + 
Na+3NH3]4+: 948.72085 found, 948.77796 calculated. 
 
General procedure for the introduction of ATTO565: 
Glycoclusters with a free amine were dissolved in DMSO (2.0 mM). To this, a stock solution of 
ATTO565-NHS (10 mM, 2 eq) and DIPEA (0.01 M, 2 eq) in DMSO was added and shaken 
protected from light for one hour. After which the product was isolated via gel filtration 
(Toyopearl HW-40S, 1.6x60 cm, 150 mM NH4HCO3, 20% ACN, UV monitoring λ: 564 nm) 
followed by lyophilization. 
 
Ac-Lys(Man1)-Lys(Man1)-Lys(Man1)-Lys(Man1)-Lys(Man1)-Lys(Man1)-Gly-Lys(ATTO565)-NH2 
(95). 
Compound 50 (300 nmol) was coupled with ATTO565-NHS using the 
general procedure. Compound 95 was obtained after purification by gel 
filtration (eluted at 29.5 – 37 mL) as a pink powder after lyophilization (127.8 
nmol, 43%, ABS = 1.704 (9 mL, λ = 564 nm)). LC-MS: Rt = 6.42 min (0 - 
50% ACN; 13 min); HRMS [C131H192N30O49 + 3H]3+: 991.12431 found, 
991.12341 calculated. 
Ac-Lys(Man3)-Lys(Man3)-Lys(Man3)-Lys(Man3)-Lys(Man3)-Lys(Man3)-Gly-Lys(ATTO565)-NH2 
(96). 
Compound 54 (300 nmol) was coupled with ATTO565-NHS using the 
general procedure. Compound 96 was obtained after purification by gel 
filtration (eluted at 26.5 – 34 mL) as a pink powder after lyophilization 
(128.6 nmol, 43%, ABS = 1.715 (9 mL, λ = 564 nm)). LC-MS: Rt = 5.75 
min (0 - 50% ACN; 13 min); HRMS [C203H312N30O109 + 4H]4+: 
1230.00614 found, 1230.00363 calculated. 
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Ac-Lys(4-SO3-GalNAc)-Lys(4-SO3-GalNAc)-Lys(4-SO3-GalNAc)-Lys(4-SO3-GalNAc)-Lys(4-SO3-
GalNAc)-Lys(4-SO3-GalNAc)-Gly-Lys(ATTO565)-NH2 (97). 
Compound 55 (100 nmol) was coupled with ATTO565-NHS using the 
general procedure. Compound 97 was obtained after purification by gel 
filtration (eluted at 30 – 42 mL) as a pink powder after lyophilization (17 
nmol, 17%, ABS = 1.031 (2 mL, λ = 564 nm)). LC-MS: Rt = 5.82 min (0 - 
50% ACN; 13 min); HRMS [C143H210N36O67S6 + 3H]3+: 1233.42735 found, 
1233.42389 calculated. 
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Chapter 3 
Large scale synthesis of a conjugation-
ready 2-butoxy-8-oxo-adenine analog 
TLR7-liganda 
Introduction 1 
Effective vaccines require at least two functionalities, a recognizable disease-related antigen and 
an adjuvant. Adjuvants can be derived from pathogen-associated molecular patterns (PAMPs) that 
induce signaling through binding of pattern recognition receptors (PRRs) stimulating antigen-
presenting cells (APCs) to mature. Maturation results in the secretion of inflammatory cytokines 
and upregulation of antigen processing and presentation, which are a necessity for an adequate 
adaptive response. The Toll-like receptor (TLR) family is intensively explored for the development 
of new vaccine adjuvants.2 Ten different TLRs which recognize different types of PAMPs can be 
found on human immune cells. They are either expressed on the cell surface (TLR1, TLR2, TLR4, 
TLR5, TLR6, and TLR10) or endosomal (TLR3, TLR7, TLR8, and TLR9).3,4 Endosomal TLRs 
 
aPart of this work is published in Hogervorst & Gential et al. 20191 
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recognize nucleic acid-based PAMPs such as viral double-stranded RNA (TLR3),5 single-stranded 
bacterial and viral RNA (TLR7 and TLR8)6–8 and bacterial and viral DNA (TLR9).9 
Small molecule agonists have been discovered as ligands for TLR7 and TLR8. Prime examples are 
imidazoquinolines based structures such as imiquimod (98) and resiquimod (99, Figure 1),10 of 
which the latter is used in the clinic for the treatment of an uncommon epidermal cancer11 and is 
tested as vaccine adjuvant.12 Derivatives of 8-oxo-adenine and 8-hydroxy-adenine are another class 
of TLR7/TLR8 agonists. Based on lead compound 100 (Figure 1), developed by Hirota et al.13 a 
multitude of structure-activity relationship studies have been described resulting in agonists such 
as SM-324405 (101).14–17 
Figure 1: TLR7/TLR8 agonists. 
 
Both classes of agonists have been functionalized to give conjugation-ready compounds such as 
102, which can be conjugated via either an isothiocyanate or a maleimide handle.18 Fujita et al. 
described the norleucine amino acid derivative 103 that can be incorporated in a peptide via solid-
phase peptide synthesis.19 Several derivatives of 8-oxo-adenine have been used for conjugation to 
antigens. For example, Weterings et al.20 generated 104, having an 2-azidoalkoxy spacer for 
attachment to a peptide antigen. The resulting conjugate showed enhanced antigen presentation 
but lost the ability to induce maturation.20 Conjugation of 105 via its 9-benzyl function as first 
described by Chan et al.,21 resulted in conjugates that maintained the maturation ability and 105 
has since been successfully used in peptide-adjuvant conjugates.22 Similar results were obtained 
with the 2-butoxy analog 106.17 
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Although structures such as 106 and 105 have been successfully used in adjuvant-antigen 
conjugates, their synthesis and subsequent conjugation are far from ideal. Two synthetic routes 
towards 106 have been described. Akinbobuyi et al.23 obtained 106 in four steps with an 61% 
overall yield starting from 6-amino-2-chloropurine (107, Scheme 1, route A). In this route, the 
benzoic acid was introduced with cyanobenzylbromide (108) to afford (109), which was converted 
to free acid 110, after the butoxy group was installed. Subsequent bromination, followed by sodium 
hydroxide treatment gave ligand 106. The authors described that the main advantage of this route 
is that all intermediates could be purified via precipitation in reactions with high conversion.  
In the second route to 106, developed by G.P.P. Gential,24 the benzoic acid is masked as a 
butylester that was deprotected in the final stage of the synthesis (route B, Scheme 1). Starting 
from purine (107), adenine 106 was obtained in four steps in a 23% overall yield. In this route, the 
butylester protection circumvented solubility issues caused by the free benzoic acid as experienced 
in route A. It was described that the electrophilic aromatic bromination to obtain 115 proceeded 
sluggishly and could only be achieved in high yield with the aid of a large excess of bromine. 
Nucleophilic aromatic substitution, demethylation and ester hydrolysis resulted in 106. The main 
advantage of route B is the solubility of all intermediates, allowing the purification by for example 
flash column chromatography. A major disadvantage is the large excess of reagents that are needed 
to introduce and substitute the bromine and the low overall yield of the route. 
A drawback of small molecule agonists for TLR7 and TLR8 is their toxicity. Therefore, imiquimod 
can only be administered topically.25 Chan et al.21 achieved a significant reduction of toxicity by 
conjugation of TLR ligand 105 to phospholipids and polyethylene glycols. Unfortunately, 
conjugation of ligands 106 and 105 via their carboxylic acid function resulted in poor yields, due 
to the poor solubility of the ligand.21 The solubility of 106 could be improved by the introduction 
of a tert-butoxycarbonyl (Boc) protecting group, but the yield of a small scale (0.15 mmol) synthesis 
of 116 did not exceed 10% (Scheme 1).24 
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Scheme 1: Previously described routes towards 106. 
 
 
This Chapter presents an improved route of synthesis of 116. Because Route A could not be 
reproduced providing enough material in sufficient purity, Route B was optimized to enable the 
production of 116 on a large scale. Having sufficient amounts of 116 available, conjugates can be 
developed that can be targeted to the endosomes of immune cells, thereby potentially increasing 
their effectiveness. Conjugation of 116 to the oligomannoside clusters, described in Chapter 2, 
would not only increase the water solubility of the TLR7 ligand, but also allow for the active 
transport toward endosomes. To test this hypothesis, this Chapter also describes the synthesis of 
three bifunctional conjugates that target both TLR7 and trafficking receptors.  
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Results and Discussion 
An improved synthetic route towards Boc protected TLR7 agonist 116 is described in Scheme 2. 
To allow for the synthesis of 116 with higher yields and on a larger scale, the synthetic procedures 
applied in route B (Scheme 1)24 were modified, learning lessons from route A.23 The main drawback 
in route B was the conversion of 114 to 116, requiring a large excess of reagents for the introduction 
and the substitution of the bromine, hindering efficient scale-up. Furthermore, 90% of 106 was 
lost in the final step introducing the Boc protection group.  
The electrophilic aromatic bromination of 114, according to route B, required nineteen equivalents 
of bromine. Subsequent quenching of the excess of bromine with a sodium thiosulphate solution 
generated HBr that lowered the pH of the solution, leading to the formation of solid elementary 
sulfur.26 On a small scale, these solids made the work-up time consuming, because they clogged 
the glassware and filters. On a larger scale, this problem was so prominent that it made work-up 
impossible. The addition of sodium acetate (as in route A)23 improved both the efficiency of 
reaction and the work-up procedure. Using only five equivalents of bromine, 115 was obtained 
within an hour in 94% yield on a 40 mmol scale (Scheme 2). Not only did the smaller excess of 
bromine reduce the amount of required thiosulphate, but the presence of sodium acetate also 
increased the pH resulting in the formation of less solid sulfur.  
Attempts to hydrolyze bromine 115 directly with NaOH were unsuccessful in route B. This was 
circumvented by using a more nucleophilic methoxide, followed by acidic cleavage of the resulting 
methyl ether and finally saponification of the remaining benzoic ester under basic condition. The 
large amount of acidic and basic solutions required for scale-up of the reaction made this three-
step method cumbersome. The two extra steps could be circumvented by refluxing 115 for three 
days in a solution of NaOH in a mixture of methanol and water. In this procedure, in situ formed 
methanolate can displace the bromine while the ether and ester are also cleaved. After acidification 
of the resulting solution, 106 could be precipitated and filtered off to provide the free acid in 89% 
yield on a multigram scale.  
106 proved to be insoluble in most organic solvents, which makes this building block unsuitable 
for conjugation. Gential described the enhancement of the solubility of the building block by the 
introduction of a Boc group. To introduce the tert-butyl carbamate, 106 was suspended in a 
water/dioxane mixture after which it was stirred with triethylamine and ten equivalents of 2-(tert-
butoxycarbonyloxyimino)-2-phenylacetonitrile (Boc-ON) for five days. The reaction proceeded 
sluggishly with only 10% conversion after five days. This result was explained by the poor solubility 
of both 106 and Boc-ON and the moderate nucleophilicity of the aromatic amine.24 Optimization 
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of this reaction (Table 1) by either changing the solvent system (entries 2 and 3), changing to the 
more soluble di-tert-butyl dicarbonate (Boc2O, entries 4-11) or changing Et3N to DMAP (entries 
2-5) improved the reaction slightly but still more than 80% of product was lost. Notably, in all 
entries, 106 was not completely dissolved, not even when diluted in DMSO (entries 2,4,8). In an 
attempt to obtain a homogenous solution, 106 was dissolved in a NaOH (1.0 M, aq.) generating 
its sodium salt, after which a solution of Boc2O in dioxane was added dropwise (entry 9). Upon 
neutralization with HCl (1.0 M, aq.) both 106 and 116 crashed out, and subsequent centrifugation 
of the suspension allowed for removal of excess reagents after which extraction of the solids with 
chloroform gave 116 in 30-40% yield while starting compound 106 could be recovered from the 
residue (entries 9-11).  
 
Scheme 2: Synthesis of building block 116 
 
Reagents and conditions a) 112, K2CO3, DMSO, 63%; b) i. NaH, n-BuOH, 120 °C; ii. H2SO4, 80 °C, 71%; c) Br2, NaOAc, 
DCM, 94%; d) NaOH, H2O, MeOH, reflux, 89%; e) NaOH, Boc2O, H2O, Dioxane, 35% (95% recovery of 106). 
 
When the reaction was performed on a 30 mmol scale (entry 11), the final extraction proved to be 
more difficult due to large amounts of solids. However, using a Soxhlet extraction apparatus, 116 
could be isolated in high yield, delivering 10.5 mmol of product (35%). By extraction of the 
remaining residue in the sock using a NaOH solution (1 M, aq.) and subsequent acidification of 
the filtrate, the precipitated 106 could be recovered in high yield (18.5 mmol, 95% recovery) and 
it could be re-subjected to the bocylation reaction. Together these optimizations improved the 
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conversion of 114 into 116 from 4% to 29%. The synthesis of 116 on a multi-mmol scale makes it 
a feasible conjugation-ready building block to be used in SPPS (as described in Chapter 4 and 5) 
or solution-based synthesis (below). 
Before conjugation of 116 to the projected glycoside clusters, a spacer was introduced (Scheme 3). 
Condensation of 116 with known triethylene glycol 117,27,28 obtained via previously described 
procedures resulted in tert-butyl ester protected 118. Simultaneous acid-mediated removal of the 
Boc group and butyl ester29 resulted in a compound that caused gelation in water and DMSO, 
thereby hindering its purification. In the end, the compound could be dissolved using NH4OAc 
(0.033 M) in a mixture of H2O/ACN/t-BuOH/AcOH (4/1/1/3, v/v/v/v) allowing the 
purification of 119 via RP-HPLC. Conversion of carboxylic acid 119 into the pentafluorophenol 
(Pfp) ester 120 improved the solubility in water and DMSO which enabled the synthesis of three 
bi-functional conjugates (Scheme 3). The mannoside clusters 50 and 54 (mono- or tri-mannoside 
clusters on a hexavalent scaffold), described in Chapter 2, were conjugated to Pfp ester 120 
resulting in clusters 121 and 122. Both clusters should be able to target DC-SIGN (see Chapter 2) 
and could route the bi-functional conjugates toward endosomes. A similar hexavalent scaffold 123 
containing six mannose-6-phosphates, described by R.N.M. Reintjes,30 was conjugated to Pfp ester 
120 forming cluster 124. This conjugate was designed to target the mannose-6-phospate receptor 
which could result in endo-/lysosomal routing. Unlike the previously described 9-benzyl-8-oxo 
adenine analog, all these bi-functional conjugates are highly water-soluble. All three conjugates are 
being tested for their ability to mature APCs and this evaluation is ongoing.  
Table 1: Optimization of Boc introduction 
Entry Boc source Solvent Base [106] Yield 
124 Boc-ON (13 eq) H2O/dioxane (1/1) Et3N (3 eq) 0.5 M 10%a 
2 Boc-ON (2 eq) DMSO DMAP (0.1 eq) 0.5 M 8%a 
3 Boc-ON (2 eq) THF DMAP (0.1 eq) 0.5 M 7%a 
4 Boc2O (4 eq) DMSO DMAP (0.1 eq) 0.5 M 14% 
5 Boc2O (4 eq) THF DMAP (0.1 eq) 0.5 M 13% 
6 Boc2O (4 eq) MeOH/H2O/Et3N (10/10/7) Et3N 0.5 M 0% 
7 Boc2O (8 eq) H2O/dioxane (1/1) Et3N (3 eq) 0.5 M 13% 
8 Boc2O (8 eq) DMSO Et3N 0.15 M 15% 
9 Boc2O (1.5 eq) H2O/dioxane (1/1) NaOH (2 eq) 0.5 M 24% 
10 Boc2O (1.2 eq) H2O/dioxane (3/1) NaOH (3 eq) 0.25 M 41% 
11 Boc2O (1.2 eq) H2O/dioxane (3/1) NaOH (3 eq) 0.25 M 35% 
 
a Formation of butyl ester was observed on LC-MS 
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Scheme 3: Synthesis of mannosylated - TLR7 agonist - conjugates 
Reagents and conditions: a) HCTU, DIPEA, DCM/DMF, 84%; b) H3PO4, H2O/toluene, 43%; c) pentafluorophenol, DIC, 
DMAP, DMSO; d) 50, 120, DIPEA, DMSO/H2O, 73%; e) 54, 120, DIPEA, DMSO/H2O, 46%; f) 120, DIPEA, 
DMSO/H2O, 2.8%. 
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Conclusion 
A major improvement in the synthesis of 2-butoxy-8-oxo-adenine analog 116 was achieved. In 
particular, the overall total yield for the conversion of 114 into 116, comprising electrophilic 
aromatic bromination, bromine hydrolysis, and introduction of a Boc group, was increased from 
4% to 29%. Furthermore, it was possible to regenerate unprotected adenine 106 during the 
introduction of the Boc group, by which the Boc-protection could be repeated, increasing the total 
overall yield further. The new synthetic procedures improved the workability of the synthetic 
route, in terms of work-up and purification, allowing for a significant increment of reaction scale. 
Which resulted in the isolation of 116 on a 10.5 mmol scale, making this building block readily 
available for further conjugations. Together with the improvement in solubility due to the 
introduction of the Boc-group, makes 116 a suitable building block for application in both solution 
and solid-phase peptide syntheses. The applicability of 116 was successfully demonstrated by the 
solution phase conjugation to three mannoside clusters forming three highly water-soluble bi-
functional conjugates of which their effectiveness to induce DC-maturation is under current 
evaluation.  
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Experimental 
General procedures: 
All reactions, purifications, and analyses were performed as described in the general procedures of 
Chapter 2. 
Butyl 4-methylbenzoate (125). 
p-Toluic acid (53.3 g, 390 mmol) was dissolved in dry n-BuOH (500 mL, 0.8 M). H2SO4 (1.9 
mL 35 mmol, 0.09 eq) was added and the mixture was refluxed for 5 hours, after which the 
reaction mixture was diluted with DCM (1 L) and washed with NaHCO3 (sat. aq.) twice. The organic layer 
was collected, dried over MgSO4, filtered and concentrated in vacuo. The mixture was co-evaporated with 
toluene (2x) yielding ester 125 as a clear oil (56.13 g, 370 mmol, 95%). TLC Rf 0.63 (Et2O/PE, 5/95, v/v); 
IR (neat, cm-1): 2957, 1713; 1H NMR (400 MHz, CDCl3, HH-COSY, HSQC): δ 7.93 (d, J = 8.3 Hz, 2H, H-
3/H-4), 7.20 (d, J = 8.0 Hz, 2H, H-3/H-4), 4.30 (t, J = 6.6 Hz, 2H, H-7), 2.37 (s, 3H, H-1), 1.80 - 1.66 (m, 
2H, H-8), 1.53 - 1.39 (m, 2H, H-9), 0.97 (t, J = 7.4 Hz, 3H, H-10); 13C NMR (100 MHz, CDCl3, HSQC): δ 
166.7 (C-6), 143.4 (C-5), 129.6, 129.0 (C-3, C-4), 127.8 (C-2), 64.6 (C-7), 30.8 (C-8), 21.6 (C-1), 19.3 (C-9), 
13.8 (C-10); HRMS [C12H16O2 +H]+: 193.12226 found, 193.12231 calculated. 
Butyl 4-(bromomethyl) benzoate (112). 
Compound 125 (54.45 g, 283 mmol) was dissolved in CCl4 (283 mL, 1.0 M) in a three liter flask 
equipped with a bump-trap and a large cooler loosely stoppered with a septum under nitrogen. 
NBS (86.5 g, 311 mmol, 1.1 eq) and α,α′-Azoisobutyronitrile (AIBN, 2.4 g, 14.6 mmol, 0.05 eq) were added 
and the mixture was carefully heated to 90 °C for six hours. After TLC analysis showed full conversion of 
the starting material the reaction mixture was concentrated in vacuo, diluted in EtOAc and washed with 
H2O. The organic layer was collected, dried over MgSO4, filtered and concentrated. Compound 112 was 
obtained after purification by silica gel chromatography (absorbed on Celite → 1/199 → 2/98, Et2O/PE, 
v/v) as a yellow oil (49.62 g, 183 mmol, 65%). TLC Rf 0.55 (Et2O/PE, 5/95, v/v); IR (neat, cm-1): 3197, 
2957, 1713; 1H NMR (400 MHz, CDCl3): δ 8.04 (d, J = 8.3 Hz, 2H, H-3/H-4), 7.48 (d, J = 8.3 Hz, 2H, H-
3/H-4), 4.52 (s, 2H, H-1), 4.35 (t, J = 6.6 Hz, 2H, H-7), 1.83 - 1.72 (m, 2H, H-8), 1.56 - 1.44 (m, 2H, H-9), 
1.01 (t, J = 7.4 Hz, 3H, H-10); 13C NMR (100 MHz, CDCl3): δ 166.2 (C-6), 142.6 (C-2), 130.6 (C-5), 130.1, 
129.1 (C-3, C-4), 65.1 (C-7), 32.4 (C-1), 30.9 (C-8), 19.4 (C-9), 13.9 (C-10); HRMS [C12H15BrO2 + H]+: 
271.11816 found, 271.03282 calculated. 
Butyl 4-((6-amino-2-chloro-9H-purin-9-yl)methyl)benzoate (113). 
To a suspension of 6-amino-2-chloropurine (107) (22.11 g, 130 mmol) in DMSO (300 mL, final 
0.3 M) at 0 °C, K2CO3 (54 g, 390 mmol, 3 eq) and a solution of compound 112 (42.3 g, 156 
mmol, 1.2 eq) in DMSO (133 mL) were added successively and the mixture was stirred for a 
day. After complete consumption of 107 the mixture was poured in H2O (3 L) and stored at 4 °C overnight. 
The suspension was filtered off, washed with H2O (3x) and the powder was dried in vacuo. Purification by 
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silica gel column chromatography (absorbed on Celite → 1/99 → 6/94, MeOH/DCM, v/v) yielded title 
compound 113 as an off-white solid (29.88 g, 83.0 mmol, 63%). TLC Rf 0.34 (MeOH/DCM, 5/95, v/v); 
IR (neat, cm-1): 3297, 3122, 2957, 1736, 1597; 1H NMR (400 MHz, CDCl3): δ 8.03 (d, J = 8.3 Hz, 2H, H-
12/H-13), 7.72 (s, 1H, H-8), 7.33 (d, J = 8.3 Hz, 2H, H-12/H-13), 6.06 (s, 2H, NH2), 5.39 (s, 2H, H-10), 
4.32 (t, J = 6.7 Hz, 2H, H-16), 1.80 - 1.71 (m, 2H, H-17), 1.51 - 1.42 (m, 2H, H-18), 0.97 (t, J = 7.4 Hz, 3H, 
H-19); 13C NMR (101 MHz, CDCl3): δ166.1, 156.3 (C-2, C-4, C-5, C-6, C-11, C-14), 140.7 (C-8), 140.0 (C-
2, C-4, C-5, C-6, C-11, C-14), 130.5, 127.8 (C-12, C-13), 65.2 (C-16), 47.1 (C-10), 30.9 (C-17), 19.4 (C-18), 
13.9 (C-19); HRMS [C17H18ClN5O2 + H]+: 360.12143 found, 360.12218 calculated. 
Butyl 4-((6-amino-2-butoxy-9H-purin-9-yl)methyl)benzoate (114). 
Compound 113 (29.88 g, 83.0 mmol) was dissolved in anhydrous n-BuOH (500 mL, 0.17 M) 
and cooled to 0 °C. To this solution NaH (33.2 g, 830 mmol, 10 eq) was added in small portions 
over three hours. The mixture was stirred at 120°C overnight, after which LC-MS analysis 
showed full conversion of the starting material into the product and a small portion hydrolyzed product. 
The mixture was cooled to 0°C and H2SO4 (53 mL, 1 mol, 1.2 eq, 98%) was added dropwise over three 
hours under vigorous stirring. After addition the reaction mixture was stirred at 80 °C for two hours. The 
mixture was diluted in DCM (1.5 L), washed with NaHCO3 (sat. aq., 3x) after which the organic layer was 
collected, dried over MgSO4, filtered and concentrated in vacuo. Remaining n-BuOH was removed by co-
evaporating with toluene (3x). Purification by silica gel column chromatography (applied in CHCl3 → 1/99 
→ 1/1, MeOH/DCM, v/v) followed by crystallization (CHCl3/toluene, 1/1, v/v) yielding title compound 
114 as an off-white solid (23.46 g, 59.0 mmol, 71%). TLC Rf 0.26 (MeOH/DCM, 5/95, v/v); IR (neat, cm-
1): 3282, 3110, 2955, 1736, 1597; 1H NMR (400 MHz, CDCl3): δ 8.01 (d, J = 8.3 Hz, 2H, H-12/H-13), 7.61 
(s, 1H, H-8), 7.34 (d, J = 8.3 Hz, 2H, H-12/H-13), 5.69 (s, 2H, NH2), 5.33 (s, 2H, H-10), 4.35 - 4.25 (m, 
4H, H-16, H-20), 1.83 - 1.69 (m, 4H, H-17, H-21), 1.56 - 1.40 (m, 4H, H-22, H-18), 0.97 (td, J = 7.4, 2.0 
Hz, 6H, H-19, H-23); 13C NMR (100 MHz, CDCl3): δ 166.2, 162.6, 156.6, 152.1, 140.8, 138.8, 130.6 (C-2, 
C-4, C-5, C-6, C-11, C-14), 130.3, 127.8 (C-12, C-13), 67.2, 65.1 (C-16, C-20), 46.7 (C-10), 31.2, 30.8 (C-17, 
C-21), 19.4, 19.4, 14.0, 13.9; HRMS [C21H27N5O3 + H]+: 398.21702 found, 398.21867 calculated. 
Butyl 4-((6-amino-8-bromo-2-butoxy-9H-purin-9-yl)methyl)benzoate (115). 
Compound 114 (16.93 g, 42.5 mmol) was dissolved in DCM (430 mL, 0.1 M), cooled to 0 °C 
and NaOAc (13.95 g, 85 mmol, 2 eq) and Br2 (10.9 mL, 212.5 mmol, 5 eq) were added 
successively. After one hour the reaction was quenched with Na2S2O3 (sat. aq.). The mixture 
was transferred to a separation funnel and the organic layer was washed with Na2S2O3 (sat. aq. 3x) and H2O 
(1x), dried over MgSO4, filtered and concentrated in vacuo. Purification by silica gel column chromatography 
(1/99, MeOH/DCM, v/v) yielded title compound 115 as an orange solid (19.0 g, 39.9 mmol, 94%). TLC 
Rf 0.52 (MeOH/DCM, 5/95, v/v); IR (neat, cm-1): 3320, 3196, 2957, 1722, 1652, 1589; 1H NMR (400 MHz, 
CDCl3): δ 8.00 (d, J = 8.3 Hz, 2H, H-12/13), 7.37 (d, J = 8.4 Hz, 2H, H-12/13), 5.89 (s, 2H, NH2), 5.35 (s, 
2H, H-10), 4.31 (td, J = 6.1, 0.9 Hz, 4H, H-16, H-20), 1.81 - 1.68 (m, 4H, H-17, H-21), 1.55 - 1.40 (m, 4H, 
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H-18, H-22), 0.96 (td, J = 7.4, 1.1 Hz, 6H, H-19, H-23); 13C NMR (100 MHz, CDCl3): δ 166.2, 162.4, 155.4, 
153.1,140.2, 130.5 (C-2, C-4, C-5, C-6, C-11, C-14, C-15), 130.2, 127.8, (C-12, C-13), 124.5 (C-8), 116.2 (C-
2, C-4, C-5, C-6, C-11, C-14, C-15), 67.4, 65.1 (C-16, C-20), 47.1 (C-10), 31.1, 30.9 (C-17, C-21), 19.4, 19.2 
(C-18, C-22), 14.0, 13.9 (C-19, C-23); HRMS [C21H26BrN5O3 + H]+: 478.12507 measured, 478.12740 
calculated. 
4-((6-Amino-2-butoxy-8-oxo-7,8-dihydro-9H-purin-9-yl)methyl)benzoic acid (106). 
Compound 115 (13.03 g, 27.3 mmol) was dissolved in MeOH (182 mL, 0.15 M) and NaOH 
(240 mL, 10 M, aq., 2.4 mol, 88 eq) was added dropwise after which the cream white 
suspension was refluxed for three days. After LC-MS analysis showed full conversion of the 
starting material the clear brown solution was cooled to 0 °C and quenched with HCl (420 mL, 6 M, aq., 
2.52 mol, 92 eq). The solution changed to a white suspension and the reaction volume was reduced by halve 
under reduced pressure. The solids were filtered off and washed with water and dried in vacuo yielding 
compound 106 as an orange solid (8.71 g, 24.4 mmol, 89%). LC-MS: Rt = 5.09 min (0 - 50% ACN; 13 min); 
IR (neat, cm-1): 3418, 3168, 1689; 1H NMR (400 MHz, DMSO-d6): δ 12.94 (s, 1H, CO2H), 10.93 (s, 1H, 
NH-7), 7.88 (d, J = 8.1 Hz, 2H, H-12/H-13), 7.36 (d, J = 8.1 Hz, 2H, H-12/H-13), 6.98 (s, 2H, NH2), 4.92 
(s, 2H, H-10), 4.11 (t, J = 6.6 Hz, 2H, H-16), 1.67 - 1.51 (m, 2H, H-17), 1.42 - 1.27 (m, 2H, H-18), 0.87 (t, 
J = 7.3 Hz, 3H, H-19); 13C NMR (101 MHz, DMSO-d6): δ 167.0, 160.0, 152.0, 148.9, 148.0, 142.2, 129.8 
(C-2, C-4, C-5, C-6, C-11, C-14, C-15), 129.6, 127.3 (C-13, C-12), 98.4 (C-2, C-4, C-5, C-6, C-11, C-14, C-
15), 65.9 (C-16), 42.1 (C-10), 30.6 (C-17), 18.7 (C-18), 13.7 (C-19); HRMS [C17H19N5O4 + H]+: 358.15009 
found, 358.15098 calculated. 
4-((6-amino-2-butoxy-7-(tert-butoxycarbonyl)-8-oxo-7,8-dihydro-9H-purin-9-yl) methyl) 
benzoic acid (116). 
Compound 106 (10.7 g, 30.0 mmol) was dissolved in a NaOH solution (1.0 M, 100 mL, 100 
mmol, 3.3 eq). To this clear dark-brown solution a solution of Boc2O in dioxane (1.2 M, 33 
mL, 39.6 mmol, 1.3 eq) was added dropwise over 10 minutes under vigorous stirring. After 
2.5 hours the reaction mixture was diluted with CHCl3 (200 mL) and acidified with HCl (1.0 M, 100 mL, 
100 mmol, 3.3 eq) dropwise over 20 minutes in which a clouded suspension formed. Separation of layers 
was achieved by spinning the mixture down at 4000 rpm for 5 min. The aqueous layer was removed and 
the solid and organic layer were combined and transferred to a soxhlet extractor. This solid was extracted 
with CHCl3 in the soxhlet apparatus until no clear color emerged from the sock (7 times). The organic layer 
was dried over MgSO4, filtered and concentrated. Purification by silica gel column chromatography (1/99 
→ 4/96, MeOH/DCM, v/v) yielded title compound 116 as an off-white solid. (4.83 g, 10.5 mmol, 35%) 
Starting material was recovered by rinsing the soxhlet with NaOH (1 M, aq.) followed by acidification of 
the aqueous layer (HCl, 1 M, aq.), results in starting material 106 as a solid that could be obtained by filtration 
(6.60 g, 18.5 mmol, 95% recovery). TLC Rf 0.27 (MeOH/DCM, 1/9, v/v); IR (neat, cm-1): 3431, 3163, 
2958, 1753, 1720, 1637; 1H NMR (400 MHz, DMSO-d6): δ 12.96 (s, 1H, CO2H), 7.90 (d, J = 8.0 Hz, 2H, 
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H-12/H-13), 7.41 (d, J = 8.0 Hz, 2H, H-12/H-13), 7.06 (s, 2H, NH2), 4.94 (s, 2H, H-10), 4.16 (t, J = 6.5 
Hz, 2H, H-16), 1.66 - 1.57 (m, 2H, H-17), 1.54 (s, 9H, t-Bu), 1.35 (dq, J = 14.7, 7.4 Hz, 2H, H-18), 0.89 (t, 
J = 7.3 Hz, 3H, H-19); 13C NMR (101 MHz, DMSO-d6): δ 167.0, 161.2, 150.5, 150.2, 149.6, 149.1, 141.1, 
130.0 (C-2, C-4, C-5, C-6, C-11, C-14, C-15), 129.6, 127.6 (C-13, C-12), 96.4 (C-2, C-4, C-5, C-6, C-11, C-
14, C-15), 85.2 (Cq t-Bu), 66.2 (C-16), 42.7 (C-10), 30.5 (C-17), 27.6 (t-Bu), 18.7 (C-18), 13.7 (C-19); HRMS 
[C22H27N5O6 + H]+: 458.2046 found, 458.2034 calculated.  
tert-butyl 6-amino-2-butoxy-9-(4-((13,13-dimethyl-11-oxo-3,6,9,12-tetraoxatetradecyl) 
carbamoyl) benzyl)-8-oxo-8,9-dihydro-7H-purine-7-carboxylate (118). 
Amine 117 (313.9 mg, 1.19 mmol 1.03 eq), Boc protected adenine 116 (528.3 mg, 1.15 mmol, 
1 eq) and HCTU (475 mg, 1.15 mmol, 1 eq) were combined and dissolved in DCM/DMF 
(4 mL, 0.28 M, 3/1, v/v) to which DIPEA (400 µL, 2.30 mmol, 2eq) was added dropwise. 
After two hours the mixture was diluted with CHCl3 washed with HCl (1 M, aq., 1x) dried 
over MgSO4 (s), filtered, concentrated in vacuo and purified by silica gel column chromatography (1/19 → 
3/22, acetone/DCM, v/v) to yield title compound 118 as a yellow oil (678 mg, 0.96 mmol, 84%). TLC Rf 
0.65 (MeOH/DCM, 1/49, v/v); 1H NMR (500 MHz, CDCl3) δ 8.01 (s, 1H), 7.75 (d, J = 8.3 Hz, 2H, H-
12/H-13), 7.47 (d, J = 8.2 Hz, 2H, H-12/H-13), 7.00 (s, 2H, NH2), 5.01 (s, 2H, H-10), 4.27 (t, J = 6.7 Hz, 
2H, H-16), 3.99 (s, 2H, O-CH2-CO), 3.69 - 3.62 (m, 12H, CH2 PEG), 1.77 - 1.68 (m, 2H, H-17), 1.62 (s, 
9H, t-Bu), 1.47 - 1.39 (m, 11H, t-Bu, H-18), 0.95 (t, J = 7.4 Hz, 3H, H-19); 13C NMR (126 MHz, CDCl3) δ 
170.2, 167.9, 161.9 (C=O), 150.9, 150.3, 150.1, 149.6, 139.2, 134.0, 128.9 (Cq), 128.7, 127.6 (C-12/C-13), 
125.9, 120.3, 109.7, 97.2 (Cq), 86.4 (Cq t-Bu), 82.5, 70.8, 70.2, 70.1, 70.0, 69.9(CH2 PEG), 68.7 (O-CH2-CO), 
67.5 (C-16), 55.6 (Cq), 43.4 (C-10), 31.0 (C-17), 28.1, 28.1 (t-Bu), 18.6 (C-18), 13.9 (C-19); HRMS 
[C34H50N6O10 + H]+: 703.36517 found, 703.36612 calculated. 
 
1-(4-((6-amino-2-butoxy-8-oxo-7,8-dihydro-9H-purin-9-yl)methyl)phenyl)-1-oxo-5,8,11-
trioxa-2-azatridecan-13-oic acid (119). 
Butyl ester 118 (170.7 mg, 0.243 mmol, 1 eq) was dissolved in toluene (0.4 mL, 0.5 M) and 
H3PO4 (0.1 mL, 85-90% wt) was added. After LCMS analysis indicated complete conversion 
the mixture was concentrated in vacuo, dissolved in a solution of NH4OAc (0.033 M) in a 
mixture of AcOH/ACN/t-BuOH/H2O (3/1/1/4, v/v/v/v, 6 mL) and purified via RP-
HPLC (linear gradient 25 - 40% B in A, 10 min, Gemini-NX 5µm C18, 110 Å, 250 x 10.0 mm, 5 mL/min) 
to yield title compound 119 as a white powder after lyophilization (57.54 mg, 105 µmol, 43%). LC-MS: Rt 
= 4.80 min (10 - 90% ACN; 13 min); 1H NMR (400 MHz, DMSO) δ 10.17 (s, 1H, COOH), 8.50 (t, J = 5.6 
Hz, 1H, NH), 7.79 (d, J = 8.3 Hz, 2H, H-12/H-13), 7.34 (d, J = 8.3 Hz, 2H, H-12/H-13), 6.56 (s, 2H, 
NH2), 4.90 (s, 2H, H-10), 4.12 (t, J = 6.6 Hz, 2H, H-16), 4.00 (s, 2H, O-CH2-CO), 3.57 - 3.48 (m, 11H, 
(CO)NH, CH2 PEG), 3.39 (q, J = 5.8 Hz, 2H, CH2-NH), 1.65 - 1.56 (m, 2H, H-17), 1.35 (dq, J = 14.7, 7.4 
O
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Hz, 2H, H-18), 0.89 (t, J = 7.4 Hz, 3H, H-19); 13C NMR (101 MHz, DMSO) δ 171.7, 166.0, 160.1 (C=O), 
152.3, 149.1, 147.8, 140.2, 133.5 (Cq), 127.4, 127.2 (C-12/C-13), 98.3 (Cq), 69.8, 69.7, 69.7, 69.6, 68.9 (CH2 
PEG), 67.6 (O-CH2-CO), 65.9 (C-16), 42.1 (C-10), 39.2 (CH2-NH), 30.6 (C-17), 18.8 (C-18), 13.7 (C-19); 
HRMS [C25H34N6O8 + H]+: 547.25105 found, 547.25109 calculated. 
perfluorophenyl 1-(4-((6-amino-2-butoxy-8-oxo-7,8-dihydro-9H-purin-9-yl)methyl)phenyl)-1-
oxo-5,8,11-trioxa-2-azatridecan-13-oate (120). 
Carboxylic acid 119 (11.04 mg, 20.1 µmol, 1 eq) was dissolved in a solution of 
pentafluorophenol (120 µL, 0.34 M, 40.8 µmol, 2 eq) and N,N′-Diisopropylcarbodiimide 
(3.42 µL, 22.1 µmol, 1.1 eq) was added. After two hours, this solution was used without 
further workup. 
 
Ac-Lys(Man1)-Lys(Man1)-Lys(Man1)-Lys(Man1)-Lys(Man1)-Lys(Man1)-Gly-Lys[1-(4-((6-amino-2-
butoxy-8-oxo-7,8-dihydro-9H-purin-9-yl)methyl)phenyl)-1-oxo-5,8,11-trioxa-2-azatridecan-
13-oic amide]-NH2 (121). 
To a solution of 50 in water (250uL, 4.0 mM, 1.0 µmol, 1 eq) a stock solution of 
Pfp ester 120 (30 µL, 0.17 M, 5.0 µmol, 5 eq) and DIPEA (0.5 µL, 3 µmol, 3 eq) 
were added. The mixture was further diluted with DMSO (250 µL) until the 
mixture was a homogenous solution, and shaken overnight. After purification via 
RP-HPLC (linear gradient 7 - 55% B in A, 10 min, Gemini-NX 5µm C18, 110 Å, 
250 x 10.0 mm, 5 mL/min) compound 121 was isolated as a white powder after 
lyophilization (2.19 mg, 727 nmol, 73%). LC-MS: Rt = 3.68 min (10 - 90% ACN; 13 min); 1H NMR (500 
MHz, D2O) δ 8.01 - 7.91 (m, 6H, trzl), 7.71 (d, J = 8.3 Hz, 2H, H-12*/H-13*), 7.40 (d, J = 8.2 Hz, 2H, H-
12*/H-13*), 5.01 (s, 2H, H-10*), 4.92 (s, 6H, H-1), 4.77 - 4.70 (m, 6H, O-CHH-trzl), 4.65 - 4.56 (m, 6H, 
O-CHH-trzl), 4.37 - 4.25 (m, 12H, CH2-trzl), 4.24 - 4.15 (m, 8H, H-16*, CH (K)), 4.13 - 4.08 (m, 1H, CH 
(K)), 3.93 - 3.50 (m, 52H, H-2, H-3, H-4, H-5, H-6, CH2 (G), CH2 (PEG, 7x)), 3.04 - 2.99 (m, 2H, CH2-
NH(CO) (K)), 1.97 (s, 3H, Ac), 1.87 - 1.62 (m, 24H, CH2 (K)), 1.61 - 1.53 (m, 2H, H-17*), 1.37 - 1.18 (m, 
20H, H-18*, CH2 (K)), 0.82 (t, J = 7.4 Hz, 3H, H-19*); HRMS [C125H196N34O52 + 3H]3+: 1003.13252 found, 
1003.13283 calculated. 
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Ac-Lys(Man3)-Lys(Man3)-Lys(Man3)-Lys(Man3)-Lys(Man3)-Lys(Man3)-Gly-Lys(1-(4-((6-amino-2-
butoxy-8-oxo-7,8-dihydro-9H-purin-9-yl)methyl)phenyl)-1-oxo-5,8,11-trioxa-2-azatridecan-
13-oic amide)-NH2 (122). 
To a solution of 54 in water (250uL, 3.74 mM, 0.935 µmol, 1 eq) a stock 
solution of Pfp ester 120 (30 µL, 0.17 M, 5.0 µmol, 5.3 eq) and DIPEA (0.5 
µL, 3 µmol, 3.2 eq) were added. The mixture was further diluted with DMSO 
(250 µL) until the mixture was a homogenous solution, and shaken 
overnight. After purification via RP-HPLC (linear gradient 7 - 55% B in A, 
10 min, Gemini-NX 5µm C18, 110 Å, 250 x 10.0 mm, 5 mL/min) 
compound 122 was isolated as a white powder after lyophilization (2.15 mg, 429 nmol, 46%). LC-MS: Rt = 
3.33 min (10 - 90% ACN; 13 min); 1H NMR (500 MHz, D2O) δ 8.02 - 7.92 (m, 6H, trzl), 7.72 (d, J = 8.1 
Hz, 2H, H-12*/H-13*), 7.40 (d, J = 8.2 Hz, 2H, H-12*/H-13*), 5.06 (s, 6H, H-1/H-1′/H-1′′), 5.02 (s, 2H, 
H-10*), 4.90 (s, 6H), 4.88 (s, 6H, H-1/H-1′/H-1′′), 4.69 - 4.59 (m, 6H, O-CHH-trzl), 4.42 - 4.27 (m, 12H, 
CH2-trzl), 4.27 - 4.16 (m, 8H, H-16*, CH (K)), 4.14 (dd, J = 5.5, 1.8 Hz, 1H, CH (K)), 4.10 - 3.50 (m, 124H, 
H-2, H-2′, H-2′′, H-3, H-3′, H-3′′, H-4, H-4′, H-4′′, H-5, H-5′, H-5′′, H-6, H-6′, H-6′′, CH2 (G), CH2 (PEG, 
7x)), 3.02 (d, J = 6.8 Hz, 2H, CH2-NH(CO) (K)), 1.98 (s, 3H, Ac), 1.91 - 1.62 (m, 24H CH2 (K)), 1.62 - 
1.52 (m, 2H, H-17*), 1.42 - 1.16 (m, 20H, H-18*, CH2 (K)), 0.83 (t, J = 7.4 Hz, 3H, H-19*); HRMS 
[C197H316N34O112 + 4H]4+: 1239.01239 found, 1239.01069 calculated. 
 
Ac-Lys(M6P)-Lys(M6P)-Lys(M6P)-Lys(M6P)-Lys(M6P)-Lys(M6P)-Gly-Lys(1-(4-((6-amino-2-
butoxy-8-oxo-7,8-dihydro-9H-purin-9-yl)methyl)phenyl)-1-oxo-5,8,11-trioxa-2-azatridecan-
13-oic amide)-NH2 (124). 
Mannose-6-phospate clusters 12330 (2.45 mg, 8.3 µmol, 1 eq) was dissolved in a 
stock solution of Pfp ester 120 (90 µL, 0.17 M, 15.0 µmol, 1.9 eq) and DIPEA 
(2 µL, 12 µmol, 1.5 eq) was added. After overnight shaking the mixture was 
purified via gel filtration (Toyopearl HW-40S, 1.6x60 cm, 150 mM NH4OAc, 
20% ACN, 1mL/min) (25 - 37 mL) followed by RP-HPLC (linear gradient 5 - 
55% B in A, 10 min, Gemini-NX 5µm C18, 110 Å, 250 x 10.0 mm, 5 mL/min) 
to isolate compound 124 as a white powder after lyophilization (0.80 mg, 231 nmol, 2.8%). LC-MS: Rt = 
5.68 min (0 - 50% ACN; 13 min); HRMS [C131H208N34O64P66- + 4NH4+ +2 Na+ + 3H+]3+: 1197.05295 
found, 1197.13554 calculated. 
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Chapter 4 
Synthesis of trifunctional mannosylated 
peptide antigen conjugates targeting DC-
SIGN and TLR7ab 
Introduction 12 
The last decades, immunotherapies have proven to be powerful in the treatment of cancers. For 
instance, inhibition of immune regulatory checkpoints can result in the restoration of immune 
responses, which has led to the successful treatment of various tumors where traditional cytotoxic 
therapies failed.3,4 To be effective, immunotherapies have to elicit or sustain a strong and tumor-
specific T cell response.5,6 A possible method to achieve this is by the use of vaccine strategies, In 
which tumor-associated antigens (TAAs) are combined with an adjuvant to generate a specific 
immune response against these antigens. Adjuvants can be derived from pathogen-associated 
molecular patterns (PAMPs) that induce immune activation via binding to pattern recognition 
receptors (PRRs), thereby stimulating antigen presenting cells (APCs) to mature and initiate an 
immune response. Maturation results in the secretion of inflammatory cytokines and upregulation 
 
aPart of this work is published in Hogervorst & Li et al. 20191 
bPart of this work has been submitted by Hogervorst & Li et al. 20202 
Synthesis of trifunctional conjugates targeting DC-SIGN and TLR7 
82 
of antigen processing and presentation, which are a necessity for an adequate adaptive immune 
response.7 Target antigens can be common TAAs, neoantigens, neo open reading frame peptides8 
or a combination of these, allowing to combat each cancer with a personalized treatment.9 One 
possible strategy to obtain such vaccines is to generate them via a synthetic approach. An advantage 
of a synthetic approach is the fact that they can be obtained as well-defined molecular structures, 
reducing the potential risk of raising autoimmune responses against self-antigens, a possible side 
effect when antigens are isolated from cancer cells. In addition, this strategy allows for the covalent 
attachment of adjuvants and antigens, an approach which has previously been successfully 
demonstrated with ligands for the Toll-Like Receptor (TLR) family,10–14 the NOD-like receptor 
(NLR) family15 or combinations thereof.16–19 It has become clear that the covalent attachment of a 
TLR agonist to an antigen can enhance antigen presentation while DC maturation via the TLR-
ligands is maintained.20,21 Another class of PRRs that is often targeted are the C-type lectin receptors 
(CLRs) as described in Chapter 1 and 2. For example, DC-SIGN has previously been successfully 
exploited to deliver cancer antigens to DCs by enhancing uptake and antigen presentation, 
generating more effective anti-cancer immunotherapies.16,17,22–24 Furthermore, it has been shown 
that the simultaneous targeting of CLRs and TLRs can lead to a synergistic more powerful immune 
response. For example, simultaneous triggering of DC-SIGN and TLR4 strengthened and 
prolonged TLR-signaling leading to enhanced pro-inflammatory cytokine production in DCs.25,26 
Based on these results, it is hypothesized that a peptide-antigen conjugate, equipped with both a 
mannose-based DC-SIGN targeting glycan and a TLR-ligand, could lead to synergy in antigen 
presentation and improve specific T cell activation.  
This Chapter describes the design and synthesis of trifunctional conjugates composed of CLR-
targeting clusters, a synthetic long peptide, and a TLR7-agonist (Figure 1). Targeting of DC-SIGN 
will be achieved with the mannoside clusters, as described in Chapter 2. As a model antigen, the 
effector T cell epitope gp100280-288 and helper T cell epitope gp10044-59 are combined to form a 
synthetic long peptide (SLP). The addition of a helper T cell epitope can result in a more durable 
immune response when compared with a stand-alone effector T cell epitope and is included for 
future assays.27 As agonist of endosomal TLR7 the 8-oxo-adenosine analog, described in Chapter 
3, is selected.28–30 The hypothesis is, that upon binding and internalization via DC-SIGN, these 
conjugates are trafficked towards the endosomes where they can activate TLR7. The benefit of 
using an endosomal receptor, instead of a PRRs residing on the cell surface, would be the 
prevention of competition between the binding of DC-SIGN and other surface PRRs.  
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Figure 1: The global structure of trifunctional mannosylated conjugates. 
 
 
Results and Discussion 
To determine the effect of the mannoside clusters on the activity of the antigen conjugates, control 
peptides were synthesized lacking these clusters (Scheme 1). These peptides were obtained using a 
Fmoc-SPPS strategy starting from Tentagel® S-RAM amide resin. A monomethoxy trityl (Mmt) 
protected lysine was used as the first amino acid to introduce an orthogonal side-chain protecting 
group that could later be selectively removed for further functionalization. The immobilized lysine 
was elongated using standard Fmoc protected amino acids generating the gp100280-288 sequence 
(YLEPGPVTA) for antigen cross-presentation to CD8+ T cells connected to the N-terminus of 
the gp10044-59 sequence for antigen presentation to CD4+ T cells (NRQLYPEWTEAQRLD). The 
presence of both CD8+ and CD4+ epitopes in the same antigen-conjugate platform will allow the 
study of both cross-presentation and presentation, which in combination with different adjuvants 
can help to determine the optimal adjuvant combinations on the same conjugate platform. The 
epitope was extended both at the C- and the N-terminus with four extra amino acids, acting as 
spacers (Figure 1). To prevent potential oxidation, Cys60 was replaced by its isosteric analog α-
aminobutyric acid, a modification that should have minimal impact on biological processing.31 
Acetylation of the N-terminus yielded immobilized peptide 126. For further functionalization of 
this peptide, the Mmt group on the C-terminal lysine was removed selectively, after which the 
lysine was elongated with spacer moiety 127 and TLR7 ligand 116 (see Chapter 3) to give 
immobilized TLR7 conjugate 128. Both 126 and 128 were released from resin by treatment with a 
cleavage cocktail (TFA/TIS/H2O, 190/5/5, v/v/v) to generate gp100 peptide 129 and 
bifunctional conjugate 130, containing the gp100 peptide and the TLR7 agonist.29 To validate that 
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the replacement of cysteine by α-aminobutyric acid does not hamper the antigen presentation 
capacity, bifunctional conjugate 133 was synthesized via similar chemistry as its isosteric isomer 130 
(Scheme 1). Both TLR-antigen conjugates 130 and 133 were tested for their antigen cross-
presentation ability. In short, five-day-old monocyte-derived dendritic cells (moDCs) were 
incubated with these conjugates, after which the moDCs were washed and co-cultured with a CD8+ 
cell clone that is specific for the gp100280-288 MHC-I epitope. Interferon γ cytokine secretion was 
measured by sandwich ELISA as a measure for T cell activation. Quantification of antigen 
presentation was achieved by normalization of the interferon γ cytokine production to secretion 
levels induced by short gp100 peptide (gp100280-288 set to 100%). Both 130 and 133 resulted in 
similar levels of antigen presentation, indicating that the replacement of cysteine in the epitope 
indeed did not hamper the presentation capacity (See Figure 2). 
 
Figure 2: Comparison of the antigen cross-presenting ability of 130 and 133. 
 
The gp100(Cys) (133) was compared to the gp100 methyl analog (130). No significant difference was seen between the two peptides in 
presence of TLR7 ligand. One representative donor out of six is shown. 
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Scheme 1: Synthesis of control gp100 peptide and control gp100-TLR7 conjugates. 
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Reagents and conditions: a) i. Fmoc-SPPS (HCTU, DIPEA, DMF); ii. Ac2O, DIPEA, DMF; b) i. TFA, DCM; ii. Fmoc-SPPS 
(127 or 116, HCTU, DIPEA, DMF); c) TFA, TIS, H2O,(phenol) (129: 9.1% over 33 couplings (93% per step); 130: 1.78% over 
35 couplings (89% per step);133: 0.23% over 35 couplings (84% per step)). 
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Two different strategies for the incorporation of the mannose clusters in mannosylated-gp100-
TLR7 conjugates were considered (Scheme 2). Route A comprises the synthesis of a gp100-TLR7 
conjugate provided with six azides (n = 6) followed by copper(I)-catalyzed alkyne-azide 
cycloadditions (CuAACs) with propargylated mannosides. The modular approach of route B 
applies the pre-assembled mannoside clusters described in Chapter 2 for a single CuAAC with a 
gp100-TLR7 conjugate provided with a single azide (Route B, Scheme 2). Both routes allow for 
the introduction of different ligands in the final stage of assembly, enabling screening of different 
PAMP combinations on the same gp100 platform. Route A would be most straightforward as six 
simultaneous cycloadditions and one purification are required. However, incomplete CuAACs may 
result in a complicated product mixture necessitating a challenging purification. Although route B 
is more lengthy, the availability of the well-defined mannoside clusters (see Chapter 2) and the 
introduction of different PAMPs via a single CuAAC could make this approach overall more 
effective. Based on these considerations, both strategies were evaluated. 
The azido-gp100-peptides were obtained using a similar Fmoc-SPPS strategy as for the control 
peptides described above. Both routes started with immobilized peptide 134, that was further 
elongated on the N-terminal valine with either one (135) or six azidolysines (136, Scheme 3). 
Treatment of resin 136, bearing six azides, with the cleavage cocktail (described above) generated 
a crude mixture of poor quality and attempts to isolate the desired peptide in sufficient amount 
failed. When resin 135, bearing only one azide, was treated with the same cocktail, the quality of 
the crude peptide was somewhat better but still too poor for large scale isolation of 137. 
Optimization of the synthesis of peptide 137 was achieved by the use of double couplings at an 
elevated temperature. The quality was further improved by the addition of phenol to the cleavage 
cocktail as an additional scavenger. Together, this allowed for the isolation of 137 in sufficient 
quantities after purification. En route to trifunctional mannosylated conjugates, the monomethoxy 
trityl (Mmt) on the C-terminal lysine of immobilized peptide 135 was selectively removed, followed 
by elongation of this position with a spacer moiety (127) and the TLR7 ligand 116 (as described in 
Scheme 1) to provide resin 138 bearing the TLR7 agonist on the C-terminus. Release of the peptide-
TLR7 conjugate from the resin and concomitant global deprotection of the side chains with the 
optimized scavenger cocktail resulted in the azido-gp100-TLR7 conjugate 139. Because of the 
successful assembly of the TLR7-functionalized antigens with the conjugation ready azide handle, 
this route was further explored and the first route, with six azidolysines incorporated in the 
antigenic peptide, was abandoned.  
The modular approach of route B requires the introduction of an alkyne handle on the mannoside 
clusters, the synthesis of which is described in Chapter 2. Treatment of mono- and hexa-valent 
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mannoside clusters 32, 33, 35, 36, and 50-54 with pent-4-ynoic acid-N-hydroxysuccinimide (NHS) 
ester (140) and purification via gel filtration yielded alkyne clusters 141-149, suitable for ensuing 
CuAAC (Scheme 4). CuAAC of the monovalent monomannoside cluster 141 with either azido-
gp100 137 or azido-gp100-TLR7 conjugate 139 yielded the bi-functional (containing both CLR 
ligand and gp100 antigen) conjugate 150 and the tri-functional (containing both CLR ligand, gp100 
antigen, and TLR ligand) conjugate 151 (Scheme 4). Applying the same procedure to hexavalent 
monomannosides cluster 145 gave comparable results, resulting in bifunctional and trifunctional 
conjugates 152 and 153, respectively. The four conjugates obtained in this manner could be purified 
and were isolated in sufficient yield, proving the feasibility of route B. This result, in combination 
with the difficulties to obtain a gp100 peptide bearing six azides (i.e. 136), the availability of the 
mannoside clusters described in Chapter 2, the ease of alkyne introduction on these clusters, and 
the possibility to introduce other ligands in a single ligation, made the modular route B preferred 
over direct route A (Scheme 2). The compound library was finalized by the assembly of the 
remaining seven mannoside clusters (142-144 and 146-149) with 137 and 139 to yield bi- and tri-
functional conjugates 154-167 (Scheme 4).  
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Scheme 2: Retrosynthesis of route A and B towards (hexavalent) mannosylated gp100 
conjugates. 
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Scheme 3: Synthesis of azido-gp100 and azido-gp100-TLR7 conjugates. 
 
Reagents and conditions: a) Fmoc-SPPS (HCTU, DIPEA, DMF); b) Ac2O, DIPEA, DMF; c) i. TFA, DCM; ii. Fmoc-SPPS 
(127 or 116, HCTU, DIPEA, DMF); d) TFA, TIS, H2O, (phenol) (137: 8.33% over 34 couplings (93% per step); 139: 5.09% 
over 36 couplings (92% per step)). 
 
Finally these conjugates with either the monovalent clusters bearing the monomannoside (150 & 
151), α1,2-di-mannoside (154 & 157), α1,6-di-mannoside (155 & 158), or α1,3-α1,6-tri-mannoside 
(156 & 159), or the hexavalent clusters with the monomannosides (152 & 153), α1,2-di-mannosides 
(160 & 164), α1,3-di-mannosides (161 & 165), α1,6-di-mannosides (162 & 166), or α1,3-α1,6-tri-
mannosides (163 & 167) were evaluated for their capacity to induce DC-maturation and present 
the model gp100 antigen. Since the number of available moDCs was limited, only the hexavalent 
series (160-167) have been tested. The mono mannoside clusters 150-153 have been evaluated in 
comparison to their C-mannoside analogs as described in Chapter 5.  
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Scheme 4: Assembly of mannosylated – (TLR7) – bi- and tri-functional gp100 conjugates. 
 
Reagents and conditions: a) 140, DIPEA, DMSO (141: 62%; 142: 71%; 143: 71%; 144: 18%; 145: 66%; 146: 96%; 147: 95%; 
148: 95%; 149: 94%); b) 137, CuI, THPTA, DIPEA, H2O, DMSO (150: 52%; 152: 34%; 154: 91%; 155: 90%; 156: 88%; 
160: 39%; 161: 62%; 162: 68%; 163: 45%;); c) 139, CuI, THPTA, DIPEA, H2O, DMSO (151: 34%; 153: 29%; 157: 21%; 
158: 19%; 159: 32%; 164: 24%; 165: 41%; 166: 18%; 167: 27%). 
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The ability to mature moDCs was quantified by measuring the expression of CD83 and CD86 after 
overnight stimulation with a selection of conjugates (Figure 3A and 3B). As expected, 129, the 
gp100 peptide without any adjuvant, did not induce maturation. All bi- and tri-functional 
conjugates induce the expression of both maturation markers. Generally, the conjugates bearing 
the TLR7 agonist led to enhanced maturation. These results show that the presence of either the 
TLR7 ligand or the mannoside clusters in conjugates does not hamper the maturation abilities of 
the ligands. Inclusion of the TLR agonist improves the maturation capacity of the conjugates most 
significantly. Besides maturation, a selection of the prepared conjugates was tested for their antigen 
cross-presentation ability using gp100 specific T cell clones as described above for 130 and 133 (see 
Figure 3C). Although significant donor variability was observed, almost all conjugates showed 
improvements when mannoside clusters were attached (Figure 3C). Unexpectedly, conjugate 164, 
bearing both the TLR7 agonist and an α1,2-di-mannoside cluster, did not enhance antigen 
presentation. Whether this outcome is due to differences in processing, signaling, uptake, or 
conjugate stability is unclear and needs additional experiments. Overall, conjugate 167 
demonstrated the most consistent and strongest response of the tested conjugates. This conjugate, 
bearing both TLR7 ligand and the tri-mannoside cluster, also effectively induced maturation, which 
would make it a good candidate for further development. Except for 164, all conjugates that 
contained both the mannoside clusters and TLR agonist, induced more maturation and higher 
levels of antigen cross-presentation when compared with their counterpart only bearing the 
mannoside cluster. This result indicates that the combination of two different adjuvants in a single 
adjuvant-antigen conjugate can further improve the effectiveness of antigen conjugates and could 
serve as a starting point for further development of antigen conjugates bearing multiple 
functionalities. 
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Figure 3: Conjugates 160-167 were compared with conjugates 129 and 130 for their ability to 
induce maturation (A and B) and their capacity to cross-present antigen (C).  
 
A, B) Expression of the DC maturation marker CD83 and CD86 upon overnight stimulation with the trifunctional conjugates is 
measured by flow cytometry. LPS stimulation (10 ng/mL) is used as positive control; C) Antigen presentation by the moDCs was 
determined by IFNγ release of the activated T cells, after stimulation with conjugates (20 µM, 30 min).  
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Conclusion 
The synthesis of conjugates that combine a model epitope with both TLR7 and DC-SIGN ligands 
has been reported. All conjugates are assembled on the same gp100 platform, which includes both 
a CD4+ and CD8+ epitope. The gp100 peptides were assembled using automated SPPS. C-terminal 
functionalization of the gp100 epitope with the TLR7 agonist, described in Chapter 3, could be 
achieved on resin via selective removal of the Mmt group on lysine. The assembly of azido 
functionalized gp100 peptides of sufficient quality and quantity required double couplings at 
elevated temperature and the presence of phenol in the cleavage cocktail. For the introduction of 
mannoside clusters, the simultaneous CuAACs of multiple propargylmannosides with the azides in 
the gp100 platform and a single CuAAC of alkyne functionalized pre-assembled clusters with one 
azide in the gp100 were planned. However, isolation of gp100 peptides bearing six azides in 
sufficient quantities proved difficult. Because the alkyne functionalized mannoside clusters were 
readily obtained and the CuAAC of these alkyne functionalized clusters to the gp100 platform was 
successful, the former route was abandoned and the latter was used to assemble a set of 
trifunctional conjugates. A selection of these conjugates was tested for their ability to induce DC 
maturation and their capacity to induce antigen cross-presentation. Although significant variation 
between DC-donors was observed, the results have shown that the combination of a TLR7 and 
DC-SIGN ligand improves the effectiveness of the antigen conjugates. Additional experiments 
with the monovalent clusters will show whether the hexavalent presentation of the mannosides is 
a requirement for the activity of the conjugates. Overall, the conjugate that combines the TLR7 
agonist with the hexavalent tri-mannoside cluster has demonstrated the most potential, inducing 
strong maturation and consistent levels of antigen-presentation, and could serve as a starting point 
for further conjugate development.  
With the here described gp100 platform and optimized synthetic protocols, further conjugates can 
be designed bearing different combinations of adjuvants that could target different PRRs such as 
other members of the TLR-, NLR- or CLR-families. Adjuvants with carboxylic acid handles could 
be introduced on either the C-terminal lysine or N-terminus on resin. The azide handle could be 
used for either addition of other alkyne functionalized adjuvants or be used in conjunction with 
“clickable” reporter groups to study the fate of these conjugates during the processing from uptake 
to presentation. The presence of the CD4+ epitope in the peptide would allow determining the 
level of antigen presentation of helper T cell epitopes. The trifunctional conjugates described in 
this Chapter and novel conjugates based on the methods described in combination with the current 
cross-presentation assay could be used to determine the best combination of adjuvants to obtain 
the most durable anti-cancer response with a single vaccine modality.  
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Experimental 
General procedures: 
All reactions, purifications, and analyses were performed as described in the general procedures of 
Chapter 2. 
General procedure for automated solid-phase synthesis of gp100 peptides: 
The solid-phase peptide synthesis was performed on a TRIBUTE® Peptide Synthesizer (Gyros 
Protein Technologies AB, Arizona, USA) applying Fmoc based protocol starting with Tentagel® 
S-RAM resin (~0.22 mmol/g) on a 100-250 µmol scale using established synthetic protocols.32 The 
consecutive steps for synthesis on 250 µmol scalea performed in each cycle were: 
1) DMF wash (1x) followed by nitrogen purge; 2) Deprotection of the Fmoc-group with 20% piperidine in 
DMF (8 mL)(3 x 3 min at 50 °C); 3) DMF wash (3x) followed by nitrogen purge; 4.1) Coupling of the 
appropriate amino acidb in four-fold excess (unless stated otherwise);c,d 4.2) Step 4.1 was repeated 5) DMF 
wash (3x) followed by nitrogen purge; 6) capping with a solution of Ac2O/DMF/DIPEA (8 mL, 10/88/2, 
v/v/v) for 2 min; 7) DMF wash (2x).  
After the complete sequence the resin was washed with DMF (3x), DCM (3x), Et2O (3x), followed by 
nitrogen purge before treatment with the cleavage cocktail. 
Val-Thr(tBu)-His(Trt)-Thr(tBu)-Tyr(tBu)-Leu-Glu(OtBu)-Pro-Gly-Pro-Val-Thr(tBu)-Ala-Asn(Trt)-
Arg(Pbf)-Gln(Trt)-Leu-Tyr(tBu)-Pro-Glu(OtBu)-Trp(Boc)-Thr(tBu)-Glu(OtBu)-Ala-Gln(Trt)-
Arg(Pbf)-Leu-Asp(OtBu)-αAbu-Trp(Boc)-Arg(Pbf)-Gly-Lys(Mmt)-Tentagel® S-Rink amide (134). 
Peptide synthesis was performed on a 250 µmol scale using the general procedure. Resulting in 
functionalized resin 134, which was used in further reactions.  
 
a All amounts are scaled-down in equimolar proportions for smaller scale. 
b The amino acids applied in this synthesis were: Fmoc-Lys(Mmt)-OH, Fmoc-Gly-OH, Fmoc-Arg(Pbf)-OH, Fmoc-
Trp(Boc)-OH, Fmoc-L-α-aminobutyric acid, Fmoc-Asp(OtBu)-OHd, Fmoc-Leu-OHd, Fmoc-Gln(Trt)-OH, Fmoc-
Ala-OH, Fmoc-Glu(OtBu)-OH, Fmoc-Thr(tBu)-OH, Fmoc-Pro-OH, Fmoc-Tyr(tBu)-OH, Fmoc-Asn(Trt)-OH, 
Fmoc-Val-OH, Fmoc-His(Trt)-OH, Fmoc-Cys(Trt)-OH and Fmoc-Lys(N3)-OH (IRIS biotech). Fmoc-AEEA-OH 
(Fmoc-8-amino-3,6-dioxaoctanoic acid)(Carbosynth) and 116. 
c Generally, the Fmoc amino acid is dissolved in a HCTU solution in DMF (5.00 mL ,0.20 M, 1.0 mmol, 4 eq) The 
resulting solution was transferred to the reaction vessel followed by a DIPEA solution in DMF (4.00 mL, 0.50 M, 2.0 
mmol, 8 eq) to initiate the coupling. The reaction vessel was shaken for 30 min at 50 °C (unless stated otherwise). 
d Aspartic acid and the adjacent Leucine and Arginine were introduced at with one hour reaction time at room 
temperature. Fmoc removal was achieved with piperide/DMF in 3 x 5 min at room temperature.35 
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Ac-Val-Thr-His-Thr-Tyr-Leu-Glu-Pro-Gly-Pro-Val-Thr-Ala-Asn-Arg-Gln-Leu-Tyr-Pro-Glu-Trp-Thr-
Glu-Ala-Gln-Arg-Leu-Asp-αAbu-Trp-Arg-Gly-Lys-NH2 (129). 
Resin 134 (theoretical loading of 25 µmol), was capped with Ac2O/DMF/DIPEA (4 mL, 10/88/2, purge 
to yield Ac-Val-Thr(tBu)-His(Trt)-Thr(tBu)-Tyr(tBu)-Leu-Glu(OtBu)-Pro-Gly-Pro-Val-Thr(tBu)-Ala-
Asn(Trt)-Arg(Pbf)-Gln(Trt)-Leu-Tyr(tBu)-Pro-Glu(OtBu)-Trp(Boc)-Thr(tBu)-Glu(OtBu)-Ala-Gln(Trt)-
Arg(Pbf)-Leu-Asp(OtBu)-αAbu-Trp(Boc)-Arg(Pbf)-Gly-Lys(Mmt)-Tentagel® S-RAM. The resin was 
transferred to a flask and treated for 120 minutes with a cleavage cocktail (10 mL, TFA/TIS/H2O, 190/5/5, 
v/v/v). The resin was filtered off and washed with neat TFA (3 x 1 mL). The filtrate was concentrated and 
transferred dropwise into a cold mixture of Et2O/pentane (45 mL, 5/4, v/v). This solution was centrifuged 
(10 minutes, 5000 rpm) after which the supernatant was removed and the precipitate was dried under 
nitrogen flow and dissolved (4 mL, DMF/H2O, 1/3, v/v). Purification via RP-HPLC (linear-gradient 19.5 
- 29.5 % B in A, 10 min, 5 mL/min, Gemini-NX 5 µm C18, 110 Å, 250 x 10.0 mm) yielded title compound 
129 as a white powder after lyophilization (8.97 mg, 2.28 µmol, 9.1% over 33 couplings, 93% per step). LC-
MS: Rt = 6.01 min (10 - 50% ACN; 13 min); Rt = 4.25 min (10 - 90% ACN; 13 min); HRMS [C178H269N51O51 
+ 5H]5+: 788.8100 found, 788.80888 calculated. 
 
Ac-Lys(N3)-Val-Thr-His-Thr-Tyr-Leu-Glu-Pro-Gly-Pro-Val-Thr-Ala-Asn-Arg-Gln-Leu-Tyr-Pro-Glu-
Trp-Thr-Glu-Ala-Gln-Arg-Leu-Asp-αAbu-Trp-Arg-Gly-Lys-NH2 (137).  
Resin 134 (theoretical loading of 250 µmol) was elongated using the general protocol after which the N-
terminus was capped with Ac2O/DMF/DIPEA (4mL, 10/88/2, v/v/v, 3 x 5 min) and the resin was washed 
with DMF (3x), DCM (3x), Et2O (3x) and dried by nitrogen purge to yield Ac-Lys(N3)-Val-Thr(tBu)-
His(Trt)-Thr(tBu)-Tyr(tBu)-Leu-Glu(OtBu)-Pro-Gly-Pro-Val-Thr(tBu)-Ala-Asn(Trt)-Arg(Pbf)-Gln(Trt)-
Leu-Tyr(tBu)-Pro-Glu(OtBu)-Trp(Boc)-Thr(tBu)-Glu(OtBu)-Ala-Gln(Trt)-Arg(Pbf)-Leu-Asp(OtBu)-
αAbu-Trp(Boc)-Arg(Pbf)-Gly-Lys(Mmt)-Tentagel® S-RAM. The resin was transferred to a flask and treated 
for 120 minutes with a cleavage cocktail (25 mL, TFA/TIS/H2O/phenol, 188/5/5/2, v/v/v/w). The 
mixture was concentrated to approximately one mL and the resin was filtered off into a cold mixture of 
Et2O/pentane (45 mL, 5/4, v/v). The resin was washed off extra with neat TFA (3x 1 mL) into the ether 
solution. This solution was centrifuged (10 minutes, 5000 rpm) after which the supernatant was removed 
and the precipitate was dried under nitrogen flow. Purification via RP-HPLC (linear-gradient 23 - 34% B in 
A, 11 min, 5 mL/min, Gemini-NX 5 µm C18, 110 Å, 250 x 10.0 mm) yielded title compound 137 as a white 
powder after lyophilization (85.2 mg, 20.8µmol, 8.33% over 34 couplings, 93% per step). LC-MS: Rt = 4.32 
min (10 - 90% ACN; 13 min); HRMS [C184H279N55O52 + 5H]5+: 819.6255 found, 819.62596 calculated. 
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Ac-Val-Thr-His-Thr-Tyr-Leu-Glu-Pro-Gly-Pro-Val-Thr-Ala-Asn-Arg-Gln-Leu-Tyr-Pro-Glu-Trp-Thr-
Glu-Ala-Gln-Arg-Leu-Asp-αAbu-Trp-Arg-Gly-Lys(Peg-TLR7L)-NH2 (130). 
Resin 134 (100 µmol scale, single couplings at room temperature) was loaded in a syringe with frit and 
treated with a TFA solution (1% in DCM) shaken for five minutes followed by filtration. This was repeated 
until the filtrate lost the orange/yellow color (~ 12x). After which the resin was washed with DCM (5x), 
DMF (5x) Piperidine (20% in DMF, 1x) and DMF (5x). The lysine was elongated with Fmoc-AEEA-OH 
using the general protocol followed by introduction of 116 (91.5 mg, 200 µmol, 2 eq) by shaking for two 
hour with HCTU (82.7 mg, 200 µmol, 2 eq) and DIPEA (69.7 µL, 400 µmol, 4 eq) in DMF (1.8 mL, 0.11 
M of 116). The resin was washed with DMF (3x), DCM (3x) and Et2O (2x) followed by nitrogen purge, 
transferred to a flask and treated for 120 minutes with a cleavage cocktail (10 mL, TFA/TIS/H2O, 190/5/5, 
v/v/v). The mixture was concentrated to approximately one mL and the resin was filtered off into a cold 
mixture of Et2O/pentane (45 mL, 5/4, v/v). The resin was washed off extra with neat TFA (3x 1 mL) into 
the ether solution. This solution was centrifuged (10 minutes, 5000 rpm) after which the supernatant was 
removed and the precipitate was dried under nitrogen flow. Purification via RP-HPLC (linear-gradient 24 - 
36 % B in A, 12 min, 5 mL/min, Gemini-NX 5 µm C18, 110 Å, 250 x 10.0 mm) yielded title compound 
130 as a white powder after lyophilization (7.85 mg, 1.78 µmol, 1.78% over 35 couplings, 89% per step). 
LC-MS: Rt = 4.94 min (10 - 90% ACN; 13 min); HRMS [C201H297N57O57 + 5H]5+: 885.6479 found, 
885.65029 calculated. 
Ac-Lys(N3)-Val-Thr-His-Thr-Tyr-Leu-Glu-Pro-Gly-Pro-Val-Thr-Ala-Asn-Arg-Gln-Leu-Tyr-Pro-Glu-
Trp-Thr-Glu-Ala-Gln-Arg-Leu-Asp-αAbu-Trp-Arg-Gly-Lys(Peg-TLR7L)-NH2 (139). 
Resin 134 (theoretical loading of 100 µmol) was elongated using the general protocol resulting in Ac-
Lys(N3)-Val-Thr(tBu)-His(Trt)-Thr(tBu)-Tyr(tBu)-Leu-Glu(OtBu)-Pro-Gly-Pro-Val-Thr(tBu)-Ala-
Asn(Trt)-Arg(Pbf)-Gln(Trt)-Leu-Tyr(tBu)-Pro-Glu(OtBu)-Trp(Boc)-Thr(tBu)-Glu(OtBu)-Ala-Gln(Trt)-
Arg(Pbf)-Leu-Asp(OtBu)-αAbu-Trp(Boc)-Arg(Pbf)-Gly-Lys(Mmt)-Tentagel® S-RAM. This was loaded in a 
syringe with frit and treated with a TFA solution (1% in DCM) shaken for five minutes, followed by 
filtration. This was repeated until the filtrate lost the orange/yellow color (~ 12x). After which the resin was 
washed with DCM (5x), DMF (5x) Piperidine (20% in DMF, 1x) and DMF (5x). The lysine was elongated 
with Fmoc-AEEA-OH using the general protocol followed by introduction of 116 (183 mg, 400 µmol, 4 
eq) by shaking for one hour with HCTU (165.4 mg, 400 µmol, 4 eq) and DIPEA (140 µL, 800 µmol, 8 eq) 
in DMF (3.6 mL, 0.11 M of 116). The resin was washed with DMF (3x), DCM (3x) and Et2O (2x) followed 
by nitrogen purge, transferred to a flask and treated for 120 minutes with a cleavage cocktail (25 mL, 
TFA/TIS/H2O/phenol, 188/5/5/2, v/v/v/w). The mixture was concentrated to approximately one mL 
and the resin was filtered off into a cold mixture of Et2O/pentane (45 mL, 5/4, v/v). The resin was washed 
off extra with neat TFA (3x 1 mL) into the ether solution. This solution was centrifuged (10 minutes, 5000 
rpm) after which the supernatant was removed and the precipitate was dried under nitrogen flow. 
Purification via RP-HPLC (linear-gradient 23 - 36 % B in A, 12 min, 5 mL/min, Gemini-NX 5 µm C18, 
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110 Å, 250 x 10.0 mm) yielded title compound 139 as a white powder after lyophilization (23.30 mg, 5.09 
µmol, 5.09% over 36 couplings, 92% per step). LC-MS: Rt = 7.05 min (10 - 50% ACN; 13 min); Rt = 4.71 
min (10 - 90% ACN; 13 min); HRMS [C207H307N61O58 + 5H]5+: 916.4700 found, 916.46737 calculated. 
Ac-Val-Thr-His-Thr-Tyr-Leu-Glu-Pro-Gly-Pro-Val-Thr-Ala-Asn-Arg-Gln-Leu-Tyr-Pro-Glu-Trp-Thr-
Glu-Ala-Gln-Arg-Leu-Asp-Cys-Trp-Arg-Gly-Lys(Peg-TLR7L)-NH2 (133). 
Ac-Val-Thr(tBu)-His(Trt)-Thr(tBu)-Tyr(tBu)-Leu-Glu(OtBu)-Pro-Gly-Pro-Val-Thr(tBu)-Ala-Asn(Trt)-
Arg(Pbf)-Gln(Trt)-Leu-Tyr(tBu)-Pro-Glu(OtBu)-Trp(Boc)-Thr(tBu)-Glu(OtBu)-Ala-Gln(Trt)-Arg(Pbf)-
Leu-Asp(OtBu)-Cys(Trt)-Trp(Boc)-Arg(Pbf)-Gly-Lys(Mmt)-Tentagel® S-RAM (100 µmol scale, single 
couplings at room temperature) was loaded in a syringe with frit and treated with a TFA (1% in DCM) 
shaken for five minutes followed by filtration. This was repeated until the filtrate lost the orange/yellow 
color (12x). After which the resin was washed with DCM (5x), DMF (5x) Piperidine (20% in DMF, 1x) and 
DMF (5x). The lysine was elongated with Fmoc-AEEA-OH using the general protocol followed by 
introduction of 116 (91.5 mg, 200 µmol, 2 eq) by shaking for two hour with HCTU (82.7 mg, 200 µmol, 2 
eq) and DIPEA (69.7 µL, 400 µmol, 4 eq) in DMF (1.8 mL, 0.11 M of 116). The resin was washed with 
DMF (3x), DCM (3x) and Et2O (2x) followed by nitrogen purge, transferred to a flask and treated for 120 
minutes with a cleavage cocktail (10 mL, TFA/TIS/H2O, 190/5/5, v/v/v). The mixture was concentrated 
to approximately one mL and the resin was filtered off into a cold mixture of Et2O/pentane (45 mL, 5/4, 
v/v). The resin was washed off extra with neat TFA (3x 1 mL) into the ether solution. This solution was 
centrifuged (10 minutes, 5000 rpm) after which the supernatant was removed and the precipitate was dried 
under nitrogen flow. Purification via RP-HPLC (linear-gradient 24 - 36 % B in A, 12 min, 5 mL/min, 
Gemini-NX 5 µm C18, 110 Å, 250 x 10.0 mm) yielded title compound 133 as a white powder after 
lyophilization (1.03 mg, 0.232 µmol, 0.23% over 35 couplings, 84% per step). LC-MS: Rt = 5.01 min (10 - 
90% ACN; 13 min); HRMS [C201H296N56O57S + 5H]5+: 889.0417 found, 889.04249 calculated. 
Pent-4-ynoic acid succinimidyl ester (140). 
Synthesis and spectral data were as described in previous literature.33 
 
General alkyne introduction procedure:  
The “general procedure” to introduce the alkyne handle: A solution of glycoclusters with a free 
amine (0.2 M, aq., 1 eq) was mixed with a stock solution of 140 (0.15 M, 3 eq) and DIPEA (0.05 
M, 1 eq) in DMSO and shaken for one hour. Reaction progress was followed via LC-MS and when 
completed, the 4-pentynoic amides were purified via gel filtration (Toyopearl HW-40S, 150 mM 
NH4HCO3, 1.6 x 60 cm, 1 mL/min) or RP-HPLC (linear-gradient, 5 mL/min, Gemini-NX 5 µm 
C18, 110 Å, 250 x 10.0 mm) followed by lyophilization. 
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Ac-Lys(Man1)-Gly-Lys(pent-4-ynoic amide)-NH2 (141). 
Compound 32 (5.72 mg, 9.28 µmol) was coupled with 140 using the general 
procedure. Compound 141 was obtained after RP-HPLC (linear-gradient 5 - 45% 
B, 10 min) as a white powder (4.01 mg, 5.75 µmol, 62%). LC-MS: Rt = 4.48 min (0 
- 50% ACN; 13 min); 1H NMR (400 MHz, D2O) δ 8.03 (s, 1H, trzl), 4.93 (d, J = 1.7 
Hz, 1H, H-1), 4.82 - 4.80 (m, 1H, O-CHH-trzl), 4.68 (d, J = 12.4 Hz, 1H, O-CHH-
trzl), 4.42 (t, J = 6.9 Hz, 2H, CH2-trzl), 4.26 - 4.14 (m, 2H, CH), 3.92 - 3.57 (m, 8H, CH2 (G), H-2, H-3, H-
4, H-5, H-6), 3.16 (t, J = 6.9 Hz, 2H, CH2-NH2), 2.49 - 2.42 (m, 2H, CH2), 2.42 - 2.36 (m, 2H, CH2), 2.32 
(t, J = 2.5 Hz, 1H, C≡CH), 1.97 (s, 3H, Ac), 1.89 (q, J = 7.3 Hz, 2H, CH2), 1.85 - 1.62 (m, 4H, CH2), 1.48 
(q, J = 8.2, 7.5 Hz, 2H, CH2), 1.34 (ddd, J = 23.0, 15.9, 7.4 Hz, 4H, CH2); 13C NMR (101 MHz, D2O) δ 
174.9 (C=O), 99.4 (C-1), 72.9, 70.4, 70.1, 69.9, 66.6, 60.8, 59.7, 53.8, 50.1, 42.4, 39.0, 34.5, 30.5, 22.3, 21.8, 
21.6 (Ac), 14.6; HRMS [C30H48N8O11 + H]+: 697.35147 found, 697.35153 calculated. 
Ac-Lys(Man1)-Lys(Man1)-Lys(Man1)-Lys(Man1)-Lys(Man1)-Lys(Man1)-Gly-Lys(pent-4-ynoic 
amide)-NH2 (145). 
Compound 50 (8.0 mg, 2.1 µmol) was coupled with 140 using the general procedure. 
Compound 145 was obtained after purification by gel filtration (eluted at 41 - 52 
mL) or RP-HPLC (linear-gradient 5 - 45% B, 10 min) as a white powder (3.52 mg, 
1.38 µmol, 66%). LC-MS: Rt = 5.09 min (0 - 50% ACN; 13 min); 1H NMR (500 
MHz, D2O) δ 7.95 (d, J = 5.6 Hz, 6H, trzl), 4.87 (d, J = 1.7 Hz, 6H, H-1), 4.71 (d, J 
= 12.5, 3.9 Hz, 6H, O-CHH-trzl), 4.58 (d, J = 12.5 Hz, 6H, O-CHH-trzl), 4.31 (t, J = 6.5 Hz, 12H, CH2-
trzl), 4.20 - 3.99 (m, 7H, CH (K)), 3.91 - 3.49 (m, 38H, H-2, H-3, H-4, H-5, H-6, CH2 (G)), 3.08 (t, J = 6.8 
Hz, 2H, CH2-NH(CO)), 2.39 - 2.22 (m, 5H, CH2, CH2, CH), 1.92 (s, 3H, Ac), 1.86 - 1.08 (m, 42H, CH2); 
13C NMR (126 MHz, D2O) δ 160.5, 99.4 (C-1), 72.9, 70.5, 69.9, 66.6 (C-2, C-3, C-4, C5), 60.8 (C-6), 59.8 
(O-CH2-trzl); HRMS [C105H168N28O46 + 2H]2+: 1280.09306 found, 1280.09210 calculated. 
Ac-Lys(1,2-Man2)-Gly-Lys(pent-4-ynoic amide)-NH2 (142). 
Compound 33 (2.37 mg, 3.04 µmol) was coupled with 140 using the general 
procedure. Compound 142 was obtained after purification by gel filtration (eluted 
at 53.5 - 61 mL) as a white powder (1.86 mg, 2.16 µmol, 71%). LC-MS: Rt = 4.72 
min (0 - 50% ACN; 13 min); HRMS [C36H58N8O16 + H] +: 859.40447 found, 
859.40435 calculated. 
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Ac-Lys(1,2-Man2)-Lys(1,2-Man2)-Lys(1,2-Man2)-Lys(1,2-Man2)-Lys(1,2-Man2)-Lys(1,2-Man2)-
Gly-Lys(pent-4-ynoic amide)-NH2 (146). 
Compound 51 (7.06 mg, 2.04 µmol) was coupled with 140 using the general 
procedure. Compound 146 was obtained after purification by gel filtration (buffer 
contained 20% ACN, eluted at 25 - 40 mL) as a white powder (6.95 mg, 1.96 µmol, 
96%). LC-MS: Rt = 4.76 min (0 - 50% ACN; 13 min); 1H NMR (500 MHz, D2O) 
δ 7.93 - 7.88 (m, 6H, trzl), 5.04 (s, 6H, H-1), 4.86 (s, 6H, H-1′), 4.66 (d, J = 12.4 
Hz, 6H, O-CHH-trzl), 4.54 (d, J = 12.7 Hz, 6H, O-CHH-trzl), 4.27 (t, J = 6.4 Hz, 
12H, CH2-trzl), 4.18 - 3.97 (m, 7H, CH), 3.96 - 3.43 (m, 74H, CH2 (G), H-2, H-2′, H-3, H-3′, H-4, H-4′, H-
5, H-5′, H-6, H-6′), 3.03 (t, J = 6.4 Hz, 2H, CH2NH2), 2.35 - 2.17 (m, 5H, CH2, CH2, C≡CH), 1.87 (s, 3H, 
Ac), 1.82 - 1.03 (m, 42H, CH2); HRMS [C141H228N28O76 + 3H]3+: 1177.83838 found, 1177.83618 calculated. 
Ac-Lys(1,3-Man2)-Lys(1,3-Man2)-Lys(1,3-Man2)-Lys(1,3-Man2)-Lys(1,3-Man2)-Lys(1,3-Man2)-
Gly-Lys(pent-4-ynoic amide)-NH2 (147). 
A solution of compound 52 (150 µL, 5mM, 750 nmol, aq.) was coupled with 
140 using the general procedure. Compound 147 was obtained after purification 
by gel filtration (buffer contained 20% ACN, eluted at 23.5 - 40 mL) as a white 
powder (2.23 mg, 645 nmol, 95%). LC-MS: Rt = 4.60 min (0 - 50% ACN; 13 
min); 1H NMR (500 MHz, D2O) δ 7.93 - 7.88 (m, 6H, trzl), 4.96 (s, 6H, H-1), 
4.80 (s, 6H, H-1′), 4.66 (d, J = 5.8 Hz, 6H, O-CHH-trzl), 4.55 (d, J = 12.6 Hz, 6H, O-CHH-trzl), 4.26 (d, J 
= 6.3 Hz, 12H, CH2-trzl), 4.14 - 3.96 (m, 7H, CH), 3.96 - 3.43 (m, 74H, CH2 (G), H-2, H-2′, H-3, H-3′, H-
4, H-4′, H-5, H-5′, H-6, H-6′), 3.03 (t, J = 6.7 Hz, 2H, CH2NH2), 2.39 - 2.16 (m, 5H, CH2, CH2, C≡CH), 
1.86 (s, 3H, Ac), 1.82 - 1.04 (m, 42H, CH2); HRMS [C141H228N28O76 + 3H]3+: 1177.83747 found, 1177.83618 
calculated. 
Ac-Lys(1,6-Man2)-Gly-Lys(pent-4-ynoic amide)-NH2 (143). 
Compound 35 (2.32 mg, 2.99 µmol) was coupled with 140 using the general 
procedure. Compound 143 was obtained after purification by gel filtration (eluted 
at 53.5 - 61 mL) as a white powder (1.81 mg, 2.11 µmol, 71%). LC-MS: Rt = 4.73 
min (0 - 50% ACN; 13 min); HRMS [C36H58N8O16 + H]+: 859.40439 found, 
859.40435 calculated. 
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Ac-Lys(1,6-Man2)-Lys(1,6-Man2)-Lys(1,6-Man2)-Lys(1,6-Man2)-Lys(1,6-Man2)-Lys(1,6-Man2)-
Gly-Lys(pent-4-ynoic amide)-NH2 (148). 
Compound 53 (2.35 mg, 679 nmol) was coupled with 140 using the general 
procedure. Compound 148 was obtained after purification by gel filtration (eluted 
at 31.5 - 42 mL) as a white powder (2.23 mg, 645 nmol, 95%). LC-MS: Rt = 4.76 
min (0 - 50% ACN; 13 min); HRMS [C141H228N28O76 + 3H]3+: 1177.83621 found, 
1177.83618 calculated. 
 
Ac-Lys(Man3)-Gly-Lys(pent-4-ynoic amide)-NH2 (144). 
Compound 36 (4.53 mg, 4.81 µmol) was coupled with 140 using the general 
procedure. Compound 144 was obtained after purification by gel filtration 
(eluted at 44.5 - 50.5 mL) as a white powder (0.98 mg, 872 nmol, 18%). LC-
MS: Rt = 4.64 min (0 - 50% ACN; 13 min); HRMS [C42H68N8O21 + H]+: 
1021.45725 found, 1021.45718 calculated. 
 
Ac-Lys(Man3)-Lys(Man3)-Lys(Man3)-Lys(Man3)-Lys(Man3)-Lys(Man3)-Gly-Lys(pent-4-ynoic 
amide)-NH2 (149). 
Compound 54 (18.77 mg, 4.24 µmol) was coupled with 140 using the general 
procedure. Compound 149 was obtained after purification by gel filtration 
(buffer contained 20% ACN, eluted at 26 - 38.5 mL) as a white powder (17.96 
mg, 3.98 µmol, 94%). LC-MS: Rt = 4.64 min (0 - 50% ACN; 13 min); 1H NMR 
(500 MHz, D2O) δ 7.92 (s, 6H, trzl), 4.95 (s, 6H, H-1), 4.80 (s, 6H, H-1′), 4.76 
(s, 6H , H-1′′), 4.68 - 4.63 (m, 6H, O-CHH-trzl), 4.57 (d, J = 12.7 Hz, 6H, O-
CHH-trzl), 4.28 (t, J = 6.3 Hz, 12H, CH2-trzl), 4.18 - 4.05 (m, 6H, CH), 4.05 - 3.39 (m, 111H, CH, CH2 (G), 
H-2, H-2′, H-2′′, H-3, H-3′, H-3′′, H-4, H-4′, H-4′′, H-5, H-5′, H-5′′, H-6, H-6′, H-6′′), 3.04 (t, J = 6.7 Hz, 2H, 
CH2NH2), 2.41 - 2.18 (m, 5H, CH2, CH2, C≡CH), 1.87 (s, 3H, Ac), 1.84 - 1.01 (m, 42H, CH2); 13C NMR 
(126 MHz, D2O) δ 143.5, 124.2 (CH trzl), 102.4, 99.7, 99.4 (C-1, C-1′, C-1′′), 78.6, 73.3, 72.7, 71.2, 70.6, 
70.3, 70.0, 69.9, 69.5, 69.5, 66.7, 65.4, 64.9, 60.9 (C-2, C-2′, C-2′′, C-3, C-3′, C-3′′, C-4, C-4′, C-4′′, C-5, C-5′, 
C-5′′, C-6, C-6′, C-6′′), 59.8 (O-CH2trzl), 53.9, 53.5 (CH), 50.0 (CH2-trzl), 42.4 (CH2 (G)), 39.1 (CH2NH2), 
34.5 (CH2), 30.0, 28.9, 22.0 (CH2), 21.7 (Ac), 14.6 (CH2); HRMS [C177H288N28O106 + 3H]3+: 1502.27589 
found, 1502.27616 calculated. 
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General procedure for the CuAAC of alkyne mannoside clusters and azido-gp100 
peptides: 
The “general click protocol” used for the conjugation of alkynes and azido-gp100 peptides: All 
solvents used in these reactions were degassed by sonicating while bubbling argon through the 
solutions. A solution of azido-peptides 137 or 139 in DMSO was mixed with a solution of alkyne 
functionalized glycoclusters in water 141-149 followed by addition of an aliquot of a stock solution 
of CuI (0.1 eq), THPTA (0.3 eq) and DIPEA (0.2 eq) in water ([Cu+] = 0.5 M). The reaction was 
stirred at 45°C and the process was followed via LC-MS. When reactions did not progress and 
turned blue, a stock solution of sodium ascorbate (0.25 M) and arginine34 (0.5 M, 0.2 - 1 eq 
ascorbate) in water was added. After completion a small amount of Quadrasil® AP (washed with 
water) was added, stirred for 1 h, filtered and purified by either gel filtration (Toyopearl HW-40S, 
150 mM NH4HCO3, buffer contained 20% ACN, 1.6x60 cm, 1 mL/min) and/or RP-HPLC (linear-
gradient, 5 mL/min, Gemini-NX 5 µm C18, 110 Å, 250 x 10.0 mm) followed by lyophilization.  
 
Ac-Lys(*[Ac-Lys(Man1)-Gly-Lys(*triazolylpentyl-5-amide)-NH2])-Val-Thr-His-Thr-Tyr-Leu-Glu-
Pro-Gly-Pro-Val-Thr-Ala-Asn-Arg-Gln-Leu-Tyr-Pro-Glu-Trp-Thr-Glu-Ala-Gln-Arg-Leu-Asp-αAbu-
Trp-Arg-Gly-Lys-NH2 (150). 
A solution of mannosides cluster 141 (100 µL, 0.02 M, 2.0 µmol, 1.15 eq, 
aq.) and undecorated gp100 137 in DMSO (88 µL, 0.2 M, 1.75 µmol, 1 
eq) were conjugated using the general click protocol. After purification 
by RP-HPLC (linear-gradient 7 - 38% B, 10 min) compound 150 was 
obtained as a white powder (4.365 mg, 911 nmol, 52%). LC-MS: Rt = 
4.09 min (10 - 90% ACN; 13 min); 1H NMR (500 MHz, D2O) δ 8.55 (d, J = 1.1 Hz, 1H, Harom (H)), 7.99 (s, 
1H, trzl), 7.71 (s, 1H, trzl), 7.48 (dd, J = 31.8, 7.9 Hz, 1Hz, 2H, Harom (W)), 7.38 (dd, J = 16.5, 8.2 Hz, 4H, 
Harom (W)), 7.26 - 7.10 (m, 5H, Harom), 7.10 - 6.95 (m, 6H, Harom), 6.83 - 6.65 (m, 4H, Harom (Y)), 4.92 (d, J = 
1.4 Hz, 1H, H-1), 4.77 - 4.51 (m, 7H), 4.47 - 4.00 (m, 34H), 3.99 - 3.47 (m, 20H), 3.35 - 2.65 (m, 31H), 2.53 
(t, J = 7.3 Hz, 2H, CH2NH2 (K)), 2.50 - 2.29 (m, 7H), 2.29 - 2.15 (m, 8H), 2.14 - 1.02 (m, 92H), 1.01 - 0.69 
(m, 30H); HRMS [C214H327N63O63 + 5H]5+: 958.89471 found, 958.89482 calculated. 
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Ac-Lys(*[Ac-Lys(Man1)-Gly-Lys(*triazolylpentyl-5-amide)-NH2])-Val-Thr-His-Thr-Tyr-Leu-Glu-
Pro-Gly-Pro-Val-Thr-Ala-Asn-Arg-Gln-Leu-Tyr-Pro-Glu-Trp-Thr-Glu-Ala-Gln-Arg-Leu-Asp-αAbu-
Trp-Arg-Gly-Lys(Peg-TLR7L)-NH2 (151). 
A solution of mannosides cluster 141 (75 µL, 0.02 M, 1.50 µmol, 1.5 
eq, aq.) and TLR-decorated gp100 139 in DMSO (100 µL, 0.01 M, 1.0 
µmol, 1 eq) were conjugated using the general click protocol. After 
purification by RP-HPLC (linear-gradient 7 - 42% B, 11 min) 
compound 151 was obtained as a white powder (1.800 mg, 341 nmol, 
34%). LC-MS: Rt = 4.51 min (10 - 90% ACN; 13 min); 1H NMR (500 
MHz, D2O) δ 8.55 (s, 1H, Harom (H)), 8.00 (s, 2H, trzl), 7.77 - 7.66 (m, 2H, Harom), 7.48 - 6.62 (m, 21H, 
Harom), 4.92 (s, 1H, H-1), 4.68 - 2.59 (m, ~106H), 2.54 (t, J = 7.0 Hz, 2H, CH2NH2 (K)), 2.49 - 0.64 (m, 
~144H); HRMS [C237H355N69O69 + 5H]5+: 1055.93685 found, 1055.93678 calculated. 
Ac-Lys(*[Ac-Lys(Man1)-Lys(Man1)-Lys(Man1)-Lys(Man1)-Lys(Man1)-Lys(Man1)-Gly-
Lys(*triazolylpentyl-5-amide)-NH2])-Val-Thr-His-Thr-Tyr-Leu-Glu-Pro-Gly-Pro-Val-Thr-Ala-Asn-
Arg-Gln-Leu-Tyr-Pro-Glu-Trp-Thr-Glu-Ala-Gln-Arg-Leu-Asp-αAbu-Trp-Arg-Gly-Lys-NH2 (152). 
A solution of mannosides cluster  (96 µL, 0.005 M, 480 nmol, 1 eq, aq.) 
and undecorated gp100 137 in DMSO (100 µL, 0.005 M, 500 nmol, 1.05 
eq) were conjugated using the general click protocol. After purification 
by RP-HPLC (linear-gradient 8 - 42% B, 10 min) compound 152 was 
obtained as a white powder (1.090 mg, 163 nmol, 34%). LC-MS: Rt = 
6.46 min (0 - 50% ACN; 13 min); 1H NMR (500 MHz, D2O) δ 8.51 (s, 1H, Harom (H)), 7.92 (s, 6H, trzl), 
7.63 (s, 1H, trzl), 7.52 - 7.28 (m, 4H, Harom), 7.25 - 6.93 (m, 11H, Harom), 6.79 - 6.62 (m, 4H, Harom), 4.87 (s, 
6H, H-1), 4.64 - 2.56 (m, nd), 2.47 (t, J = 7.8 Hz, 2H, CH2NH2 (K)), 2.41 - 0.58 (m, nd). HRMS 
[C289H447N83O98 + 5H]5+: 1331.25941 found, 1331.25988 calculated. 
Ac-Lys(*[Ac-Lys(Man1)-Lys(Man1)-Lys(Man1)-Lys(Man1)-Lys(Man1)-Lys(Man1)-Gly-
Lys(*triazolylpentyl-5-amide)-NH2])-Val-Thr-His-Thr-Tyr-Leu-Glu-Pro-Gly-Pro-Val-Thr-Ala-Asn-
Arg-Gln-Leu-Tyr-Pro-Glu-Trp-Thr-Glu-Ala-Gln-Arg-Leu-Asp-αAbu-Trp-Arg-Gly-Lys(Peg-TLR7L)-
NH2 (153). 
A solution of mannosides cluster 145 (120 µL, 0.01 M, 1.20 µmol, 1.2 
eq, aq.) and TLR-decorated gp100 139 in DMSO (100 µL, 0.01 M, 1.0 
µmol, 1 eq) were conjugated using the general click protocol. After 
purification by RP-HPLC (linear-gradient 8 - 42% B, 10 min) 
compound 153 was obtained as a white powder (2.085 mg, 292 nmol, 
29%). LC-MS: Rt = 7.19 min (0 - 50% ACN; 13 min); Rt = 4.38 min 
(10 - 90% ACN; 13 min); 1H NMR (500 MHz, D2O) δ 8.56 (s, 1H, Harom (H)), 7.96 (s, 7H, trzl), 7.91 - 6.62 
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(m, 23H, Harom), 4.89 (s, 6H, H-1), 4.76 - 0.64 (m, nd); HRMS [C312H475N89O104 + 6H]6+: 1190.41891 found, 
1190.41941 calculated. 
Ac-Lys(*[Ac-Lys(1,2-Man2)-Gly-Lys(*triazolylpentyl-5-amide)-NH2])-Val-Thr-His-Thr-Tyr-Leu-
Glu-Pro-Gly-Pro-Val-Thr-Ala-Asn-Arg-Gln-Leu-Tyr-Pro-Glu-Trp-Thr-Glu-Ala-Gln-Arg-Leu-Asp-
αAbu-Trp-Arg-Gly-Lys-NH2 (154). 
A solution of mannosides cluster 142 (80 µL, 0.01 M, 0.80 µmol, 1 eq, 
aq.) and undecorated gp100 137 in DMSO (100 µL, 0.01 M, 1.0 µmol, 
1.25 eq) were conjugated using the general click protocol. After 
purification by gel-filtration (eluted at 42 - 57 mL) compound 154 was 
obtained as a white powder (3.633 mg, 734 nmol, 91%). LC-MS: Rt = 
4.48 min (10 - 90% ACN; 13 min); HRMS [C220H337N63O68 + 5H]5+: 
991.30528 found, 991.30539 calculated. 
Ac-Lys(*[Ac-Lys(1,2-Man2)-Gly-Lys(*triazolylpentyl-5-amide)-NH2])-Val-Thr-His-Thr-Tyr-Leu-
Glu-Pro-Gly-Pro-Val-Thr-Ala-Asn-Arg-Gln-Leu-Tyr-Pro-Glu-Trp-Thr-Glu-Ala-Gln-Arg-Leu-Asp-
αAbu-Trp-Arg-Gly-Lys(Peg-TLR7L)-NH2 (157). 
A solution of mannosides cluster 142 (80 µL, 0.01 M, 0.80 µmol, 1 eq, 
aq.) and TLR-decorated gp100 139 in DMSO (100 µL, 0.01 M, 1.0 
µmol, 1.25 eq) were conjugated using the general click protocol. After 
purification by gel-filtration (eluted at 32 - 54.5 mL) compound 157 
was obtained as a white powder (0.915 mg, 168 nmol, 21%). LC-MS: 
Rt = 4.83 min (10 - 90% ACN; 13 min); HRMS [C243H365N69O74 + 
5Na]5+: 1110.78537 found, 1110.73038 calculated. 
Ac-Lys(*[Ac-Lys(1,2-Man2)-Lys(1,2-Man2)-Lys(1,2-Man2)-Lys(1,2-Man2)-Lys(1,2-Man2)-Lys(1,2-
Man2)-Gly-Lys(*triazolylpentyl-5-amide)-NH2])-Val-Thr-His-Thr-Tyr-Leu-Glu-Pro-Gly-Pro-Val-
Thr-Ala-Asn-Arg-Gln-Leu-Tyr-Pro-Glu-Trp-Thr-Glu-Ala-Gln-Arg-Leu-Asp-αAbu-Trp-Arg-Gly-Lys-
NH2 (160). 
A solution of mannosides cluster 146 (125 µL, 0.01 M, 1.25 µmol, 1 eq, 
aq.) and undecorated gp100 137 in DMSO (125 µL, 0.016 M, 1.95 µmol, 
1.5 eq) were conjugated using the general click protocol. After 
purification by gel-filtration (eluted at 28 - 35.5 mL) compound 160 was 
obtained as a white powder (3.73 mg, 491 nmol, 39%). LC-MS: Rt = 6.99 
min (0 - 50% ACN; 13 min); 1H NMR (500 MHz, D2O) δ 8.03 - 7.89 (m, 
7H, trzl), 7.71 - 6.62 (m, 19H, Harom), 5.12 (s, 6H, H-1), 4.94 (s, 6H, H-1′), 4.89 - 0.61 (m, nd); HRMS 
[C325H507N83O128 + 5H]5+: 1525.72868 found, 1525.72330 calculated. 
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Ac-Lys(*[Ac-Lys(1,2-Man2)-Lys(1,2-Man2)-Lys(1,2-Man2)-Lys(1,2-Man2)-Lys(1,2-Man2)-Lys(1,2-
Man2)-Gly-Lys(*triazolylpentyl-5-amide)-NH2])-Val-Thr-His-Thr-Tyr-Leu-Glu-Pro-Gly-Pro-Val-
Thr-Ala-Asn-Arg-Gln-Leu-Tyr-Pro-Glu-Trp-Thr-Glu-Ala-Gln-Arg-Leu-Asp-αAbu-Trp-Arg-Gly-
Lys(Peg-TLR7L)-NH2 (164). 
A solution of mannosides cluster 146 (71.5 µL, 0.01 M, 715 nmol, 1 eq, 
aq.) and TLR-decorated gp100 139 in DMSO (75 µL, 0.01 M, 750 
µmol, 1.05 eq) were conjugated using the general click protocol. After 
purification by RP-HPLC (linear-gradient 8 - 42% B, 10 min) 
compound 164 was obtained as a white powder (1.395 mg, 172 nmol, 
24%). LC-MS: Rt = 7.10 min (0 - 50% ACN; 13 min); HRMS 
[C348H535N89O134 + 6H]6+: 1352.47638 found, 1352.47226 calculated. 
Ac-Lys(*[Ac-Lys(1,3-Man2)-Lys(1,3-Man2)-Lys(1,3-Man2)-Lys(1,3-Man2)-Lys(1,3-Man2)-Lys(1,3-
Man2)-Gly-Lys(*triazolylpentyl-5-amide)-NH2])-Val-Thr-His-Thr-Tyr-Leu-Glu-Pro-Gly-Pro-Val-
Thr-Ala-Asn-Arg-Gln-Leu-Tyr-Pro-Glu-Trp-Thr-Glu-Ala-Gln-Arg-Leu-Asp-αAbu-Trp-Arg-Gly-Lys-
NH2 (161). 
A solution of mannosides cluster 147 (112 µL, 0.005 M, 560 nmol, 1 
eq, aq.) and undecorated gp100 137 in DMSO (168 µL, 0.01 M, 1.68 
µmol, 3 eq) were conjugated using the general click protocol. After 
purification by gel-filtration (eluted at 28 - 35.5 mL) compound 161 
was obtained as a white powder (2.650 mg, 349 nmol, 62%). LC-MS: 
Rt = 6.40 min (10 - 50 % ACN; 13 min); 1H NMR (500 MHz, D2O) 
δ 8.32 (s, 1H, Harom (H)), 7.88 (s, 7H, trzl), 7.64 - 6.51 (m, 19H, Harom), 4.96 (s, 6H, H-1), 4.79 (s, 6H, H-1′), 
4.76 - 0.46 (m, nd); HRMS [C325H507N83O128 + 6H]6+: 1271.77597 found, 1271.77109 calculated. 
Ac-Lys(*[Ac-Lys(1,3-Man2)-Lys(1,3-Man2)-Lys(1,3-Man2)-Lys(1,3-Man2)-Lys(1,3-Man2)-Lys(1,3-
Man2)-Gly-Lys(*triazolylpentyl-5-amide)-NH2])-Val-Thr-His-Thr-Tyr-Leu-Glu-Pro-Gly-Pro-Val-
Thr-Ala-Asn-Arg-Gln-Leu-Tyr-Pro-Glu-Trp-Thr-Glu-Ala-Gln-Arg-Leu-Asp-αAbu-Trp-Arg-Gly-
Lys(PEG-TLR7L)-NH2 (165). 
A solution of mannosides cluster 147 (38 µL, 0.005 M, 190 nmol, 1 
eq, aq.) and TLR-decorated gp100 139 in DMSO (28.5 µL, 0.01 M, 
285 µmol, 1.5 eq) were conjugated using the general click protocol. 
After purification by RP-HPLC (linear-gradient 8 - 42% B, 10 min) 
compound 165 was obtained as a white powder (0.630 mg, 78 nmol, 
41%). LC-MS: Rt = 7.12 min (10 - 50% ACN; 13 min); HRMS 
[C348H535N89O134 + 6H]6+: 1352.47991 found, 1352.47226 calculated. 
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Ac-Lys(*[Ac-Lys(1,6-Man2)-Gly-Lys(*triazolylpentyl-5-amide)-NH2])-Val-Thr-His-Thr-Tyr-Leu-
Glu-Pro-Gly-Pro-Val-Thr-Ala-Asn-Arg-Gln-Leu-Tyr-Pro-Glu-Trp-Thr-Glu-Ala-Gln-Arg-Leu-Asp-
αAbu-Trp-Arg-Gly-Lys-NH2 (155). 
A solution of mannosides cluster 143 (80 µL, 0.01 M, 0.80 µmol, 1 eq, 
aq.) and undecorated gp100 137 in DMSO (100 µL, 0.01 M, 1.0 µmol, 
1.25 eq) were conjugated using the general click protocol. After 
purification by gel-filtration (eluted at 32 - 54.5 mL) compound 155 was 
obtained as a white powder (3.570 mg, 721 nmol, 90%). LC-MS: Rt = 
4.48 min (10 - 90% ACN; 13 min); HRMS [C220H337N63O68 + 5H]5+: 
991.30570 found, 991.30539 calculated. 
Ac-Lys(*[Ac-Lys(1,6-Man2)-Gly-Lys(*triazolylpentyl-5-amide)-NH2])-Val-Thr-His-Thr-Tyr-Leu-
Glu-Pro-Gly-Pro-Val-Thr-Ala-Asn-Arg-Gln-Leu-Tyr-Pro-Glu-Trp-Thr-Glu-Ala-Gln-Arg-Leu-Asp-
αAbu-Trp-Arg-Gly-Lys(Peg-TLR7L)-NH2 (158). 
A solution of mannosides cluster 143 (80 µL, 0.01 M, 0.80 µmol, 1 eq, 
aq.) and TLR-decorated gp100 139 in DMSO (100 µL, 0.01 M, 1.0 
µmol, 1.25 eq) were conjugated using the general click protocol. After 
purification by gel-filtration (eluted at 32 - 54.5 mL) compound 158 
was obtained as a white powder (0.840 mg, 154 nmol, 19%). LC-MS: 
Rt = 4.77 min (10 - 90% ACN; 13 min); HRMS [C243H365N69O74 + 
6H]6+: 906.82311 found, 906.78974 calculated. 
Ac-Lys(*[Ac-Lys(1,6-Man2)-Lys(1,6-Man2)-Lys(1,6-Man2)-Lys(1,6-Man2)-Lys(1,6-Man2)-Lys(1,6-
Man2)-Gly-Lys(*triazolylpentyl-5-amide)-NH2])-Val-Thr-His-Thr-Tyr-Leu-Glu-Pro-Gly-Pro-Val-
Thr-Ala-Asn-Arg-Gln-Leu-Tyr-Pro-Glu-Trp-Thr-Glu-Ala-Gln-Arg-Leu-Asp-αAbu-Trp-Arg-Gly-Lys-
NH2 (162). 
A solution of mannosides cluster 148 (35 µL, 0.01 M, 350 nmol, 1 eq, 
aq.) and undecorated gp100 137 in DMSO (40 µL, 0.01 M, 400 nmol, 
1.15 eq) were conjugated using the general click protocol. After 
purification by gel-filtration (eluted at 36 - 45 mL) compound 162 was 
obtained as a white powder (1.805 mg, 238 nmol, 68%). LC-MS: Rt = 
4.32 min (10 - 90% ACN; 13 min); HRMS [C325H507N83O128 + H + Na 
+ 3NH3]5+: 1540.12657 found, 1540.13201 calculated. 
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Ac-Lys(*[Ac-Lys(1,6-Man2)-Lys(1,6-Man2)-Lys(1,6-Man2)-Lys(1,6-Man2)-Lys(1,6-Man2)-Lys(1,6-
Man2)-Gly-Lys(*triazolylpentyl-5-amide)-NH2])-Val-Thr-His-Thr-Tyr-Leu-Glu-Pro-Gly-Pro-Val-
Thr-Ala-Asn-Arg-Gln-Leu-Tyr-Pro-Glu-Trp-Thr-Glu-Ala-Gln-Arg-Leu-Asp-αAbu-Trp-Arg-Gly-
Lys(Peg-TLR7L)-NH2 (166). 
A solution of mannosides cluster 148 (35 µL, 0.01 M, 350 nmol, 1 eq, 
aq.) and TLR-decorated gp100 139 in DMSO (40 µL, 0.01 M, 400 
nmol, 1.15 eq) were conjugated using the general click protocol. After 
purification by gel-filtration (eluted at 37.5 - 49.5 mL) compound 166 
was obtained as a white powder (0.520 mg, 64 nmol, 18%). LC-MS: Rt 
= 4.68 min (10 - 90% ACN; 13 min); HRMS [C348H535N89O134 + 5H]5+: 
1622.56900 found, 1622.56470 calculated. 
Ac-Lys(*[Ac-Lys(Man3)-Gly-Lys(*triazolylpentyl-5-amide)-NH2])-Val-Thr-His-Thr-Tyr-Leu-Glu-
Pro-Gly-Pro-Val-Thr-Ala-Asn-Arg-Gln-Leu-Tyr-Pro-Glu-Trp-Thr-Glu-Ala-Gln-Arg-Leu-Asp-αAbu-
Trp-Arg-Gly-Lys-NH2 (156). 
A solution of mannosides cluster 144 (40 µL, 0.01 M, 400 nmol, 1 eq, 
aq.) and undecorated gp100 137 in DMSO (45 µL, 0.01 M, 450 µmol, 
1.13 eq) were conjugated using the general click protocol. After 
purification by gel-filtration (eluted at 30 - 54.5 mL) compound 156 
was obtained as a white powder (1.802 mg, 352 nmol, 88%). LC-MS: 
Rt = 4.48 min (10 - 90% ACN; 13 min); HRMS [C226H347N63O73 + 
4Na]4+: 1301.63838 found, 1301.62576 calculated. 
Ac-Lys(*[Ac-Lys(Man3)-Gly-Lys(*triazolylpentyl-5-amide)-NH2])-Val-Thr-His-Thr-Tyr-Leu-Glu-
Pro-Gly-Pro-Val-Thr-Ala-Asn-Arg-Gln-Leu-Tyr-Pro-Glu-Trp-Thr-Glu-Ala-Gln-Arg-Leu-Asp-αAbu-
Trp-Arg-Gly-Lys(Peg-TLR7L)-NH2 (159). 
A solution of mannosides cluster 144 (40 µL, 0.01 M, 400 nmol, 1 
eq, aq.) and TLR-decorated gp100 139 in DMSO (45 µL, 0.01 M, 
450 µmol, 1.13 eq) were conjugated using the general click protocol. 
After purification by gel-filtration (eluted at 30 - 54.5 mL) 
compound 159 was obtained as a white powder (0.721 mg, 129 
nmol, 32%). LC-MS: Rt = 5.56 min (10 - 90% ACN; 13 min); HRMS 
[C249H375N69O79 + 4Na]4+: 1421.97944 found, 1422.17613 calculated. 
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Ac-Lys(*[Ac-Lys(Man3)-Lys(Man3)-Lys(Man3)-Lys(Man3)-Lys(Man3)-Lys(Man3)-Gly-
Lys(*triazolylpentyl-5-amide)-NH2])-Val-Thr-His-Thr-Tyr-Leu-Glu-Pro-Gly-Pro-Val-Thr-Ala-Asn-
Arg-Gln-Leu-Tyr-Pro-Glu-Trp-Thr-Glu-Ala-Gln-Arg-Leu-Asp-αAbu-Trp-Arg-Gly-Lys-NH2 (163). 
A solution of mannosides cluster 149 (175 µL, 0.01 M, 1.75 µmol, 1 
eq, aq.) and undecorated gp100 137 in DMSO (263 µL, 0.01 M, 263 
µmol, 1.5 eq) were conjugated using the general click protocol. After 
purification by gel-filtration (eluted at 29 - 38 mL) followed by RP-
HPLC (linear-gradient 8 - 42% B, 10 min) compound 163 was 
obtained as a white powder (6.760 mg, 786 nmol, 45%). LC-MS: Rt = 
6.37 min (10 - 50% ACN; 13 min); 1H NMR (500 MHz, D2O) δ 8.40 (s, 1H, Harom (H)), 7.90 (d, J = 11.1 
Hz, 7H, trzl), 7.63 - 6.50 (m, 19H, Harom), 4.94 (s, 6H, H-1), 4.79 (s, 6H, H-1′), 4.76 (s, 6H, H-1′′), 4.71 - 0.54 
(m, nd); HRMS [ C361H567N83O158+ 6H]6+: 1433.82676 found, 1433.82394 calculated. 
Ac-Lys(*[Ac-Lys(Man3)-Lys(Man3)-Lys(Man3)-Lys(Man3)-Lys(Man3)-Lys(Man3)-Gly-
Lys(*triazolylpentyl-5-amide)-NH2])-Val-Thr-His-Thr-Tyr-Leu-Glu-Pro-Gly-Pro-Val-Thr-Ala-Asn-
Arg-Gln-Leu-Tyr-Pro-Glu-Trp-Thr-Glu-Ala-Gln-Arg-Leu-Asp-αAbu-Trp-Arg-Gly-Lys(Peg-TLR7L)--
NH2 (167). 
A solution of mannosides cluster 149 (200 µL, 0.01 M, 2.0 µmol, 2 
eq, aq.) and TLR-decorated gp100 139 in DMSO (100 µL, 0.01 M, 
1.0 µmol, 1 eq) were conjugated using the general click protocol. 
After purification by RP-HPLC (linear-gradient 8 - 42% B, 10 min) 
compound 167 was obtained as a white powder (2.483 mg, 273 
nmol, 27%). LC-MS: Rt = 7.07 min (10 - 50% ACN; 13 min); 1H 
NMR (500 MHz, D2O) δ 8.55 (s, 1H, Harom (H)), 7.98 (s, 7H, trzl), 7.74 - 6.60 (m, 23H, Harom), 5.03 (s, 6H, 
H-1), 4.88 (s, 6H, H-1′), 4.85 (s, 6H, H-1′′), 4.77 - 1.40 (m, nd), 1.38 (s, 3H, Ac), 1.36 (s, 3H, Ac), 1.35 - 0.66 
(m, nd); HRMS [C384H595N89O164 + 6H]6+: 1514.69741 found, 1514.69225 calculated. 
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Chapter 5 
Development of a C-mannoside function-
alized lysine for the synthesis of acid-stable 
mannosylated peptidesa 
Introduction1 
The uptake, processing, and (cross)-presentation of antigens is a complex process, which has not 
yet been fully elucidated.2,3 Studying the process, starting from cellular uptake and ending with the 
presentation at the surface of antigen-presenting cells remains challenging, since the introduction 
of accessory molecular motives to follow the fate of the antigens, such as fluorescent labels, can 
influence the antigen processing pathway significantly.4 To circumvent this issue, small bio-
orthogonal handles with minimal impact on the structure of peptide conjugates can be applied, 
allowing the introduction of reporter groups during the process. Especially the azide-alkyne 
cycloaddition is ideal for this purpose since the conjugation of these reaction partners is selective 
and fast, with the small azide and alkyne handles being well tolerated in biological systems and 
usually only having minimal effects on biological processes.5,6 The tri-functional conjugates, 
described in Chapter 4, demonstrate the potential of combining ligands for C-type lectin receptors 
 
aPart of this work is published by Hogervorst & Li et al. 20201 
Development of a C-mannoside functionalized lysine for acid-stable mannosylated peptides 
112 
(CLRs) and Toll-like receptors (TLRs) with an antigenic peptide in a single conjugate. The 
development of these conjugates comprised the incorporation of an azide handle in the peptide, 
allowing the introduction of an additional adjuvant after the solid-phase peptide synthesis (SPPS). 
This approach however, requires an extra azide-alkyne cycloaddition and an extra purification step 
to obtain the final conjugates. Furthermore, the use of an azide/alkyne combination limits the 
options for the inclusion of orthogonal handles for further conjugation and excludes the use of 
alkyne reporter groups that could help study antigen-conjugate processing in more detail. 
 
This Chapter describes the design and synthesis of a C-mannose functionalized lysine building 
block that can be used in SPPS (168, Scheme 1). Utilizing a C-mannoside derivative that lacks the 
exo-cyclic anomeric oxygen, the glycosidic linkage can withstand the acidic conditions required for 
the release from resin and general deprotection that is part of a standard automated SPPS. The 
stabilized sugar amino acid block can be incorporated in an ‘in-line’ fashion, obviating the post-
synthesis conjugation step and thus preventing the use of an azide-alkyne click reaction. Building 
block 168 is designed with a spacer of similar length as the previously described triazole O-
mannoside conjugates in Chapter 2 and 4, allowing a side by side comparison. Potential side 
reactions on the mannose hydroxyls during peptide assembly are prevented by the protection of 
these functionalities with the acid-labile para-methoxybenzyl (PMB) groups which can be removed 
simultaneously with the amino acid side-chain protecting groups during the general deprotection 
and cleavage protocol of the projected peptide conjugates. Protection of the N-terminus with a 
temporary Fmoc protecting group allows for the controlled use of 168 in standard Fmoc-SPPS. 
Scheme 1: Retrosynthesis of C-mannoside peptide conjugates. 
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Results and Discussion 
The key step in the synthesis of 168 is the introduction of the α-C-glycosidic bond (Scheme 2). 
Based on previously reported work by Girard et al.7, the anomeric allyl was introduced via a 
Hosomi-Sakurai reaction using allyltrimethylsilane (allyl-TMS). In this reaction, the glycosyl donor 
is activated using a strong Lewis acid forming an electrophilic oxocarbenium ion that can react 
with the poor nucleophilic allyl-TMS. When peracetylated mannose 169 was used, it gave allyl 173 
with poor stereoselectivity.8–10 On the other hand, a similar reaction with non-participating 
perbenzylated donor 171 gave allyl 172 almost exclusively as the α-anomer (α:β; ≥15:1).10,11 Since 
separation of the anomeric mixtures in initial experiments proved to be tedious, the additional 
steps accompanying the perbenzylated route were considered an unavoidable obstacle that had to 
be taken. 
The synthetic route to 168 shown in Scheme 2 starts with the benzylation of methyl α-ᴅ-
mannopyranoside 170 to obtain methyl 2,3,4,6-tetra-O-benzyl-α-ᴅ-mannopyranoside 171. The allyl 
group was introduced by treatment of the methyl mannoside with allyltrimethyl silane and 
trimethylsilyl triflate in acetonitrile to provide C-mannoside 172. This reaction proceeded with high 
stereoselectivity and was complete within an hour when assisted by ultrasound irradiation.12 
Selective removal of the benzyl ethers in the presence of the allyl functionality was achieved using 
BCl3. Unfortunately, this reaction proved to be difficult to scale up. The recently described method 
using a Birch-type reduction in liquid ammonia13 was discarded because condensation of large 
volumes of toxic ammonia was considered too time-consuming and hazardous. Therefore, an 
alternative method was sought, and a Birch-type reduction using lithium naphthalenide in THF 
allowed for the removal of the four benzyls from 172. This reaction could be run on a 80 mmol 
scale, to provide the desired tetra-ol, which was acetylated to allow for easy purification, yielding 
173. After the installment of four PMB ethers, allyl 174 was elongated by cross-metathesis with 
methyl acrylate or benzyl acrylate to afford α,β-unsaturated ketones 175 & 176, respectively. The 
reduction of the double bond in these products with RuCl3 in the presence of NaBH4 and MeOH,14 
was followed by saponification of the resulting esters 177 & 178 to obtain carboxylic acid 179. On 
a small scale, these three reactions gave the highest yield with the methyl ester, so the synthesis on 
large scale was performed with methyl acrylate. Fully protected amino acid 180 was obtained by 
coupling of carboxylic acid 179 with the methyl ester of Nα-Fmoc protected lysine 181, using 
HCTU as condensation agent. Selective hydrolysis of the ester in the presence of the Fmoc group 
was achieved with LiOOH,15,16 which is more nucleophilic but less basic than LiOH,a resulting in 
 
a pKa of H2O2 = 11.6; pKa of H2O = 15.827 
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the isolation of 168 in 79% yield.17 Altogether, SPPS compatible C-mannose functionalized lysine 
building block 168 was synthesized in 20% over 11 steps. 
 
Scheme 2: Synthesis of C-mannoside lysine 168. 
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Reagents and conditions: a) NaH, BnBr, TBAI, DMF, 78%; b) allylTMS, TMSOTf, ACN, 73%; c) either i. BCl3, DCM; ii. 
Ac2O, pyridine 95% or i. Li, naphthalene, THF, -20°C; ii. Ac2O, pyridine, 54%; d) i. NaOMe, MeOH; ii. NaH, PMBCl, TBAI, 
DMF, 69%; e) methyl acrylate or benzyl acrylate, Grubbs 2nd gen. catalyst, DCM (175: 74%; 176: 73%); f) RuCl3, NaBH4, 
DCE/MeOH: (177: 91%; 178: 93%); g) KOH, THF/H2O (177 → 179: 90%; 178 → 179: qnt.); h) 181, HCTU, DIPEA, 
DMF, 99% ; i) LiOH, H2O2, THF/H2O/t-BuOH, 79%. 
 
With sufficient amounts of building block 168 available, the assembly of clusters containing 1, 2, 
3, or 6 copies of the C-mannose lysine was undertaken via SPPS (Scheme 3). Using Tentagel® S-
RAM amide resin, Fmoc-Lys(Boc)-OH and Fmoc-Gly-OH were introduced successively followed 
by elongation with C-mannose functionalized lysine building block 168 using a standard Fmoc 
protocol and HCTU as coupling agent. To prevent the use of a large excess of 168, it was 
introduced manually, using fewer equivalents of the building block than commonly used in SPPS 
with prolonged coupling times (2eq, overnight). After completion of the sequence, the N-termini 
were capped with acetyls resulting in immobilized peptides 182-185 (Scheme 3). When resins 182-
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185 were subjected to a cleavage cocktail of TFA/TIS/H2O (190/5/5, v/v/v), the Boc and PMB 
ethers were successfully removed and the peptide clusters were isolated after RP-HPLC 
purification to obtain monovalent- (186), bivalent- (187), trivalent- (188) and hexavalent- (189) 
clusters in 7%, 14%, 6%, and 2% yield, respectively. It was initially hypothesized that the relatively 
low yield originated from incomplete precipitation of the peptides after cleavage from the solid 
support, but when a different workup method was applied for 186 & 189, in which the cleavage 
cocktail was concentrated instead of precipitated, the yields were not increased. LC-MS analysis of 
the crude products showed multiple side products, possibly due to side reactions during the 
cleavage reaction which will be addressed later in this chapter. 
To validate whether C-mannosides were able to bind the target CLRs, the clusters 186-189 were 
functionalized with a biotin moiety to enable the visualization of the clusters using fluorescently 
labeled streptavidin. The clusters were treated with biotin-N-hydroxysuccinimide (NHS) ester to 
give the biotinylated mannoside clusters 190-193 (R = R2, Scheme 3). This allowed for the side by 
side comparison with their O-mannoside analogs 59, 64, 69, and 74 via flow cytometry as described 
in Chapter 2.18 Thus, DC-SIGN expressing MoDCs were exposed to the C- and O-mannoside 
clusters at 4 oC, after which the cells were washed and treated with fluorescent streptavidin which 
was quantified by FACS analysis. Figure 1A shows that the C-mannoside clusters are binding 
equally as well as their O-counterparts, with better binding with an increasing number of 
mannosides on the scaffold. Similar to the experiments described in Chapter 2, the clusters were 
tested for their rate of uptake. Active internalization can take place when the cells are allowed to 
warm to room temperature, and the rate of reduction of the signal as a function of time, is an 
indication for the rate of uptake over time. Also, in these experiments, the C-mannose clusters 
behaved very similar to their O-mannose analogs (Figure 1B).  
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Scheme 3: Synthesis of C-mannoside clusters. 
 
Reagents and conditions: a) Fmoc-SPPS (168, HCTU, DIPEA, DMF); b) TFA, TIS, H2O, (octanethiol, phenol) (186: 7.0%; 187: 
14%; 188: 6.0%; 189: 2.1%); c) Biotin-NHS, DIPEA, DMSO (190: 94%; 191: 72%; 192: 99%; 193: 80%); d) ATTO655-
NHS, DIPEA, DMSO, 194: 55%. 
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Figure 1: comparison of affinity and uptake of O- and C- mannoside clusters for DC-SIGN. 
 
A) Binding of the biotinylated mannoside library to DC-SIGN on moDC was measured by flow cytometry. Normalized to the negative 
control. MoDCs were incubated with biotinylated constructs (30 min, 4 °C, 10 µM).  (-) = negative control (PBS); (+) = positive control 
(1 µg/mL of Lewis Y conjugated polyacrylamide); Serie A in gray; C-mannoside in green; B) The internalization of the mannoside 
clusters by moDCs was measured by flow cytometry. One donor is depicted here as representation of four. Cells were incubated with clusters 
(20 µM on ice for one hour and after incubated at 37 °C for different time spans). Quantification with an external fluorophore allowed 
quantification of the remaining clusters on the cell surface as an indirect measure of uptake.  
Figure 2: STORM experiments. 
 
 
A) CHO-MR cells were incubated with 194 (5 nM) and imaged with a 640 nm laser (40 mW); B) CHO-MR cells were incubated 
with 85 (5 nM) and imaged with a 640 nm laser (40 mW); C) CHO-K1 cells were incubated with 194 (5 nM) and imaged with a 640 
nm laser (40 mW); D) Incubation of CHO-MR cells with probes 85, 194, 87 and 88 at 37°C allowed for singe particle tracking. 
Trajectory lengths from at least 5 images per probes were combined, plotted in a histogram and fitted with a single exponential decay function 
wherefrom τ was determined. The used structures are depicted on the next page. 
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Finally, 189 was decorated with an ATTO655 laser dye (R = R3, Scheme 2) to obtain 194, which 
was compared with its O-analogue 85 in a mannose receptor (MR) binding experiment. In this 
setup for stochastic optical reconstruction microscopy (STORM) (As used in Chapter 2), only 
clusters that remain at the same location for a certain time will be observed. Since unbound clusters 
move to fast due to diffusion, only clusters that are fixed will be observed. This can be either in 
cellular compartments or bound to receptors. When Chinese hamster ovary (CHO) cells 
transfected with the MR were subjected to cluster 194, the clusters were localized on the cell 
surface (see Figure 2A). When the same experiments were performed with CHO cells that lack the 
MR, the clusters did not localize indicating that this localization is MR dependent (Figure 2C). 
When these MR+ CHO cells were subjected to 85, the O-analogue of 194 (see Figure 2B), both 
clusters showed similar localization. Additionally, by following individual fluorescent events, an 
average binding time can be determined, which correlates with the affinity of the cluster for the 
receptor. Both C- and O- mannoside clusters showed similar affinities (Figure 2D). Together these 
results indicated that DC-SIGN and the MR well tolerate the O to CH2 modification, encouraging 
the use of such clusters in an antigen-adjuvant conjugate. 
Encouraged by these results, the synthesis of C-mannose peptide conjugates in which the 
melanoma tumor antigen gp100 is incorporated were undertaken (see also Chapter 4). The SPPS 
of the gp100 antigen 134 containing the N-terminal monomethoxy trityl (Mmt) protected lysine, 
as described in Chapter 4, was followed by either one or six couplings with 168 to obtain C-
mannosylated 195 & 196, respectively (Scheme 4). Next, 195 & 196 were functionalized at their N-
termini with theTLR7 ligand 2-butoxy-8-oxo-adenine, using the building block described in 
Chapter 3, to give immobilized conjugates 197 & 198. Alternatively, the N-termini were acetylated 
to obtain resins 199 & 200, which could be further functionalized at the C-termini by subsequent 
selective removal of the monomethoxy trityl (Mmt) on the C-terminal lysines followed by the 
introduction of the TLR7 ligand to provide 201 & 202 bearing the TLR7 agonist on the C-
terminus.19 Having fully protected and immobilized conjugates 197-202 available, the ensuing 
deprotection and cleavage from the solid support was evaluated. When resin 199 was treated with 
a cleavage cocktail of TFA/TIS/H2O (190/5/5, v/v/v, Chapter 4), LC-MS analysis revealed the 
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formation of a complex mixture. It was hypothesized that the poor quality of the crude material 
was due to side reactions of the cleavage and deprotection step and not due to incomplete 
couplings. Reactive cationic species are liberated during the acidic removal of the PMB ethers, 
which could potentially react with functional groups in the unprotected peptide.20 Howard et al.21 
effectively scavenged PMB-cations using phenol as an electron-rich aromatic additive and when 
resin 199 was subjected to a modified cleavage cocktail, that included octanethiol and phenol, LC-
MS analysis showed a crude mixture with improved quality and 203 as the main product. Further 
optimization of the cleavage cocktail was achieved by increasing concentration of the scavengers 
(up to 10% of the total volume) and increasing the volume of cleavage medium (effectively diluting 
the concentration of reactive cationic species and reactive functional groups on the peptide). Using 
this optimized cleavage protocol, bi-functional conjugates 203 & 204 were effectively released and 
deprotected to give the purified conjugates in 2.5% yield over 34 couplings and 0.7% yield over 
39 couplings respectively (90% and 88% per step). The treatment of resin 197 with these optimized 
conditions resulted in tri-functional monovalent C-mannose conjugate 205 in 2.6% yield over 36 
couplings (average of 90% per step). Exposure of 198 delivered the tri-functional hexavalent C-
mannose conjugate 206 in 1.3% yield over 41 couplings (average of 90% per step). When resins 
201 & 202 were treated with this optimized cocktail however, a complex mixture was obtained. 
LC-MS analysis of the crude of 207 indicated not only the formation of the desired product but 
also more lipophilic products, having a higher molecular mass increasing with 484.2 Da per step. 
This increment corresponded with the addition of an extra ethylene glycol - TLR7 ligand (PEG-
TLR7L, see Figure 4A). Since this was not observed for the C-mannose conjugates without C-
terminal elongation, it was hypothesized that PMB ethers were partly removed during the removal 
of the Mmt, liberating C-mannose hydroxyls, which could then react with the activated HCTU 
esters in the next coupling reaction. This was confirmed by treatment of the cleaved crude peptide 
mixture with aqueous ammonia, which removed the heavier ester byproducts (Figure 4B). 
Therefore milder conditions were explored for the removal of the C-terminal Mmt-group. 
Eventually it was found that the use of acetic acid in a mixture of trifluoroethanol (TFE) and DCM 
(1/2/7, v/v/v), a cocktail first described to selectively cleave the Mmt over methyltrityl and trityl-
groups,22 was effective. After the introduction of the ethylene glycol moiety and TLR7 ligand 116, 
no byproducts were observed that contained additional PEG-TLR7L esters, supporting the notion 
that the previously observed side products were formed due to partial cleavage of PMB ethers 
during the Mmt removal. Using the milder AcOH/TFE/DCM Mmt removal conditions, 
trifunctional conjugates 207 & 208 were successfully synthesized and isolated in 2.1% over 36 
couplings and 0.6% over 41 couplings respectively (90% and 88% per step). 
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Scheme 4: Synthesis of gp100 conjugates. 
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Reagents and conditions: a) Fmoc-SPPS (168, HCTU, DIPEA, DMF); b) Fmoc-SPPS (127 or 116, HCTU, DIPEA, DMF); c) 
Ac2O, DIPEA, DMF; d) AcOH, TFE, DCM; e) TFA, TIS, H2O, octanethiol, phenol (205: 2.60% over 36 couplings (90% per 
step); 206: 1.30% over 41 couplings (90% per step); 203: 2.51% over 34 couplings (90% per step); 204: 0.73% over 39 couplings 
(88% per step); 207: 2.10% over 36 couplings (90% per step); 208: 0.60% over 41 couplings (88% per step)). 
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Figure 4: LC-MS spectra of 207 after release from resin. 
 
A) LC-MS spectra of 207 (Mmt removal with 1% TFA); B) LC-MS Spectra of the same batch of 207 after treatment with aqueous 
ammonia. 
 
These conjugates were tested for their ability to induce maturation, activation, and their antigen 
(cross-)presentation capacity. DC maturation is a necessity for the induction of an efficient 
immune response. By quantification of co-stimulatory molecules, maturation was measured 
(Figure 5B). All conjugates induced higher levels of CD86 when compared with the 
unfunctionalized gp100 129, and the O to C modification did not result in different expression 
levels. To determine whether these constructs were still able to activate DCs, the concentration of 
secreted cytokines from four donors were determined as a measure of activation by the 
quantification of four key cytokines. IL-6 and IL-12 are primarily inflammatory cytokines that help 
with DC maturation and Th1 skewing. IL-10 is an anti-inflammatory cytokine that interferes with 
DC maturation and can skew naïve T cells to regulatory T cells (Tregs).23 TNFα is an inflammatory 
cytokine required for DC activation and proliferation.24 When comparing the cytokine profiles of 
the here described C-mannoside conjugates with their O-mannoside analogs (Figure 5C), similar 
cytokine profiles are induced. However, for the conjugates with both C-mannoside and TLR ligand 
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on the N-terminus (205 and 206), the production of inflammatory cytokines (IL-6, IL-12, TNFα) 
was almost completely diminished.a  
Finally, the prepared clusters were tested for their antigen presentation ability using gp100 specific 
T cell clones (see Figure 5D). In short, five-day-old moDCs were incubated with the peptide 
conjugates, after which the moDcs were washed and co-cultured with either a CD8 cell clone that 
is specific for the gp100280-288 MHC-I epitope or with a CD4 cell clone, specific for the gp10040-59 
MHC-II epitope. Interferon γ cytokine secretion was measured by sandwich ELISA as a measure 
for T-cell activation. Quantification of antigen presentation was achieved by normalization of the 
interferon γ cytokine production with secretion levels induced by short gp100 peptide (gp100280-
288) and long gp100 peptide (gp100280-288, 40-59) set to 100%. The C-mannoside-conjugates (203-208) 
were tested side-by-side with the O-mannoside-conjugate conjugates (150-153) described in 
Chapter 4 to reveal any differences between the two types of conjugates.  
When the antigen presentation induced by the monovalent O-mannose-clusters 150 & 151 and C-
mannose-clusters 203 & 207 are compared it becomes clear that both conjugates induce antigen 
and cross-presentation equally well. Furthermore, when compared with the stand-alone gp100 
peptide (129) or the TLR7-gp100 conjugate (130), antigen (cross)-presentation capacity was 
enhanced. However, conjugation of both the C-mannoside and the TLR7 ligand to the N-terminus 
of the peptide (205) led to a decrease in antigen presentation. Comparable effects were observed 
for the hexavalent clusters, although here, the C-mannoside conjugates (204 & 208) showed 
somewhat lower antigen presentation than their O-counterparts (152 & 153). The difference 
appears to be larger for MHC-II presentation than for the MHC-I mediated presentation, which 
could be the result of the effect that the metabolically stable C-mannosides have on the processing 
of the conjugates. Antigen (cross)-presentation was again significantly diminished when the TLR7 
ligand and the hexavalent C-mannose clusters where both conjugated to the N-terminus of the 
peptide (206). This effect could be caused by steric hindrance preventing the TLR7 ligand to bind 
properly to its receptor, the TLR7 appendage hindering CLR mediated uptake, or because the 
processing of a longer sequence of unnatural amino acids hampers the processing and presentation 
of these conjugates.  
 
 
 
a Expression levels of CD86 however showed similar levels compared with the other conjugates bearing the TLR7 
ligand. 
CHAPTER 5 
123 
Figure 5: Effectiveness of conjugates. 
 
A) Cartoon representation of used C- and O-conjugates; B) Expression of the DC maturation marker CD86 upon overnight stimulation 
with the trifunctional conjugates is measured by flow cytometry. LPS stimulation (10 ng/mL) is used as positive control; C) IL-6, IL-
10, IL-12p70, and TNFα secretion of four donors was measured using ELISA upon overnight stimulation with conjugates; D) Antigen 
cross-presentation (left) and presentation (right) by the moDCs was determined by IFNγ release of the activated T cells, after stimulation 
with conjugates (20 µM, 30 min). 
 
Development of a C-mannoside functionalized lysine for acid-stable mannosylated peptides 
124 
Conclusion 
The synthesis of a new C-mannoside lysine building block has been reported. This building block 
is synthetically readily accessible and the C-glycosidic linkage renders it stable towards acidic 
reaction conditions. This, in combination with the temporary Fmoc-group installed on the lysine-
Nα, and the permanent PMB protection, masking the mannose hydroxyl groups, enabled the use 
of this building block in online SPPS. The building block was successfully applied for the 
generation of various glycopeptide-conjugates. All these conjugates were synthesized on resin, 
which obviates post-SPPS conjugation steps after release from resin. At first, the cleavage and 
global deprotection of these conjugates were met with poor results, due to side reactions caused 
by the release of reactive PMB cations during the cleavage/deprotection step, that reacted with 
functional groups on the peptide. The addition of extra scavengers and dilution of the reaction 
mixture prevented these undesired side reactions. The assembly of the conjugates, functionalized 
at the C-terminal end, required the chemoselective removal of the C-terminal lysine Mmt group, 
for which the use of AcOH in a mixture of TFE and DCM proved effective. Different peptidic 
antigen conjugates were generated. First, it was established that clusters, comprising 1, 2, 3, or 6 
copies of the C-mannose lysine show similar binding to, and similar uptake in moDCs compared 
with their O-mannose analogs. The retention time for the clusters bound to the MR on transfected 
CHO cells were also identical. These results show that the O to CH2 modification is well-tolerated 
by these CLRs. Next gp100-peptide antigens were equipped with multiple copies of the C-
mannoside and an additional TLR7 ligand. Conjugates having both the mannose cluster and the 
TLR7 ligand on the same (N-terminal) side of the antigen, or attached to different sides of the 
antigen (the mannose cluster on the N-terminal side, the TLR7 ligand on the C-terminus), were 
successfully assembled. Evaluation of the conjugates in antigen (cross)-presentation assays 
revealed that the antigen (cross)-presentation of the conjugates was not significantly hampered by 
the O to CH2 modification. The monovalent C-mannose conjugates with the TLR7 ligand on the 
C-terminus significantly enhanced the antigen presentation. The combination of both the TLR7 
ligand and the C-mannoside cluster on the N-terminus hampered (cross)-presentation and 
maturation, likely due to the steric hindrance of the TLR7 ligand. With the ‘SPPS-compatible’ 
mannoside amino acid building block 168 available and chemistry developed for its introduction 
and deprotection, further conjugates can now be designed that employ mannose-binding lectins 
for enhanced uptake. In these conjugates, chemically or enzymatically labile spacers may be 
introduced to enhance the processing of the antigen-conjugates.25 Azide-alkyne handles can be 
introduced to follow the processing of these glycopeptide conjugates in more detail. 
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Experimental 
General procedures: 
All reactions, purifications, and analyses were performed as described in the general procedures of 
Chapter 2. 
 
Nα-Fmoc-Nε-(Boc)-L-lysine-methyl ester (209). 
Fmoc-lys-(Boc)-OH (14.06 g, 30.0 mmol, 1 eq) was dissolved in DMF (50 mL, 0.2 M), K2CO3 
(12.4 g, 90 mmol, 3 eq) and stirred at rt for 15 min. The mixture was cooled to 0 ◦C and MeI 
(1.87 mL, 30 mmol, 3 eq) was added and the mixture was stirred for two hour after which it 
was quenched with H2O. The mixture was extracted with Et2O (2x) and the organic layers where combined, 
and washed with brine (1x), dried over MgSO4 (s), filtered, and concentrated in vacuo. Purification using 
silica gel column chromatography (1/9, → 4/1, Et2O/PE, v/v) yielded title compound 209 as a white solid 
(14.34 g, 29.7 mmol, 99%). TLC Rf: 0.68 (Et2O/PE, 4/1, v/v); 1H NMR (400 MHz, CDCl3) δ 7.74 (d, J = 
7.5 Hz, 2H, Harom), 7.63 - 7.51 (m, 2H, Harom), 7.38 (t, J = 7.4 Hz, 2H, Harom), 7.34 - 7.23 (m, 2H, Harom), 
5.60 (d, J = 7.5 Hz, 1H, NαH), 4.69 (s, 1H, NεH), 4.36 (m, 3H, H-2, CH2-Fmoc), 4.20 (t, J = 7.0 Hz, 1H, 
CH-Fmoc),3.72 (s, 3H, OMe), 3.09 (s, 2H, H-6), 1.86 - 1.58 (m, 2H, H-3), 1.47 - 1. 32 (m, 13H, H-4, H-5, 
tBu); 13C NMR (101 MHz, CDCl3) δ 143.9, 141.5 (Cq), 127.8, 127.2, 125.2, 120.1 (CHarom), 67.14 (CH2-
Fmoc), 53.8 (C-2), 52.6 (COOMe), 47.3 (CH-Fmoc), 40.1 (C-6), 32.3 (C-3), 29.8 (C-5), 28.5 (CH3 Boc), 22.5 
(C-4); HRMS [C27H34N2O6+ Na]+: 505.23094 found, 505.23091 calculated. 
Nα-Fmoc-Nε-(HCl)-L-lysine-methyl ester (181). 
Boc protected lysine 209 (4.74 g, 9.8 mmol, 1 eq) was dissolved in HCl (20 mL, 4.0 M in 
dioxane) at 0 °C. After four hours the solvent was partly removed in vacuo after which the 
product was precipitated, filtered, washed with little EtOAc and dried in vacuo to yield title 
compound 181 as a white solid (4.744 g, 9.1 mmol, 94%). TLC Rf: 0 (EtOAc/PE, 1/1, v/v); 1H NMR (400 
MHz, MeOD) δ 7.83 (d, J = 7.5 Hz, 2H, Harom), 7.69 (t, J = 7.5 Hz, 2H, Harom), 7.42 (t, J = 7.4 Hz, 2H, 
Harom), 7.34 (td, J = 7.4, 0.9 Hz, 2H, Harom), 4.55 – 4.33 (m, 2H, CH2-Fmoc), 4.28 – 4.17 (m, 2H, CH-Fmoc, 
H-2), 3.74 (s, 3H, OMe), 2.94 (t, J = 7.0 Hz, 2H, H-6), 1.98 – 1.82 (m, 1H, H-3a), 1.82 – 1.60 (m, 3H, H-
3b, H-5), 1.58 – 1.39 (m, 2H, H-4); 13C NMR (101 MHz, MeOD) δ 142.6, 141.5 (Cq), 128.8, 128.2, 126.2, 
126.1, 121.0 (CHarom), 67.9 (CH2-Fmoc), 55.0 (C-2), 52.8 (COOMe), 48.4 (CH-Fmoc), 40.5 (C-6), 32.0 (C-
3), 28.0 (C-5), 23.8 (C-4); HRMS [C22H26N2O4+ H]+: 383.1973 found, 383.19653 calculated. 
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Methyl 2,3,4,6-tetra-O-benzyl-α-ᴅ-mannopyranoside (171). 
Methyl α-ᴅ-mannopyranoside (29.13 g, 150 mmol) was co-evaporated with toluene (2x), 
dissolved in DMF (900 mL, 0.17 M) and cooled to 0 °C. NaH (60% dispersion in mineral oil) 
(36.0 g, 900 mmol, 6 eq) was added in small portions under a continuous flow of argon. BnBr (80.28 mL, 
675 mmol, 4.5 eq) and TBAI (5.54 g, 15 mmol, 0.1 eq) were added and the reaction mixture was stirred at 
room temperature. After three days the mixture was quenched with MeOH at 0°C, diluted in Et2O and 
washed with brine. The aqueous layer was back-extracted with Et2O, the organic fractions combined, 
washed with brine (2x), dried over MgSO4 (s), filtered and concentrated in vacuo. Purification using silica gel 
column chromatography (1/8, → 1/4, PE/Et2O/PE, v/v) yielded compound 171 as a colorless oil (64.5 
g, 116.3 mmol, 77.5% ). TLC Rf: 0.67 (1/4, EtOAc/PE, v/v); IR (neat, cm−1): 3020, 2905, 1495, 1453, 
1362, 1261, 1098, 1058, 1026, 967, 910, 846, 801, 733, 695; 1H NMR (400 MHz, CDCl3) δ 7.40 - 7.22 (m, 
18H, Harom), 7.18 - 7.14 (m, 2H, Harom), 4.88 (d, J = 10.8 Hz, 1H, CHH Bn), 4.79 - 4.64 (m, 4H, CHH-Bn, 
CH2-Bn, H-1), 4.61 (s, 2H, CH2-Bn), 4.53 (dd, J = 20.7, 11.5 Hz, 2H, CHH-Bn (2x)), 3.97 (t, J = 9.1 Hz, 
1H, H-4), 3.88 (dd, J = 9.3, 3.1 Hz, 1H, H-3), 3.81 - 3.70 (m, 4H, H-2, H-5, H-6), 3.32 (s, 3H, OMe); 13C 
NMR (101 MHz, CDCl3) δ 138.6, 138.6, 138.5, 138.5 (Cq), 128.4, 128.4, 128.4, 128.0, 127.9, 127.8, 127.7, 
127.6, 127.6, 127.5 (CHarom), 99.0 (C-1), 80.3 (C-3), 75.1 (CH2-Bn), 75.0(C-4), 74.6 (C-2), 73.4, 72.6, 72.2 
(CH2-Bn), 71.8 (C-5), 69.4 (C-6), 54.8 (OMe); HRMS [C35H38O6 + H]+: 555.27512 found, 555.27412 
calculated. 
 
3-(2,3,4,6-Tetra-O-benzyl-α-ᴅ-mannopyranoside)-1-propene (172). 
Compound 171 (53.61 g, 96.64 mmol) was co-evaporated with toluene (3x) under argon, 
dissolved in ACN (133 mL, 0.73 M) and cooled to 0 °C. Allyltrimethylsilane (41.5 mL, 260.93 
mmol, 2.7 eq) and TMSOTf (21.0 mL, 116.0 mmol, 1.2 eq) were added and the reaction mixture was 
irradiated with ultrasound for 50 min after which the reaction mixture was quenched by addition of Et3N. 
The reaction mixture was diluted in Et2O washed with brine (3x), dried over MgSO4 (s), filtered and 
concentrated in vacuo. Purification using silica gel column chromatography (1/4, → 1/1, Et2O/PE, v/v) 
yielded compound 172 as a colorless oil (56.1 g, 70.48 mmol, 73%). TLC Rf: 0.61 (EtOAc/PE, 1/4, v/v); 
IR (neat, cm−1): 3021, 2905, 2855, 1495, 1453, 1363, 1262, 1090, 1072, 1027, 1001, 912, 733, 695; 1H NMR 
(400 MHz, CDCl3) δ 7.39 - 7.24 (m, 18H, Harom), 7.22 - 7.18 (m, 2H, Harom), 5.83 - 5.68 (m, 1H, H-2), 5.08 
- 4.93 (m, 2H, H-1), 4.70 (d, J = 11.3 Hz, 1H, CHH-Bn), 4.62 - 4.49 (m, 7H, CH2-Bn (3x), CHH-Bn), 4.04 
(q, J = 6.3 Hz, 1H, H-4), 3.92 - 3.66 (m, 5H, H-6, H-7, H-8, H-9), 3.62 (dd, J = 4.6, 3.1 Hz, 1H, H-5), 2.32 
(hept, J = 6.8 Hz, 2H, H-3); 13C NMR (101 MHz, CDCl3) δ 138.5, 138.4, 138.3, 138.2 (Cq), 134.4 (C-2), 
128.5, 128.4, 128.4, 128.1, 128.1, 128.0, 127.8, 127.8, 127.7, 127.5 (CHarom), 117.3 (C-1), 76.9 (C-6/7/8), 
75.2 (C-5), 75.0 (C-6/7/8), 73.9 (CH2-Bn), 73.8 (C-6/7/8), 73.4 (CH2-Bn), 72.4 (C-4), 72.1, 71.6 (CH2-Bn), 
69.2 (C-9), 34.7 (C-3); HRMS [C37H40O5 + H]+: 565.29569 found, 565.29485 calculated. 
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3-(2,3,4,6-Tetra-O-Acetyl-α-ᴅ-mannopyranoside)-1-propene (173). 
Method a) BCl3 
Compound 172 (6.44 g, 11.4 mmol) was co-evaporated with toluene (3x) under argon, dissolved in DCM 
(10 mL) and cooled to -78°C. To this solution BCl3 (100 mL, 1.0 M in DCM, 100 mmol, >8 eq) was added 
dropwise. After overnight stirring at -78°C the reaction mixture was quenched by the addition of MeOH 
(100 mL) at -78°C after which the mixture was concentrated in vacuo and co-evaporated with toluene (5x). 
The crude pink oil was dissolved in pyridine (20 mL, 0.6 M) and Ac2O (6.5 mL, 69.0 mmol, 6 eq) was added 
dropwise at 0°C. After overnight stirring at rt the reaction was quenched with MeOH, diluted in Et2O and 
washed with HCl (1 M, aq., 4x). The organic layer was collected, dried over MgSO4 (s), filtered, and 
concentrated in vacuo. Purification using silica gel column chromatography (1/9, → 1/1, Et2O/PE, v/v) 
yielded title compound 173 as a colourless oil (4.003 g, 10.7 mmol, 95%). 
Method b) Li-naphthalenide 
Compound 172 (45.8 g, 81 mmol) was co-evaporated with toluene (3x) under argon and dissolved in 
distilled anhydrous THF (180 mL). This solution was added dropwise to a lithium napthalenide solution at 
-78°C and stirred for five days at -20°C with a glass stirring rod. Li-napthalenide solution was prepared 
from Li (9.2 g, 1.3 mol, 14 eq) and naphthalene (15.5 g, 121 mmol, 1.5 eq) in distilled anhydrous THF (400 
mL). The reaction was quenched with MeOH, neutralized with Amberlite H+ resin, filtered and 
concentrated in vacuo. After co-evaporation with toluene (3x) the mixture was dissolved in pyridine (135 
mL, 0.6 M), cooled to 0°C and Ac2O (46 mL, 486 mmol, 6 eq) was added dropwise. After overnight stirring 
at rt, the reaction was quenched with MeOH, diluted with Et2O and washed with HCl (1 M, aq.). The 
aqueous layer was back-extracted with Et2O (2x) and the organic layers were combined, washed with HCl 
(1.0 M, aq., 2x), dried over MgSO4 (s), filtered and concentrated in vacuo. Purification using silica gel column 
chromatography (1/9, → 1/1, Et2O/PE, v/v) yielded title compound 173 as a colorless oil (16.38 g, 44 
mmol, 54%). 
TLC Rf: 0.34 (Et2O/PE, 6/4, v/v); IR (neat, cm−1): 2905, 1739, 1369, 1213, 1144, 1114, 1045, 
986, 918, 802; 1H NMR (400 MHz, CDCl3) δ 5.78 (ddt, J = 17.1, 10.2, 6.9 Hz, 1H, H-2), 5.27 
(dd, J = 8.9, 3.3 Hz, 1H, H-6), 5.23 - 5.13 (m, 4H, H-7, H-5, H-1), 4.33 (dd, J = 12.1, 6.3 Hz, 1H, H-9a), 
4.11 (dd, J = 12.1, 2.9 Hz, 1H, H-9b), 4.08 - 4.02 (m, 1H, H-4), 3.90 (ddd, J = 8.9, 6.5, 2.9 Hz, 1H, H-8), 
2.59 - 2.48 (m, 1H, H-3a), 2.48 - 2.36 (m, 1H, H-3b), 2.13 (s, 3H, Ac), 2.09 (s, 3H, Ac), 2.07 (s, 3H, Ac), 
2.03 (s, 3H, Ac); 13C NMR (101 MHz, CDCl3) δ 170.8, 170.3, 170.0, 169.8 (C=O), 132.6 (C-2), 118.4 (C-1), 
74.2 (C-4), 70.7 (C-8), 70.1 (C-5), 68.9 (C-6), 67.1 (C-7), 62.5 (C-9), 33.7 (C-3), 21.0, 20.8, 20.8 (Ac (4x)); 
HRMS [C17H24O9 + H]+: 373.14931 found, 373.14931 calculated. 
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3-(2,3,4,6-Tetra-O-paramethoxybenzyl-α-ᴅ-mannopyranoside)-1-propene (174). 
Compound 173 (18.84 g, 50.6 mmol) was dissolved in MeOH (83 mL, 0.6 M) and NaOMe (4.5 
mL, ~5.4 M, 20.25 mmol, 0.4 eq) was added dropwise. After overnight stirring, the mixture 
was neutralized with Amberlite H+ resin, filtrated and concentrated in vacuo. After co-evaporation with 
toluene (3x) the crude was dissolved in DMF (253 mL, 0.2 M) cooled to 0°C and NaH (12.14 g, 60% wt 
dispersion in mineral oil, 303.6 mmol, 6 eq), PMBCl (41.2 mL, 303.6 mmol, 6 eq) and TBAI (3.7 g, 10.1 
mmol, 0.2 eq) were added in portions. After overnight stirring at rt, the mixture was quenched with H2O 
at 0°C and extracted with Et2O (2x). The organic layers were combined, washed with brine (3x), dried over 
MgSO4 (s), filtrated and concentrated in vacuo. Purification using silica gel column chromatography (1/9, → 
1/4, EtOAc/PE, v/v) yielded title compound 174 as a colorless oil (23.8 g, 34.7 mmol, 69%). TLC Rf: 0.38 
(EtOAc/PE, 1/4, v/v); IR (neat, cm−1): 3054, 2988, 1612, 1514, 1422, 1264, 1174, 1083, 896, 824, 732, 
704; 1H NMR (400 MHz, CDCl3) δ 7.24 (t, J = 8.3 Hz, 4H, Harom), 7.18 (d, J = 8.6 Hz, 2H, Harom), 7.09 (d, 
J = 8.6 Hz, 2H, Harom), 6.87 - 6.79 (m, 8H, Harom), 5.74 (ddt, J = 18.2, 9.1, 6.9 Hz, 1H, H-2), 5.06 - 4.96 (m, 
2H, H-1), 4.61 (d, J = 10.9 Hz, 1H, CHH-PMB), 4.56 - 4.37 (m, 7H, CH2-PMB (3x), CHH-PMB), 4.04 - 
3.94 (m, 1H, H-4), 3.84 - 3.75 (m, 14H, OMe (4x), H-6, H-8), 3.71 (dt, J = 7.4, 4.0 Hz, 2H, H-9a, H-7), 3.65 
(dd, J = 10.1, 2.9 Hz, 1H, H-9b), 3.57 (dd, J = 4.6, 3.1 Hz, 1H, H-5), 2.32 (tt, J = 12.2, 6.6 Hz, 2H, H-3); 
13C NMR (101 MHz, CDCl3) δ 159.3, 159.3, 159.2 (Cq), 134.6 (C-2), 130.7, 130.6, 130.5, 130.4 (Cq), 129.7, 
129.7, 129.6, 129.5 (CHarom), 117.2 (C-2), 113.8, 113.8, 113.8 (CHarom), 76.5 (C-7), 74.7 (C-5), 74.6, 73.8 (C-
6, C-8), 73.5, 73.0 (CH2-PMB), 72.4 (C-4)), 71.7, 71.1 (CH2-PMB), 68.9 (C-9), 55.4, 55.3 (OMe (4x)), 34.8 
(C-3); HRMS [C41H48O9 + Na]+: 707.31913 found, 707.31905 calculated. 
Benzyl-but-4-(2,3,4,6-tetra-O-paramethoxybenzyl-α-ᴅ-mannopyranoside)-cis/trans-2-enoate 
(175). 
Allyl 174 (803.1 mg, 1.17 mmol, 1 eq) and benzylacrylate (531.3 mg, 3.276 mmol, 2.8 eq) where 
combined and co-evaporated with toluene (3x) under argon after which they were dissolved in 
DCM (40 mL, 1 M) and purged by bubbling with N2 gas for twenty minutes. Grubbs second 
generation catalyst (19,9 mg, 23.4 µmol, 0.02 eq) was added and the reaction mixture was refluxed protected 
from light. After three days the mixture was concentrated on Celite and purified via silica gel column 
chromatography (1/9 → 1/3, EtOAc/PE, v/v) to yield 175 as a brown oil (707.8 mg, 0.86 mmol, 74%). 
TLC Rf: 0.23 (EtOAc/PE, 1/4, v/v); IR (neat, cm−1): 2920, 2880, 1716, 1610, 1511, 1318, 1302, 1244, 1210, 
1171, 1082, 1030, 990, 845, 755; 1H NMR (400 MHz, CDCl3) δ 7.39 – 7.27 (m, 5H, Harom), 7.20 (d, J = 8.4 
Hz, 4H, Harom), 7.12 (t, J = 8.7 Hz, 4H, Harom), 6.97 (dt, J = 15.5, 7.1 Hz, 1H, H-3), 6.82 (t, J = 8.7 Hz, 8H, 
Harom), 5.89 (d, J = 15.7 Hz, 1H, H-2), 5.16 (s, 2H, CH2-Bn), 4.53 – 4.36 (m, 8H, CH2-PMB), 4.05 – 3.93 
(m, 1H, H-5), 3.88 – 3.66 (m, 16H, Ome (4x), H-7, H-8, H-9, H-10a), 3.61 (dd, J = 10.3, 4.6 Hz, 1H, H-
10b), 3.51 (dd, J = 6.4, 2.6 Hz, 1H, H-6), 2.55 – 2.34 (m, 2H, H-4); 13C NMR (101 MHz, CDCl3) δ 166.2 
(C-1), 159.4, 159.2 (Cq), 145.8 (C-3), 130.5, 130.3, 130.2, 130.1 (Cq), 129.8, 129.6, 129.6, 129.5, 128.6, 128.3, 
128.2 (CHarom), 123.2 (C-2), 113.9, 113.9, 113.8 (CHarom), 75.1, 74.8, 74.3, 74.1 (C-6, C-7, C-8, C-9), 73.0, 
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72.7, 71.9, 71.1 (CH2-PMB), 70.4 (C-5), 68.3 (C-10), 66.1 (CH2-Bn), 55.4, 55.4, 55.4 (OMe), 33.8 (C-4); 
HRMS [C49H54O11 + H]+: 819.37936 found, 819.37389 calculated. 
Benzyl-4-(2,3,4,6-tetra-O-paramethoxybenzyl-α-ᴅ-mannopyranoside)-butanoate (177). 
Compound 175 (937.3 mg, 1.14 mmol, 1 eq) and RuCl3 (47.5 mg, 0.228 mmol, 0.2 eq) were 
dissolved in 1,2-dichloroethane (4.4 mL, 0.2 M) and purged with N2 for twenty minutes. To 
this solution NaBH4 (138.5 mg, 3.65 mmol, 3.2 eq) was added, the flask was sealed with a 
septum and three empty balloons were fitted. The mixture was cooled to 0°C and MeOH (1.3 mL) was 
added dropwise over thirty minutes time after which the reaction was allowed to warm up and stirred for 
five hours. The septum was removed and the reaction was quenched by addition of a small amount of H2O 
at 0°C, after which it was concentrated and purified via silica gel column chromatography (1/9 → 3/7, 
EtOAc/PE, v/v) to yield 177 as a colorless oil (847.1 mg, 1.03 mmol, 91%). TLC Rf: 0.23 (EtOAc/PE, 
1/4, v/v); IR (neat, cm−1): 2905, 2855, 1733, 1612, 1511, 1361, 1301, 1244, 1210, 1172, 1078, 1031, 846, 
818, 752, 686; 1H NMR (400 MHz, CDCl3) δ 7.39 – 7.26 (m, 5H, Harom), 7.26 – 7.16 (m, 6H, Harom), 7.08 
(d, J = 8.5 Hz, 2H, Harom), 6.92 – 6.72 (m, 8H, Harom), 5.09 (s, 2H, CH2-Bn), 4.60 – 4.38 (m, 8H, CH2-PMB), 
3.98 – 3.85 (m, 1H, H-5), 3.84 – 3.58 (m, 17H, Ome (4x), H-7, H-8, H-9, H-10), 3.49 (dd, J = 6.4, 3.1 Hz, 
1H, H-6), 2.35 (t, J = 7.2 Hz, 1H, H-2), 1.86 – 1.39 (m, 4H, H-3, H-4); 13C NMR (101 MHz, CDCl3) δ 
173.3 (C-1), 159.3, 159.2, 136.2, 130.6 (Cq), 130.6, 130.5, 129.7, 129.5, 128.7, 128.3, 113.8, 113.8, 113.8 
(CHarom), 76.9 (C-5), 75.6 (C-6), 74.5, 73.5 (C-7, C-8), 73.5, 73.0, 71.8, 71.2 (CH2-PMB), 72.4 (C-9), 68.8 (C-
10), 66.2 (CH2-Bn), 55.3, 55.3 (OMe), 34.0 (C-2), 29.2 (C-4), 21.4 (C-3); HRMS [C49H56O11 + Na]+: 
843.37181 found, 843.37148 calculated. 
Methyl-but-4-(2,3,4,6-tetra-O-paramethoxybenzyl-α-ᴅ-mannopyranoside)-cis/trans-2-
enoate (176). 
Compound 174 (24.77 g, 36.2 mmol) was co-evaporated with CHCl3 (1x), dissolved in DCM 
(40 mL, 1 M) and purged by bubbling with N2 gas for twenty minutes. To this mixture methyl 
acrylate (16.3 mL, 181 mmol, 5 eq) and Grubbs second generation catalyst (0.68 g, 0.80 mmol, 
0.02 eq) were added, the mixture was purged with N2 for twenty minutes more, after which it was refluxed 
protected from light. After two days the mixture was concentrated on Celite and purified via silica gel 
column chromatography (1/9 → 1/3, EtOAc/PE, v/v) to yield unreacted starting material 174 (6.27 g, 
9.16 mmol, 25%) and product 176 as a brown oil (19.60 g, 26.4 mmol, 73%). TLC Rf: 0.22 (EtOAc/PE, 
1/4, v/v); IR (neat, cm−1): 2936, 2837, 1720, 1659, 1611, 1586, 1512, 1463, 1440, 1362, 1302, 1245, 1172, 
1082, 1033, 819, 733, 702; 1H NMR (400 MHz, CDCl3) δ 7.24 - 7.09 (m, 8H, Harom), 6.96 - 6.87 (m, 1H, H-
3), 6.87 - 6.80 (m, 8H, Harom), 5.83 (d, J = 15.7 Hz, 1H, H-2), 4.51 (d, J = 11.4 Hz, 1H, CHH-PMB), 4.47 - 
4.37 (m, 7H, CH2-PMB (3x), CHH-PMB), 4.04 - 3.96 (m, 1H, H-5), 3.89 - 3.83 (m, 1H, H-9), 3.83 - 3.75 
(m, 12H, OMe (3x)), 3.75 - 3.65 (m, 6H, H-7, H-8, CO2Me , H-10a), 3.65 - 3.59 (m, 1H, H-10b), 3.50 (dd, 
J = 6.4, 2.5 Hz, 1H, H-6), 2.55 - 2.37 (m, 2H, H-4); 13C NMR (101 MHz, CDCl3) δ 166.7 (C-1), 159.3, 159.1 
(Cq), 145.3 (C-3), 130.4, 130.2, 130.1, 130.0 (Cq), 129.7, 129.6, 129.4 (CHarom), 123.0 (C-2), 113.8, 113.7 
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(CHarom), 74.9 (C-6), 74.7, 74.2 (C-7, C-8), 73.9 (C-9), 72.9, 72.6, 71.8, 71.0 (CH2-PMB), 70.3 (C-5), 68.2 (C-
10), 55.3 (OMe (4x)), 51.4 (COOMe), 33.7 (C-4); HRMS [C43H50O11 + Na]+: 765.32463 found, 765.32453 
calculated. 
Methyl-4-(2,3,4,6-tetra-O-paramethoxybenzyl-α-ᴅ-mannopyranoside)-butanoate (178). 
Compound 176 (19.60 g, 26.4 mmol) and RuCl3 (1.1 g, 5.3 mmol, 0.2 eq) were dissolved in 1,2-
dichloroethane (100 mL, 0.26 M) and purged with N2 for twenty minutes. To this solution 
NaBH4 (3.2 g, 84.5 mmol, 3.2 eq) was added, the flask was sealed with a septum and three 
empty balloons were fitted. The mixture was cooled to 0°C and MeOH (34 mL) was added dropwise over 
thirty minutes time after which the reaction was allowed to warm up and stirred for four hours. The septum 
was removed and the reaction was quenched by addition of a small amount of H2O at 0°C, after which it 
was concentrated and purified via silica gel column chromatography (1/9 → 3/7, EtOAc/PE, v/v) to yield 
178 as a yellow oil (18.35 g, 24.6 mmol, 93%). TLC Rf: 0.34 (EtOAc/PE, 3/7, v/v); 1H NMR (400 MHz, 
CDCl3) δ 7.29 - 7.22 (m, 4H, Harom), 7.19 (d, J = 8.6 Hz, 2H, Harom), 7.08 (d, J = 8.6 Hz, 2H, Harom), 6.88 - 
6.80 (m, 8H, Harom), 4.63 - 4.38 (m, 8H, CH2-PMB), 3.90 (dd, J = 8.6, 4.2 Hz, 1H, H-5), 3.84 - 3.60 (m, 
20H, OMe (5x), H-7, H-8, H-9, H-10), 3.50 (dd, J = 4.7, 3.1 Hz, 1H, H-6), 2.30 (t, J = 7.1 Hz, 2H, H-2), 
1.83 - 1.41 (m, 4H, H-3, H-4); 13C NMR (101 MHz, CDCl3) δ 173.6 (C-1), 159.1, 159.1, 159.0, 130.4, 130.3, 
130.2 (Cq), 129.9, 129.4, 129.3, 129.2, 129.0, 113.6, 113.5, 113.5 (CHarom), 76.5 (C-7, C-8, C-9), 75.4 (C-6), 
74.3, 73.4 (C-7, C-8, C-9), 73.1, 72.7 (CH2-PMB), 72.1 (C-5), 71.5, 71.0 (CH2-PMB), 68.5 (C-10), 55.0, 55.0 
(OMe), 51.2 (COOMe), 33.5 (C-2), 29.0, 21.1 (C-3, C-4); HRMS [C43H52O11 + H]+: 745.35731 found, 
745.35824 calculated. 
4-(2,3,4,6-tetra-O-paramethoxybenzyl-α-ᴅ-mannopyranoside)-butanoic acid (179). 
Methyl ester 178 (18.34 g, 24.6 mmol)a was dissolved in THF (123 mL, 0.2 M) and cooled to 
0°C, followed by the dropwise addition of KOH (31 mL, 4.0 M, aq., 124 mmol, 5 eq). The 
mixture was heated to 50°C and stirred overnight. After acidification of the reaction mixture 
with HCl (1 M aq., pH ± 2), the product was extracted with Et2O (3x), the organic layers were combined, 
dried over MgSO4 (s), filtered and concentrated in vacuo. Purification using silica gel column 
chromatography (3/7 → 1/0, EtOAc/PE, v/v) yielded title compound 179 as a clear oil (18.01 g, 24.6 
mmol, qnt.). TLC Rf: 0.27 (EtOAc/PE, 7/3, v/v); IR (neat, cm−1): 3055, 2920, 1513, 1422, 1264, 1034, 896, 
733, 704; 1H NMR (400 MHz, CDCl3) δ 7.27 - 7.21 (m, 4H, Harom), 7.18 (d, J = 8.6 Hz, 2H, Harom), 7.08 (d, 
J = 8.6 Hz, 2H, Harom), 6.83 (ddd, J = 8.5, 5.4, 2.5 Hz, 8H, Harom), 4.60 - 4.36 (m, 8H, CH2-PMB), 3.90 (dt, 
J = 8.5, 4.6 Hz, 1H, H-5), 3.83 - 3.66 (m, 18H, OMe (4x) H-7, H-8, H-9, H-10a), 3.66 - 3.60 (m, 1H, H-
10b), 3.50 (dd, J = 5.0, 2.9 Hz, 1H, H-6), 2.34 (t, J = 7.0 Hz, 2H, H-2), 1.81 - 1.49 (m, 4H, H-3, H-4); 13C 
NMR (101 MHz, CDCl3) δ 178.5 (C-1), 159.3, 159.2, 130.5, 130.5, 130.4 (Cq), 129.7, 129.7, 129.6, 129.6, 
113.9 (CHarom), 76.6 (C-7, C-8, C-9), 75.6 (C-6), 74.5, 73.6 (C-7, C-8, C-9), 73.3, 73.0 (CH2-PMB), 72.2 (C-
 
a Using the same procedure, hydrolysis of 177 (847.1 mg, 1.03 mmol) resulted in 179 (764.4 mg, 0.92 mmol, 90 %). 
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5), 71.9, 71.3 (CH2-PMB), 68.8 (C-10), 55.4, 55.4 (OMe), 33.6 (C-2), 29.1 (C-4), 21.2 (C-3); HRMS 
[C42H50O11 + Na]+: 753.32470 found, 753.32453 calculated. 
Nα-Fmoc-Nε-[butan-4-(2,3,4,6-tetra-O-paramethoxybenzyl-α-ᴅ-mannopyranoside)-amide]-
L-lysine-methyl ester (180). 
Carboxylic acid 178 (6.25 g, 8.55 mmol) was combined with amine 181 (3.58 g, 8.55 mmol, 
1 eq) and HCTU (3.54 g, 8.55 mmol, 1 eq), dissolved in DMF (42.8 mL, 0.2 M) and 
DIPEA (4.47 mL, 25.65 mmol, 3 eq) was added dropwise. After two hours the mixture 
diluted with EtOAc, washed with a mixture of HCl (1 M, aq.) and brine (1/1, v/v) after which ] the aqueous 
layer was backextracted with EtOAc (1x). The organic layers were combined, washed with brine (1x), dried 
over MgSO4 (s), filtered and concentrated in vacuo. Purification using silica gel column chromatography (1/1 
→ 9/1, EtOAc/PE, v/v) yielded title compound 180 as a white solid (9.30 g, 8.49 mmol, 99%). TLC Rf: 
0.34 (EtOAc/PE, 4/1, v/v); IR (neat, cm−1): 3331, 2934, 1720, 1648, 1611, 1585, 1512, 1451, 1301, 1246, 
1173, 1082, 1033, 820, 760, 740; 1H NMR (400 MHz, CDCl3) δ 7.75 (d, J = 7.5 Hz, 2H, Harom), 7.60 (d, J = 
7.1 Hz, 2H, Harom), 7.39 (t, J = 7.4 Hz, 2H, Harom), 7.30 (t, J = 7.4 Hz, 2H, Harom), 7.27 - 7.14 (m, 6H, Harom), 
7.09 (d, J = 8.4 Hz, 2H, Harom), 6.83 (dd, J = 7.5, 5.0 Hz, 8H, Harom), 5.94 (s, 1H, NεH), 5.48 (d, J = 8.1 Hz, 
1H, NαH), 4.59 (d, J = 11.1 Hz, 1H, CHH-PMB), 4.53 - 4.36 (m, 9H, CHH-PMB, CH2-PMB (3x), CH2-
Fmoc), 4.36 - 4.27 (m, 1H, H-2), 4.22 (t, J = 6.9 Hz, 1H, CH-Fmoc), 3.94 - 3.86 (m, 1H, H-5′), 3.84 - 3.55 
(m, 21H, OMe (5x), H-7′, H-8′, H-9′, H-10′), 3.51 - 3.45 (m, 1H, H-6′), 3.18 - 3.03 (m, 2H, H-6), 2.29 - 2.09 
(m, 2H, H-2′), 1.86 - 1.58 (m, 4H, H-3, H-3′), 1.58 - 1.44 (m, 2H, H-4′), 1.44 - 1.25 (m, 4H, H-4, H-5); 13C 
NMR (101 MHz, CDCl3) δ 173.4, 173.1 (C-1, C-1′), 159.4, 159.4, 159.4, 159.3, 143.9, 141.4, 130.5, 130.5, 
130.3 (Cq), 129.7, 129.6, 129.6, 127.8, 127.2, 125.2, 120.1, 113.9, 113.9, 113.9 (CHarom),76.8 (C-7′,C-8′, C-9′), 
75.9 (C-6′), 74.8, 73.6 (C-7′,C-8′, C-9′), 73.4 (CH2-PMB), 73.2 (C-5′), 73.2, 71.9, 71.4(CH2-PMB), 69.4 (C-
10′), 67.1 (CH2-Fmoc), 53.8 (C-2), 52.5 (COOMe), 47.3 (CH-Fmoc), 39.0 (C-6), 35.7 (C-2′), 32.1 (C-3), 29.2 
(C-5), 28.3 (C-4′), 22.9 (C-3′), 22.6 (C-4); HRMS [C64H74N2O14 + Na]+: 1117.50383 found, 1117.50323 
calculated. 
Nα-Fmoc-Nε-[butan-4-(2,3,4,6-tetra-O-paramethoxybenzyl-α-ᴅ-mannopyranoside)-amide]-
L-lysine (168). 
Methyl ester 180 (2.19 g, 2.0 mmol) was dissolved in THF (20 mL, 0.1 M) and t-BuOH 
(2 mL) and cooled to 0°C. A solution of LiOH (240 mg, 10.0 mmol, 5 eq) in H2O2 (50% 
wt. aq., 4 mL, 2 M) was added dropwise (pH >10) and stirred at 0°C for four hours. The 
mixture was diluted with EtOAc, washed with HCl (1 M, aq., 1x), the organic layer was dried over MgSO4 
(s), filtered, concentrated in vacuo and purified using silica gel column chromatography (2/8 → 8/2, 
Acetone/DCM, v/v) to yield title compound 168 as a fluffy white powder after lyophilization from 1,4-
dioxane (1.70 g, 1.57 mmol, 79%). TLC Rf: 0.23 (AcOH/EtOAc/PE, 1/80/20, v/v/v); IR (neat, cm−1): 
3333, 2933, 1718, 1612, 1586, 1512, 1451, 1301, 1246, 1174, 1080, 1032, 819, 760, 740; 1H NMR (400 MHz, 
CDCl3) δ 7.76 (d, J = 7.5 Hz, 2H, Harom), 7.61 (d, J = 5.9 Hz, 2H, Harom), 7.39 (t, J = 7.4 Hz, 2H, Harom), 
O
OPMB
PMBO
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PMBO
O
H
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7.30 (t, J = 7.1 Hz, 2H, Harom), 7.27 - 7.08 (m, 8H, Harom), 6.89 - 6.78 (m, 8H, Harom), 5.93 (t, J = 5.9 Hz, 1H, 
NεH), 5.61 (d, J = 7.1 Hz, 1H, NαH), 4.58 (d, J = 11.2 Hz, 1H, CHH-PMB), 4.52 - 4.30 (m, 10H, CHH-
PMB, CH2-PMB (3x), CH2-Fmoc, H-2), 4.22 (t, J = 7.1 Hz, 1H, CH-Fmoc), 3.93 - 3.87 (m, 1H, H-5′), 3.83 
- 3.76 (m, 13H, OMe (4x), H-7′/ H-8′/ H-9′), 3.72 - 3.55 (m, 4H, H-10′, H-7′/ H-8′/ H-9′), 3.49 (dd, J = 
5.4, 2.5 Hz, 1H, H-6′), 3.20 (dt, J = 11.6, 5.3 Hz, 1H, H-6a), 3.09 - 2.96 (m, 1H, H-6b), 2.26 (dt, J = 14.3, 
6.5 Hz, 1H, H-2a′), 2.11 (dt, J = 13.8, 6.3 Hz, 1H, H-2b′), 1.90 - 1.58 (m, 4H, H-3, H-3′), 1.53 - 1.27 (m, 
6H, H-4′, H-4, H-5); 13C NMR (101 MHz, CDCl3) δ 174.1, 173.8 (C-1, C-1′), 159.5, 159.5, 159.4, 156.1, 
143.9, 141.4, 130.2 (Cq), 129.9, 129.8, 129.8, 129.6, 127.8, 127.2, 125.3, 120.1, 113.9, 113.9, 113.9 (CHarom), 
76.2 (C-7′,C-8′, C-9′), 75.9 (C-6′), 74.7, 73.5 (C-7′,C-8′, C-9′), 73.3 (CH2-PMB), 73.2 (C-5′), 73.2, 72.0, 71.5 
(CH2-PMB), 69.1 (C-10′), 67.1 (CH2-Fmoc), 55.4 (OMe), 53.6 (C-2), 47.3 (CH-Fmoc), 39.0 (C-6), 35.5 (C-
2′), 31.8 (C-3), 29.8 (C-5), 28.8 (C-4′), 23.2 (C-3′), 21.9 (C-4); HRMS [C63H72N2O14 + H]+: 1081.50810 found, 
1081.50588 calculated. 
 
General procedure for manual solid phase synthesis: 
The solid-phase peptide synthesis was performed starting with Tentagel® S-RAM resin (~0.22 
mmol/g) on a 45-50 µmol scale using established Fmoc protocols.26 The consecutive steps 
performed in each cycle were: 
1) DMF wash (1x) followed by nitrogen purge; 2) Deprotection of the Fmoc-group with 20% 
piperidine in DMF (4 mL, 3 x 5 min); 3) DMF wash (3x) followed by nitrogen purge; 4) Coupling 
of the appropriate amino acida in five-fold excess (unless stated otherwise)b,c; 5) DMF wash (3x) 
followed by nitrogen purge; 6) capping with a Ac2O/DMF/DIPEA solution (4mL, 20/88/2, 
v/v/v) for 2 min; 7) DMF wash (2x). 
After the complete sequence capping was achieved by utilization of steps 1,2 & 3 followed by 6 
and washing with DMF (3x), DCM (3x) and Et2O (2x) followed by nitrogen purge. 
 
 
a The Fmoc amino acids applied in this synthesis were: Fmoc-Lys(Boc)-OH, Fmoc-Gly-OH, 168c. 
b For couplings on 50 µmol scale: generally the Fmoc amino acid was dissolved in a HCTU solution in DMF (1.25 
mL ,0.20 M, 0.25 mmol, 5 eq) This solution was transferred to the reaction vessel followed by a DIPEA solution in 
DMF (1.00 mL, 0.50 M, 0.50 mmol, 10 eq) to initiate the coupling. Next, the reaction vessel was shaken for 60 min at 
room temperature. 
c For C-mannoside couplings less equivalents with prolonged reaction times were used. Generally 168 (2eq) was 
dissolved in a solution of HCTU in DMF (0,5 mL ,0.20 M, 100 µmol, 2 eq), followed by a DIPEA solution in DMF 
(0.40 mL, 0.5 M, 200 µmol, 4 eq) and shaken overnight. 
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Ac-CMAN-Gly-Lys-NH2 (186). 
Ac-CMAN-Gly-Lys(Boc)-Tentagel® S-RAM (loading: 50 µmol) was transferred to a 
flask and treated for 120 minutes with a cleavage cocktail (20 mL, 
TFA/DCM/TIS/H2O/phenol21/octanethiol, 3600/60/100/72/72/100, v/v/v/v/ 
w/v). The resin was filtered off and washed with neat TFA (3 x 1 mL). The filtrate was 
concentrated and purified via gel filtration (Toyopearl HW40S, 150 mM NH4HCO3, 1.6 x 60 cm, 1 
mL/min, eluted at 51.5 - 60 mL) followed by purification via RP-HPLC (linear gradient 0 - 30% B in A, 10 
min, Gemini-NX 5µm C18, 110 Å, 250 x 10.0 mm, 5 mL/min) yielded title compound 186 as a white 
powder after lyophilization (2.11 mg, 3.49 µmol, 7.0% over 3 couplings, 41% per step). LC-MS: Rt = 3.42 
min (0 - 50% ACN; 13 min); 1H NMR (500 MHz, D2O) δ 4.27 (dd, J = 9.5, 4.9 Hz, 1H, CH (Cman)), 4.19 
(dd, J = 8.6, 5.8 Hz, 1H, CH (K)), 3.96 - 3.86 (m, 3H, CH2 (G), H-5′), 3.86 - 3.79 (m, 2H, H-6′, H-10a′), 
3.76 (dd, J = 9.4, 3.3 Hz, 1H, H-7′), 3.69 (dd, J = 12.2, 6.2 Hz, 1H, H-10b′), 3.59 (t, J = 9.5 Hz, 1H, H-8′), 
3.50 - 3.44 (m, 1H, H-9′), 3.15 (t, J = 7.0 Hz, 2H, CH2-NHC=O), 2.90 (t, J = 7.7 Hz, 2H, CH2-NH2), 2.26 
(hept, J = 7.2 Hz, 2H, H-2′), 2.01 (s, 3H, Ac), 1.91 - 1.27 (m, 16H, H-3′, H-4′, CH2 (6x)); 13C NMR (126 
MHz, D2O) δ 176.7, 176.3, 175.2, 174.5, 171.4 (C=O), 77.9 (C-5′), 73.5 (C-9′), 71.4 (C-6′), 70.8 (C-7′), 67.3 
(C-8′), 61.2 (C-10′), 54.1 (CH (K)), 53.2 (CH (CMan)), 42.5 (CH2 (G)), 39.3 (CH2-NH2), 38.9 (CH2-
NHC=O), 35.2 (C-2′), 30.3, 27.8, 26.9, 26.7, 22.3, 22.0, 21.8 (C-3′, C-4′, CH2 (6x)), 21.6 (Ac); HRMS 
[C26H48N6O10 + H]+: 605.35031 found, 605.35047 calculated. 
Ac-CMAN-Gly-CMAN-Gly-Lys-NH2 (187). 
Ac-CMAN-Gly-CMAN-Gly-Lys(Boc)-Tentagel® S-RAM (loading: 45 µmol) was 
transferred to a flask and treated for 120 minutes with a cleavage cocktail (10 mL, 
TFA/TIS/H2O, 190/5/5, v/v/v). The mixture was concentrated to approximately 
one mL after which the resin was filtered off into cold Et2O (45 mL) and the resin was 
washed off with neat TFA (3 x 1 mL) into the ether solution. This solution was 
centrifuged (10 min, 5000 rpm) after which the supernatant was removed and the precipitate was dried 
under nitrogen flow. Purification via RP-HPLC (linear gradient 0 - 30% B in A, 10 min, Gemini-NX 5µm 
C18, 110 Å, 250 x 10.0 mm, 5 mL/min) yielded title compound 187 as a white powder after lyophilization 
(6.43 mg, 6.29 µmol, 14% over 5 couplings, 67% per step). LC-MS: Rt = 0.91 min (10 - 90% ACN; 13 min); 
1H NMR (400 MHz, CDCl3) δ 4.28 (td, J = 8.6, 7.9, 5.3 Hz, 2H, CH (Cman)), 4.21 (dd, J = 8.7, 5.7 Hz, 1H, 
CH (K)), 3.96 - 3.91 (m, 4H, CH2 (G)), 3.91 - 3.86 (m, 2H, H-5′), 3.86 - 3.80 (m, 4H, H-6′, H-10a′), 3.77 
(dd, J = 9.3, 3.3 Hz, 2H, H-7′), 3.70 (dd, J = 12.1, 6.2 Hz, 2H, H-10b′), 3.61 (t, J = 9.5 Hz, 2H, H-8′), 3.48 
(ddd, J = 9.1, 6.2, 2.2 Hz, 2H, H-9′), 3.16 (t, J = 6.9 Hz, 4H, CH2-NHC=O), 2.98 (t, J = 7.5 Hz, 2H, CH2-
NH2), 2.34 - 2.19 (m, 4H, H-2′), 2.02 (s, 3H, Ac), 1.93 - 1.23 (m, 26H, H-3′, H-4′, CH2); 13C NMR (101 
MHz, CDCl3) δ 176.6, 176.3, 176.3, 175.2, 174.8, 174.5, 171.6, 171.4 (C=O), 77.9 (C-5′), 73.5 (C-9′), 71.4 
(C-6′), 70.8 (C-7′), 67.3 (C-8′), 61.3 (C-10′), 54.2 (CH (K)), 53.9, 53.1 (CH (Cman)), 42.5, 42.4 (CH2 (G)) 
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39.2 (CH2-NH2), 38.9 (CH2-NHC=O), 35.2 (C-2′), 30.3, 27.8, 26.7, 26.1, 22.4, 22.0, 21.98 (C-3′, C-4′, CH2), 
21.7 (Ac); ESI-MS [C44H79N9O18 + H]+: 1022.400 found, 1022.562 calculated. 
Ac-CMAN-Gly-CMAN-Gly-CMAN-Gly-Lys-NH2 (188). 
Ac-CMAN-Gly-CMAN-Gly-CMAN-Gly-Lys(Boc)-Tentagel® S-RAM (loading: 45 
µmol) was transferred to a flask and treated for 120 minutes with a cleavage cocktail 
(10 mL, TFA/TIS/H2O, 190/5/5, v/v/v). The resin was filtered off into cold Et2O 
(45 mL) and the resin was washed off with neat TFA (3 x 1 mL) into the ether solution. 
This solution was centrifuged (10 min, 5000 rpm) after which the supernatant was 
removed and the precipitate was dried under nitrogen flow. Purification via RP-HPLC (linear gradient 0 - 
30% B in A, 10 min, Gemini-NX 5µm C18, 110 Å, 250 x 10.0 mm, 5 mL/min) yielded title compound 188 
as a white powder after lyophilization (3.91 mg, 2.71 µmol, 6.0% over 7 couplings, 67% per step). LC-MS: 
Rt = 4.54 min (20 - 50% ACN; 13 min); 1H NMR (400 MHz, CDCl3) δ 4.32 - 4.24 (m, 3H, CH (Cman)), 
4.21 (dd, J = 8.6, 5.6 Hz, 1H, CH (K)), 3.96 - 3.86 (m, 9H, CH2 (G), H-5′), 3.86 - 3.80 (m, 6H, H-6′, H-
10a′), 3.77 (dd, J = 9.3, 3.3 Hz, 3H, H-7′), 3.70 (dd, J = 12.1, 6.2 Hz, 3H, H-10b′), 3.61 (t, J = 9.5 Hz, 3H, 
H-8′), 3.48 (ddd, J = 9.3, 6.2, 2.2 Hz, 3H, H-9′), 3.15 (d, J = 6.5 Hz, 6H, CH2-NHC=O), 2.98 (t, J = 7.4 Hz, 
2H, CH2-NH2), 2.34 - 2.18 (m, 6H, H-2′), 2.02 (s, 3H, Ac), 1.92 - 1.22 (m, 36H, H-3′, H-4′, CH2); ESI-MS 
[C62H110N12O26 + H]+: 1439.533 found, 1439.773 calculated. 
Ac-CMAN-CMAN-CMAN-CMAN-CMAN-CMAN-Gly-Lys-NH2 (189). 
Ac-CMAN-CMAN-CMAN-CMAN-CMAN-CMAN-Gly-Lys(Boc)-Tentagel® S-
RAM (loading: 50 µmol) was transferred to a flask and treated for 120 minutes with 
a cleavage cocktail (20 mL, TFA/DCM/TIS/H2O/phenol21/octanethiol, 
3600/60/100/72/72/100, v/v/v/v/w/v). The resin was filtered off and washed 
with neat TFA (3 x 1 mL). The filtrate was concentrated and purified via gel 
filtration (Toyopearl HW40S, 150 mM NH4HCO3, 1.6 x 60 cm, 1 mL/min, eluted 
at 34 - 49 mL) followed by purification via RP-HPLC (linear gradient 0 - 30% B in A, 10 min, Gemini-NX 
5µm C18, 110 Å, 250 x 10.0 mm, 5 mL/min) to yield title compound 189 as a white powder after 
lyophilization (2.56 mg, 1.06 µmol, 2.1% over 8 couplings, 62% per step). LC-MS: Rt = 4.22 min (0 - 50% 
ACN; 13 min); 1H NMR (500 MHz, D2O) δ 4.30 - 4.18 (m, 6H, CH (Cman)), 4.18 - 4.14 (m, 1H, CH (K)), 
3.93 (s, 2H, CH2 (G)), 3.88 (dd, J = 10.0, 3.4 Hz, 6H, H-5′), 3.86 - 3.79 (m, 12H, H-6′, H-10a′), 3.76 (dd, J 
= 9.4, 3.3 Hz, 6H, H-7′), 3.69 (dd, J = 12.1, 6.2 Hz, 6H, H-10b′), 3.60 (t, J = 9.5 Hz, 6H, H-8′), 3.47 (ddd, 
J = 9.0, 6.2, 2.1 Hz, 6H, H-9′), 3.17 - 3.09 (m, 12H, CH2-NHC=O), 2.97 (t, J = 7.2 Hz, 2H, CH2-NH2), 
2.24 (hept, J = 7.6 Hz, 12H, H-2′), 2.01 (s, 3H, Ac), 1.89 - 1.25 (m, 66H, H-3′, H-4′, CH2); HRMS 
[C106H188N16O45 + 3H]3+: 803.10536 found, 803.10546 calculated. 
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General procedure for biotinylation: 
The general procedure to introduce the biotin handle: Glycoclusters described above with a free amine 
were dissolved in DMSO (0.02 M). To this, a stock solution of Biotin-NHS (0.15 M, 3-4 eq) and DIPEA 
(0.015M, 0.3-0.4 eq) in DMSO was added and shaken overnight after which compounds were purified via 
RP-HPLC (linear-gradient 10 - 16% B in A, 12 min, 5 mL/min, Develosil RPAQUEOUS 10.0 x 250 mm) 
followed by lyophilization.  
 
Ac-CMAN-Gly-Lys(biotin)-NH2 (190). 
Compound 186 (1.54 mg, 1.23 µmol) was coupled with biotin-NHS using the general 
procedure. Compound 190 was obtained after purification by RP-HPLC as a white 
powder (1.98 mg, 2.38 µmol, 94%). LC-MS: Rt = 5.23 min (0 - 50% ACN; 13 min); 
HRMS [C36H62N8O12S +H]+: 831.42807 found, 831.42807 calculated. 
 
Ac-CMAN-Gly-CMAN-Gly-Lys(biotin)-NH2 (191). 
Compound 187 (6.43 mg, 6.30 µmol) was coupled with biotin-NHS using the general 
procedure. Compound 191 was obtained after purification by RP-HPLC as a white 
powder (5.64 mg, 4.51 µmol, 72%). LC-MS: Rt = 5.21 min (0 - 50% ACN; 13 min); 
1H NMR (500 MHz, D2O) δ 4.62 (dd, J = 7.9, 4.4 Hz, 1H), 4.44 (dd, J = 7.9, 4.5 Hz, 
1H), 4.33 - 4.27 (m, 2H), 4.25 (dd, J = 8.7, 5.7 Hz, 1H), 3.98 - 3.95 (m, 4H), 3.95 - 
3.91 (m, 2H), 3.90 - 3.84 (m, 4H), 3.81 (dd, J = 9.4, 3.4 Hz, 2H), 3.74 (dd, J = 12.1, 6.2 Hz, 2H), 3.65 (t, J 
= 9.5 Hz, 2H), 3.52 (ddd, J = 9.2, 6.2, 2.3 Hz, 2H), 3.35 (dt, J = 9.7, 5.3 Hz, 1H), 3.20 (dt, J = 6.9, 3.6 Hz, 
6H), 3.01 (dd, J = 13.1, 5.0 Hz, 1H), 2.79 (d, J = 13.0 Hz, 1H), 2.36 - 2.23 (m, 6H), 2.06 (s, 3H), 1.92 - 1.30 
(m, 32H); HRMS [C54H93N11O20S +2H]2+: 624.82361 found, 624.82323 calculated. 
Ac-CMAN-Gly-CMAN-Gly-CMAN-Gly-Lys(biotin)-NH2 (192).  
Compound 188 (3.91 mg, 2.72 µmol) was coupled with biotin-NHS using the general 
procedure. Compound 192 was obtained after purification by RP-HPLC as a white 
powder (9.29 mg, 5.58 µmol, 99%). LC-MS: Rt = 5.16 min (0 - 50% ACN; 13 min); 
HRMS [C72H124N14O28S +2H]2+: 833.42889 found, 833.42879 calculated.  
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Ac-CMAN-CMAN-CMAN-CMAN-CMAN-CMAN-Gly-Lys(biotin)-NH2 (193). 
Compound 189 (2.09 mg, 0.87 µmol) was coupled with biotin-NHS using the general 
procedure. Compound 193 was obtained after purification by RP-HPLC as a white 
powder (1.84 mg, 0.70 µmol, 80%). LC-MS: Rt = 5.06 min (0 - 50% ACN; 13 min); 
HRMS [C116H202N18O47S +3H]3+: 1317.19385 found, 1317.19348 calculated. 
 
 
Ac-CMAN-CMAN-CMAN-CMAN-CMAN-CMAN-Gly-Lys(ATTO655)-NH2 (194). 
Compound 189 (155 nmol) was dissolved in DMSO (2.0 mM). To this a solution 
of ATTO655-NHS (5.0 mM, 2 eq) and DIPEA (0.01 M, 2 eq) in DMSO was 
added, shaken protected from light for one hour. After which compound 194 was 
obtained after purification by gel filtration (eluted at 46 - 58 mL) as a blue powder 
after lyophilization (0.247 mg, 85 nmol, 55%). LC-MS: Rt = 6.08 min (0 - 50% 
ACN; 13 min); HRMS [C133H219N19O50S + 3H]3+: 972.83825 found, 972.83828 
calculated. 
 
General procedure for automated solid-phase synthesis of gp100 peptides: 
The solid-phase peptide synthesis was performed on a TRIBUTE® Peptide Synthesizer (Gyros 
Protein Technologies AB, Arizona, USA) applying Fmoc based protocol starting with Tentagel® 
S-RAM resin (~0.22 mmol/g) on a 100-250 µmol scale using established synthetic protocols.26 
The consecutive steps for synthesis on 250 µmol scalea performed in each cycle were: 
1) DMF wash (1x) followed by nitrogen purge; 2) Deprotection of the Fmoc-group with 20% 
piperidine in DMF (8 mL)(3 x 3 min at 50 °C); 3) DMF wash (3x) followed by nitrogen purge; 4.1) 
 
a All amounts were scaled-down in equimolar proportions for smaller scale. 
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Coupling of the appropriate amino acida in four-fold excess (unless stated otherwise);b ,c,d 4.2) Step 
4.1 was repeated 5) DMF wash (3x) followed by nitrogen purge; 6) capping with a solution of 
Ac2O/DMF/DIPEA (8mL, 10/88/2, v/v/v) for 2 min; 7) DMF wash (2x).  
After the complete sequence, the resin was washed with DMF (3x), DCM (3x), Et2O (3x), followed 
by nitrogen purge before treatment with the cleavage cocktail. 
 
Ac-CMAN-Val-Thr-His-Thr-Tyr-Leu-Glu-Pro-Gly-Pro-Val-Thr-Ala-Asn-Arg-Gln-Leu-Tyr-Pro-
Glu-Trp-Thr-Glu-Ala-Gln-Arg-Leu-Asp-αAbu-Trp-Arg-Gly-Lys-NH2 (203). 
Resin 134 (theoretical loading: 25 µmol) was elongated with 168 (54 mg, 50 µmol, 2 
eq) by shaking overnight at room temperature with HCTU (20.7 mg, 50 µmol, 2 eq) 
and DIPEA (17.4 µL, 100 µmol, 4 eq) in DMF (450 µL, 0.11 M of 168). After washing 
(steps 7,1) and Fmoc removal (steps 2, 3) the N-terminus was capped with 
Ac2O/DMF/DIPEA (4mL, 10/88/2, v/v/v, 3 x 5 min) and the resin was washed 
with DMF (3x), DCM (3x), Et2O (3x) and dried by nitrogen purge to yield Ac-CMAN-Val-Thr(tBu)-
His(Trt)-Thr(tBu)-Tyr(tBu)-Leu-Glu(OtBu)-Pro-Gly-Pro-Val-Thr(tBu)-Ala-Asn(Trt)-Arg(Pbf)-Gln(Trt)-
Leu-Tyr(tBu)-Pro-Glu(OtBu)-Trp(Boc)-Thr(tBu)-Glu(OtBu)-Ala-Gln(Trt)-Arg(Pbf)-Leu-Asp(OtBu)-
αAbu-Trp(Boc)-Arg(Pbf)-Gly-Lys(Mmt)-Tentagel® S-RAM (199). The resin was transferred to a flask and 
treated for 120 minutes with a cleavage cocktail (20 mL, TFA/DCM/TIS/H2O/phenol21/octanethiol, 
3600/60/100/72/72/100, v/v/v/v/w/v). The resin was filtered off and washed with neat TFA (3 x 1 mL). 
The filtrate was concentrated and transferred dropwise into a cold mixture of Et2O/pentane (45 mL, 5/4, 
v/v) This solution was centrifuged (10 minutes, 5000 rpm) after which the supernatant was removed and 
the precipitate was dried under nitrogen flow, re-dissolved in magic (5 mL, t-BuOH/ACN/H2O, 1/1/1, 
v/v/v) and lyophilized. Purification via RP-HPLC (linear-gradient 20 - 30% B in A, 10 min, Gemini-NX 
5µm C18, 110 Å, 250 x 10.0 mm, 5 mL/min) yielded title compound 203 as a white powder after 
 
a The amino acids applied in this synthesis were: Fmoc-Lys(Mmt)-OH, Fmoc-Gly-OH, Fmoc-Arg(Pbf)-OH, Fmoc-
Trp(Boc)-OH, Fmoc-L-α-aminobutyric acid, Fmoc-Asp(OtBu)-OHd, Fmoc-Leu-OHd, Fmoc-Gln(Trt)-OH, Fmoc-
Ala-OH, Fmoc-Glu(OtBu)-OH, Fmoc-Thr(tBu)-OH, Fmoc-Pro-OH, Fmoc-Tyr(tBu)-OH, Fmoc-Asn(Trt)-OH, 
Fmoc-Val-OH, Fmoc-His(Trt)-OH, Fmoc-AEEA-OH (Fmoc-8-amino-3,6-dioxaoctanoic acid), 116 and 168.e 
b Generally, the Fmoc amino acid is dissolved in a HCTU solution in DMF (5.00 mL ,0.20 M, 1.0 mmol, 4 eq) The 
resulting solution was transferred to the reaction vessel followed by a DIPEA solution in DMF (4.00 mL, 0.50 M, 2.0 
mmol, 8 eq) to initiate the coupling. The reaction vessel was shaken for 30 min at 50 °C (unless stated otherwise). 
c Aspartic acid and the adjacent Leucine and Arginine were introduced at with one hour reaction time at room 
temperature. Fmoc removal was achieved with piperide/DMF in 3 x 5 min at room temperature.28 
d For C-mannoside couplings less equivalents with prolonged reaction times were used. Generally for elongation on 
100 µmol scale, 168 (2eq) was dissolved in a solution of HCTU in DMF (1,0 mL ,0.20 M, 200 µmol, 2 eq), followed 
by a DIPEA solution in DMF (0.80 mL, 0.5 M, 400 µmol, 4 eq) and shaken overnight. 
NH2[AA]
N
H
O
NH2
N
H
O
O
OH
HO
HO
HO
O
NH
O
Development of a C-mannoside functionalized lysine for acid-stable mannosylated peptides 
138 
lyophilization (2.69 mg, 626 nmol, 2.51% over 34 couplings, 90% per step). LC-MS: Rt = 4.16 min (10 - 
90% ACN; 13 min); HRMS [C194H297N53O58 + 4H]4+: 1075.80691 found, 1075.80670 calculated. 
Ac-CMAN-CMAN-CMAN-CMAN-CMAN-CMAN-Val-Thr-His-Thr-Tyr-Leu-Glu-Pro-Gly-Pro-
Val-Thr-Ala-Asn-Arg-Gln-Leu-Tyr-Pro-Glu-Trp-Thr-Glu-Ala-Gln-Arg-Leu-Asp-αAbu-Trp-Arg-
Gly-Lys-Tentagel® S-RAM (200). 
Resin 134 (theoretical loading: 100 µmol) was elongated with 168 (216 mg, 200 µmol, 2 eq) by shaking 
overnight at room temperature with HCTU (82.6 mg, 200 µmol, 2 eq) and DIPEA (69.5 µL, 400 µmol, 4 
eq) in DMF (1.8 mL, 0.11 M of 168). followed by Fmoc removal and washing steps as described in general 
protocol (steps 7,1,2 and 3), these steps were repeated (6x total). After these cycles, the resin was washed 
(steps 7,1), the Fmoc removed (steps 2, 3), the N-terminus was capped with Ac2O/DMF/DIPEA (8mL, 
10/88/2, v/v/v, 3 x 5 min) and the resin was washed with DMF (3x), DCM (3x), Et2O (3x) and dried by 
nitrogen purge to yield Ac-CMAN-CMAN-CMAN-CMAN-CMAN-CMAN-Val-Thr(tBu)-His(Trt)-
Thr(tBu)-Tyr(tBu)-Leu-Glu(OtBu)-Pro-Gly-Pro-Val-Thr(tBu)-Ala-Asn(Trt)-Arg(Pbf)-Gln(Trt)-Leu-
Tyr(tBu)-Pro-Glu(OtBu)-Trp(Boc)-Thr(tBu)-Glu(OtBu)-Ala-Gln(Trt)-Arg(Pbf)-Leu-Asp(OtBu)-αAbu-
Trp(Boc)-Arg(Pbf)-Gly-Lys(Mmt)-Tentagel® S-RAM (200).  
Ac-CMAN-CMAN-CMAN-CMAN-CMAN-CMAN-Val-Thr-His-Thr-Tyr-Leu-Glu-Pro-Gly-Pro-
Val-Thr-Ala-Asn-Arg-Gln-Leu-Tyr-Pro-Glu-Trp-Thr-Glu-Ala-Gln-Arg-Leu-Asp-αAbu-Trp-Arg-
Gly-Lys-NH2 (204). 
Resin 200 (theoretical loading: 25 µmol) was transferred to a flask and treated for 120 
minutes with a cleavage cocktail (40 mL, TFA/DCM/TIS/H2O/phenol21/ 
octanethiol, 3600/60/100/72/72/100, v/v/v/v/w/v). The resin was filtered off and 
washed with neat TFA (3 x 1 mL). The filtrate was concentrated and transferred 
dropwise into a cold mixture of Et2O/pentane (45 mL, 5/4, v/v) This solution was 
centrifuged (10 minutes, 5000 rpm) after which the supernatant was removed and the precipitate was dried 
under nitrogen flow, re-dissolved in magic (5 mL, t-BuOH/ACN/H2O, 1/1/1, v/v/v) and lyophilized. 
Purification via RP-HPLC (linear-gradient 20 - 30% B in A, 10 min, Gemini-NX 5µm C18, 110 Å, 250 x 
10.0 mm, 5 mL/min) yielded title compound 204 as a white powder after lyophilization. (1.115 mg, 182 
nmol, 0.73% over 39 couplings, 88% per step). LC-MS: Rt = 3.91 min (10 - 90% ACN; 13 min); HRMS 
[C274H437N63O93 + 5H]5+: 1221.23680 found, 1221.23707 calculated. 
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Ac-CMAN-Val-Thr-His-Thr-Tyr-Leu-Glu-Pro-Gly-Pro-Val-Thr-Ala-Asn-Arg-Gln-Leu-Tyr-Pro-
Glu-Trp-Thr-Glu-Ala-Gln-Arg-Leu-Asp-αAbu-Trp-Arg-Gly-Lys(Peg-TLR7L)-NH2 (207). 
Resin 134 (theoretical loading: 25 µmol) was elongated with 168 (54 mg, 50 
µmol, 2 eq) by shaking overnight at room temperature with HCTU (20.7 mg, 
50 µmol, 2 eq) and DIPEA (17.4 µL, 100 µmol, 4 eq) in DMF (450 µL, 0.11 
M of 168). After washing (steps 7,1) and Fmoc removal (steps 2, 3) the N-
terminus was capped with Ac2O/DMF/DIPEA (4mL, 10/88/2, v/v/v, 3 x 
5 min) and the resin was washed with DMF (3x), DCM (3x), Et2O (3x) and dried by nitrogen purge to yield 
199. This resin was loaded in a syringe with frit and treated with a mixture of AcOH in TFE and DCM 
(1/2/7, v/v/v) shaken for 15 minutes followed by filtration22. This was repeated until the filtrate lost the 
yellow color (~ 8x). After which the resin was washed with DCM (5x), DMF (5x) Piperidine (20% in DMF, 
2x) and DMF (5x). The lysine was elongated with Fmoc-AEEA-OH (127) using the general protocol 
followed by introduction of 116 (45.7 mg, 100 µmol, 4 eq) by shaking for one hour with HCTU (41.3 mg, 
100 µmol, 4 eq) and DIPEA (35 µL, 200 µmol, 8 eq) in DMF (0.9 mL, 0.11 M of 116) yielding Ac-CMAN-
Val-Thr(tBu)-His(Trt)-Thr(tBu)-Tyr(tBu)-Leu-Glu(OtBu)-Pro-Gly-Pro-Val-Thr(tBu)-Ala-Asn(Trt)-
Arg(Pbf)-Gln(Trt)-Leu-Tyr(tBu)-Pro-Glu(OtBu)-Trp(Boc)-Thr(tBu)-Glu(OtBu)-Ala-Gln(Trt)-Arg(Pbf)-
Leu-Asp(OtBu)-αAbu-Trp(Boc)-Arg(Pbf)-Gly-Lys(PEG-TLR7L)-Tentagel® S-RAM (201). The resin was 
washed with DMF (3x), DCM (3x) and Et2O (3x) and dried by nitrogen purge, transferred to a flask and 
treated for 120 minutes with a cleavage cocktail (20 mL, TFA/DCM/TIS/H2O/phenol21/octanethiol, 
3600/60/100/72/72/100, v/v/v/v/w/v). The resin was filtered off and washed with neat TFA (3 x 1 mL). 
The filtrate was concentrated and transferred dropwise into a cold mixture of Et2O/pentane (45 mL, 5/4, 
v/v) This solution was centrifuged (10 min, 5000 rpm) after which the supernatant was removed and the 
precipitate was dried under nitrogen flow, re-dissolved in magic (5 mL, t-BuOH/ACN/H2O, 1/1/1, v/v/v) 
and lyophilized. Purification via RP-HPLC (linear-gradient 21 - 36% B in A, 15 min, Gemini-NX 5µm C18, 
110 Å, 250 x 10.0 mm, 5 mL/min) yielded title compound 207 as a white powder after lyophilization (2.51 
mg, 525 nmol, 2.10% over 36 couplings, 90% per step) LC-MS: Rt = 4.53 min (10 - 90% ACN; 13 min); 
HRMS [C217H325N59O64 + 5H]5+: 957.68821 found, 957.68822 calculated. 
Ac-CMAN-CMAN-CMAN-CMAN-CMAN-CMAN-Val -Thr-His-Thr-Tyr-Leu-Glu-Pro-Gly-Pro-
Val-Thr-Ala-Asn-Arg-Gln-Leu-Tyr-Pro-Glu-Trp-Thr-Glu-Ala-Gln-Arg-Leu-Asp-αAbu-Trp-Arg-
Gly-Lys(Peg-TLR7L)-NH2 (208). 
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Mmt removal with 1% TFA: 
Resin 200 (theoretical loading: 12.5 µmol) was loaded in a syringe with frit and treated with TFA (1% in 
DCM) shaken for five minutes followed by filtration. This was repeated until the filtrate lost the 
orange/yellow color (~ 12x). After which the resin was washed with DCM (5x), DMF (5x) Piperidine (20% 
in DMF, 2x) and DMF (5x). The lysine was elongated with Fmoc-AEEA-OH (127) using the general 
protocol followed by introduction of 116 (22.9 mg, 50 µmol, 4 eq) by shaking for one hour with HCTU 
(20.7 mg, 500 µmol, 4 eq) and DIPEA (17 µL, 100 µmol, 8 eq) in DMF (0.45 mL, 0.11 M of 116) yielding 
Ac-CMAN-CMAN-CMAN-CMAN-CMAN-CMAN-Val-Thr(tBu)-His(Trt)-Thr(tBu)-Tyr(tBu)-Leu-
Glu(OtBu)-Pro-Gly-Pro-Val-Thr(tBu)-Ala-Asn(Trt)-Arg(Pbf)-Gln(Trt)-Leu-Tyr(tBu)-Pro-Glu(OtBu)-
Trp(Boc)-Thr(tBu)-Glu(OtBu)-Ala-Gln(Trt)-Arg(Pbf)-Leu-Asp(OtBu)-αAbu-Trp(Boc)-Arg(Pbf)-Gly-
Lys(PEG-TLR7L)-Tentagel® S-RAM (202). The resin was washed with DMF (3x), DCM (3x) and Et2O 
(3x) and dried by nitrogen purge, transferred to a flask and treated for 120 minutes with a cleavage cocktail 
(10 mL, TFA/DCM/TIS/H2O/phenol21/octanethiol, 3600/60/100/72/72/100, v/v/v/v/w/v). The 
resin was filtered off and washed with neat TFA (3 x 1 mL). The filtrate was concentrated and transferred 
dropwise into a cold mixture of Et2O/pentane (45 mL, 5/4, v/v) This solution was centrifuged (10 min, 
5000 rpm) after which the supernatant was removed and the precipitate was dried under nitrogen flow, re-
dissolved in magic (5 mL, t-BuOH/ACN/H2O, 1/1/1, v/v/v) and lyophilized. LC-MS analysis showed 
multiple AEEA-TLR conjugations. Treatment of the crude mixture with ammonia (1mL, 35%wt NH3 aq.) 
resulted in the disappearance of peaks corresponding with multiple conjugations. After lyophilization the 
mixture was purified by RP-HPLC (linear-gradient 22.5 - 30% B in A, 15 min, Gemini-NX 5µm C18, 110 
Å, 250 x 10.0 mm, 5 mL/min) to yield title compound 208 as a white powder after lyophilization (0.247 
mg, 37.4 nmol, 0.30% over 41 couplings, 86.8% per step). 
Mmt removal with AcOH in TFE/DCM: 
Resin 200 (theoretical loading: 62.5 µmol) was loaded in a syringe with frit and treated with a mixture of 
AcOH in TFE and DCM (1/2/7, v/v/v) shaken for 15 minutes followed by filtration22. This was repeated 
until the filtrate lost the yellow color (~ 8x). After which the resin was washed with DCM (5x), DMF (5x) 
Piperidine (20% in DMF, 2x) and DMF (5x). The lysine was elongated with Fmoc-AEEA-OH (127) using 
the general protocol followed by introduction of 116 (115 mg, 250 µmol, 4 eq) by shaking for one hour 
with HCTU (103 mg, 250 µmol, 4 eq) and DIPEA (87 µL, 500 µmol, 8 eq) in DMF (2.25 mL, 0.11 M of 
116) yielding resin 202. The resin was washed with DMF (3x), DCM (3x) and Et2O (3x) and dried by 
nitrogen purge, transferred to a flask and treated for 120 minutes with a cleavage cocktail (40 mL, 
TFA/DCM/TIS/H2O/phenol21/octanethiol, 3600/60/100/72/72/100, v/v/v/v/w/v). The resin was 
filtered off and washed with neat TFA (3 x 1 mL). The filtrate was concentrated and transferred dropwise 
into a cold mixture of Et2O/pentane (45 mL, 5/4, v/v) This solution was centrifuged (10 min, 5000 rpm) 
after which the supernatant was removed and the precipitate was dried under nitrogen flow, re-dissolved 
in magic (5 mL, t-BuOH/ACN/H2O, 1/1/1, v/v/v) and lyophilized. LC-MS analysis of this crude mixture 
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showed no ions for multiple AEEA-TLR conjugations. Purification via RP-HPLC (linear-gradient 22.5 - 
30% B in A, 15 min, Gemini-NX 5µm C18, 110 Å, 250 x 10.0 mm, 5 mL/min) yielded title compound 208 
as a white powder after lyophilization (2.48 mg, 376 nmol, 0.60% over 41 couplings, 88.3 % per step). LC-
MS: Rt = 7.11 min (0 - 50% ACN; 13 min); HRMS [C297H465N69O99 + 4H]4+: 1647.34697 found, 1647.34628 
calculated. 
TLR7L-PEG-CMAN-Val-Thr-His-Thr-Tyr-Leu-Glu-Pro-Gly-Pro-Val-Thr-Ala-Asn-Arg-Gln-Leu-
Tyr-Pro-Glu-Trp-Thr-Glu-Ala-Gln-Arg-Leu-Asp-αAbu-Trp-Arg-Gly-Lys-NH2 (205). 
Resin 134 (theoretical loading: 25 µmol) was elongated with 168 (54 mg, 50 
µmol, 2 eq) by shaking overnight at room temperature with HCTU (20.7 mg, 
50 µmol, 2 eq) and DIPEA (17.4 µL, 100 µmol, 4 eq) in DMF (450 µL, 0.11 
M of 168). Fmoc-AEEA-OH (127)(4eq) was introduced using the general 
protocol followed by introduction of 116 (46 mg, 100 µmol, 4 eq) by shaking 
for two hour with HCTU (41 mg, 100 µmol, 4 eq) and DIPEA (34.8 µL, 200 µmol, 8 eq) in DMF (0.90 
mL, 0.11 M of 116) after which the resin was washed with DMF (3x), DCM (3x), Et2O (3x) and dried by 
nitrogen purge to yield TLR7L-PEG-CMAN-Val-Thr(tBu)-His(Trt)-Thr(tBu)-Tyr(tBu)-Leu-Glu(OtBu)-
Pro-Gly-Pro-Val-Thr(tBu)-Ala-Asn(Trt)-Arg(Pbf)-Gln(Trt)-Leu-Tyr(tBu)-Pro-Glu(OtBu)-Trp(Boc)-
Thr(tBu)-Glu(OtBu)-Ala-Gln(Trt)-Arg(Pbf)-Leu-Asp(OtBu)-αAbu-Trp(Boc)-Arg(Pbf)-Gly-Lys(Mmt)-
Tentagel® S-RAM (197). This resin was transferred to a flask and treated for 120 minutes with a cleavage 
cocktail (20 mL, TFA/DCM/TIS/H2O/phenol21/octanethiol, 3600/60/100/72/72/100, v/v/v/v/w/v). 
The resin was filtered off and washed with neat TFA (3 x 1 mL). The filtrate was concentrated and 
transferred dropwise into a cold mixture of Et2O/pentane (45 mL, 5/4, v/v). This solution was centrifuged 
(10 min, 5000 rpm) after which the supernatant was removed and the precipitate was dried under nitrogen 
flow, re-dissolved in magic (5 mL, t-BuOH/ACN/H2O, 1/1/1, v/v/v) and lyophilized. Purification via 
RP-HPLC (linear-gradient 25 - 35% B in A, 10 min, Gemini-NX 5µm C18, 110 Å, 250 x 10.0 mm, 5 
mL/min) yielded title compound 205 as a white powder after lyophilization (3.09 mg, 651 nmol, 2.60% 
over 36 couplings, 90% per step). LC-MS: Rt = 4.46 min (10 - 90% ACN; 13 min); Rt = 7.29 min (0 - 50% 
ACN; 13 min); HRMS [C215H323N59O63 + 6H]6+: 791.23965 found, 791.23964 calculated. 
TLR7L-PEG-CMAN-CMAN-CMAN-CMAN-CMAN-CMAN-Val-Thr-His-Thr-Tyr-Leu-Glu-Pro-
Gly-Pro-Val-Thr-Ala-Asn-Arg-Gln-Leu-Tyr-Pro-Glu-Trp-Thr-Glu-Ala-Gln-Arg-Leu-Asp-αAbu-
Trp-Arg-Gly-Lys-NH2 (206). 
Resin Val-Thr(tBu)-His(Trt)-Thr(tBu)-Tyr(tBu)-Leu-Glu(OtBu)-Pro-Gly-
Pro-Val-Thr(tBu)-Ala-Asn(Trt)-Arg(Pbf)-Gln(Trt)-Leu-Tyr(tBu)-Pro-
Glu(OtBu)-Trp(Boc)-Thr(tBu)-Glu(OtBu)-Ala-Gln(Trt)-Arg(Pbf)-Leu-
Asp(OtBu)-αAbu-Trp(Boc)-Arg(Pbf)-Gly-Lys(Boc)-Tentagel® S-RAM 
(theoretical loading: 50 µmol) was elongated with 168 (216 mg, 200 µmol, 2 
eq) by shaking overnight at room temperature with HCTU (82.6 mg, 200 µmol, 2 eq) and DIPEA (69.5 µL, 
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400 µmol, 4 eq) in DMF (1.8 mL, 0.11 M of 168). followed by Fmoc removal and washing steps as described 
in general protocol (steps 7,1,2 and 3), these steps were repeated (6x total). Fmoc-AEEA-OH (127, 4 eq) 
was introduced using the general protocol followed by introduction of 116 (92 mg, 200 µmol, 4eq) by 
shaking for two hour with HCTU (82 mg, 200 µmol, 4eq) and DIPEA (70 µL, 400 µmol, 8 eq) in DMF 
(1.80 mL, 0.11 M of 116) after which the resin was washed with DMF (3x), DCM (3x), Et2O (3x) and dried 
by nitrogen purge to yield resin TLR7L-PEG-CMAN-CMAN-CMAN-CMAN-CMAN-CMAN-Val-
Thr(tBu)-His(Trt)-Thr(tBu)-Tyr(tBu)-Leu-Glu(OtBu)-Pro-Gly-Pro-Val-Thr(tBu)-Ala-Asn(Trt)-Arg(Pbf)-
Gln(Trt)-Leu-Tyr(tBu)-Pro-Glu(OtBu)-Trp(Boc)-Thr(tBu)-Glu(OtBu)-Ala-Gln(Trt)-Arg(Pbf)-Leu-
Asp(OtBu)-αAbu-Trp(Boc)-Arg(Pbf)-Gly-Lys(Boc)-Tentagel® S-RAM. This resin was transferred to a flask 
and treated for 120 minutes with a cleavage cocktail (20 mL, TFA/DCM/TIS/H2O/phenol21/octanethiol, 
3600/60/100/72/72/100, v/v/v/v/w/v). The resin was filtered off and washed with neat TFA (3 x 1 mL). 
The filtrate was concentrated and transferred dropwise into a cold mixture of Et2O/pentane (45 mL, 5/4, 
v/v) This solution was centrifuged (10 min, 5000 rpm) after which the supernatant was removed and the 
precipitate was dried under nitrogen flow, re-dissolved in magic (5 mL, t-BuOH/ACN/H2O, 1/1/1, v/v/v) 
and lyophilized. Purification via RP-HPLC (linear-gradient 16 - 28% B in A, 10 min, Gemini-NX 5µm C18, 
110 Å, 250 x 12.0 mm, 5 mL/min) yielded title compound 206 as a white powder after lyophilization. (4.125 
mg, 650 nmol, 1.30% over 41 couplings, 90% per step). LC-MS: Rt = 7.73 min (15 - 40% ACN; 15 min); 
Rt = 5.82 min (10 - 50% ACN; 13 min); HRMS [C295H463N69O98 + 6H]6+: 1091.56505 found, 1091.56485 
calculated. 
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Chapter 6 
Synthesis of glycosylated BTA-core-
monomers for the formation of dynamic 
self-assembling supramolecular fibersa 
Introduction1 
Carbohydrate recognition often requires multiple carbohydrates in close proximity to each other, 
so that the combined weak interaction of each separate carbohydrate and the effective local high 
concentration results in strong enough binding to induce an effect of the recognizing receptor. 
This multivalency-effect allows receptors to distinguish between single carbohydrates or larger 
glycosylated pathogens such as viruses and bacteria.2 Multivalent presentation of mannosides, for 
example, can result in inflammatory responses induced by the binding of C-type lectin receptors 
(CLRs), as described in previous chapters. Alternatively, multivalent macromolecules can also 
mimic natural systems with structural functions. An example would be mimicking the extracellular 
matrix (ECM), which serves functions such as signaling, water immobilization, cell attachment and 
aids in structural properties such as increasing stiffness of the framework around cells. The ECM 
 
aPart of this work is published in Hendrikse and Su et al.1 
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consist of a network of proteins and carbohydrates such as heparin and hyaluronic acid (HA). A 
multitude of multivalent biomaterials have been described such as dendrimers, nanoparticles, and 
polymers, that are designed to mimic the ECM3–5 or viral particles.6–9 However, the synthesis of 
these materials usually requires many reaction steps, and variations in the composition of these 
materials often involve new synthetic approaches. Especially when variations in the ratio between 
components of such polymers are desired, the generation of these static polymers can be labor-
intensive. Dynamic systems such as self-assembling polymers are considered to be an attractive 
alternative. Such systems would allow to more easily adapt the ratio of components by simply 
varying the ratio of the used monomers.  
Self-assembling supramolecular polymer systems have been studied extensively as biomaterial 
mimics.10,11 One of these systems is based on an N,N′,N′′-trialkylbenzene-1,3,5-tricarboxamide 
(BTA) scaffold, that bears three amphipathic arms (210, Figure 1), having a hydrophobic inner 
C12 spacer extended by an outer hydrophilic tetra-ethylene glycol (teEG) arm. These BTA based 
monomers can self-assemble into micrometer long fibers in aqueous solutions due to hydrogen 
bond formation between the amides and hydrophobic effects of the amphipathic arms.12,13 In 
addition, polymerization of functionalized monomers allows for the introduction of additional 
functionality on the surface of the fibers (e.g., fluorophores).14 Combining different monomers 
would in principle allow for an infinite number of different polymers and materials. Such a feature 
could be useful for screening different combinations of adjuvants and antigens in the search for 
the most optimal vaccine formulation. However, a major drawback of this approach is that most 
of these monomer building blocks rely on poly(ethylene glycol) (PEG) moieties for their water 
solubility. This large number of PEG moieties on the surface of the fibers could induce immune 
responses against PEG, which would limit their in vivo application,15–17 especially in combination 
with immuno-stimulating adjuvants. Previous work by Leenders et al.18 successfully incorporated 
glycosides on BTA based scaffolds using click chemistry of propargyl glycosides with azido 
functionalized teEG BTA monomers (211) to obtain glycosylated BTAs (212, Figure 1). This 
chapter describes different synthetic routes toward new BTA based monomeric building blocks 
(213-218), in which glycosides are used instead of tetra-ethylene glycol to form more “natural” 
BTA based fibers. By the incorporation of different glycosides, their effect on the behavior of the 
fibers can be assessed. The results of the self-assembly ability of the mannose, glucose, and 
cellobiose BTA monomers (213, 214, and 215) in comparison with the previously reported tetra-
ethylene-glycol functionalized BTA monomer (210) are also presented. Finally, this chapter 
describes the synthesis of a glucoside based BTA in which one glucose residue is provided with an 
azide handle for the introduction of future functionalities (218).  
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Figure 1: BTA based monomers. 
 
Results and discussion 
The synthesis of the target glycosylated BTA cores comprises glycosylations and amide bond 
formations, the sequence of which can be reversed leading to two strategies (Scheme 1). Route A 
starts with glycosylation of a masked amino-dodecan-1-ol spacer, that after deprotection would 
result in an amine-functionalized glycoside which could be coupled with acyl chloride 219 or other 
BTA activated esters. The second route, route B, entails coupling of an amino-dodecan-1-ol spacer 
and BTA acyl chloride, subsequent glycosylation of the produced triol 220, and finally, global 
deprotection. Route A would allow for the intermediate purification of the individual glycosides, 
which should be more straightforward compared with the purification of three coupled glycosides. 
The benefit of route B would be that incomplete amide formation for 220 would not waste more 
(synthetically) costly glycosides as could happen in route A. Both routes were evaluated to reveal 
the most suitable option (Scheme 1).  
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Scheme 1: Retrosynthesis of BTA-core-monomers. 
 
 
Monosaccharides ᴅ-mannose and ᴅ-glucose and disaccharides cellobiose, lactose, and maltose 
were selected to functionalize the BTA cores. All donors should be equipped with a participating 
protecting group on their 2-O position to achieve 1,2-trans-selective glycosylations. The benzoyl 
(Bz) protecting group is preferred over the acetyl (Ac) to minimize unwanted ortho-ester 
formation and potential acyl migration. The trichloroacetimidate method was chosen as the 
glycosylation procedure, and all trichloroacetimidoyl donors were synthesized from the starting 
carbohydrates by successive per-benzoylation, anomeric debenzoylation with hydrazine acetate 
and finally trichloroacetimidate introduction. This approach resulted in mannose donor 221, 
glucose donor 222, cellobiose donor 223, lactose donor 224, and maltose donor 225. Thiophenyl 
maltoside 226 was also synthesized, as an alternative for the imidate donor 225. Finally, the 6-azido 
glucoside donor 228 was synthesized using standard protecting and functional group 
manipulations, as previously reported,19 for further functionalization of the BTA core. 
CHAPTER 6 
149 
Scheme 2: Synthesis of the glycosyl donors. 
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Reagents and conditions: a) i. BzCl, pyridine; ii. H2NNH2·OAc, DMF; iii. K2CO3, CCl3CN, DCM, (references: 221 20; 222 21; 
223 22; 224 23; 225 22); b) reference19; c) i. NIS, TFA, DCM; ii. K2CO3, CCl3CN, DCM, 70%; d) i. BzCl, pyridine; ii. PhSH, 
BF3·OEt2, DCM, 28%. 
With these seven donors at hand, both glyco-BTA assembly routes were explored. The acceptors, 
12-N-phthalimide-dodeca-1-ol (229), and the azido analog 12-azido-dodeca-1-ol (230) were 
synthesized according to published procedures.24,25 As part of route A, the glycosylation efficiency 
was tested using both thio and imidate maltose donors 226 and 225 and both linkers 229 and 230 
(Table 1 and Scheme 3). Glycosylation of thio donor 226 and the phthalimide (Phth) linker 229 
was met with poor conversion (Table 1, entry 1). Increasing the temperature, reaction time, 
equivalents of the acceptor, and concentration of the donor 226 improved the yield (entry 2). 
Coupling of imidate donor 225 with 229 at 0 °C resulted in the formation of the spacer equipped 
maltose in 51% yield (entry 3). Additional experiments demonstrated poor solubility of the 
phthalimide linker (229) at lower temperatures, but decreasing the concentration of the donor and 
using fewer equivalents of acceptor improved the yield to 99% (entry 4). Applying these conditions 
for the condensation of 225 with the azido acceptor 230 gave the same yield (entry 5).  
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Table 1: Glycosylations with dodecanol spacers. 
Entry Donor Acceptor Ratio [Donor] Activation (eq.) T time yield 
1 226 229 1/1.2 0.1 M NIS (1.3), TfOH (0.3) 0°C 3h 25% 
2 226 229 1/2 0.2 M NIS (1.3), TfOH (0.3) 4°C 48h 55% 
3 225 229 1/2 0.1 M TMSOTf (0.2) 0°Ca 4h 51% 
4 225 229 1/1.2 0.05 M TMSOTf (0.2) 4°C 14h 99% 
5 225 230 1/1.2 0.05 M TMSOTf (0.2) 4°C 14h 99% 
 
Scheme 3: Glycosylations with dodecanol spacers. 
 
Reagents and conditions: a) 230, TMSOTf, DCM (232: 99%; 234: 85%; 236: 61%; 238: 67%); b) i. NaOMe, MeOH/DCM; 
ii. PtO, H2, dioxane, t-BuOH, H2O (233: 48%; 235: 93%; 237: 88%; 239: 46%); c) ethylene-1,2-diamine, EtOH, inseparable 
mixture of products. 
 
 
a With lower temperatures than -10°C the reaction mixture crashes out and form a white solid. 
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Unfortunately, the simultaneous deprotection of all benzoyls and the phthalimide from 231 was 
not successful. A complex mixture resulted after refluxing the substrate in ethanol for ten days in 
the presence of ethyl diamine, and the product could not be isolated (Scheme 3). On the other 
hand, removal of the benzoyl groups of azido maltoside 232 was successful. Subsequent reduction 
of the azide was hindered since 232 formed micelles that shielded the azide from the aqueous 
phase. This micelle formation was due to the amphiphilic properties of the starting material, 
originating from the highly hydrophilic maltose residue and the hydrophobic C12-azide spacer. 
Therefore the hydrogenation of the azide was performed in a solvent mixture of t-BuOH/H2O 
with ultrasound irradiation and this protocol delivered the target amine 233 in 48% yield (Scheme 
3). Following this approach, azide linker 230 was also condensed with cellobiose imidate donor 
223, lactose imidate 224, and glucose imidate 222 to result in cellobioside 234, lactoside 236, and 
glucoside 238 in 85%, 61%, and 67% respectively. Benzoyl removal, followed by hydrogenation 
with the optimized conditions, proceeded uneventfully, resulting in cellobioside 235, lactoside 237, 
and glucoside 239 in 93%, 88%, and 46%, respectively (Scheme 3).  
In the next phase of route A, the coupling of the amine-functionalized glycosides with benzene 
triacylchloride 219 was undertaken. (Scheme 4A). Unfortunately, the poor solubility of the reaction 
partners resulted in incomplete couplings, and purification of the target trifunctional BTAs could 
not be achieved at this stage. Therefore, route A was abandoned, and attention was directed to 
route B by condensing benzene triol 220 with glucose donor 222 or cellobiose donor 223 (Scheme 
4B). Condensation of acceptor 220 and donors 222 or 223 resulted in a poor coupling efficiency 
because of poor solubility of the BTA-triol. The use of a large volume of dichloromethane did not 
improve the solubility of 220, which proved to be insoluble in other solvents that are commonly 
used in glycosylations. It appeared that 220 was too polar, necessitating the use of a highly polar 
solvent. Eventually it was found that a homogenous reaction mixture could be obtained using a 
solvent mixture of DCM and 1,1,1,3,3,3-hexafluoroisopropanol (HFIP), a combination previously 
described to dissolve poorly soluble peptides.26 HFIP is a weak nucleophile which could potentially 
compete with triol 220 for activated donor, but a test glycosylation in which donor 222 was 
activated in HFIP/DCM (1/4, v/v) did not result in a significant amount the HFIP condensation 
product. De et al.27 have previously described the use of HFIP as a solvent for the synthesis of 
2,3-unsaturated glucosides from an acetyl glucal, and in this synthesis, the condensation of HFIP 
was observed. The difference in reactivity between both systems can be explained by the more 
reactive glucal used by De et al. and the reluctance of dioxolenium ions to react with poor 
nucleophiles.  
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Scheme 4: Attempts toward glycosylated BTA monomers. 
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Donors 222, 221, 223, 224, and 225 were coupled with triol 220 in DCM/HFIP resulting in the 
protected mannoside 240, glucoside 241, cellobioside 242, lactoside 243, and maltoside 244 in 78%, 
92%, 50%, 98%, and 70% yield, respectively (Scheme 5). Unfortunately, in the glycosylations of 
glucose 241 and cellobiose 242, (partial) benzoyl migration to one of the hydroxyls of the BTA 
acceptor was observed. The polarity of these side products was quite similar to the polarity of the 
target compounds, and the products could therefore not be purified at this stage. Therefore, the 
benzoyl groups in glucoside 241 were removed with sodium methanolate, and LC-MS analysis of 
the obtained crude mixture showed a difference in retention between product 214 and the side 
product having two glucosides. Purification via RP-HPLC gave pure 214 in 41% yield. The 
unwanted transesterification of the benzoyls was averted using fewer equivalents of TfOH in the 
glycosylation reaction, but as a consequence, ortho-esters were formed. Eventually, the use of 0.5 
equivalents of TfOH per triol 220 gave the most favorable ratio of product versus side-products 
for all donors. Coupling of the more reactive mannose donor 221 with 220 was completed in the 
shortest reaction time of all used donors. After removal of the benzoyl in 240, LC-MS analysis 
indicated that the mannosylation was not accompanied by benzoyl migration, and mannoside 213 
was isolated in 48% yield. All other BTA-glycosides were subjected to similar benzoyl removal 
conditions as described for glucose-BTA 214 and purification via RP-HPLC delivered cellobioside 
215, lactoside 216, and maltoside 217 in 19%, 13%, and 27% yield, respectively.  
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Scheme 5: Glycosylation with BTA core. 
 
Reagents and conditions: a) 220, TfOH, DCM, HFIP (240: 92%; 241: 78%; 242: 50%; 243: 98%; 244: 70%); b) NaOMe, 
MeOH, t-BuOH, dioxane (213: 48%; 214: 41%; 215: 19%; 216: 13%; 217: 27%). 
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The self-assembly of the glucose, mannose, and cellobiose BTA monomers (213, 214, and 215) 
were assessed and compared with the previously reported tetra-ethylene-glycol functionalized BTA 
monomer (210, see Figure 1). In short, aqueous solutions of the constructs were investigated using 
UV spectroscopy, circular dichroism (CD) spectroscopy, static light scattering (SLS), cryogenic 
transmission electron microscopy (cryo-TEM) and hydrogen/deuterium exchange mass 
spectrometry (HDX-MS).1 These results are summarized in Figure 2 and Figure 3 and show that 
both the mannose (213) and glucose (214) can assemble in supramolecular fibers (two absorption 
maxima at 211 and 225 nm, characteristic of fibrous structures, Figure 2A). Cellobiose 215 was 
only able to form fibers when co-assembled with the ethylene glycol 210), since assembly of solely 
215 generated small micellar aggregates (one maximum at 196 nm, Figure 2A, 2B). Unlike the 
fibers formed from the teEG BTA 210, the fibers formed with 213 and 214 assembled with a 
preference in helicity. CD spectroscopy indicated a biphasic Cotton effect for glucose 214 and a 
mirror image biphasic Cotton effect for mannose 213 (Figure 2C). Surprisingly, co-assembly of 
210 with cellobiose 215 (glucose-β1,4-glucose) displayed a mirror image biphasic Cotton effect 
opposite of 214 (β-glucose, Figure 2D). Micrometers long fibers for 214 and 213 with a diameter 
between 5 and 10 nm were observed using cryogenic transmission electron microscopy (cryo-
TEM, see Figure 3). Cellobiose 215 assembled into small micelles of approximately 5 nm.  
Figure 2: UV and CD spectra of assembled BTA monomers.  
 
A) UV spectra of 213, 214 and 215. 213 and 214 show the typical BTA maxima at 211 and 225 nm, whereas 215 show maxima at 
196 nm; B) UV spectra of 215 co assembled with 210 in different ratios; C) CD spectra of 214, 213 and 215. 213 and 214 show a 
biphasic positive and negative mirror Cotton effect, whereas 215 is CD silent; D) CD spectra of 215 co-assembled with 210 in different 
ratios. 
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Figure 3: Cryo-TEM of fibers. 
 
Cryo-TEM of A) 214; B) 213 and; C) 215; Micrometers long fibrous structures were observed for 213 and 214 while micellar structures 
for 215. Scale bars indicate 50 nm. Used concentrations of BTA = 250 or 500 μM. 
The result of the self-assembly study was an incentive to investigate the synthesis of an azido 
functionalized glucose-BTA monomer. The target structure contains two glucoses and a single 6-
azido-6-deoxy glucose moiety (218, Scheme 6). First attempts towards the target molecule were 
directed at the functionalization of the BTA-triol with a single 6-azido glucoside or a double 
glycosylation with glucose donor 222 with triol 220 (Route A and B, Scheme 6). However, both 
condensations resulted in a complex mixture of various products, differing in glycosylation degree. 
The mixture of the glycosylation with azido donor 228 contained acceptor 220, the expected 
product 245, and the double coupled side product. For the glycosylation with glucose donor 222 
not only the product 246 was obtained, but also single and triple coupled side products. In addition, 
ortho-esters were formed, or benzoyl migration to acceptor 220 occurred. Besides, the purification 
was hindered by the poor solubility of 220 in common eluents and the similar polarity of the 
product, ortho-ester, and benzoylated BTA side products. The ortho-ester formation and the 
benzoyl migration could be partially suppressed by adjusting the amount of activator, but these 
side reactions could never be completely prevented. Together these side reactions hindered the 
isolation of the relevant intermediates in sufficient yields. However, a test glycosylation using 
starting material 245 that was partly purified delivered 247, in a mixture of compounds. 
Debenzoylation of this mixture of compounds provided a mixture that was analyzed by LC-MS to 
show a distinct peak for the desired product. Therefore, a one-pot procedure was performed, 
comprising of an initial glycosylation of acceptor 220 with one equivalent of azido glucose donor 
228, after which two equivalents of donor 222 were added (Route C, Scheme 6). Purification by 
size exclusion gave a mixture of compounds, of which the BTA arms were functionalized with 
either benzoyl, glucose or 6-azido-6-deoxy glucose. NMR analysis of this mixture indicated the 
presence of 0.3 eq. of migrated benzoyl groups, 1.6 eq. of the glucose appendage, and 1.1 eq of 
azido glucose per BTA core. After benzoyl removal with NaOMe, LC-MS analysis showed not 
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only the presence of triple glycosylated BTA compounds such as product 218, tri-glucose 214, 
double azido glucose and another glucose (248) but also BTA compounds originating from 
benzoyl migration, bearing two glycosides (249 and 250). The five BTA products, 
218/214/248/249/250, were formed in an approximate 3/2/2/1/1 ratio as indicated by LC-MS 
analysis. RP-HPLC purification resulted in the isolation of both target 218 and 214 in 9% and 13% 
yield, respectively. With the recovery of the side products, this methodology can produce the target 
molecule and other relevant functionalized BTA monomers in a short amount of time. Further 
assessment of the effect of the azide on the self-assembly is under evaluation. 
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Scheme 6: Synthesis of azido functionalized BTA monomer 218. 
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Reagents and conditions: a) 220, TfOH, DCM, HFIP; b) 222, TfOH, DCM; c) 220, TfOH, DCM, HFIP; d) 228, TfOH, 
DCM; e) 220, TfOH, DCM, HFIP, then 222 (qnt.a); f) NaOMe, MeOH (218: 9%; 214: 13%). 
  
 
a As a mixture of products 
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Conclusion 
The synthesis of benzene-1,3,5-tricarboxyamide (BTA) monomers functionalized with various 
glycosides has been reported. Two different synthetic approaches have been assessed, both of 
which were hampered by solubility issues. The first approach in which glycosides containing 
amino-dodecyl spacer were condensed with activated BTA cores proved to be unsuccessful. The 
second approach in which imidate donors were coupled with a BTA-triol, provided with an amino-
dodecyl spacer was successful when an unusual solvent mixture, composed of 1,1,1,3,3,3-
hexafluoroisopropanol and DCM, was used to dissolve the acceptor. Most glycosylations also 
suffered from the competition of side reactions such as ortho-ester formation and benzoyl 
migration. The formation of the side products could not be completely avoided, but the pure target 
BTA monomers were isolated after removal of the benzoyl protecting groups and RP-HPLC 
purification. Using this methodology, BTA monomers bearing glucose, mannose, cellobiose, 
lactose, and maltose were synthesized. The first three have been tested for their ability to self-
assemble. The cellobiose BTA showed micelle aggregates and could only assemble in fibers when 
co-assembled with other monomers. Both the mannose and glucose constructs were able to self-
assemble in 2D fibers. Notably, the sugar residues induced the formation of fibers of opposite 
helicity. Furthermore, the synthesis of a BTA monomer, bearing two glucose and one 6-azido-6-
deoxy-glucose residue, is described. Different approaches were evaluated, and eventually, a one-
pot glycosylation procedure led to the isolation of the target BTA monomer. Further co-assembly 
studies of the obtained BTA monomers could shed light on the dynamics of glycosylated fibers 
and could be the start to obtain bio-compatible self-assembling fibers. 
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Experimental 
General procedures: 
All reactions, purifications, and analyses were performed as described in the general procedures of 
Chapter 2. 
General procedure for generation of perbenzylated trichloro imidate donors: 
Per-benzoylated donors were dissolved in DMF (0.2 M) and hydrazine acetate (2 eq) was added at 0°C in 
portions after which the reaction mixture was stirred at 0°C until the starting material was consumed (2-6 
h). After this, the reaction mixture was diluted in Et2O and washed with HCl (1 M, aq., 3x), NaHCO3 (sat. 
aq., 2x) and brine after which the organic layer was dried over MgSO4 (s), filtered, concentrated and when 
necessary purified by silica gel column chromatography (Et2O/PE). The hemi-acetals were re-dissolved in 
DCM (0.2 M) and K2CO3 (4 eq) and trichloro acetonitrile (3 eq) were added at 0°C and the mixture was 
stirred at rt until starting material was consumed (4-16 h). After filtration over Celite, imidate donors were 
purified by silica gel column chromatography (Et2O/PE) and stored under N2 at -20°C. 
2,3,4,6-Tetra-O-benzoyl-1-O-(N-trichloroacetimidoyl)-α/β-ᴅ-mannopyranoside (221). 
Spectral data as described in previous literature.20  
 
2,3,4,6-Tetra-O-benzoyl-1-O-(N-trichloroacetimidoyl)-α/β-ᴅ-glucopyranoside (222). 
Spectral data as described in previous literature.21  
 
4-O-(2,3,4,6-tetra-O-benzoyl-β-ᴅ-glucopyranosyl)-2,3,6-tri-O-benzoyl-1-O-(N-
trichloroacetimidoyl)-α/β-ᴅ-glucopyranoside (223). 
Spectral data as described in previous literature.22 
 
4-O-(2,3,4,6-tetra-O-benzoyl-β-ᴅ-galactopyranosyl)-2,3,6-tri-O-benzoyl-1-O-(N-
trichloroacetimidoyl)-α/β-ᴅ-glucopyranoside (224). 
Spectral data as described in previous literature.23 
 
4-O-(2,3,4,6-tetra-O-benzoyl-α-ᴅ-glucopyranosyl)-2,3,6-tri-O-benzoyl-1-O-(N-
trichloroacetimidoyl)-α/β-ᴅ-glucopyranoside (225). 
Spectral data as described in previous literature.22 
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Phenyl 4-O-(2,3,4,6-tetra-O-benzoyl-α-ᴅ-glucopyranosyl)-2,3,6-tri-O-benzoyl-1-thio-β-ᴅ-
glucopyranoside (226). 
Per-benzoylated lactose (5.27 g, 4.49 mmol) was co-evaporated with toluene (2x) and 
dissolved in anhydrous DCM (5 mL, 0.9 M) under N2. The solution was cooled to 0°C 
and thiophenol (0.46 mL, 4.45 mmol, 0.99 eq) and BF3·OEt2 (1.11 mL, 9 mmol, 2eq) were added dropwise. 
After overnight stirring, the reaction mixture was quenched with Et3N, diluted in DCM, washed with 
NaOH (1 M, aq. 3x) after which the organic layer was dried over MgSO4 (s) filtered and concentrated in 
vacuo. Purification using silica gel column chromatography (1/8, → 1/1, Et2O/PE, v/v) yielded compound 
226 as a white foam (1.44 g, 1.24 mmol, 28%). TLC Rf: 0.35 (3/2, Et2O/PE, v/v); IR (neat, cm−1): 1734, 
1717, 1506, 1264, 1090, 1067, 1026, 705; 1H NMR (400 MHz, CDCl3) δ 8.14 (dd, J = 8.3, 1.2 Hz, 2H, 
Harom), 8.08 - 8.03 (m, 2H, Harom), 7.96 - 7.87 (m, 4H, Harom), 7.78 (ddd, J = 8.4, 3.5, 1.2 Hz, 4H, Harom), 7.69 
- 7.63 (m, 3H, Harom), 7.58 - 7.13 (m, 25H, Harom), 6.13 (t, J = 10.1 Hz, 1H, H-3′), 5.86 (t, J = 9.2 Hz, 1H, 
H-3), 5.78 (d, J = 3.9 Hz, 1H, H-2), 5.71 (t, J = 9.8 Hz, 1H, H-4′), 5.37 - 5.28 (m, 2H, H-2, H-2′), 5.12 - 
5.03 (m, 2H, H-6a′, H-1), 4.79 (dd, J = 12.1, 4.7 Hz, 1H, H-6b′), 4.55 - 4.45 (m, 3H, H-4, H-5′, H-6a), 4.38 
- 4.31 (m, 1H, H-6b), 4.20 (ddd, J = 9.5, 4.6, 2.2 Hz, 1H, H-5); 13C NMR (101 MHz, CDCl3) δ 166.2, 165.9, 
165.7, 165.5, 165.2, 165.1, 165.1 (C=O), 133.6, 133.5, 133.5, 133.3, 133.3, 133.2, 133.2, 132.1 (CHarom), 131.4 
(Cq), 130.0, 130.0, 129.9, 129.9, 129.8, 129.7 (CHarom), 129.6, 129.5, 129.5, 129.2, 129.1, 128.9 (Cq), 128.9, 
128.8, 128.7, 128.6, 128.5, 128.5, 128.4, 128.4, 128.3, 128.2 (CHarom), 96.5 (C-1′), 85.7 (C-1), 76.9 (C-5), 76.3 
(C-3), 73.0 (C-4/C-5′), 70.9 (C-2, C-2′), 69.9 (C-3′), 69.3, 69.2 (C-4′, C-4/C-5′), 63.6 (C-6′), 62.6 (C-6); HRMS 
[C67H54O17S + NH4]+: 1180.34275 found, 1180.34200 calculated. 
Phenyl 6-azido-2,3,4,-tri-O-benzoyl-6-deoxy-1-thio-β-ᴅ-mannopyranoside (227). 
Synthesis and spectral data as described in previous literature.19  
 
6-Azido-2,3,4,-tri-O-benzoyl-6-deoxy-α/β-ᴅ-mannopyranoside (251). 
Thioglycoside 227 (3.34 g, 5.50 mmol) was dissolved in DCM (55 mL, 0.1 M) and cooled to 
0˚C, N-Iodosuccinimide (1.37 g, 6.05 mmol, 1.1 eq) and TFA (0.50 mL, 6.05 mmol, 1.1 eq) 
were added and the mixture was stirred for 1.5 h. The reaction mixture was quenched with Na2S2O3 (sat. 
aq.) and NaHCO3 (sat. aq.) and stirred for an extra hour after which the mixture was extracted with EtOAc. 
The organic layer was washed with brine (2x), dried over MgSO4 (s) filtered and concentrated in vacuo. 
Purification using silica gel column chromatography (3/7, → 1/1, Et2O/PE, v/v) yielded compound 251 
as a colorless oil (2.31 g, 4.46 mmol, 81%, α/β ratio = 4/1). TLC Rf: 0.29 (1/4, EtOAc/PE, v/v); IR (neat, 
cm−1): 3019, 2106, 1728, 1602, 1452, 1263, 1214; 1H NMR (400 MHz, CDCl3) δ 8.01 - 7.81 (m, 6H, Harom), 
7.56 - 7.23 (m, 9H, Harom), 6.23 (t, J = 9.9 Hz, 1H, H-3), 5.79 (d, J = 3.6 Hz, 1H, H-1), 5.55 (t, J = 9.8, 1.6 
Hz, 1H, H-4), 5.31 (dd, J = 10.2, 3.6 Hz, 1H, H-2), 4.54 - 4.47 (m, 1H, H-5), 3.53 - 3.40 (m, 2H, H-6); 13C 
NMR (101 MHz, CDCl3) δ 166.0, 166.0, 165.6 (C=O), 133.7, 133.6, 133.3, 130.1, 130.0, 130.0, 130.0, 129.8, 
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129.8 (CHarom), 129.1, 129.0, 128.7, 128.6 (Cq), 128.6, 128.6, 128.5, 128.4 (CHarom), 90.4 (C-1), 72.3 (C-2), 
70.1, 70.0 (C-3, C-4), 69.0 (C-5), 51.3 (C-6); HRMS [C27H23N3O8 + Na]+: 540.1387 found, 540.13774 
calculated. 
6-Azido-2,3,4,-tri-O-benzoyl-6-deoxy-1-O-(N-trichloroacetimidoyl)-α/β-ᴅ-mannopyranoside 
(228). 
Hemiacetal 251 (1.55 g, 3.00 mmol) was dissolved in DCM (15 mL, 0.2 M), cooled to 0°C 
and trichloroacetonitrile (0.90 mL, 9.0 mmol; 3 eq) and K2CO3 (1.66 g, 12.0 mmol; 4 eq) 
were added successfully. After stirring overnight, the reaction mixture was filtered over Celite and 
concentrated in vacuo. Purification using silica gel column chromatography (2/8, → 1/1, Et2O/PE, v/v) 
yielded compound 228 as a yellow oil (1.71 g, 2.58 mmol, 86%). TLC Rf: 0.73 (1/4, EtOAc/PE, v/v); IR 
(neat, cm−1): 3345, 3019, 2106, 1731, 1677, 1602, 1452, 1262, 1091, 1068; 1H NMR (400 MHz, CDCl3) δ 
8.72 (s, 1H, NH), 8.00 - 7.94 (m, 4H, Harom), 7.89 - 7.85 (m, 2H, Harom), 7.54 - 7.42 (m, 2H, Harom), 7.42 - 
7.29 (m, 6H, Harom), 7.25 (t, J = 7.8 Hz, 2H, Harom), 6.89 (d, J = 3.6 Hz, 1H, H-1), 6.28 (t, J = 9.9 Hz, 1H, 
H-3), 5.72 (t, J = 9.9 Hz, 1H, H-4), 5.64 (dd, J = 10.2, 3.7 Hz, 1H, H-2), 4.54 - 4.45 (m, 1H, H-5), 3.56 - 
3.46 (m, 2H, H-6); 13C NMR (101 MHz, CDCl3) δ 165.6, 165.3, 165.2 (C=O), 160.3 (C=N), 133.7, 133.6, 
133.3, 129.9, 129.9, 129.7 (CHarom), 128.8 (Cq), 128.5, 128.4, 128.3 (CHarom), 92.9 (C-1), 71.9 (C-2), 70.6 (C-
5), 69.9 (C-3), 69.2 (C-4), 50.7 (C-6); HRMS [C29H23Cl3N4O8 + Na]+: 685.0465 found, 685.04442 calculated. 
N1, N3, N5-Tris(dodecan-12-ol)-benzene-1,3,5-tricarboxamide (220). 
To a co-evaporated solution of benzene-1,3,5-tricarbonyl trichloride (0.535 g, 2.04 mmol, 1 
eq) in anhydrous DCM (20 mL, 0.1 M) at 0°C under N2, was added dropwise (>4 h) a co-
evaporated solution of 12-amino-dodecan-1-ol (1.32 g, 6.56 mmol, 3.3 eq) and Et3N (0.94 
mL, 6.73 mmol, 3.3 eq) in anhydrous DCM (33 mL, 0.2 M). The mixture was stirred overnight after which 
the mixture was absorbed on silica and purified using silica gel column chromatography (1/19, 
MeOH/CHCl3, v/v) yielded compound 220 as a white solid (1.09 g, 1.44 mmol, 71%). TLC Rf: 0.73 (1/9, 
MeOH/CHCl3, v/v); IR (neat, cm−1): 3266, 2916, 1629, 1541, 1466, 1293, 1056; 1H NMR (400 MHz, 
MeOD) δ 8.34 (s, 3H, BTA-Harom), 3.51 (t, J = 6.6 Hz, 6H, CH2-O), 3.37 (t, J = 7.1 Hz, 6H, CH2-N), 1.66 
- 1.55 (m, 6H, CH2), 1.55 - 1.44 (m, 6H, CH2), 1.44 - 1.23 (m, 48H, CH2); 13C NMR (101 MHz, MeOD) δ 
168.7 (C=O), 136.9 (Cq), 129.7 (CHarom), 63.0 (CH2-O), 41.2 (CH2-N), 33.7, 30.8, 30.7, 30.7, 30.6, 30.5, 30.5, 
28.1, 27.0 (CH2); HRMS [C45H81N3O6 + H]+: 760.6223 found, 760.61981 calculated. 
12-N-Phthalimido-dodecan-1-ol (229). 
Synthesis and spectral data as described in previous literature.24  
12-azido-dodecan-1-ol (230). 
Synthesis and spectral data as described in previous literature.25  
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12-N-Phthalimido-dodecyl 4-O-(2,3,4,6-tetra-O-benzoyl-α-ᴅ-glucopyranosyl)-2,3,6-tri-O-
benzoyl-β-ᴅ-glucopyranoside (231). 
Acceptor 230 (38 mg, 0.11 mmol, 1.2eq) and donor 225 (116 mg, 95 µmol, 1eq) were 
combined and co-evaporated with toluene (3x) under N2 atmosphere, dissolved in 
anhydrous DCM (1.9 mL, 0.05 M) and stirred with activated molecular sieves (3Å) for 30 min. The reaction 
mixture was cooled to 0 ˚C, TMSOTf (3.4 µL, 19 µmol, 0.2eq) was added dropwise and the mixture was 
stirred at 4 ˚C overnight. The reaction was quenched with Et3N (0.1 mL), diluted in DCM, washed with 
NaHCO3 (sat aq. 1x), dried over MgSO4 (s), filtered and concentrated in vacuo. Purification using size 
exclusion (Sephadex LH20, 1/1, MeOH/DCM, v/v) yielded compound 231 as a white solid (130 mg, 94 
µmol, 99%). TLC Rf: 0.31 (3/2, Et2O/PE, v/v); IR (neat, cm−1): 1709, 1264, 1090, 1067, 1024, 705; 1H 
NMR (400 MHz, CDCl3) δ 8.14 - 8.07 (m, 2H, Harom), 8.02 - 7.96 (m, 2H, Harom), 7.91 - 7.80 (m, 6H, Harom), 
7.78 - 7.62 (m, 8H, Harom), 7.60 - 7.27 (m, 18H, Harom), 7.25 - 7.16 (m, 4H, Harom), 6.09 (t, J = 10.0 Hz, 1H, 
H-3′), 5.80 - 5.72 (m, 2H, H-3, H-1′), 5.65 (t, J = 9.8 Hz, 1H, H-4′), 5.31 (dd, J = 9.5, 7.6 Hz, 1H, H-2), 5.25 
(dd, J = 10.5, 3.9 Hz, 1H, H-2′), 4.91 (dd, J = 12.0, 2.4 Hz, 1H, H-6a′), 4.81 - 4.72 (m, 2H, H-1, H-6b′), 4.55 
- 4.42 (m, 2H, H-4, H-5′), 4.39 (dd, J = 12.3, 3.0 Hz, 1H, H-6a), 4.26 (dd, J = 12.3, 3.8 Hz, 1H, H-6b), 4.13 
- 4.06 (m, 1H, H-5), 3.87 (dt, J = 9.7, 6.2 Hz, 1H, CHH-O), 3.71 - 3.63 (m, 2H, CH2-N), 3.48 (dt, J = 9.6, 
6.7 Hz, 1H, CHH-O), 1.65 (dd, J = 14.3, 7.1 Hz, 2H, CH2), 1.47 (dq, J = 14.9, 6.6 Hz, 2H, CH2), 1.38 - 
1.25 (m, 4H, CH2), 1.21 - 0.93 (m, 12H, CH2); 13C NMR (101 MHz, CDCl3) δ 168.6, 166.3, 166.0, 165.8, 
165.5, 165.3, 165.2 (C=O), 134.0, 133.6, 133.5, 133.4, 133.3, 133.2, 133.1 (CHarom), 132.3 (Cq), 130.1, 130.0, 
129.9, 129.8, 129.7 (CHarom), 129.6, 129.5, 129.4, 129.0, 128.9, 128.8 (Cq), 128.7 (CHarom), 128.6 (Cq), 128.5, 
128.5, 128.3, 128.2, 123.3 (CHarom), 100.9 (C-1), 96.5 (C-1′), 75.1 (C-3), 73.3 (C-4), 72.9 (C5), 72.4 (C-2), 
71.0 (C-2′), 70.3 (CH2-O), 70.0 (C-3), 69.2 (C-5′, C-4′), 63.7 (C-6′), 62.6 (C-6), 38.2 (CH2-N), 29.6, 29.6, 29.5, 
29.5, 29.3, 29.3, 28.7, 27.0, 25.9 (CH2); HRMS [C81H77NO20 + H]+: 1384.51389 found, 1384.51117 
calculated. 
12-Azido-dodecyl 4-O-(2,3,4,6-tetra-O-benzoyl-α-ᴅ-glucopyranosyl)-2,3,6-tri-O-benzoyl-β-ᴅ-
glucopyranoside (232). 
Acceptor 230 (31.3 mg, 0.138 mmol, 1.2eq) and donor 225 (139.3 mg, 0.115 mmol, 
1eq) were combined and co-evaporated with toluene (3x) under N2 atmosphere, 
dissolved in anhydrous DCM (2.29 mL, 0.05 M) and stirred with activated molecular sieves (3Å) for 30 
min. The reaction mixture was cooled to 0 ˚C, a stock solution of TMSOTf in DCM (100 µL, 0.23 M ,23 
µmol, 0.2eq) was added dropwise and the mixture was stirred at 4 ˚C overnight. The reaction was quenched 
with Et3N (0.1 mL), diluted in DCM, washed with NaHCO3 (sat aq. 1x), dried over MgSO4 (s), filtered and 
concentrated in vacuo. Purification using size exclusion (Sephadex LH20, 1/1, MeOH/DCM, v/v) yielded 
compound 232 as a white solid (146 mg, 0.115 mmol, 99%). TLC Rf: 0.67 (3/2, Et2O/PE, v/v); IR (neat, 
cm−1): 2924, 2853, 2094, 1720, 1264, 1092, 1068, 1026, 703; 1H NMR (400 MHz, CDCl3) δ 8.10 (d, J = 7.5 
Hz, 2H, Harom), 7.99 (d, J = 7.4 Hz, 2H, Harom), 7.85 (t, J = 6.7 Hz, 4H, Harom), 7.78 - 7.62 (m, 6H, Harom), 
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7.62 - 7.27 (m, 18H, Harom), 7.24 - 7.15 (m, 4H, Harom), 6.08 (t, J = 10.0 Hz, 1H, H-3′), 5.83 - 5.71 (m, 2H, 
H-3, H-1′), 5.65 (t, J = 9.8 Hz, 1H, H-4′), 5.30 (dd, J = 11.1, 6.0 Hz, 1H, H-2), 5.25 (dd, J = 10.5, 3.8 Hz, 
1H, H-2′), 4.91 (d, J = 10.1 Hz, 1H, H-6a′), 4.79 - 4.68 (m, 2H, H-6b′, H-1), 4.54 - 4.35 (m, 3H, H-4, H-5′, 
H-6a), 4.26 (dd, J = 12.3, 3.6 Hz, 1H, H-6b), 4.13 - 4.03 (m, 1H, H-5), 3.86 (dt, J = 9.7, 6.3 Hz, 1H, CHH-
O), 3.54 - 3.42 (m, 1H, CHH-O), 3.24 (t, J = 7.0 Hz, 2H, CH2-N3), 1.57 (q, J = 7.3 Hz, 2H, CH2), 1.53 - 
1.40 (m, 2H, CH2), 1.40 - 0.95 (m, 16H, CH2); 13C NMR (101 MHz, CDCl3) δ 166.3, 166.0, 165.8, 165.5, 
165.3, 165.2 (C=O), 133.6, 133.5, 133.4, 133.3, 133.2, 133.1, 132.1, 131.7, 130.1, 130.0, 129.9, 129.8, 129.7 
(CHarom), 129.6, 129.5, 129.4, 129.1, 129.0, 128.9(Cq), 128.7 (CHarom), 128.6 (Cq), 128.5, 128.3, 128.2, 128.1, 
127.9, 114.4, 113.9 (CHarom), 100.9 (C-1), 96.5 (C-1′), 75.1 (C-3), 73.3 (C-4), 72.9 (C-5), 72.4 (C-2), 71.0 (C-
2′), 70.3 (CH2-O), 70.0 (C-3′), 69.2 (C-5′, C-4′), 63.7 (C-6′), 62.6 (C-6), 51.6 (CH2-N3), 29.6, 29.5, 29.3, 29.3, 
29.0, 26.8, 25.9 (CH2); HRMS [C73H73N3O18 + NH4]+: 1297.52278 found, 1297.52274 calculated. 
12-Amino-dodecyl 4-O-(α-ᴅ-glucopyranosyl)-β-ᴅ-glucopyranoside (233). 
232 (144 mg, 0.10 mmol) was dissolved in a mixture of MeOH/DCM (0.5 mL, 0.2 M, 
1/1, v/v) and NaOMe (0.010 mL, 5.4 M, 0.05 mmol, 0.5eq) was added dropwise. and 
the mixture was stirred for 2 h after which it was neutralized using Amberlite H+ resin, filtrated and 
concentrated in vacuo. This crude was dissolved in a mixture of H2O/t-BuOH/dioxane (2 mL, 0.05 M, 
1/1/1, v/v/v) and HCl (1 M, 1 drop) was added. The mixture was flushed with N2 gas, and PtO (scoop) 
was added. The mixture was flushed with H2 and was sonicated for 1 h. After which the mixture was filtered 
over a Whatman filter. Purification using size exclusion (Sephadex LH20, 1/9, H2O/MeOH, v/v) yielded 
compound 233 as a white powder after lyophilization (25 mg, 0.048 mmol, 48%). TLC Rf: 0.52 (3/7, NH3 
(aq.)/i-PrOH, v/v); IR (neat, cm−1): 3330, 2921, 2852, 1060, 1027, 992; 1H NMR (400 MHz, DMSO) δ 5.00 
(d, J = 3.8 Hz, 1H, H-1′), 4.14 (d, J = 7.8 Hz, 1H, H-1), 3.79 - 3.16 (m, 12H), 3.06 (t, J = 9.2 Hz, 1H), 3.02 
- 2.95 (m, 1H, H-2, H-3, H-4, H-5, H-6, H-2′, H-3′. H-4′, H-5′, H-6′, CH2-O), 2.57 (t, J = 7.0 Hz, 2H, CH2-
NH2), 1.56 - 1.45 (m, 2H, CH2), 1.36 (dd, J = 13.5, 6.9 Hz, 2H, CH2), 1.24 (s, 6H, CH2); 13C NMR (101 
MHz, DMSO) δ 102.7 (C-1), 100.8 (C-1′), 79.7, 76.5, 75.1, 73.5, 73.3, 73.0, 72.5, 69.9, 68.7 (C-2, C-3, C-4, 
C-5, C-2′, C-3′, C-4′, C-5′), 60.8 (CH2-O), 60.6 (C-6, C-6′), 40.9 (CH2-N), 31.6, 29.3, 29.0, 28.9, 26.3, 25.5 
(CH2); HRMS [C24H47NO11 + H]+: 526.32237 found, 526.32219 calculated. 
12-Azido-dodecyl 4-O-(2,3,4,6-tetra-O-benzoyl-β-ᴅ-glucopyranosyl)-2,3,6-tri-O-benzoyl-β-ᴅ-
glucopyranoside (234). 
Acceptor 230 (1.12 g, 4.90 mmol, 1.1eq) and donor 223 (5.47 g, 4.50 mmol, 1eq) 
were combined and co-evaporated with toluene (3x) under N2 atmosphere, dissolved 
in anhydrous DCM (45 mL, 0.1 M) and stirred with activated molecular sieves (3Å) for 30 min. The reaction 
mixture was cooled to 0 ˚C, TMSOTf (160 µL, 0.9 mmol, 0.2eq) was added dropwise and the mixture was 
stirred at 0 ˚C for 4 h. The reaction was quenched with Et3N (0.1 mL), diluted in DCM, washed with 
NaHCO3 (sat aq. 1x), dried over MgSO4 (s), filtered and concentrated in vacuo. Purification using silica gel 
column chromatography (1/9 → 7/13, Et2O/PE, v/v) yielded compound 234 as a white solid (4.89 g, 3.81 
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mmol, 85%). TLC Rf: 0.38 (3/2, Et2O/PE, v/v); IR (neat, cm−1): 2926, 2096, 1720, 1266, 1093, 1067, 1027, 
704; 1H NMR (400 MHz, CDCl3) δ 8.02 - 7.88 (m, 10H, Harom), 7.79 - 7.71 (m, 4H, Harom), 7.60 - 7.18 (m, 
21H, Harom), 5.78 (t, J = 9.4 Hz, 1H, H-3), 5.72 (t, J = 9.6 Hz, 1H, H-3′), 5.51 (dd, J = 9.8, 8.0 Hz, 1H, H-
2′), 5.44 - 5.33 (m, 2H, H-2, H-4′), 4.92 (d, J = 7.9 Hz, 1H, H-1′), 4.68 - 4.56 (m, 2H, H-1, H-6a), 4.45 (dd, 
J = 12.1, 4.4 Hz, 1H, H-6b), 4.23 (t, J = 9.5 Hz, 1H, H-4), 4.05 (dd, J = 11.8, 2.8 Hz, 1H, H-6a′), 3.84 - 3.75 
(m, 3H, H-5, H-5′, CHH-O), 3.72 (dd, J = 11.8, 5.7 Hz, 1H, H-6b′), 3.44 - 3.35 (m, 1H, CHH-O), 3.25 (t, J 
= 7.0 Hz, 2H, CH2-N3), 1.63 - 1.52 (m, 4H, CH2), 1.50 - 0.92 (m, 16H, CH2); 13C NMR (101 MHz, CDCl3) 
δ 165.9, 165.8, 165.7, 165.6, 165.3, 165.1, 164.9 (C=O), 133.5, 133.4, 133.2, 129.9, 129.9, 129.8 (CHarom), 
129.6, 129.5, 128.8, 128.7 (Cq), 128.6, 128.4, 128.4, 128.4 (CHarom), 101.1, 101.0 (C-1, C-1′), 76.7 (C-4), 73.1, 
72.9 (C-3, C-3′), 72.5 (C-5, C-5′), 72.0 (C-2, C-2′), 70.4 (CH2-O), 69.5 (C-4′), 62.7, 62.6 (C-6, C-6′), 51.6 
(CH2-N3), 29.5, 29.3, 29.0, 26.8, 25.8 (CH2); HRMS [C73H73N3O18 + NH4]+: 1297.52353 found, 1297.52274 
calculated. 
12-Azido-dodecyl 4-O-(β-ᴅ-glucopyranosyl)-β-ᴅ-glucopyranoside (252). 
Compound 234 (3.47 g, 2.70 mmol) was dissolved in a mixture of MeOH/DCM (13.5 
mL, 0.2 M, 1/1, v/v) and NaOMe (0.1 mL, 5.4 M, 0.54 mmol, 0.2eq) was added 
dropwise. and the mixture was stirred for 2 h after which it was neutralized using Amberlite H+ resin, 
filtrated and concentrated in vacuo to yield 252 as a white solid (1.38 g, 2.50 mmol, 93%). TLC Rf: 0.08 (1/9, 
MeOH/DCM, v/v); IR (neat, cm−1): 3421, 2920, 2850, 2094, 1087, 1025, 990; 1H NMR (400 MHz, MeOD) 
δ 4.39 (d, J = 7.8 Hz, 1H, H-1′), 4.26 (d, J = 7.8 Hz, 1H, H-1), 3.90 - 3.81 (m, 4H, H-6′, H-6a, CHH-O), 
3.68 - 3.61 (m, 1H, H-6b), 3.58 - 3.45 (m, 3H, CHH-O, H-3, H-4), 3.41 - 3.15 (m, 8H, H-3′, H-4′, H-5, H-
5′, H-2, H-2′, CH2-N3), 1.58 (dp, J = 14.4, 6.8 Hz, 4H, CH2), 1.42 - 1.25 (m, 16H, CH2); 13C NMR (101 
MHz, MeOD) δ 104.6 (C-1′), 104.2 (C-1), 80.7 (C-4), 78.1, 77.8, 76.4 (C-5, C-5′, C-3′), 76.4 (C-3), 74.9, 
74.8(C-2, C-2′), 71.3 (C-4′), 70.9 (CH2-O), 62.4, 61.8 (C-6, C-6′), 52.4 (CH2-N3), 30.8, 30.7, 30.7, 30.7, 30.6, 
30.6, 30.3, 29.9, 27.8, 27.1 (CH2); HRMS [C24H45N3O11 + NH4]+: 569.33907 found, 569.33923 calculated. 
12-Amino-dodecyl 4-O-(β-ᴅ-glucopyranosyl)-β-ᴅ-glucopyranoside (235). 
Azide 252 (57 mg, 0.10 mmol) was dissolved in a mixture of H2O/t-BuOH/dioxane 
(3 mL, 0.033 M, 1/1/1, v/v/v) and HCl (1 M, 2 drops) was added. The mixture was 
flushed with N2 gas, and PtO (1 scoop) was added. The mixture was flushed with H2 and was sonicated for 
1 h. After which the mixture was filtered over a Whatman filter. Purification using size exclusion (Sephadex 
LH20, 1/9, H2O/MeOH, v/v) yielded compound 235 as a white powder after lyophilization (54 mg, 0.10 
mmol, qnt). TLC Rf: 0.05 (3/7, MeOH/DCM, v/v); IR (neat, cm−1):3421, 3321, 2920, 2851, 2094, 1074, 
1027, 991; 1H NMR (400 MHz, DMSO) δ 7.86 (s, 2H, NH2), 5.26 (d, J = 4.9 Hz, 1H, 2-OH/2′-OH), 5.14 
- 5.02 (m, 3H, 3-OH, 3′-OH, 2-OH/2′-OH), 4.67 (s, 1H, 4′-OH), 4.61 (dt, J = 16.5, 5.7 Hz, 2H, 6-OH, 6′-
OH), 4.25 (d, J = 7.9 Hz, 1H, H-1/H-1′), 4.15 (d, J = 7.9 Hz, 1H, H-1/H-1′), 3.79 - 3.52 (m, 4H, H-6′, H-
6a, CHH-O), 3.46 - 3.32 (m, 2H, CHH-O, H-6b), 3.32 - 3.22 (m, 3H, H-4, H-5, H-5′), 3.21 - 3.11 (m, 2H, 
H-3, H-3′), 3.09 - 3.02 (m, 1H, H-4′), 3.02 - 2.93 (m, 2H, H-2, H-2′), 2.77 - 2.69 (m, 2H, CH2-N), 1.60 - 1.43 
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(m, 4H, CH2), 1.25 (s, 16H, CH2); 13C NMR (101 MHz, DMSO) δ 103.2, 102.5 (C-1, C-1′), 80.6 (C-4), 76.8, 
76.5 (C-3, C-3′), 75.1, 74.8 (C-5, C-5′), 73.3, 73.1 (C-2, C-2′), 70.0 (C-4′), 68.7 (CH2-O), 61.0 (C-6), 60.4 (C-
6′), 38.7 (CH2-N), 29.3, 29.0, 28.9, 28.9, 28.5, 27.0, 25.8, 25.5 (CH2); HRMS [C24H47NO11 + H]+: 526.32220 
found, 526.32219 calculated. 
12-Azido-dodecyl 4-O-(2,3,4,6-tetra-O-benzoyl-β-ᴅ-galactopyranosyl)-2,3,6-tri-O-benzoyl-β-ᴅ-
glucopyranoside (236). 
Acceptor 230 (106 mg, 466 µmol, 1.1eq) and donor 224 (515.0 mg, 424 µmol, 1eq) 
were combined and co-evaporated with toluene (3x) under N2 atmosphere, dissolved 
in anhydrous DCM (4.24 mL, 0.1 M) and stirred with activated molecular sieves (3Å) for 30 min. The 
reaction mixture was cooled to 0 ˚C, TMSOTf (15 µL, 85 µmol, 0.2eq) was added dropwise and the mixture 
was stirred at 0 ˚C for 2 h. The reaction was quenched with Et3N (0.1 mL), diluted in DCM, washed with 
NaHCO3 (sat aq. 1x), dried over MgSO4 (s), filtered and concentrated in vacuo. Purification using silica gel 
column chromatography (1/9 → 7/13, Et2O/PE, v/v) yielded compound 236 as a white foam (328.6 mg, 
257 µmol, 61%). TLC Rf: 0.39 (3/2, Et2O/PE, v/v); IR (neat, cm−1): 2927, 2855, 2095, 1724, 1259, 1090, 
1067, 1026, 705; 1H NMR (400 MHz, CDCl3) δ 8.06 - 7.93 (m, 10H, Harom), 7.90 (d, J = 7.3 Hz, 2H, Harom), 
7.73 (d, J = 7.4 Hz, 2H, Harom), 7.67 - 7.28 (m, 17H, Harom), 7.21 (t, J = 7.8 Hz, 2H, Harom), 7.14 (t, J = 7.7 
Hz, 2H, Harom), 5.80 (t, J = 9.5 Hz, 1H, H-3), 5.76 - 5.67 (m, 2H, H-2′, H-4′), 5.45 (dd, J = 9.7, 8.0 Hz, 1H, 
H-2), 5.36 (dd, J = 10.3, 3.3 Hz, 1H, H-3′), 4.86 (d, J = 7.9 Hz, 1H, H-1′), 4.67 (d, J = 7.9 Hz, 1H, H-1), 
4.60 (dd, J = 11.0, 1.5 Hz, 1H, H-6a), 4.48 (dd, J = 12.1, 4.2 Hz, 1H, H-6b), 4.25 (t, J = 9.5 Hz, 1H, H-4), 
3.92 - 3.78 (m, 3H, H-5′, H-5, CHH-O), 3.78 - 3.64 (m, 2H, H-6′), 3.49 - 3.38 (m, 1H, CHH-O), 3.25 (t, J 
= 7.0 Hz, 2H, CH2-N3), 1.58 (p, J = 7.0 Hz, 2H, CH2), 1.51 - 1.40 (m, 2H, CH2), 1.40 - 0.94 (m, 16H, CH2); 
13C NMR (101 MHz, CDCl3) δ 166.0, 165.7, 165.5, 165.3, 165.3, 164.9 (C=O), 133.7, 133.5, 133.4, 133.3, 
130.1, 129.9, 129.8, 129.8, 129.7 (CHarom), 129.7, 129.5, 129.0, 128.8 (Cq), 128.8, 128.7, 128.7, 128.4, 128.4 
(CHarom), 101.3 (C-1), 101.1 (C-1′), 76.2 (C-4), 73.1, 73.0 (C-3, C-5), 71.9, 71.9 (C-2, C-3′), 71.5 (C-5′), 70.5 
(CH2-O), 70.0, 67.6 (C-2′, C-4′), 62.6 (C-6), 61.2 (C-6′), 51.6 (CH2-N3), 29.6, 29.5, 29.5, 29.3, 29.3, 29.0, 26.8, 
25.8 (CH2); HRMS [C73H73N3O18 + NH4]+: 1297.52439 found, 1297.52274 calculated. 
12-Azido-dodecyl 4-O-(β-ᴅ-galactopyranosyl)-β-ᴅ-glucopyranoside (253). 
Compound 236 (305.7 mg, 0.24 mmol) was dissolved in a mixture of MeOH/DCM 
(1.2 mL, 0.2 M, 1/1, v/v) and NaOMe (0.025 mL, 5.4 M, 0.048 mmol, 0.2eq) was 
added dropwise. and the mixture was stirred for 2 h after which it was neutralized using Amberlite H+ resin, 
filtrated and concentrated in vacuo to yield 253 as a white solid (118.3 mg, 0.21 mmol, 89%). TLC Rf: 0.07 
(1/9, MeOH/DCM, v/v); IR (neat, cm−1): 3650, 3384, 2920, 2850, 2095, 1096, 1061, 770; 1H NMR (400 
MHz, DMSO) δ 4.22 - 4.13 (m, 2H, H-1′, H-1), 3.80 - 3.69 (m, 2H, CHH-O, H-6a), 3.63 - 3.22 (m, 13H, 
H-4, CHH-O, H-6b, H-6′, H-3, H-3′,CH2-N3, H-5, H-5′, H-4′,H-2′), 3.03 - 2.95 (m, 1H, H-2), 1.51 (q, J = 
6.4, 5.8 Hz, 4H, CH2), 1.25 (s, 16H, CH2); 13C NMR (101 MHz, DMSO) δ 103.9 (C-1′), 102.5 (C-1), 80.9, 
75.5, 75.0, 74.8 (C-2′/C-3/C-3′/C-4′/C-5/C-5′), 73.2 (C-2), 73.2, 70.5 (C-2′/C-3/C-3′/C-4′/C-5/C-5′), 68.7 
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(CH2-O), 68.1 (C-4), 60.5, 60.4 (C-6, C-6′), 50.6 (CH2-N3), 29.3, 29.1, 29.0, 29.0, 29.0, 28.6, 28.3, 26.2, 25.5 
(CH2); HRMS [C24H45N3O11 + H]+: 552.31251 found, 552.31269 calculated. 
12-Amino-dodecyl 4-O-(β-ᴅ-galactopyranosyl)-β-ᴅ-glucopyranoside (237). 
Azide 253 (70.5 mg, 0.13 mmol) was dissolved in a mixture of H2O/t-BuOH/dioxane 
(3 mL, 0.033 M, 1/1/1, v/v/v) and HCl (1 M, 2 drops) was added. The mixture was 
flushed with N2 gas, and PtO (scoop) was added. The mixture was flushed with H2 and was sonicated for 
1 h. After which the mixture was filtered over a Whatman filter. Purification using size exclusion (Sephadex 
LH20, 1/9, H2O/MeOH, v/v) yielded compound 237 as a white powder after lyophilization (67.9 mg, 0.13 
mmol, 99%). IR (neat, cm−1): 3381, 3245, 2919, 2850, 1097, 1062, 1020; 1H NMR (400 MHz, DMSO) δ 
7.94 (s, 2H, NH2), 4.22 - 4.18 (m, 1H, H-1′), 4.16 (d, J = 7.8 Hz, 1H, H-1), 3.78 - 3.68 (m, 2H, CHH-O, H-
6a), 3.64 - 3.22 (m, 11H, H-4, CHH-O, H-6b, H-6′, H-3, H-3′, H-5, H-5′, H-4′,H-2′), 2.98 (t, J = 8.1 Hz, 
1H, H-2), 2.80 - 2.68 (m, 2H, CH2-N), 1.58 - 1.44 (m, 4H, CH2), 1.36 - 1.16 (m, 16H, CH2); 13C NMR (101 
MHz, DMSO) δ 103.9 (C-1′), 102.5 (C-1), 80.8, 75.5, 75.0, 74.8, 73.3, 73.2, 70.6(C-2, C-2′, C-3, C-3′, C-4′, 
C-5, C-5′), 68.7 (CH2-O), 68.1 (C-4), 60.5, 60.3 (C-6, C-6′), 38.7 (CH2-N), 29.3, 29.1, 29.0, 29.0, 28.9, 28.6, 
27.0, 25.8, 25.5 (CH2); HRMS [C24H47NO11 + H]+: 526.32191 found, 526.32219 calculated. 
 
12-Azido-dodecyl-2,3,4,6-tetra-O-benzoyl-β-ᴅ-glucopyranoside (238). 
Acceptor 230 (403 mg, 1.77 mmol, 1.5eq) and donor 222 (874 mg, 1.18 mmol, 1eq) were 
combined and co-evaporated with toluene (3x) under N2 atmosphere, dissolved in 
anhydrous DCM (12 mL, 0.1 M) and stirred with activated molecular sieves (3Å) for 30 min. The reaction 
mixture was cooled to 0 ˚C, TMSOTf (43 µL, 236 µmol, 0.2eq) was added dropwise and the mixture was 
stirred at 0 ˚C for 3 h. The reaction was quenched with Et3N (0.1 mL), diluted in DCM, washed with 
NaHCO3 (sat aq. 1x), dried over MgSO4 (s), filtered and concentrated in vacuo. Purification using size 
exclusion (Sephadex LH20, 1/1, MeOH/DCM, v/v) followed by silica gel column chromatography (1/9 
→ 1/4, Et2O/PE, v/v) yielded compound 238 as a clear oil (634 mg, 0.786 mmol, 67%). TLC Rf: 0.39 
(3/2, Et2O/PE, v/v); IR (neat, cm−1): 2926, 2855, 2095, 1724, 1259, 1090, 1067, 1026, 705; 1H NMR (400 
MHz, CDCl3) δ 8.05 - 7.99 (m, 2H, Harom), 7.99 - 7.93 (m, 2H, Harom), 7.93 - 7.87 (m, 2H, Harom), 7.87 - 7.81 
(m, 2H, Harom), 7.57 - 7.27 (m, 12H, Harom), 5.91 (t, J = 9.7 Hz, 1H, H-3), 5.68 (t, J = 9.7 Hz, 1H, H-4), 5.53 
(dd, J = 9.7, 7.9 Hz, 1H, H-2), 4.84 (d, J = 7.9 Hz, 1H, H-1), 4.64 (dd, J = 12.1, 3.3 Hz, 1H, H-6a), 4.51 
(dd, J = 12.1, 5.2 Hz, 1H, H-6b), 4.21 - 4.11 (m, 1H, H-5), 3.92 (dt, J = 9.7, 6.3 Hz, 1H, CHH-O), 3.54 (dt, 
J = 9.6, 6.7 Hz, 1H, CHH-O), 3.25 (t, J = 7.0 Hz, 2H, CH2-N3), 1.54 (dh, J = 30.3, 7.9, 7.4 Hz, 4H, CH2), 
1.40 - 0.99 (m, 16H, CH2); 13C NMR (101 MHz, CDCl3) δ 166.3, 166.0, 165.3, 165.2 (C=O), 133.5, 133.3, 
133.3, 133.2, 129.9, 129.9, 129.9 (CHarom), 129.7, 129.5, 128.9, 128.9 (Cq), 128.5, 128.5, 128.4, 128.4 (CHarom), 
101.4 (C-1), 73.0 (C-3), 72.3 (C-5), 72.0 (C-2), 70.5 (CH2-O), 70.0 (C-4), 63.4 (C-6), 51.6 (CH2-N3), 29.6, 
29.6, 29.6, 29.5, 29.5, 29.3, 29.3, 29.0, 26.8, 25.9 (CH2); HRMS [C46H51N3O10 + Na]+: 828.34680 found, 
828.34667 calculated. 
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12-Azido-dodecyl-β-ᴅ-glucopyranoside (254). 
Glucoside 238 (600 mg, 0.70 mmol) was dissolved in a mixture of MeOH/DCM (3.5 mL, 
0.2 M, 1/1, v/v) and NaOMe (0.025 mL, 5.4 M, 0.14 mmol, 0.2eq) was added dropwise. and 
the mixture was stirred for 2 h after which it was neutralized using Amberlite H+ resin, filtrated and 
concentrated in vacuo. Purification using size exclusion (Sephadex LH20, 1/1, MeOH/DCM, v/v) yielded 
compound 254 as a white solid (150 mg, 0.382 mmol, 55%). TLC Rf: 0.33 (1/9, MeOH/DCM, v/v); IR 
(neat, cm−1): 3380, 3247, 2921, 2850, 2095, 1284, 1254, 1167, 1070, 1034, 994; 1H NMR (400 MHz, MeOD) 
δ 4.22 (d, J = 7.8 Hz, 1H, H-1), 3.92 - 3.80 (m, 2H, CHH-O, H-6a), 3.64 (dd, J = 11.8, 5.1 Hz, 1H, H-6b), 
3.51 (dt, J = 9.3, 6.8 Hz, 1H, CHH-O), 3.36 - 3.18 (m, 5H, CH2-N3, H-3, H-4, H-5), 3.14 (t, J = 8.4 Hz, 
1H, H-2), 1.66 - 1.49 (m, 4H, CH2), 1.43 - 1.22 (m, 16H, CH2); 13C NMR (101 MHz, MeOD) δ 104.3 (C-
1), 78.1 (C-3), 77.9 (C-4/C-5), 75.1 (C-2), 71.6 (C-4/C-5), 70.9 (CH2-O), 62.7 (C-6), 52.4 (CH2-N3), 30.8, 
30.7, 30.7, 30.7, 30.6, 30.3, 29.9, 27.8, 27.1 (CH2); HRMS [C18H35N3O6 + Na]+: 412.24191 found, 412.24181 
calculated.  
12-Amino-dodecyl-β-ᴅ-glucopyranoside (239). 
Glucose 254 (131 mg, 0.34 mmol) was dissolved in a mixture of H2O/t-BuOH/dioxane (6 
mL, 0.05 M, 1/1/1, v/v/v) and HCl (1 M, 2 drops) was added. The mixture was flushed 
with N2 gas, and PtO (1 scoop) was added. The mixture was flushed with H2 and was sonicated for 1 h. 
After which the mixture was filtered over a Whatman filter. Purification using size exclusion (Sephadex 
LH20, 1/9, H2O/MeOH, v/v) yielded compound 239 as a white powder after lyophilization (102 mg, 0.28 
mmol, 83%). TLC Rf: 0.05 (1/9, MeOH/DCM, v/v); IR (neat, cm−1): 3367, 2921, 2852, 1077, 989; 1H 
NMR (400 MHz, DMSO) δ 7.92 (s, 1H, NH), 7.51 - 7.14 (m, 2H, NH), 4.09 (d, J = 7.7 Hz, 1H, H-1), 3.78 
- 3.69 (m, 1H, CHH-O), 3.65 (d, J = 11.4 Hz, 1H, H-6a), 3.47 - 3.35 (m, 2H, H-6b, CHH-O), 3.14 (t, J = 
8.5 Hz, 1H, H-3), 3.10 - 2.99 (m, 2H, H-4, H-5), 2.93 (t, J = 8.3 Hz, 1H, H-2), 2.81 - 2.66 (m, 2H, CH2-N), 
1.59 - 1.43 (m, 4H, CH2), 1.24 (s, 16H, CH2); 13C NMR (101 MHz, DMSO) δ 103.0 (C-1), 76.9 (C-3, C-
4/C-5), 73.7 (C-2), 70.3 (C-4/C-5), 68.8 (CH2-O), 61.3 (C-6), 39.0 (CH2-N), 29.5, 29.2, 29.1, 29.0, 28.8, 
28.3, 27.1, 26.0, 25.8, 24.9 (CH2); HRMS [C18H37NO6 + H]+: 364.26926 found, 364.26936 calculated. 
N1, N3, N5-Tris-(dodecyl-12-O-[2,3,4,6-tetra-O-benzoyl-α-ᴅ-mannopyranosyl])-benzene-1,3,5-
tricarboxamide (240). 
Acceptor 220 (76 mg, 0.10 mmol, 1 eq) and donor 221 (296 mg, 0.40 mmol, 4 eq) were 
combined and co-evaporated with toluene (3x) under N2 atmosphere, dissolved in a 
mixture of anhydrous DCM/HFIP (4 mL, 0.025 M, 4/1, v/v) and stirred with 
activated molecular sieves (3Å) for 30 min. The reaction mixture was cooled to 0 ˚C, TfOH (9 µL, 0.1 
mmol, 1 eq) was added dropwise and the mixture was stirred at 0 ˚C for three hours. The reaction was 
quenched with Et3N (0.1 mL), diluted in DCM, washed with NaHCO3 (sat aq., 3x), dried over MgSO4 (s), 
filtered and concentrated in vacuo. Purification using size exclusion (Sephadex LH20, 1/1, MeOH/DCM, 
v/v) yielded compound 240 as a transparent solid (229 mg, 0.092 mmol, 92%). TLC Rf: 0.72 (Et2O); IR 
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(neat, cm−1): 2942, 2853, 1717, 1560, 1507, 1259, 1066, 1026, 705; 1H NMR (400 MHz, CDCl3) δ 8.34 (s, 
3H, BTA-Harom), 8.12 - 8.01 (m, 12H, Harom), 7.99 - 7.93 (m, 6H, Harom), 7.86 - 7.81 (m, 6H, Harom), 7.63 - 
7.33 (m, 30H, Harom), 7.27 (t, J = 8.2 Hz, 6H, Harom), 6.47 (t, J = 5.6 Hz, 3H, NH), 6.10 (t, J = 10.0 Hz, 3H, 
H-4), 5.93 (dd, J = 10.1, 3.3 Hz, 3H, H-3), 5.70 (dd, J = 3.2, 1.8 Hz, 3H, H-2), 5.09 (d, J = 1.5 Hz, 3H, H-
1), 4.69 (dd, J = 12.0, 2.4 Hz, 3H, H-6a), 4.49 (dd, J = 12.1, 4.5 Hz, 3H, H-6b), 4.45 - 4.38 (m, 3H, H-5), 
3.82 (dt, J = 9.5, 6.8 Hz, 3H, CHH-O), 3.57 (dt, J = 9.5, 6.7 Hz, 3H, CHH-O), 3.44 (q, J = 6.8 Hz, 6H, 
CH2-N), 1.75 - 1.65 (m, 6H, CH2), 1.65 - 1.55 (m, 6H, CH2), 1.45 - 1.23 (m, 48H, CH2); 13C NMR (101 
MHz, CDCl3) δ 166.3, 165.7, 165.6, 165.6, 165.6, 165.6 (C=O), 135.4 (Cq), 133.6, 133.3, 133.2, 130.0, 129.9, 
129.9 (CHarom), 129.5, 129.2, 129.1 (Cq), 128.7, 128.6, 128.4, 128.0 (CHarom), 97.8 (C-1), 70.8 (C-2), 70.3 (C-
3), 68.9 (CH2-O), 68.9 (C-5), 67.1 (C-4), 63.1 (C-6), 40.5 (CH2-N), 29.7, 29.7, 29.7, 29.5, 29.4, 27.1, 26.3 
(CH2); HRMS [C147H159N3O33 + H + NH4]2+: 1257.06660 found, 1257.06502 calculated. 
N1,N3,N5-Tris-(dodecyl-12-O-[2,3,4,6-tetra-O-benzoyl-β-ᴅ-glucopyranosyl])-benzene-1,3,5-
tricarboxamide (241). 
Acceptor 220 (0.99 g, 1.30 mmol, 1 eq) and donor 222 (4.82 g, 6.50 mmol, 5 eq) were 
combined and co-evaporated with toluene (3x) under N2 atmosphere, dissolved in a 
mixture of anhydrous DCM/HFIP (57 mL, 0.023 M, 4/1, v/v) and stirred with 
activated molecular sieves (3Å) for 30 min. The reaction mixture was cooled to 0 ˚C, TfOH (115 µL, 1.3 
mmol, 1 eq) was added dropwise and the mixture was stirred at 4 ˚C overnight. The reaction was quenched 
with Et3N (0.6 mL), diluted in DCM, washed with NaHCO3 (sat aq., 3x), dried over MgSO4 (s), filtered and 
concentrated in vacuo. Purification using size exclusion (Sephadex LH20, 1/1, MeOH/DCM, v/v) and silica 
gel column chromatography (3/7, Et2O/PE, v/v → 100% Et2O) yielded title compound 241 as a white 
solid (2.52 g, 1.01 mmol, 78%). TLC Rf: 0.51 (Et2O); IR (neat, cm−1): 2925, 2853, 1720, 1560, 1260, 1090, 
1067, 1026, 705; 1H NMR (400 MHz, CDCl3) δ 8.37 (s, 3H, BTA-Harom), 8.05 - 7.80 (m, 24H, Harom), 7.57 
- 7.24 (m, 36H, Harom), 6.61 (t, J = 5.3 Hz, 3H, NH), 5.92 (t, J = 9.7 Hz, 3H, H-3), 5.68 (t, J = 9.7 Hz, 3H, 
H-4), 5.53 (dd, J = 9.8, 7.9 Hz, 3H, H-2), 4.85 (d, J = 7.9 Hz, 3H, H-1), 4.64 (dd, J = 12.1, 3.2 Hz, 3H, H-
6a), 4.51 (dd, J = 12.1, 5.2 Hz, 3H, H-6b), 4.21 - 4.13 (m, 3H, H-5), 3.91 (dt, J = 9.7, 6.3 Hz, 3H, CHH-O), 
3.54 (dt, J = 9.7, 6.7 Hz, 3H, CHH-O), 3.43 (q, J = 6.7 Hz, 6H, CH2-N), 1.65 - 1.46 (m, 12H, CH2), 1.40 - 
0.95 (m, 48H, CH2); 13C NMR (101 MHz, CDCl3) δ 166.3, 165.9, 165.8, 165.3, 165.2 (C=O), 135.4 (Cq), 
133.5, 133.3, 133.3, 133.2, 129.9, 129.8 (CHarom), 129.8 (Cq), 129.7 (CHarom), 129.6, 129.4, 128.9, 128.9 (Cq), 
128.5, 128.4, 128.4, 128.4, 128.1 (CHarom), 101.4 (C-1), 73.0 (C-3), 72.2 (C-5), 72.0 (C-2), 70.5 (CH2-O), 69.9 
(C-4), 63.3 (C-6), 40.5 (CH2-N), 29.6, 29.6, 29.6, 29.5, 29.5, 29.5, 29.4, 29.3, 27.1, 25.8 (CH2); HRMS 
[C147H159N3O33 + 2H]2+: 1248.55472 found, 1248.55174 calculated. 
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N1, N3, N5-Tris-(dodecyl-12-O-[4-O-(2,3,4,6-tetra-O-benzoyl-β-ᴅ-glucopyranosyl)-2,3,6-tri-O-
benzoyl-β-ᴅ-glucopyranosyl])-benzene-1,3,5-tricarboxamide (242). 
Acceptor 220 (1.33 g, 1.75 mmol, 1 eq) and donor 223 (10.66 g, 8.77 mmol, 
5 eq) were combined and co-evaporated with toluene (3x) under N2 
atmosphere, dissolved in a mixture of anhydrous DCM/HFIP (76 mL, 0.023 
M, 4/1, v/v) and stirred with activated molecular sieves (3Å) for 30 min. The reaction mixture was cooled 
to 0 ˚ C, TfOH (155 µL, 1.75 mmol, 1 eq) was added dropwise and the mixture was stirred at 4 ˚ C overnight. 
The reaction was quenched with Et3N (0.5 mL), diluted in DCM, washed with NaHCO3 (sat aq., 3x), dried 
over MgSO4 (s), filtered and concentrated in vacuo. Purification using silica gel column chromatography 
(1/1, EtOAc/PE, v/v) followed by purification using size exclusion (Sephadex LH20, 1/1, MeOH/DCM, 
v/v) yielded compound 242 as a white powder (3.46 g, 0.88 mmol, 50%). TLC Rf: 0.75 (9/1, Et2O/PE, 
v/v); IR (neat, cm−1): 2924, 2853, 1684, 1670, 1654, 1636, 1617, 1497,1260, 1090, 1070, 1025, 705; 1H NMR 
(400 MHz, CDCl3) δ 8.35 (s, 3H, BTA-Harom), 8.01 - 7.89 (m, 30H, Harom), 7.79 - 7.71 (m, 12H, Harom), 7.60 
- 7.17 (m, 63H, Harom), 6.49 (t, J = 5.3 Hz, 3H, NH), 5.78 (t, J = 9.4 Hz, 3H, H-3), 5.72 (t, J = 9.6 Hz, 3H, 
H-3′), 5.51 (dd, J = 9.8, 7.9 Hz, 3H, H-2′), 5.43 - 5.33 (m, 6H, H-2, H-4′), 4.93 (d, J = 7.9 Hz, 3H, H-1′), 
4.69 - 4.55 (m, 6H, H-1, H-6a), 4.45 (dd, J = 12.1, 4.5 Hz, 3H, H-6b), 4.23 (t, J = 9.4 Hz, 3H, H-4), 4.05 
(dd, J = 11.9, 2.9 Hz, 3H, H-6a′), 3.87 - 3.67 (m, 12H, H-5, H-5′, CHH-O, H-6b′), 3.50 - 3.35 (m, 9H, CH2-
N, CHH-O), 1.66 - 1.52 (m, 6H, CH2), 1.51 - 1.39 (m, 6H, CH2), 1.39 - 0.93 (m, 48H, CH2); 13C NMR (101 
MHz, CDCl3) δ 165.9, 165.8, 165.7, 165.6, 165.3, 165.1, 164.9 (C=O), 135.4 (Cq), 133.5, 133.4, 133.2, 129.9, 
129.8, 129.8, 129.6 (CHarom), 129.5, 128.8, 128.7, 128.7 (Cq), 128.6, 128.6, 128.4, 128.4, 128.4, 128.1 (CHarom), 
101.1, 101.0 (C-1, C-1′), 76.6 (C-4), 73.1, 72.9 (C-3, C-3′), 72.5 (C-5, C-5′), 72.1, 72.0 (C-2, C-2′), 70.4 (CH2-
O), 69.5 (C-4′), 62.8 (C-6′), 62.6 (C-6), 40.5 (CH2-N), 29.6, 29.6, 29.5, 29.4, 29.3, 27.1, 25.8 (CH2); HRMS 
[C228H221D3N3O57 + 2H]2+: 1961.60894 found, 1961.76000 calculated. 
N1, N3, N5-Tris-(dodecyl-12-O-[4-O-(2,3,4,6-tetra-O-benzoyl-β-ᴅ-galactopyranosyl)-2,3,6-tri-O-
benzoyl-β-ᴅ-glucopyranoside])-benzene-1,3,5-tricarboxamide (243). 
Acceptor 220 (84 mg, 0.11 mmol, 1 eq) and donor 224 (674 mg, 0.55 mmol, 
5 eq) were combined and co-evaporated with toluene (3x) under N2 
atmosphere, dissolved in a mixture of anhydrous DCM/HFIP (4.8 mL, 0.023 
M, 4/1, v/v) and stirred with activated molecular sieves (3Å) for 30 min. The reaction mixture was cooled 
to 0 ˚C, TfOH (10 µL, 0.11 mmol, 1 eq) was added dropwise and the mixture was stirred at 4 ˚C overnight. 
The reaction was quenched with Et3N (0.1 mL), diluted in DCM, washed with NaHCO3 (sat aq., 3x), dried 
over MgSO4 (s), filtered and concentrated in vacuo. Purification using size exclusion (Sephadex LH20, 1/1, 
MeOH/DCM, v/v) yielded compound 243 as a white foam (425 mg, 0.108 mmol, 98%). TLC Rf: 0.80 
(9/1, Et2O/PE, v/v); IR (neat, cm−1): 2923, 2853, 1734, 1717, 1647, 1560, 1260, 1093, 1066, 1025, 704; 1H 
NMR (400 MHz, CDCl3) δ 8.35 (s, 3H, BTA-Harom), 8.04 - 7.93 (m, 30H, Harom), 7.92 - 7.88 (m, 6H, Harom), 
7.74 - 7.69 (m, 6H, Harom), 7.66 - 7.27 (m, 51H, Harom), 7.21 (t, J = 7.8 Hz, 6H, Harom), 7.14 (t, J = 7.8 Hz, 
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6H, Harom), 6.63 - 6.47 (m, 3H, NH), 5.80 (t, J = 9.5 Hz, 3H, H-3), 5.76 - 5.68 (m, 6H, H-2′, H-4′), 5.45 (dd, 
J = 9.8, 8.0 Hz, 3H, H-2), 5.37 (dd, J = 10.3, 3.4 Hz, 3H, H-3′), 4.87 (d, J = 7.9 Hz, 3H, H-1′), 4.68 (d, J = 
7.9 Hz, 3H, H-1), 4.63 - 4.56 (m, 3H, H-6a), 4.49 (dd, J = 12.2, 4.3 Hz, 3H, H-6b), 4.25 (t, J = 9.5 Hz, 3H, 
H-4), 3.89 (t, J = 6.5 Hz, 3H, H-5′), 3.86 - 3.77 (m, 6H, H-5, CHH-O), 3.77 - 3.63 (m, 6H, H-6′), 3.51 - 3.37 
(m, 9H, CH2-N, CHH-O), 1.66 - 1.53 (m, 6H, CH2), 1.53 - 1.39 (m, 6H, CH2), 1.39 - 0.92 (m, 48H, CH2); 
13C NMR (101 MHz, CDCl3) δ 166.0, 165.7, 165.7, 165.6, 165.5, 165.3, 165.3, 164.9 (C=O), 135.4 (Cq), 
133.7, 133.5, 133.5, 133.5, 133.4, 133.3, 133.2, 130.1, 129.9, 129.8, 129.8, 129.7 (CHarom), 129.6, 129.6, 129.5, 
129.5, 128.9, 128.8, 128.7 (Cq), 128.6, 128.4, 128.4, 128.3, 128.0 (CHarom), 101.3 (C-1), 101.1 (C-1′), 76.2 (C-
4), 73.1, 73.0 (C-3, C-5), 71.9, 71.9 (C-2, C-3′), 71.5 (C-5′), 70.5 (CH2-O), 70.0, 67.6 (C-2′, C-4′), 62.6 (C-6), 
61.2 (C-6′), 40.5 (CH2-N), 29.7, 29.6, 29.6, 29.5, 29.4, 29.4, 29.4, 29.3, 27.1, 25.8 (CH2); HRMS 
[C228H222D3N3O57 + H]2+: 1961.60487 found, 1961.76000 calculated. 
N1, N3, N5-Tris-(dodecyl-12-O-[4-O-(2,3,4,6-tetra-O-benzoyl-α-ᴅ-glucopyranosyl)-2,3,6-tri-O-
benzoyl-β-ᴅ-glucopyranosyl])-benzene-1,3,5-tricarboxamide (244). 
Acceptor 220 (100 mg, 0.132 mmol, 1 eq) and donor 225 (814 mg, 0.66 mmol, 
5 eq) were combined and co-evaporated with toluene (3x) under N2 
atmosphere, dissolved in a mixture of anhydrous DCM/HFIP (5.7 mL, 0.023 
M, 4/1, v/v) and stirred with activated molecular sieves (3Å) for 30 min. The reaction mixture was cooled 
to 0 ˚ C, TfOH (12 µL, 0.132 mmol, 1 eq) was added dropwise and the mixture was stirred at 4 ˚ C overnight. 
The reaction was quenched with Et3N (0.1 mL), diluted in DCM, washed with NaHCO3 (sat aq., 3x), dried 
over MgSO4 (s), filtered and concentrated in vacuo. Purification using size exclusion (Sephadex LH20, 1/1, 
MeOH/DCM, v/v) yielded compound 244 as a transparent glasslike solid (360 mg, 0.092 mmol, 70%). 
TLC Rf: 0.60 (19/1, Et2O/PE, v/v); IR (neat, cm−1): 1721, 1654, 1601, 1451, 1262, 1090, 1025, 705; 1H 
NMR (500 MHz, CDCl3) δ 8.29 (s, 3H, BTA-Harom), 8.04 (dd, J = 8.3, 1.3 Hz, 7H, Harom), 7.98 (dd, J = 8.4, 
1.3 Hz, 7H, Harom), 7.95 - 7.89 (m, 14H, Harom), 7.88 - 7.79 (m, 14H, Harom), 7.57 - 7.18 (m, 63H, Harom), 6.61 
(t, J = 5.6 Hz, 3H, NHCO), 6.17 (t, J = 9.9 Hz, 3H, H-3, H-3′), 5.96 (d, J = 3.8 Hz, 3H, H-1′), 5.72 (t, J = 
9.9 Hz, 3H, H-4′), 5.40 (dd, J = 10.4, 3.8 Hz, 3H, H-2′), 4.93 (dd, J = 9.0, 7.9 Hz, 3H, H-2), 4.83 (dd, J = 
11.9, 1.8 Hz, 3H, H-6a), 4.62 - 4.54 (m, 9H, H-5′, H-1, H-6b), 4.51 (dd, J = 12.4, 2.9 Hz, 3H, H-6a′), 4.41 
(dd, J = 12.4, 4.1 Hz, 3H, H-6b′), 3.99 (dd, J = 9.6, 8.5 Hz, 3H, H-4), 3.95 - 3.79 (m, 9H, H-3, H-5, CHH-
O), 3.49 - 3.35 (m, 9H, CHH-O, CH2-N), 1.62 - 1.52 (m, 6H, CH2), 1.52 - 1.38 (m, 6H, CH2), 1.38 - 0.99 
(m, 48H, CH2); 13C NMR (126 MHz, CDCl3) δ 166.5, 166.3, 166.2, 166.0, 165.8, 165.8, 165.3 (C=O), 135.2 
(Cq), 133.5, 133.4, 133.3, 133.3, 133.3, 133.1, 130.0, 129.9, 129.9, 129.8 (CHarom), 129.8, 129.7 (Cq), 129.7 
(CHarom), 129.5, 129.3, 129.2, 129.0 (Cq), 128.6, 128.5, 128.5, 128.4, 128.4, 128.1 (CHarom), 100.7 (C-1), 97.0 
(C-1′), 78.3 (C-4), 75.9 (C-3), 75.4 (C-2), 72.6 (C-5), 71.6 (C-2′), 70.2 (CH2-O), 70.2 (C-3′), 69.3 (C-4′), 69.0 
(C-5′), 63.8 (C-6), 62.9 (C-6′), 40.5 (CH2-N), 29.6, 29.5, 29.4, 29.3, 29.2, 27.1, 25.9 (CH2); HRMS 
[C228H221D3N3O57 + 2H]2+: 1961.60642 found, 1961.76000 calculated. 
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N1, N3, N5-Tris-(dodecyl-12-O-α-ᴅ-mannopyranoside)-benzene-1,3,5-tricarboxamide (213). 
Mannoside 240 (38 mg, 15 µmol) was dissolved in a mixture of dioxane, t-BuOH and 
MeOH (3 mL, 0.005 M, 1/1/1, v/v/v), a solution of NaOMe was added (3 drops) 
and the mixture was stirred overnight. Purification via RP-HPLC (linear gradient 15 - 
85 % B in A, 10 min, Gemini-NX 5µm C18, 110 Å, 250 x 12.0 mm, 5 mL/min) yielded title compound 213 
as a white powder after lyophilization (9.0 mg, 7.2 µmol, 48%). LC-MS: Rt = 6.83 min (0 - 90% ACN; 13 
min); IR (neat, cm−1): 3567, 3012, 1647, 1560, 1013, 952; 1H NMR (500 MHz, DMSO) δ 8.62 (t, J = 5.6 
Hz, 3H, NH), 8.35 (s, 3H, BTA-Harom), 4.57 (d, J = 1.5 Hz, 3H, H-1), 3.63 (dd, J = 11.6, 2.1 Hz, 3H, H-
6a), 3.61 - 3.55 (m, 6H, CHH-O, H-2), 3.46 - 3.40 (m, 6H, H-6b, H-3), 3.36 (t, J = 9.4 Hz, 3H, H-4), 3.32 
- 3.24 (m, 12H, H-5, CHH-O, CH2-N), 1.57 - 1.43 (m, 12H, CH2), 1.35 - 1.20 (m, 48H, CH2); 13C NMR 
(126 MHz, DMSO) δ 165.4 (C=O), 135.1 (Cq), 128.3 (CHarom), 99.7 (C-1), 73.9 (C-5), 71.0 (C-3), 70.4 (C-
2), 67.0 (C-4), 66.2 (CH2-O), 61.3 (C-6), 39.4 (CH2-N), 29.1, 29.0, 29.0, 28.9, 28.8, 26.5, 25.8 (CH2); 13C-
GATED (126 MHz, DMSO) δ 99.7 (d, J = 169 Hz, C-1); HRMS [C63H111N3O21 + NH4]+: 
1263.80652found, 1263.80483 calculated. 
N1, N3, N5-Tris-(dodecyl-12-O-β-ᴅ-glucopyranoside)-benzene-1,3,5-tricarboxamide (214). 
Glucoside 241 (1.47 g, 0.59 mmol) was dissolved in a mixture of dioxane, t-BuOH 
and MeOH (17 mL, 0.035 M, 3/5/10, v/v/v), a solution of NaOMe was added (10 
mL, 25% wt, 44 mmol, 75 eq) and the mixture was refluxed for three days. The 
mixture was quenched with Amberlite H+ and concentrated. After purification by RP-HPLC compound 
214 was isolated as a white powder after lyophilizing (305 mg, 0.24 mmol, 41%). LC-MS: Rt = 6.03 min (0 
- 90% ACN; 13 min); IR (neat, cm−1): 3307, 2922, 2852, 1641, 1540, 1435, 1077, 1023; 1H NMR (400 MHz, 
DMSO) δ 8.65 (t, J = 5.5 Hz, 3H, NH), 8.35 (s, 3H, BTA-Harom), 4.08 (d, J = 7.8 Hz, 3H, H-1), 3.74 (dt, J 
= 9.4, 6.8 Hz, 3H, CHH-O), 3.69 - 3.61 (m, 3H, H-6a), 3.48 - 3.33 (m, 6H, H-6b, CHH-O), 3.26 (q, J = 6.5 
Hz, 6H, CH2-N), 3.15 - 2.97 (m, 9H, H-3, H-4, H-5), 2.92 (t, J = 8.3 Hz, 3H, H-2), 1.58 - 1.44 (m, 12H, 
CH2), 1.37 - 1.19 (m, 48H, CH2); 13C NMR (101 MHz, DMSO) δ 165.4 (C=O), 135.1 (Cq), 128.3 (BTA-
CHarom), 102.9 (C-1), 76.8, 76.8 (C-3, C-4/C-5), 73.5 (C-2), 70.1 (C-4/C-5), 68.6 (CH2-O), 61.1 (C-6), 39.4 
(CH2-N), 29.3, 29.1, 28.9, 26.6, 25.6 (CH2); HRMS [C63H111N3O21 + H]+: 1246.78139 found, 1246.77828 
calculated. 
N1, N3, N5-Tris-(dodecyl-12-O-[4-O-(β-ᴅ-glucopyranosyl)-β-ᴅ-glucopyranoside])-benzene-
1,3,5-tricarboxamide (215). 
Compound 242 (3.46 g, 0.88 mmol) was dissolved in a mixture of water, 
MeOH, t-BuOH (65 mL, 1/6/6, v/v/v) to which KOH (15 mL, 1 M, aq., 15 
mmol, 17eq) was added dropwise after which the mixture was refluxed for 
three days after which it was neutralized with acetic acid. Purification usig C18 functionalized silica gel 
column chromatography (100% H2O → 1/1, H2O/ACN, v/v) yielded compound 215 as a white powder 
after lyophilizing (683 mg, 0.17 mmol, 19%). LC-MS: Rt = 5.82 min (5 - 100% ACN; 10 min); 1H NMR 
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(400 MHz, MeOD) δ 8.35 (s, 3H, BTA-Harom), 4.39 (d, J = 7.8 Hz, 3H, H-1′), 4.25 (d, J = 7.8 Hz, 3H, H-
1), 3.93 - 3.80 (m, 12H, H-6′, H-6a, CHH-O), 3.64 (dd, J = 11.8, 5.3 Hz, 3H, H-6b), 3.59 - 3.44 (m, 9H, 
CHH-O, H-3, H-4), 3.40 - 3.27 (m, 18H, CH2-N, H-5, H-5′, H-3′, H-4′), 3.25 - 3.18 (m, 6H, H-2, H-2′), 
1.58 (dd, J = 15.0, 6.7 Hz, 12H, CH2), 1.31 (d, J = 26.4 Hz, 48H, CH2); 13C NMR (101 MHz, MeOD) δ 
136.8 (Cq), 129.8 (CHarom), 104.6, 104.2 (C-1, C-1′), 80.7 (C-4), 78.1, 77.8 (C-3, C-3′), 76.4, 76.4 (C-5, C-5′), 
74.9, 74.8 (C-2, C-2′), 71.3 (C-4′), 70.9 (CH2-O), 62.4, 61.8 (C-6, C-6′), 41.2 (CH2-N), 30.7, 30.6, 30.5, 28.1, 
27.1 (CH2); HRMS [C81H141N3O36 + H]+: 1732.93776 found, 1732.93675 calculated. 
N1, N3, N5-Tris-(dodecyl-12-O-[4-O-(β-ᴅ-galactopyranosyl)-β-ᴅ-glucopyranoside])-benzene-
1,3,5-tricarboxamide (216). 
Lactoside 243 (153.1 mg, 39 µmol) was dissolved in a mixture of dioxane, t-
BuOH and MeOH (4 mL, 0.01 M, 1/1/1, v/v/v), a solution of NaOMe was 
added (3 drops) and the mixture was stirred overnight. Purification via RP-
HPLC (linear gradient 25 - 70 % B in A, 10 min, Gemini-NX 5µm C18, 110 Å, 250 x 12.0 mm, 5 mL/min) 
yielded title compound 216 as a white powder after lyophilization (8.9 mg, 5.1 µmol, 13%). LC-MS: Rt = 
6.02 min (10 - 90% ACN; 13 min); IR (neat, cm−1): 3565, 2921, 2852, 1647, 1064, 1024, 704; 1H NMR (500 
MHz, DMSO) δ 8.62 (t, J = 5.6 Hz, 3H, NH), 8.34 (s, 3H, BTA-Harom), 5.07 (t, J = 5.1 Hz, 6H, 2-OH, -
OH), 4.82 - 4.73 (m, 3H, -OH), 4.69 - 4.60 (m, 6H, -OH), 4.56 - 4.47 (m, 6H, 6-OH, 6′-OH), 4.19 (d, J = 
7.5 Hz, 3H, H-1′), 4.16 (d, J = 7.9 Hz, 3H, H-1), 3.78 - 3.69 (m, 6H, CHH-O, H-6a), 3.64 - 3.23 (m, 39H, 
CHH-O, H-6b, H-6′, H-4, H-3′, H-5, H-5′, H-2′, H-3, CH2-N), 3.02 - 2.95 (m, 3H, H-2), 1.57 - 1.45 (m, 
12H, CH2), 1.35 - 1.19 (m, 48H, CH2); 13C NMR (126 MHz, DMSO) δ 165.4 (C=O), 135.1 (Cq), 128.3 
(CHarom), 103.9 (C-1′), 102.5 (C-1), 80.8, 75.5, 75.0, 74.8, 73.2, 73.1, 70.5 (C-2, C-2′, C-3, C-3′, C-4′, C-5, C-
5′), 68.7 (CH2-O), 68.1 (C-4), 60.5 (C-6′), 60.4 (C-6), 39.7 (CH2-N), 29.3, 29.1, 29.0, 29.0, 29.0, 28.8, 26.5, 
25.5 (CH2); 13C-GATED (126 MHz, CDCl3) δ 103.9 (d, J = 160 Hz, C-1′), 102.5 (d, J = 159 Hz, C-1); 
HRMS [C81H141N3O36 + 2H]2+: 866.97174 found, 866.97202 calculated. 
N1, N3, N5-Tris-(dodecyl-12-O-[4-O-(α-ᴅ-glucopyranosyl)-β-ᴅ-glucopyranoside])-benzene-
1,3,5-tricarboxamide (217). 
Maltoside 244 (166.4 mg, 42 µmol) was dissolved in a mixture of dioxane, t-
BuOH and MeOH (4 mL, 0.01 M, 1/1/1, v/v/v), a solution of NaOMe was 
added (3 drops) and the mixture was stirred overnight. Purification via RP-
HPLC (linear gradient 29 - 66 % B in A, 10 min, Gemini-NX 5µm C18, 110 Å, 250 x 12.0 mm, 5 mL/min) 
yielded title compound 217 as a white powder after lyophilization (19.8 mg, 11.4 µmol, 27%). LC-MS: Rt = 
9.69 min (0 - 50% ACN; 13 min); IR (neat, cm−1): 3328, 2923, 2853, 1647, 1289, 1021, 912; 1H NMR (500 
MHz, DMSO) δ 8.63 (t, J = 5.6 Hz, 3H, NH), 8.36 (s, 3H, BTA-Harom), 5.01 (d, J = 3.9 Hz, 3H, H-1′), 4.15 
(d, J = 7.8 Hz, 3H, H-1), 3.75 (dt, J = 9.5, 6.8 Hz, 3H, CHH-O), 3.70 (d, J = 10.3 Hz, 3H, H-6a), 3.64 - 
3.60 (m, 3H, H-6a′), 3.59 - 3.34 (m, 18H, H-3, H-3′, CHH-O, H-6b, H-6b′, H-5′), 3.34 - 3.25 (m, 9H, CH2-
N, H-4), 3.25 - 3.19 (m, 6H, H-2′, H-5), 3.07 (t, J = 9.2 Hz, 3H, H-4′), 3.03 - 2.96 (m, 3H, H-2), 1.52 (dq, J 
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= 14.1, 6.8 Hz, 12H, CH2), 1.28 (d, J = 22.2 Hz, 48H, CH2); 13C NMR (126 MHz, DMSO) δ 165.4 (C=O), 
135.1 (Cq), 128.3 (CHarom), 102.7 (C-1), 100.8 (C-1′), 79.7 (C-4), 76.4 (C-3), 75.1 (C-5), 73.5 (C-5′), 73.3 (C-
3′), 73.0 (C-2), 72.5 (C-2′), 69.9 (C-4′), 68.7 (CH2-O), 60.8 (C-6′), 60.6 (C-6), 39.4 (CH2-N), 29.3, 29.1, 29.1, 
29.0, 28.8, 26.5, 25.5 (CH2); 13C-GATED (126 MHz, DMSO) δ 102.7 (d, J = 160 Hz, C-1), 100.8 (d, J = 
170 Hz, C-1′); HRMS [C81H141N3O36 + H]+: 1732.93655 found, 1732.93675 calculated. 
N1-(Dodecyl-12-O-[6-azido-6-deoxy-β-ᴅ-glucopyranoside])- N3,N5-bis-(dodecyl-12-O-β-ᴅ-
glucopyranoside)-benzene-1,3,5-tricarboxamide (218). 
Acceptor 220 (78 mg, 0.10 mmol, 1 eq) and donor 228 (112.4 mg, 0.17 mmol, 1.7 
eq) were combined and co-evaporated with toluene (3x) under N2 atmosphere, 
dissolved in a mixture of anhydrous DCM/HFIP (4 mL, 0.025 M, 4/1, v/v) and 
stirred with activated molecular sieves (3Å) for 30 min. The reaction mixture was 
cooled to 0 ˚C, TfOH (8.8 µL, 0.1 mmol, 1 eq) was added dropwise and the mixture was stirred at 0 ˚C for 
15 min after which a solution of donor 221 (222.2 mg, 0.30 mmol, 3 eq) in anhydrous DCM (0.6 mL, 0.5 
M) was added dropwise over 10 minutes. The reaction mixture was stirred for an additional 3 hours after 
which it was quenched by addition of Et3N (0.3 mL). The mixture was filtrated, concentrated in vacuo and 
purified using size exclusion (Sephadex LH20, 1/1, MeOH/DCM, v/v) yielding a mixture of compounds 
as a transparent solid (251 mg, 0.1 mmol, qnt). Based on 1H NMR the mixture contains an average of 0.3 
equivalent of migrated benzoyl, 1.6 equivalent of normal glucosides and 1.1 eq of azido glucose per BTA 
(based on bold integrals). 1H NMR (400 MHz, CDCl3) δ 8.38 (s, 3.00H, BTA-Harom), 8.05 – 7.77 (m, 21H, 
Harom), 7.57 – 7.23 (m, 34H, Harom), 6.72 (s, 3H, NH), 5.91 (dt, J = 11.9, 9.7 Hz, 2.68H, H-3, H-3*), 5.68 (t, 
J = 9.7 Hz, 1.67H, H-4), 5.57 – 5.48 (m, 2.76H, H-2, H-2*), 5.45 (t, J = 9.7 Hz, 1H, H-4*), 4.85 (d, J = 7.8 
Hz, 2.64H, H-1, H-1*), 4.64 (dd, J = 12.1, 3.2 Hz, 1.60H, H-6a), 4.51 (dd, J = 12.1, 5.2 Hz, 1.59H, H-6b), 
4.31 (t, J = 6.7 Hz, 0.56H, CH2-OBz), 4.21 – 4.13 (m, 1.63H, H-5), 4.03 – 3.87 (m, 3.96H, H-5*, CHH-
O-Glu), 3.62 – 3.50 (m, 4.01H, C-6a*, CHH-O-Glu), 3.42 (q, J = 6.7 Hz, 6.24H, CH2-N), 3.30 (dd, J = 
13.4, 2.3 Hz, 1.09H, C-6b*), 1.65 – 1.45 (m, 12H, CH2), 1.39 – 0.92 (m, 48H, CH2); 13C NMR (101 MHz, 
CDCl3) δ 166.2, 165.9, 165.9, 165.8, 165.4, 165.3, 165.2, 165.1 (C=O), 135.4 (Cq), 133.7, 133.5, 133.3, 133.3, 
133.3, 133.2, 133.2, 129.9, 129.9, 129.8, 129.8 (CHarom), 129.7, 129.6, 129.4, 129.4, 128.9, 128.9, 128.8, 128.6 
(Cq), 128.6, 128.5, 128.4, 128.4, 128.4, 128.1 (CHarom), 101.4 (C-1), 101.1 (C-1*), 74.2 (C-5*), 73.0, 72.7 (C-
3, C-3*), 72.2 (C-5), 72.0, 71.9 (C-2, C-2*), 70.5 (C-4*), 70.5, 70.3 (CH2-O-Glu), 69.9 (C-4), 65.2 (CH2-
OBz), 63.3 (C-6), 51.4 (C-6*), 40.5 (CH2-N), 29.6, 29.6, 29.6, 29.5, 29.5, 29.5, 29.4, 29.3, 27.1, 25.8, 25.8 
(CH2). This mixture of compounds (125 mg, ~51 µmol) was dissolved in a mixture of dioxane, t-BuOH 
and MeOH (2 mL, 0.01 M, 1/1/1, v/v/v), a solution of NaOMe was added (3 drops) and the mixture was 
stirred overnight. Purification via RP-HPLC (linear gradient 35 - 66 % B in A, 10 min, Gemini-NX 5µm 
C18, 110 Å, 250 x 12.0 mm, 5 mL/min) followed by a second RP-HPLC purification (linear gradient 36 - 
42 % B in A, 12 min, Vydac 219TP Diphenyl, 5 µm, 250 x 10.0 mm, 5 mL/min) yielded title compound 
218 as a white powder after lyophilization (6 mg, 4.7 µmol, 9%) (careful separation also allowed for the 
isolation of 214 as side product in 8.2 mg, 6.6 µmol, 13%). LC-MS: Rt = 6.62 min (10 - 90% ACN; 13 min); 
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LC-MS: Rt = 10.20 min (10 - 90% ACN; 21 min, Diphenyl) IR (neat, cm−1): 3370, 2922, 2852, 2097, 1641, 
1528, 1075, 1023; 1H NMR (500 MHz, DMSO) δ 8.64 (t, J = 5.4 Hz, 3H, NH), 8.35 (s, 3H, BTA-Harom), 
5.41 (s, 1H, -OH), 5.20 – 5.02 (m, 3H, -OH), 4.96 – 4.84 (m, 5H, -OH), 4.46 (t, J = 5.8 Hz, 2H, -OH), 4.19 
(d, J = 7.8 Hz, 1H, H-1*), 4.08 (d, J = 7.8 Hz, 2H, H-1), 3.73 (ddd, J = 15.6, 9.1, 6.9 Hz, 3H, CHH-O), 
3.65 (dd, J = 10.9, 4.9 Hz, 2H, H-6a), 3.47 – 3.30 (m, 8H, H-6b, CHH-O, H-6*, H-5*), 3.26 (q, J = 6.6 Hz, 
6H, CH2-NH), 3.17 – 2.98 (m, 8H, H-3, H-4, H-5, H-4*, H-3*), 2.97 (dd, J = 8.3, 3.6 Hz, 1H, H-2*), 2.92 
(td, J = 8.5, 4.7 Hz, 2H, H-2), 1.50 (dt, J = 14.1, 6.9 Hz, 12H, CH2), 1.36 – 1.16 (m, 48H, CH2); 13C NMR 
(126 MHz, DMSO) δ 165.4 (C=O), 135.1 (Cq), 128.3 (BTA-CHarom), 102.8 (C-1), 102.7 (C-1*), 76.8, 76.8 
(C-3, C-5), 76.3 (C-3*), 75.4 (C-5*), 73.4 (C-2), 73.3 (C-2*), 71.0 (C-4*), 70.1 (C-4), 68.6 (CH2-O), 61.1 (C-
6), 51.4 (C-6*), 39.3 (CH2-N), 29.3, 29.1, 29.0, 29.0, 28.8, 26.5, 25.6 (CH2); 13C-GATED (126 MHz, CDCl3) 
δ 102.8 (d, J = 159 Hz, C-1), 102.7 (d, J = 158 Hz, C-1*); HRMS [C63H110N6O20 + H]+: 1271.78499 found, 
1271.78477 calculated. 
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Chapter 7 
Summary and future prospects 
The adaptive immune system is able to efficiently and selectively battle pathogens and aberrant 
cells. Tailored immune responses have been exploited in many therapeutic approaches, combatting 
both infections and tumors. One of these approaches trains naïve immune cells using a vaccine 
strategy, in which antigens and adjuvants are administered to antigen-presenting cells (APCs). The 
adjuvant is a necessary component of a vaccine, as it stimulates the APC to mature, thereby 
upregulating the levels of antigen presentation and co-stimulatory factors. Adjuvants can be 
recognized by pathogen recognizing receptors (PRRs) present on APCs. Two sub-families of PRRs 
have been targeted extensively with synthetic ligands and vaccines: the toll-like receptors (TLRs) 
and C-type lectin receptors (CLRs). TLRs are often exploited for their ability to mature APCs, 
while CLRs are targeted for their capacity to endocytose pathogens. A subset of these CLRs (MR, 
DC-SIGN, and langerin) can recognize mannose based glycans and these receptors have been 
extensively studied and targeted with mannosylated constructs, as summarized in Chapter 1. 
Signaling pathways initiated by these CLRs often work in concert with those triggered by TLR 
activation, and it has been demonstrated that simultaneous targeting of these receptors can 
improve and prolong the immune response synergistically. The work presented in this thesis 
studies and exploits the activation of the immune system with antigen-adjuvant conjugates, 
equipped with well-defined mannosylated conjugates. 
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The affinity of mannosylated constructs for DC-SIGN, langerin, and the mannose receptor have 
been extensively studied. Due to the multimeric nature of the three CLRs, a large number of 
multivalent constructs has been designed and tested in a variety of assays. Because of the variation 
in structure and nature of the interaction assays, clear structure-activity relationship can be difficult 
to assess. Chapter 2 describes the synthesis of a systematic library that investigates the effect of 
the number of mannoside copies and the structure of these mannosides on binding affinity for 
DC-SIGN, langerin and the MR, and cell uptake by these receptors. It has previously been difficult 
to study the MR in vitro due to the lability of this receptor when isolated. To allow affinity studies 
with this receptor, selected members from the mannoside library have been decorated with a laser-
dye to enable the tracking of single molecules in a super-resolution microscopy assay. This 
approach allowed, for the first time, the determination of relative affinities for the MR in a natural 
setting. The affinity studies for all three CLRs have revealed a similar structure-activity trend, with 
an increasing number of mannosides leading to increased affinity, in line with previous reports. 
Affinity for the MR significantly increases when comparing constructs bearing 1 or 2 mannosides 
with that carrying 6 copies. The difference in affinity for DC-SIGN was neglectable for clusters 
bearing 3 or 6 mannoside copies. However, the type of mannosides in the clusters  had a large 
influence on the affinity for DC-SIGN, which shows a preference for α1,2-dimannosides. Since 
the affinity of the largest mannoside (an α1,3-α1,6-tri-mannoside) seemed to decrease when six 
instead of three copies were installed on the clusters, it would be relevant to test whether this was 
the result of the scaffold used. By synthesizing a scaffold containing six azido lysines which are all 
spaced with glycines similar to the n = 3 scaffold (255, Scheme 1), followed by CuAAC ligation of 
the propargyl mannosides, hexavalent mannoside clusters 256 could be synthesized. These clusters 
could be compared with their shorter analogs described in Chapter 2. Longer spacers between the 
mannosides and the lysine scaffold may also be explored. 
Langerin and the MR did not show a clear preference for the configuration of the mannosides in 
the clusters, as observed for DC-SIGN. Both di- and tri- mannosides showed comparable affinities 
for these receptors. Since the MR has multiple CRDs that can recognize mannosides, but only one 
domain that can bind sulfated galactosides, both ligands could be used to gain a deeper insight of 
the binding interactions with the MR. The results of this assay for example, indicated that the 
increase in binding affinity for mannosides with higher valency is most likely due to rebinding of 
the CRDs in close proximity rather than the binding of multiple CRDs simultaneously or even 
multiple receptors simultaneously. 
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Scheme 1: Synthesis of hexavalent clusters with similar spacing as the previously described 
n=3 & n=2 clusters.  
 
 
The simultaneous targeting of both TLR and CLR has been a promising approach to generate 
more effective vaccines. To improve the synthetic accessibility of conjugates targeting TLR7, 
Chapter 3 describes improvements in the synthesis of a TLR7 agonist which can be incorporated 
‘in-line’ during a solid-phase peptide synthesis (SPPS) campaign. The alterations made to the 
synthetic steps improved the workability of the synthetic route and allowed for the large scale 
preparation of a Boc-protected building block. Chapter 3 also describes the synthesis of 
bifunctional ligands that can bind both mannose-binding CLRs and TLR7. 
In Chapter 4, elements from the previous two chapters are combined in the synthesis of 
trifunctional conjugates that bear both a TLR7 ligand and mannoside clusters combined with a 
model gp100 antigen. The SPPS of the azido gp100 peptide required double couplings at elevated 
temperature and the addition of phenol to the cleavage cocktail to obtain sufficient quantities of 
product. For the introduction of the mannosides, both the simultaneous CuAAC of multiple 
propargyl mannosides and the conjugation of a pre-assembled mannoside clusters were planned. 
The pre-assembly of conjugatable mannoside clusters was easily achieved, whereas the synthesis 
of the gp100 peptide bearing six azides proved difficult. Therefore, the route requiring multiple 
simultaneous CuAAC events was abandoned. Evaluation of the conjugates showed that the 
addition of the TLR7 ligand improved the effectiveness of the conjugates. Conjugation to the 
hexavalent mannoside clusters further improved the activity of the gp100 conjugates. The synthetic 
route towards this gp100 platform allows for the conjugation of a carbohydrate cluster at a late 
stage of the synthesis, which allows for the generation of conjugates bearing different type of 
adjuvants. The presence of both an MHC-II and MHC-I epitope in the same peptide can be used 
to establish which combination of adjuvants would lead to optimal (cross-)presentation. The 
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platform allows for the variation of the ligands introduced via CuAAC (R2, Figure 1) and ligands 
introduced during SPPS on either the N-terminus, C-terminal lysine or both (R1, Figure 1). Instead 
of the TLR7 adjuvant, other TLR-ligands can be introduced, such as Pam3Cys targeting TLR2,1 
CPG like conjugates to target TLR9,2 or a poly-I:C ligand to target TLR3.3 Combining lipophilic 
conjugates such as Pam3Cys with hydrophilic carbohydrates such as the mannosides clusters can 
enhance the poor water solubility of the lipophilic peptides.4 Instead of (oligo)mannosides, the 
antigen can also be combined with other glycans or adjuvants. For example, the introduction of 
fucosylated glycans such as the Lewis antigens can skew the type of Th cell response.5,6 Another 
possibility would be to pivot the immune response from inflammatory towards anti-inflammatory. 
By the introduction of sialic acid-containing structures, sialic acid-binding immunoglobulin-type 
lectins (SIGLECs) can be targeted.7 Instead of targeting CLRs, an alternative would be the 
introduction of a muramyl dipeptide (MDP) which can lead to the engagement of the NOD2 
receptor.8  
Figure 1: Variations on the gp100 conjugates.  
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To improve the stability, and to allow the ‘inline’ introduction of mannoside clusters, Chapter 5 
describes the synthesis of a stabilized C-mannosyl functionalized Fmoc protected lysine building 
block, in which acid-labile para-methoxybenzyl (PMB) groups are used to mask the hydroxyl 
groups to prevent unwanted side reactions on these functionalities. This C-mannosyl building 
block was successfully used in SPPS to generate both small clusters and gp100 conjugates. The 
deprotection and cleavage from the resin required additional scavengers to prevent side reactions 
originating from the released PMB cations. The use of PMB groups could be combined with the 
use of a monomethoxy trityl (Mmt) protecting group, when the latter was removed with a mixture 
of acetic acid, trifluoroethanol, and dichloromethane. The C-mannoside clusters and conjugates 
bind with similar affinity to CLRs as their O-mannoside analogs, and also the antigen presentation 
of conjugates bearing the C-mannosides was comparable to their O-mannoside counterparts. The 
ability to introduce these clusters ‘in-line’ allowed for the synthesis of clusters with both CLR and 
TLR clusters on the same terminus. However, this configuration hampered the effectiveness of 
these constructs. A potential solution for this would be to use a self-immolative linker between 
the C-mannosides and TLR7 agonist.9 The use of the C-mannoside also allows for the introduction 
of an azide handle in the conjugates, which can be used for tracking of the antigens (e.g., 257, 
Figure 2).  
Figure 2: Second generation of C-mannosyl conjugates. 
 
 
Chapter 6 describes the synthesis of glycosylated benzene-1,3,5-tricarboxyamide (BTA) 
monomers, which can self-assemble into supramolecular fibers in an aqueous environment. Two 
synthetic strategies have been assessed, both suffering from solubility issues. Eventually, the 
assembly of the BTA monomers was successful by the condensation of glycosyl imidate donors 
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and a BTA-triol in an unusual solvent system, compromising a mixture of 1,1,1,3,3,3-
hexafluoroisopropanol (HFIP) and DCM. The nucleophilicity of the HFIP proved to be 
sufficiently low to prevent any significant competition during the condensation reactions. The 
glycosylations was met with side reactions such as the formation of ortho-esters and benzoyl 
migration. These side-products proved to be difficult to remove from the product mixture, but 
after cleavage of the benzoyl groups, the products and side-products could be separated via RP-
HPLC. Both the mannose and glucose BTAs were able to self-assemble in 2D fibers. Notably, the 
sugar residues induced the formation of fibers of opposite helicity. Since these two constructs 
differ at two positions in the carbohydrate appendage, it would be of interest to determine whether 
the helicity is caused by the configuration at C-2 or the stereochemistry of the anomeric bond. By 
synthesis of the 1,2-cis gluco and manno-isomers, this could be studied. A potential synthetic route 
towards these constructs can use donor 258 bearing acid-labile benzyl-like protecting groups (Nap 
or PMB, see Scheme 2). Activation of donor 258 by TMSI in the presence triphenyl oxide allows 
for cis-selective couplings with a primary alcohol such as 220.10 The obtained α-glucoside 259 could 
then be deprotected using HCl in HFIP to obtain target construct 260.11 For the β-mannoside 
BTA, a benzylidene protected mannoside imidate donor such as 261 could be used at low 
temperature to generate cis-mannoside 262.12 This mannoside could generate β-mannoside 263 by 
acidic deprotection. It will be of interest to establish whether these glycosylations tolerate the use 
of HFIP as a co-solvent. 
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Scheme 2: Synthetic route towards the BTA mannose and glucose stereoisomers. 
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-40°C.12,13 
 
The synthesis of a BTA monomer that bears two glucose and one 6-azido-6-deoxy-glucose residue 
is also described in Chapter 6. The azide handle in this monomer can be used for further decoration 
with reporter groups, adjuvants (e.g., 265), or epitopes (e.g., 264). For example, the co-assembly 
of mannosylated-BTA monomers (213) in combination with BTA cores functionalized with the 
gp100 epitope (266) and TLR7 agonist (267) could form a multivalent system that can target both 
CLRs and TLR7. By mixing the components in different ratios, many self-assembled polymers 
(268) can be evaluated (see Scheme 3).  
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Scheme 3: Assembly of BTA fibers that bear antigen, a TLR7 agonist and mannosides. 
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# 
Samenvatting 
Het adaptieve immuunsysteem is in staat om efficiënt en selectief pathogenen en afwijkende cellen 
te bestrijden. Veel therapeutische behandelingen tegen infecties en tumoren maken gebruik van 
specifieke immuunreacties om zieke of vreemde cellen op te ruimen. Een van deze behandelingen 
traint naïeve immuun cellen tegen specifieke structuren (antigenen) welke tot expressie komen op 
het pathogeen of de zieke cel. Deze vaccinatiestrategie combineert een antigeen met een 
moleculaire structuur die kan worden herkend door een antigeen presenterende cel (APC) en die 
instaat is om deze cel te activeren, een zogenaamd adjuvans. Het adjuvans is een noodzakelijke 
component van een vaccin, omdat het de APCs stimuleert tot maturiteit waardoor de mate van 
antigen presentatie en de productie van co-stimulatoire factoren toenemen. Adjuvans kunnen 
worden herkend met behulp van pathogeen herkennende receptoren (PRRs) die aanwezig zijn/tot 
expressie komen op APCs. Twee subfamilies van de pathogeen herkennende receptoren zijn het 
aangrijpingspunt voor vele synthetische liganden en vaccins: de Toll-like receptoren (TLRs) en de 
C-type lectine receptoren (CLRs). TLRs worden vaak gebruikt voor hun capaciteit om APCs te 
matureren terwijl de CLRs worden gebruikt voor hun capaciteit om pathogenen te endocyteren. 
Een sub-set van deze CLRs, namelijk de mannose receptor (MR, CD206), DC-SIGN (CD-209) 
en langerin (CD-207), kunnen op mannose gebaseerde koolhydraten herkennen. Deze receptoren 
zijn uitgebreid bestudeerd en veelal het aangrijpingspunt voor gemannosyleerde constructen zoals 
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beschreven in Hoofdstuk 1. Signaleringsroutes geïnitieerd door deze CLRs werken vaak samen 
met door TLR geactiveerde signaleringsroutes en het is voorheen aangetoond dat het simultaan 
activeren van zowel een TLR als CLR de immuunrespons synergistisch kan verbeteren en 
verlengen. Het werk beschreven in dit proefschrift bestudeert en gebruikt de activatie van het 
immuunsysteem met behulp van antigeen-adjuvans conjugaten die zijn uitgerust met goed 
gedefinieerde gemannosyleerde conjugaten.  
De affiniteit van gemannosyleerde constructen voor DC-SIGN, langerin en de MR is uitgebreid 
getest. Omdat alle drie de receptoren een multimere structuur hebben, zijn er in het verleden een 
groot aantal multivalente constructen getest. Echter, door verschillen in de structuur en opzet van 
de test opstellingen, is het lastig om een duidelijke structuur-activiteit relatie te bepalen voor deze 
constructen. Daarom wordt in Hoofdstuk 2 de synthese van een systematische bibliotheek van 
verbindingen beschreven, die zowel het effect van het aantal mannoside kopieën als het effect van 
de mannoside structuur op de affiniteit voor DC-SIGN, MR en langerin bepaald, alsmede het 
effect op cel opname via de respectievelijke receptoren. Het is voorheen gebleken dat het 
bestuderen van de MR in vitro lastig is door de labiliteit van de geïsoleerde receptor. Om deze 
receptor toch te kunnen bestuderen, is een deel van de constructen in de hiervoor beschreven 
bibliotheek gefunctionaliseerd met een fluorescent label, dat gebruikt kan worden voor super-
resolutie microscopie om de constructen per molecuul te kunnen volgen. Hiermee kan voor het 
eerst de relatieve affiniteit voor de MR worden bepaald in een ‘natuurlijke’ omgeving. De resultaten 
van deze affiniteit studies zijn vergelijkbaar met eerder beschreven structuur-activiteit trends 
waarbij affiniteit toeneemt met het verhogen van het aantal mannoside kopieën. Affiniteit voor de 
MR wordt significant vergroot wanneer constructen met één of twee kopieën worden vergeleken 
met zes kopieën. Voor DC-SIGN zijn de verschillen tussen clusters met drie of zes mannoside 
kopieën verwaarloosbaar, maar de structuur van de gebruikte mannosides heeft een grote invloed 
op de affiniteit, met de hoogste affiniteit voor clusters uitgerust met α1,2-dimannosides. Voor 
zowel de MR als langerin is de voorkeur voor mannoside structuur niet zo duidelijk als voor DC-
SIGN, en zowel de di- als tri-mannosides vertonen vergelijkbare affiniteiten voor deze receptoren. 
Gezien het feit dat de MR verscheidene mannose herkennende bindingsdomeinen (CRDs) kent, 
maar slechts één domein heeft dat gesulfateerde galactosides kan herkennen, zijn beide liganden 
gebruikt om een beter begrip van de bindingsinteracties van de receptor te krijgen. Uit deze 
experimenten is het af te leiden dat het meer waarschijnlijk is dat de verhoogde affiniteit voor 
multivalente mannoside clusters wordt veroorzaakt door het her-binden van de naastgelegen 
CRDs in plaats van het tegelijk binden van verschillende CRDs op dezelfde receptor, of zelfs het 
binden van verschillende CRDs op verschillende receptoren.  
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Het simultaan gebruiken van zowel een TLR als CLR is een veelbelovende aanpak voor het creëren 
van meer effectieve vaccins. Om de synthetische toegankelijkheid van conjugaten die op TLR7 
gericht zijn te vergroten, wordt in Hoofdstuk 3 een verbetering in de synthese van een TLR7 
agonist beschreven. Dit ligand kan worden ingebouwd tijdens een vaste drager peptide chemie 
synthese (SPPS). De aanpassingen van de synthese stappen verbeteren de werkbaarheid van de 
route en maken het mogelijk om een tert-butyloxycarbonyl (Boc) beschermde TLR7-bouwsteen 
op grote schaal te produceren. Verder beschrijft hoofdstuk 3 de synthese van bi-functionele 
liganden die zowel kunnen binden aan mannose bindende CLRs als TLR7. 
In Hoofdstuk 4 worden elementen uit de voorgaande hoofdstukken gebruikt voor de synthese 
van tri-functionele conjugaten, die een TLR7-ligand en een mannose cluster combineren met een 
gp100 antigen. De SPPS van het azide gefunctionaliseerde gp100 peptide vereiste dubbele 
koppelingen bij verhoogde temperaturen en toevoeging van phenol aan de afsplitscocktail om 
voldoende hoeveelheden product te kunnen isoleren. Voor de introductie van de mannose clusters 
waren twee strategieën bedacht. De eerste strategie behelst het simultaan koppelen van meerdere 
propargyl mannosides met behulp van een koper gekatalyseerde “klik-reactie” (CuAAC), terwijl de 
tweede aanpak gebruik maakt van vooraf geassembleerde oligomannoside clusters. Waar de 
synthese van vooraf geassembleerde conjugeerbare mannoside clusters gemakkelijk werd 
gerealiseerd, bleek de uitvoering van de eerste strategie moeilijker en daarom werd deze route niet 
verder uitgewerkt. Evaluatie van de conjugaten liet zien dat de toevoeging van het TLR-ligand de 
effectiviteit van de conjugaten vergroot. De conjugatie van hexavalente clusters verbeterde de 
activiteit van de conjugaten verder. Een bijkomend voordeel van de ontwikkelde synthese route is 
dat dit gp100 platform het mogelijk maakt om een koolhydraat cluster in een laat stadium van de 
synthese te introduceren. Dit maakt het makkelijk om verschillende conjugaten te genereren met 
variërende adjuvantia. 
Om de stabiliteit van de mannoses te verbeteren en om de introductie van mannose clusters, 
middels een directe vaste drager synthese mogelijk te maken, beschrijft Hoofdstuk 5 de synthese 
van een C-mannose gefunctionaliseerde lysine bouwsteen. In deze verbinding worden de mannose 
hydroxyl groepen gemaskeerd met zuur-labiele para-methoxybenzyl (PMB) groepen om 
ongewenste neven reacties op deze functionele groepen te voorkomen. Deze C-mannosyl lysine 
bouwsteen werd succesvol toegepast in SPPS om zowel kleine clusters als gp100 conjugaten te 
genereren. Het afsplitsen en ontschermen van de peptiden van de vaste drager vereiste additionele 
scavengers om neven reacties te voorkomen van de PMB-kationen, die gegenereerd werden tijdens 
de ontscherming. De PMB-groepen konden worden gebruikt in combinatie met een tijdelijke 
monomethoxy trityl (Mmt) bescherm-groep, wanneer deze laatste selectief werd verwijderd met 
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een mengsel van azijnzuur, trifluoroethanol en dichloromethane. De C-mannose clusters en 
conjugaten binden CLRs met vergelijkbare affiniteit als hun O-mannoside tegenhangers. Ook de 
antigen presentatie van de C-mannoside conjugaten was vergelijkbaar met de O-analogen. De 
mogelijkheid om deze clusters direct te introduceren in de peptide antigenen middels een SPPS 
aanpak, maakte het mogelijk om constructen te maken waarbij de CLR- en TLR-liganden aan 
dezelfde kant van het peptide werden verbonden. Deze configuratie belemmerde echter de 
effectiviteit van de constructen.  
Hoofdstuk 6 omschrijft de synthese van geglycosyleerde benzene-1,3,5-tricarboxyamide (BTA) 
monomeren die in waterig milieu kunnen zelf-assembleren tot supramoleculaire vezels. Voor de 
synthese zijn twee strategieën beoordeeld en beide hadden te kampen met de geringe 
oplosbaarheid van de bouwstenen. Uiteindelijk zijn de BTA-monomeren succesvol geassembleerd 
met behulp van  condensatie van glycosyl imidaat donoren en een BTA-triol in een ongebruikelijk 
oplosmiddel systeem, bestaande uit een mengsel van 1,1,1,3,3,3-hexafluoroisopropanol (HFIP) en 
dichloromethaan. De nucleofiliciteit van HFIP bleek voldoende laag te zijn om significante 
competitie tijdens de condensatiereactie te voorkomen. Tijdens deze reactie traden er echter andere 
nevenreacties op, die leidden tot de vorming van ortho-esters en migratie van benzoyl groepen. 
Deze bijproducten waren lastig te verwijderen uit het reactiemengsel, maar na het afsplitsen van 
de benzoyl groepen, konden de producten worden gezuiverd met behulp van HPLC. Zowel de 
mannose- en glucose-BTAs waren in staat om te zelf-assembleren tot 2D vezels, welke een 
tegengestelde heliciteit hadden. Ook omschrijft Hoofdstuk 6 de synthese van BTA-monomeren 
met twee glucose eenheden en één 6-azido-glucose functionaliteit. Het azide handvat in dit 
monomeer kan worden gebruikt voor verdere decoratie met functionele groepen zoals adjuvantia 
(bv. 265) of epitopen (bv. 264). Deze kunnen worden gebruikt voor bijvoorbeeld de co-assemblage 
van het gemannosyleerde BTA-monomer (213) in combinatie met gp100 gedecoreerde BTA-
monomeren (226) en een TLR7-agonist (267) zodat ze een multivalent systeem kunnen vormen, 
dat interacties kan aangaan met zowel CLRs als TLRs. Door de componenten in verschillende 
verhoudingen te mengen kunnen gemakkelijk verschillende zelf-assemblerende polymeren worden 
verkregen en vergeleken (zie Schema 1).  
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Schema 1: Opbouw van BTA vezels, die een antigen, TLR7 agonist en mannosides. 
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